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The pathological hallmark of Amyotrophic lateral sclerosis (ALS) is the presence of 
ubiquitylated protein inclusions in affected motor neurons, which is indicative of disruption in 
the mechanisms that maintain proteome homeostasis (proteostasis) in these cells. Moreover, 
many of the genes in which mutations are associated with ALS encode proteins that have 
important roles in the maintenance of proteostasis. It is thus hypothesised that dysfunction in 
the proteostasis network underlies motor neuron degeneration in ALS. Whilst proteostasis 
dysfunction in ALS has been a major focus of research in the past two decades, there is an 
urgent need to identify the precise molecular mechanisms that lead to this dysfunction. 
Addressing this gap in knowledge is a necessary step towards understanding what causes 
neurodegeneration in ALS, and to the identification of novel therapeutic targets to prevent this.  
In work presented in Chapter III, yeast were used as a model biological system for high-
throughput screening to identify alterations in the proteostasis network caused by expression 
of pathological isoforms of TDP-43, FUS and SOD1. Whilst the expression of SOD1A4V in 
yeast was not toxic, it was associated with up-regulation of proteins involved in mRNA 
metabolism (DCP2 and ASC1), the ubiquitin-proteasome system (UPS) and the endoplasmic 
reticulum-associated degradation pathway (ERAD) (UBA1, PRE2 and UFD1). The expression 
of FUSWT was moderately toxic to yeast, while TDP-43WT expression markedly reduced yeast 
viability. Up-regulation of UFD1, a key protein in maintaining ER proteostasis, correlated with 
suppression of SOD1A4V toxicity and increased cellular capacity to manage pathological FUS. 
Moreover, changes in abundance of HAC1 (involved in the unfolded protein response), DSK2 
(ubiquitin-dependent protein degradation in the ERAD pathway and the UPS) and PBP1 
(involved in diverse RNA processing pathways that control gene expression) were key 
differences between expression of TDP-43WT versus FUSWT, with these proteins being down-
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regulated in TDP-43WT-expressing yeast and up-regulated in FUSWT-expressing yeast. The 
increased abundance of these proteins in FUSWT-expressing yeast may have augmented the 
cellular capacity to restore ER proteostasis and UPS activity. Moreover, the decreased 
abundance of these proteins in TDP-43WT-expressing yeast, which correlated with higher 
toxicity, suggests that disruptions in ubiquitin-dependent protein degradation and ER 
proteostasis may be associated with TDP-43 associated pathology. Hence, disruptions in gene 
expression regulation, ER proteostasis and UPS activity could underlie different genetic forms 
of ALS.  
Through work presented in Chapter IV, a key hit from the SOD1A4V yeast screen (the E1 
ubiquitin-activating enzyme, UBA1) was validated, demonstrating that increased UBA1 
expression suppresses mutant SOD1 toxicity in neuronal cells (NSC-34). The expression of 
SOD1A4V in NSC-34 cells caused disruption to UPS activity, and this correlated with cellular 
toxicity. SOD1A4V aggregation into large inclusions was a prominent feature in these cells. 
Remarkably, increased expression of catalytically-active UBA1, but not a catalytically-inactive 
mutant, improved cell viability. Interestingly, the protective mechanism by which increased 
UBA1 expression prevented toxicity in these cells did not involve suppression of SOD1A4V 
aggregation. It has been previously reported that aggregates formed by SOD1 promote cellular 
toxicity by sequestering ubiquitin, causing ubiquitin dyshomeostasis. Hence, increasing the 
levels of UBA1 in NSC-34 cells expressing SOD1A4V may have improved cell viability through 
amelioration of SOD1A4V-mediated deficiency in the cellular pool of activated ubiquitin.   
The work presented in Chapter V involved the use of conformationally-destabilised mutants of 
firefly luciferase (Fluc) to develop a high content screening (HCS) assay to examine protein 
folding/re-folding capacity in NSC-34 cells expressing SOD1A4V and CCNFS621G. It was 
demonstrated that these Fluc isoforms can be used in high-throughput format to report on 
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reductions in the activity of the chaperone network that result from the expression of SOD1A4V, 
providing multiplexed information at single-cell resolution. In addition to SOD1A4V and 
CCNFS621G, NSC-34 cell models of ALS-associated mutants of TDP-43, FUS, VAPB, VCP, 
OPTN and UBQLN2 were generated that, in future work, can be screened using this assay. For 
ALS-associated mutant proteins that do cause reductions in the protein quality control capacity 
of neuronal cells, as is the case for SOD1A4V, this assay has potential to be applied in drug 
screening studies to identify candidate compounds that are able to ameliorate this deficiency. 
In summary, this PhD thesis describes the development and use of two novel high-throughput 
methodologies to investigate proteostasis disturbances caused by mutations in ALS-associated 
genes. The common alterations identified in the proteostasis network caused by pathological 
TDP-43, FUS and SOD1 expression lay the groundwork for further research in this area. In the 
future both methodologies can be exploited for drug screening applications. Continued 
development of HCS assays capable of measuring deficiencies in the proteostasis network will 
be valuable in the search for therapeutic targets and development of drugs to treat ALS. Overall, 
the work achieved in this PhD provides substantial foundation for further investigation into the 
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ANOVA  Analysis of variance 
APC   Anaphase-promoting complex 
ARF   Adenosine diphosphate (ADP) ribosylation factor 
ATP   Adenosine triphosphate 
ATXN2  Ataxin-2 
BCA   Bicinchoninic acid 
C9ORF72  Chromosome 9 open reading frame 72 
CCNF   Cyclin F 
CFP   Cyan fluorescent protein 
CJD   Creutzfeldt-Jakob disease 
CYLD   CYLD lysine 63 deubiquitinase 
DBP   DNA-binding protein 
DDR   DNA damage response 
DENN   Differentially Expressed in Normal and Neoplasia (protein domain) 
DMEM/F-12  Dulbecco’s modified eagle medium/Nutrient mixture F12 
DMSO   Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
DPR   Dipeptide-repeat protein 
DsRed   Red fluorescent protein from Discosoma species 
DUB   De-ubiquitylating enzyme 
ECFP   Enhanced cyan fluorescent protein 
EDTA   Ethylenediaminetetraacetic acid 
EGFP   Enhanced green fluorescent protein 
xix 
 
ER   Endoplasmic reticulum 
ERAD   Endoplasmic reticulum-associated degradation 
ERGIC  ER-Golgi intermediate compartment 
EWSR1  Ewing sarcoma breakpoint region 1 
fALS   Familial amyotrophic lateral sclerosis 
FBS   Foetal bovine serum 
FI   Fluorescence intensity 
Fluc   Firefly luciferase 
FlucDM   ‘Double mutant’ firefly luciferase (containing two mutations) 
FlucSM   ‘Single mutant’ firefly luciferase (containing a single mutation)  
FlucWT   Wild-type firefly luciferase 
FTD   Frontotemporal dementia 
FUS   Fused in sarcoma 
GALDsRedempty  pAG416GAL-ccdB-DsRed vector control 
GDP   Guanosine diphosphate 
GEF   GDP/GTP exchange factor 
GO   Gene ontology 
GRR   Glycine-rich region 
GTP   Guanosine triphosphate 
HCS   High content screening 
HD   Huntington’s disease 
hnRNP  Heterogeneous nuclear ribonucleoprotein 
hnRNPA1  Heterogeneous nuclear ribonucleoprotein A1 
HRP   Horseradish peroxidase 
HSE   Heat shock element 
HSP   Heat shock protein 
HSR   Heat shock response 
Htt   Huntingtin 
xx 
 
IBMPFD Inclusion body myopathy with Paget’s disease of bone and 
frontotemporal dementia 
IC50 The half maximal inhibitory concentration 
ICC Immunocytochemistry 
IgG Immunoglobulin G 
IPOD Insoluble protein deposit 
IPSC Induced pluripotent stem cell 
JUNQ Juxtanuclear quality control compartment 
LTP Long-term potentiation 
MATR3 Matrin-3 
mCherry Monomeric cherry fluorescent protein 
MJD Machado-Joseph disease  
mRNA Messenger RNA 
MW Molecular weight 
N2 Molecular nitrogen 
NF-κB Nuclear factor kappa B 
NLS   Nuclear localisation sequence 
NSC-34  Murine motor neuron-like neuroblastoma × spinal cord hybrid cell line 
OD   Optical density 
OPTN   Optineurin 
ORF   Open reading frame 
P-body   Processing body 
PBS   Phosphate-buffered saline 
PCR   Polymerase chain reaction 
PD   Parkinson’s disease 
PEG   Polyethylene glycol 
PEST   Proline-, glutamic acid-, serine-, threonine-enriched (protein domain) 
PFA   Paraformaldehyde 
PFN1   Profilin-1 
xxi 
 
PMN   Piecemeal microautophagy of the nucleus 
POAG   Primary open angle glaucoma 
RAC   19S proteasome regulatory particle assembly-chaperones 
RAD   Ribosome-associated degradation 
RAN   Repeat-associated non-ATG-initiated (translation) 
RBP   RNA-binding protein 
RIPA   Radioimmunoprecipitation assay buffer 
RNA   Ribonucleic acid 
RNP   Ribonucleoprotein 
RQC   Ribosome quality control 
RRM   RNA recognition motif 
RSC   Remodel the Structure of Chromatin (chromatin-remodelling complex) 
sALS   Sporadic amyotrophic lateral sclerosis 
SCF   SKP1-cullin-F-Box protein ubiquitin ligase complex 
SD   Synthetic medium supplemented with glucose 
SDS   Sodium dodecyl sulphate 
SG   Stress granule 
SGA   Synthetic genetic array 
SGal   Synthetic medium supplemented with galactose 
SGD   Saccharomyces Genome Database 
SHRED  Stress-induced homeostatically-regulated protein degradation 
SMA   Spinal muscular atrophy 
SMN   Survival motor neuron 
SOC   Super optimal broth with catabolite repression 
SOD1   Copper/zinc superoxide dismutase 
SQSTM1  Sequestosome-1/p62 
SRaf   Synthetic medium supplemented with raffinose 
STUbL  SUMO-targeted ubiquitin ligase 
SUMO   Small ubiquitin-like modifier 
xxii 
 
TAF15   TATA box-binding protein-associated factor 15 
TBK1   TANK-binding kinase 1 
TBS   Tris-buffered saline 
TBS-T   Tris-buffered saline Tween-20 
TDP-43  TAR DNA-binding protein 43 
tdTomato  Tandem tomato fluorescent protein 
tGFP   Turbo green fluorescent protein 
UBA   Ubiquitin-associated domain 
UBA1   Ubiquitin-activating enzyme E1 
UBL   Ubiquitin-like domain 
UBQLN2  Ubiquilin-2 
UPR   Unfolded protein response 
UPS   Ubiquitin-proteasome system 
VAPB   VAMP (vesicle-associated membrane protein)-associated protein B 
VC   Vector control 
VCP   Transitional endoplasmic reticulum ATPase/p97 
v/v   Volume per volume 
WT   Wild-type 
w/v   Weight for volume 
XL-SMA  X-linked spinal muscular atrophy 
YNB   Yeast nitrogen base 
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Amyotrophic lateral sclerosis (ALS) is one of the most prevalent forms of motor neuron disease 
worldwide (Dormann et al. 2010). Now considered to be a heterogeneous disorder (Robberecht 
and Philips 2013), it is typified by the progressive loss of motor neurons of the motor cortex, 
brainstem and spinal cord. The muscles served by these motor neurons consequently atrophy, 
weaken and become vulnerable to spasticity and fasciculations. Typically, death results within 
3-5 years of symptom onset as degeneration progresses to the motor neurons serving the 
respiratory muscles and diaphragm, resulting in respiratory failure (Boillee et al. 2006). 
However, in some cases disease duration can be quite variable (Strong et al. 2005, Wang et al. 
2008).  
A significant proportion of patients also suffer cognitive and behavioural impairment. In fact, 
ALS and frontotemporal dementia (FTD) are increasingly recognised as being part of a 
pathological spectrum (Basso et al. 2009, Robberecht and Philips 2013, van der Zee et al. 2013). 
ALS itself is classified as either familial (fALS) or sporadic (sALS). fALS comprises ~10% of 
all reported cases, with the remaining ~90% of sALS patients having no apparent family history 
of disease (Ilieva et al. 2009). Genetic studies of fALS patients have led to the identification of 
a growing list of causative genetic mutations that segregate with disease. The first of these were 
discovered in SOD1 (copper/zinc superoxide dismutase) (Rosen et al. 1993), and this list has 
grown to include TARDBP (TAR DNA-binding protein 43; TDP-43) (Neumann et al. 2006), 
FUS (Fused in Sarcoma) (Kwiatkowski et al. 2009, Vance et al. 2009), C9ORF72 (chromosome 
9 open reading frame 72) (DeJesus-Hernandez et al. 2011), VAPB (VAMP (vesicle-associated 
membrane protein)-associated protein B) (Nishimura et al. 2004, Nishimura et al. 2004), OPTN 
(optineurin) (Maruyama et al. 2010), ANG (angiogenin) (Greenway et al. 2006), SETX 
(senataxin) (Chen et al. 2004), VCP (transitional endoplasmic reticulum ATPase/p97) (Johnson 




ribonucleoprotein A1) (Kim et al. 2013), MATR3 (matrin-3) (Johnson et al. 2014), CCNF 
(cyclin F) (Williams et al. 2016), PFN1 (profilin-1) (Wu et al. 2012), SQSTM1 (p62) (Fecto et 
al. 2011), TBK1 (TANK-binding kinase 1) (Cirulli et al. 2015), CYLD (CYLD lysine 63 
deubiquitinase) (Dobson-Stone et al. 2013), EWSR1 (Ewing sarcoma breakpoint region 1) 
(Couthouis et al. 2012) and TAF15 (TATA box-binding protein-associated factor 15) (Ticozzi 
et al. 2011), among others. This list is not exhaustive, with more than 50 potential ALS genes 
now published. Establishing the causality of many of these mutations, however, has remained 
challenging for geneticists.  
Mutations in many of the genes associated with fALS have also been detected in sALS patients, 
including C9ORF72 (Shatunov et al. 2010), TARDBP (Sreedharan et al. 2008), FUS (Belzil et 
al. 2009, Corrado et al. 2010, DeJesus-Hernandez et al. 2010, Lai et al. 2011), ANG (Greenway 
et al. 2006), MATR3 (Lin et al. 2015, Leblond et al. 2016), EWSR1 (Couthouis et al. 2012), 
OPTN (van Blitterswijk et al. 2012), VCP (Koppers et al. 2012) and SQSTM1 (Fecto et al. 
2011, Teyssou et al. 2013). The genetic contribution to sALS is estimated to be ~65% (Al-
Chalabi et al. 2010, Al-Chalabi and Visscher 2014), but current methodologies for genetic 
analysis have fallen short in identifying genetic variants in the majority of sALS cases 
(Andersen and Al-Chalabi, 2011, Renton et al. 2014, Dharmadasa et al. 2017, Nguyen et al. 
2018). In terms of clinical presentation and pathological features, sALS and fALS are largely 
indistinguishable. Rather, fALS and sALS are distinguished based on the presence of a recorded 
family history of ALS. However, advances in genetic analysis techniques are paving the way 
towards the identification of previously unknown familial relatedness between individuals with 
sALS carrying identical ALS-associated gene variants (Twine et al. 2019). The hallmark 
pathology of ubiquitylated TDP-43-positive inclusions in affected motor neurons is observed 
in post-mortem tissue from both individuals with sALS and those with fALS (Leigh et al. 1991, 




individuals with ALS, there is no definitive delineation between those with fALS and those 
with sALS. Thus, continued efforts to identify relatedness amongst individuals with sALS and 
to identify genetic variants that contribute to sALS risk are warranted to aid diagnosis and 
prognosis of individuals with fALS and sALS, improve patient outcomes and provide insight 
into the genetic mechanisms that contribute to ALS pathogenesis. 
The currently identified ALS-associated genes cover a diverse range of molecular functions and 
thus it is becoming increasingly apparent that motor neuron dysfunction and death is unlikely 
to be caused by one mechanism alone. The key to understanding ALS will be to discern how 
the ALS-associated genes and their respective molecular pathways interconnect. As a starting 
point, it is well established that inclusion bodies (inclusions) containing aggregated proteins are 
a characteristic feature of the affected motor neurons in post-mortem spinal cord tissue from 
ALS patients. The universal presence of inclusions in ALS indicates that there is disruption of 
the cellular mechanisms that maintain proteome homeostasis (proteostasis) in motor neurons. 
The objective of this introductory chapter is to summarise current evidence for, and 
understanding of, the potential roles of ALS-associated mutant proteins in proteostasis 
dysfunction in motor neurons and how they contribute to disease. 
 Proteostasis involves the co-ordination of interacting molecular processes 
The primary function of motor neurons is to respond to the binding of neurotransmitters to cell 
surface receptors and to generate, propagate and transmit action potentials for rapid information 
transfer from the motor areas of the brain to the muscles. This is dependent on homeostasis of 
the intra- and extracellular environment (Kanning et al. 2010). Proteostasis is defined as the 
maintenance of all proteins in the cellular proteome in a conformation, concentration and 
location that is required for their correct function (Balch et al. 2008). It involves stringent 
regulation of the processes of transcription, RNA processing and transport, translation, protein 




al. 2016) (Figure 1.1). This requires readaptation of the innate biology of the cell in response to 
constant intrinsic and extrinsic changes. These processes are intricately connected to each other, 
creating a dynamic system in equilibrium, such that disturbances in one component lead to 








Figure 1.1. Summary of the interacting molecular processes that maintain proteome homeostasis 
(proteostasis). The maintenance of cellular proteostasis requires stringent regulation of the processes constituting 
RNA metabolism and protein quality control. RNA metabolic processes include (A) transcription, (B) mRNA 
splicing and processing, (C) mRNA transport into the cytosol or the rough endoplasmic reticulum (rER) and (D) 
mRNA decay. From the moment (E) a nascent protein has been translated, it enters the realm of the protein quality 
control network. (F) Molecular chaperones (G) mediate folding of nascent proteins into their native conformation. 
When molecular chaperones are unable to fold aberrant misfolded proteins into their native conformation, (H) 
ubiquitylation can direct the misfolded proteins for proteasomal degradation. The ubiquitin-proteasome system is 
also responsible for the regulated degradation of many proteins with key roles in signalling pathways. 
Alternatively, (I) ubiquitylation can assist in the active segregation of misfolded proteins from the cytosol into 
distinct types of inclusions that function as protein quality control compartments, e.g. aggresomes. (J) In some 
instances, misfolded proteins that escape these mechanisms can aggregate. (K) Molecular chaperones can assist in 
directing aggregates for proteolytic degradation through the selective macroautophagy pathway, which is also the 
primary degradative pathway for the clearance of long-lived proteins, macromolecular structures and old or 
damaged organelles.  
 
1.2.1 RNA metabolism 
Fundamentally, the appropriate levels of proteins in the cell are maintained through the correct 
regulation of transcription, mRNA splicing and processing, transport from the nucleus to 
distinct locations in the cytoplasm, and translation into nascent polypeptides. A multitude of 
DNA- and RNA-binding proteins (D/RBPs) exist that interact with nascent and mature mRNA 
molecules to ensure their proper functioning (Baltz et al. 2012, Castello et al. 2012). Together, 
these DBPs and RBPs form an elaborate network crucial to maintaining the appropriate levels 
of mRNAs and their encoded proteins (Janssens and Van Broeckhoven 2013). The regulation 
of RNA metabolism is crucial in the preservation of a functional cellular environment, and 
multiple neurodegenerative diseases have now been linked to dysfunctional RNA metabolism 
(Cooper et al. 2009, Todd and Paulson 2010, Belzil et al. 2013). For example, the survival 
motor neuron (SMN) protein, genetically linked to the motor neuron disease spinal muscular 
atrophy (SMA), is critical for efficient splicing activity (Liu et al. 1997, Pellizzoni et al. 1998). 
SMN assists in assembly of the spliceosome, a molecular complex responsible for splicing pre-
mRNA transcripts (Liu et al. 1997, Pellizzoni et al. 1998). Loss of SMN function due to SMA-
causing mutations leads to impaired spliceosomal activity (Wan et al. 2005). Moreover, 
knockdown of SMN in zebrafish and mouse models causes splicing defects and motor neuron 




deficiency have also been implicated as a risk factor for sALS (Veldink et al. 2005, Corcia et 
al. 2006). Although SMN has multiple functions in cells beyond splicing activity (Rossoll et 
al. 2003, Zhang et al. 2003, Carrel et al. 2006, Zhang et al. 2006), these data nevertheless 
suggest that there is a crucial role for efficient mRNA splicing in the maintenance of motor 
neuron health. Furthermore, dysregulation of proper splicing activity is prevalent in ALS 
caused by mutations in TARDBP and FUS (Hoell et al. 2011, Polymenidou et al. 2011, Lagier-
Tourenne et al. 2012, Arnold et al. 2013). 
Once an mRNA has been translated into a nascent polypeptide, regulation of the fate of the 
mRNA is crucial for proper control of gene expression and cellular protein levels (Wang et al. 
2002, Yang et al. 2003). Integral in mRNA regulation are mechanisms of mRNA decay, which 
are intricately controlled by highly conserved networks of enzymes in eukaryotes (Parker and 
Song 2004). Typically, mRNA decay is deadenylation-dependent, initiating through the 
removal of the mRNA poly(A) tail by any of several different poly(A)-specific 
exoribonucleases (Boeck et al. 1996, Körner et al. 1998, Tucker et al. 2001). Following this, 
the deadenylated mRNA is degraded through either a 5’ to 3’ directed pathway or a 3’ to 5’ 
directed pathway. The 5’ to 3’ pathway proceeds through the action of decapping enzymes, 
DCP1 and DCP2, that remove the 5’ cap of the mRNA (Steiger et al. 2003). This then facilitates 
completion of the decay pathway by the XRN1 exonuclease (Larimer et al. 1992). 
Alternatively, structures comprised of a network of exonucleases, termed exosome complexes, 
degrade their mRNA substrates through the 3’ to 5’ direction (Anderson and Parker 1998, 
Mukherjee et al. 2002, Wang et al. 2002). As for the nascent polypeptide, it enters the realm of 
the protein quality control network. This network encompasses the proteins and pathways that 
regulate protein folding and re-folding, trafficking of proteins to their correct cellular location, 
and that monitor the efficient compartmentalisation and clearance of misfolded proteins and 




1.2.2 Protein quality control 
Mechanisms of protein folding, re-folding and the prevention of protein aggregation are 
managed by networks of molecular chaperones and co-chaperones (Balch et al. 2008, Yerbury 
and Kumita 2010). These include several systems of ‘heat-shock proteins’ (HSPs); the small 
HSP (sHSP), HSP40, HSP60 (chaperonin), HSP70, HSP90 and HSP100 systems. Hartl et al. 
(2011) provides an expansive review of the molecular chaperone networks and so this will not 
be covered here. The full repertoire of chaperones, co-chaperones, folding enzymes and 
adaptors that make up these systems in human cells, the chaperone network (chaperome), has 
been quantified to comprise 332 proteins (Brehme et al. 2014). Many proteins of the chaperome 
are abundantly expressed in cells and encompass a considerable proportion of the cellular 
machinery (Bukau et al. 2006, Ron and Walter 2007). Under normal physiological conditions, 
the various proteins of the chaperome have diverse roles in regulating correct protein folding, 
preventing protein folding intermediates and aberrant proteins from misfolding, and targeting 
stressed or aberrant proteins for degradation (Sherman and Goldberg 2001, Gidalevitz et al. 
2006, Douglas and Dillin 2010, Yerbury and Kumita 2010, Gidalevitz et al. 2011, Yerbury et 
al. 2013). Extensive evidence indicates that they do this by recognising and binding to exposed 
hydrophobic stretches of the target protein’s amino acid sequence, thereby preventing 
unfavourable interactions between non-native protein species (Voisine et al. 2010, Hartl et al. 
2011, Wyatt et al. 2013).  
Abnormal physiological demands on the proteostasis network, such as the overexpression of 
proteins above normal concentrations, can alter the chaperone-substrate balance. Mutations that 
increase the propensity of a protein to aggregate can also tip this balance to disfavour 
proteostasis by exceeding the cellular chaperome capacity (Gidalevitz et al. 2006, Yerbury et 
al. 2013). Age itself leads to a decline in the capacity of the chaperome. Gene expression 




chaperone-encoding genes are down-regulated (Brehme et al. 2014). A considerable proportion 
of this chaperome deterioration was also detected in post-mortem brain tissue from patients 
with Alzheimer’s (AD), Parkinson’s (PD) and Huntington’s disease (HD). Moreover, a subset 
of these repressed chaperones was identified to comprise an intricate subnetwork that is critical 
in buffering against proteotoxic stress during cellular aging. As with ALS, AD, PD and HD are 
age-correlated diseases and are each primarily associated with genetic mutations that introduce 
increased proteostatic burden through the production of aggregation-prone proteins. It stands to 
reason that a declining capacity of the protective chaperone subnetwork (Brehme et al. 2014) 
with increased age may make this system highly vulnerable to genetic mutations that lead to 
accumulation of mutant, aggregation-prone proteins. 
1.2.2.1 Ubiquitin-dependent protein degradation 
When molecular chaperones are unable to fold aberrant proteins into their native conformation, 
regulatory components and co-factors of the HSP40, HSP70 and HSP90 systems help to prepare 
and direct the substrate proteins for proteolytic degradation through the ubiquitin-proteasome 
system (UPS) or through selective macroautophagy (Arndt et al. 2007, Ding and Yin 2008, 
Gamerdinger et al. 2009, Arndt et al. 2010, Kampinga and Craig 2010, Jin et al. 2013). 
Ubiquitylation of substrate proteins, i.e. the conjugation of ubiquitin molecules to substrate 
proteins, is critically important for directing proteins through these proteolytic systems (Tan et 
al. 2008, Kraft et al. 2010). The UPS is the main proteolytic system for the degradation of 
regulatory proteins and damaged, misfolded proteins. Substrate proteins are ubiquitylated 
through the co-ordinated action of E1 ubiquitin-activating, E2 ubiquitin-conjugating and E3 
ubiquitin-ligase enzymes in a multistep cascade of enzymatic reactions, and subsequently 
targeted to the 19S regulatory particle of the 26S proteasome (Hershko and Ciechanover 1998, 
Crews 2003, Kleiger and Mayor 2014). Inside the 20S core particle of the proteasome, substrate 




(referred to as autophagy from hereon) is primarily responsible for the clearance of long-lived 
proteins, macromolecular complexes, organelles and aggregates formed by misfolded proteins, 
and is a highly conserved pathway among eukaryotes (Hughes and Rusten 2007, Jin et al. 2013).  
Ubiquitylation also plays a role in alternative routes of protein quality control, assisting in the 
active segregation of misfolded proteins from the cytosol into distinct types of inclusions 
(Kawaguchi et al. 2003, Tan et al. 2008, Zhang and Qian 2011). These structures have been 
reported to contain high concentrations of quality control machinery. For instance, aggresomes 
and the related juxtanuclear quality control compartment (JUNQ) contain ubiquitylated proteins 
targeted for proteasomal degradation, active proteasomes, HSP70 and other chaperones 
(Johnston et al. 1998, Kopito 2000, Arrasate et al. 2004, Kaganovich et al. 2008, Treusch et al. 
2009, Zhang and Qian 2011, Weisberg et al. 2012, Polling et al. 2014). However, in a cell that 
has been exposed to excessive protein-folding stress, the capacity of these quality control 
mechanisms can be exceeded, enabling misfolded proteins to escape compartmentalisation or 
degradation. Critically, rogue misfolded proteins are then able to amplify this initial deficiency 
in the proteostasis network. Through their abnormal conformations they can interact aberrantly 
with other proteins, including components of the proteostasis network, impairing their normal 
functions and further disrupting mechanisms of proteostasis (Matsumoto et al. 2005, Gidalevitz 
et al. 2006, Weisberg et al. 2012).   
1.2.2.2 Diverse cellular processes are governed by the ubiquitin-proteasome system 
The UPS is not only crucial for the clearance of damaged, aberrant proteins that escape the 
chaperone network in the cell, but it is also responsible for the turnover of short-lived proteins 
and numerous other cellular functions, including cell cycle progression and DNA repair 
pathways (Ciechanover 1998, Ciechanover 2006). The UPS plays a key role in cellular 
responses to stimuli, including stress, which require the concentrations and localisation of 




Ciechanover and Stanhill (2014)). For instance, the UPS is involved in spatiotemporal 
regulation of the levels of different transcriptional activators, coactivators and repressors that 
are required for the coordination of cellular responses to diverse stimuli. Its role in transcription 
regulation extends beyond degradative control of transcriptional activators and repressor 
concentrations (Muratani and Tansey 2003) to controlling their localisation (Hoppe et al. 2000) 
and proteolytically modulating their structure to convert them into functional states (Palombella 
et al. 1994). 
At least 38 E2 and > 600 E3 genes have now been identified in the human genome, along with 
2 E1 ubiquitin-activating enzymes, UBA1 and UBA6 (Deshaies and Joazeiro 2009, Schulman 
and Harper 2009, Ye and Rape 2009, Kaneko et al. 2016). These E1, E2 and E3 enzymes work 
in highly organised sequential enzymatic reactions to conjugate ubiquitin to specific protein 
substrates and direct their fate. The full repertoire of E1, E2 and E3 enzymes, de-ubiquitylating 
enzymes (DUBs), and the total population of ubiquitin molecules at any one time in a human 
cell is estimated to account for ~1.3% of the total cellular proteome (Kulak et al. 2014). 
Ubiquitin itself is a highly conserved, small 76-amino acid protein that is encoded by four genes 
at different loci in the genome; two polyubiquitin precursor genes, UBB, UBC, and two 
ribosomal fusion genes, UBA52 and RPS27A (Wiborg et al. 1985). UBB is comprised of head-
to-tail repeats of three ubiquitin units, UBC of nine ubiquitin units, while UBA52 and 
RPS27A/UBA80 encode ribosomal subunits that are each fused to the C terminus of a single 
ubiquitin unit. Following translation, various DUBs process the ubiquitin repeats to generate 
free ubiquitin (Monia et al. 1989, Wilkinson et al. 1995). 
Ubiquitylation serves functions beyond protein degradation via the UPS, and does so by 
circulating in different cellular ‘pools’ (Dantuma et al. 2006, Groothuis et al. 2006) at levels 
estimated to be ~8 × 107 copies, or 85 µM, in a human cell (Kaiser et al. 2011). In one of these 




monomeric entity, monoubiquitin, or as polyubiquitin chains of various topologies 
(comprehensively reviewed in Komander and Rape (2012)). ‘Activated’ ubiquitin comprises 
another pool, thioester-linked via its carboxyl terminus to a catalytic cysteine residue of an E1 
ubiquitin-activating enzyme (Haas and Rose 1982). This forms the initial step of the E1-E2-E3 
multistep enzymatic cascade that leads to the conjugation of ubiquitin to substrate proteins. 
‘Free’ ubiquitin makes up a third pool. The distribution of ubiquitin in these pools is in a 
constant state of flux as competing ubiquitin-dependent processes extract free ubiquitin, 
decreasing its availability while replenishment occurs through combinations of de novo 
ubiquitin synthesis and the actions of diverse DUBs that release conjugated ubiquitin (Monia 
et al. 1989, Wilkinson et al. 1995, Verma et al. 2002, Yao and Cohen 2002, Nijman et al. 2005). 
1.2.2.3 Ubiquitin conjugation comprises a versatile cellular signalling system 
A huge diversity of molecular processes depend on the signalling specificity provided by the 
conjugation of ubiquitin in defined linkage arrangements (Figure 1.2). In human cells, 
monoubiquitin-conjugates (Figure 1.2) account for more than 60% of the total cellular ubiquitin 
pool, with a majority of this comprised of monoubiquitylated histone H2A (Joo et al. 2007, 
Kaiser et al. 2011). Monoubiquitylation of histone H2A is required for gene silencing (de 
Napoles et al. 2004, Wang et al. 2004, Baarends et al. 2005) and changes in the ubiquitylation 
status of histone H2A are involved in cellular responses to various stressors by modulating 
expression of key genes (Carlson et al. 1987, Mimnaugh et al. 1997). Monoubiquitylation can 
mediate internalisation of cell surface receptors and regulation of their levels, and further 
regulates the activity of proteins involved in different stages of endocytosis (Terrell et al. 1998, 
Lucero et al. 2000, Nakatsu et al. 2000, Roth and Davis 2000, Katzmann et al. 2001). In 
addition, monoubiquitylation is involved in the process of enveloped viruses budding from the 
plasma membrane of infected cells (Ott et al. 1998, Harty et al. 2000, Patnaik et al. 2000, Strack 




As well as monoubiquitylation, additional ubiquitin molecules can be progressively added to 
the first conjugated ubiquitin of substrate proteins to form an extensive number of defined 
polyubiquitin chains. The diversity of polyubiquitin chains that exist are possible due to the 
seven internal lysine residues of ubiquitin (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48, Lys63), 
and in some cases the Met1 at its amino-terminus, which serve as sites for the carboxyl-terminus 
glycine residue of an additional ubiquitin to link to (Chau et al. 1989, Thrower et al. 2000, 
Dammer et al. 2011, Walczak et al. 2012). About 11% of the total ubiquitin pool is used for 
polyubiquitylation of a vast range of protein substrates (Kaiser et al. 2011). Polyubiquitin 
chains can have varying lengths, and linkages that are either homogenous throughout the chain, 
or heterogenous with changes in the Lys or Met1 residue used for each successive ubiquitin. 
The fates of proteins tagged with homogenous Lys11, Lys48 and Lys63 polyubiquitin linkages 
have been studied extensively, whereas Lys6, Lys27, Lys29 and Lys33 are less well understood 
and account for less than 1% of total cellular ubiquitin (Figure 1.2) (Peng et al. 2003, Xu et al. 
2009, Kaiser et al. 2011). Homogenous Lys48-linked chains are widely understood to be the 
main signal for proteasomal degradation, while Lys11-, Lys29- and Lys63- linkages have also 
been implicated as proteasome-targeting signals for a lower proportion of protein substrates 
(Johnson et al. 1995, Baboshina and Haas 1996, Thrower et al. 2000, Ravid and Hochstrasser 
2008, Xu et al. 2009, Kaiser et al. 2011, Kim et al. 2011). As for the targeting of substrates for 
lysosomal degradation via the autophagy pathway, both monoubiquitylation and 
polyubiquitylation with Lys63-linkages can serve as signals to adaptor proteins that link 
substrates to the autophagy machinery (Figure 1.2) (reviewed in Kirkin et al. (2009) and 






Figure 1.2. Schematic representation of the diversity of ubiquitin signals in cells. The conjugation of ubiquitin 
in defined linkage arrangements to various substrates in the cell provides unparalleled signalling specificity for 
diverse molecular processes. Ubiquitylation is an ATP-dependent process and occurs through the co-ordinated 
action of E1, E2 and E3 enzymes. Monoubiquitylation is involved in the regulation of gene silencing and the 
expression of genes involved in cellular stress responses. Monoubiquitylation also mediates endocytosis, and can 
additionally serve as a signal for selective autophagy. Beyond monoubiquitylation, additional ubiquitin molecules 
can be progressively added to form an extensive number of defined polyubiquitin chains. The diversity of 
polyubiquitin chains that exist are possible due to the seven internal lysine residues of ubiquitin (Lys6, Lys11, 
Lys27, Lys29, Lys33, Lys48, Lys63), and in some cases the Met1 at its amino-terminus. Specificity of 
polyubiquitin chain linkages is enabled through the activity of the specific E2 and E3 enzymes involved. At least 
38 E2 and > 600 E3 genes have now been identified in the human genome, along with 2 E1 ubiquitin-activating 
enzymes, UBA1 and UBA6 (Deshaies and Joazeiro 2009, Schulman and Harper 2009, Ye and Rape 2009, Kaneko 
et al. 2016). Lys48-polyubiquitin chains constitute the main signal for proteasomal degradation. Lys11-, Lys29- 
and Lys63-linkages have also been implicated as proteasome-targeting signals for a lower proportion of protein 
substrates. Lys63-polyubiquitin chains serve as a major signal to adaptor proteins that link substrates to the 
autophagy machinery. Lys6, Lys27, Lys29 and Lys33 are less well understood and account for less than 1% of 




The stunning diversity of polyubiquitin chain linkages are generated through the coordinated 
action of E1, E2 and E3 enzymes in a multistep cascade of enzymatic reactions, with specificity 




2009, Rotin and Kumar 2009, Schulman and Harper 2009, Ye and Rape 2009, Zimmerman et 
al. 2010, Budhidarmo et al. 2012, Primorac and Musacchio 2013, Berndsen and Wolberger 
2014, Spratt et al. 2014, Vittal et al. 2015). The conjugation process begins when the active site 
cysteine of an E1 ubiquitin-activating enzyme forms a thioester linkage with the carboxyl 
terminus of ubiquitin, activating the ubiquitin molecule (Haas et al. 1982) (Figure 1.2). The 
next step involves an E2 ubiquitin-conjugating enzyme with high affinity for the activated 
ubiquitin (Hershko et al. 1983, Pickart and Rose 1985). The activated ubiquitin is transferred 
to the active site cysteine of the E2 enzyme via trans-thioesterification, in coordination with 
relinquishment of the E1 enzyme (Eletr et al. 2005). Finally, linking the activated ubiquitin to 
the target substrate protein depends on the specificity provided by the E2 enzyme and its 
cognate E3 ubiquitin-ligase. E3 enzymes of the Really Interesting New Gene (RING)/U-box 
families (comprising > 600 human genes) link their associated E2 enzyme, charged with 
ubiquitin, to their specific substrate protein (Figure 1.3, a) (Deshaies and Joazeiro 2009, 
Budhidarmo et al. 2012). In contrast, ubiquitin can be transferred from the E2 enzyme to an 
active site cysteine of an E3 enzyme of the Homologous to E6-AP Carboxyl Terminus (HECT) 
family (~30 human genes) or of the RING between RING (RBR) family (~12 human genes) 






Figure 1.3. E3 ubiquitin-ligase enzymes of the RING, HECT and RBR families link ubiquitin to substrate 
proteins through different mechanisms. The conjugation of activated ubiquitin to its target substrate depends 
on the specificity provided by the E2 ubiquitin-conjugating enzyme and its cognate E3 ubiquitin-ligase enzyme. 
(A) E3 enzymes of the Really Interesting New Gene (RING)/U-box families (comprising > 600 human genes) link 
their associated E2 enzyme, charged with ubiquitin, to the specific substrate. (B) In contrast, ubiquitin can be 
transferred from the E2 enzyme to an active site cysteine of an E3 enzyme of the Homologous to E6-AP Carboxyl 
Terminus (HECT) family (~30 human genes) or of the RING between RING (RBR) family (~12 human genes). 
 
 
 Ubiquitin homeostasis and proteostasis in motor neurons: a challenging cellular 
environment 
As structurally and functionally complex post-mitotic cells, the specialised environments within 
different neuron sub-types of the central nervous system (CNS) have uniquely high demands 
for efficient ubiquitin homeostasis and overall proteostasis (Yerbury et al. 2016). While exit 
from the cell cycle is necessary for the differentiation of neurons (Herrup 2013, Anda et al. 
2016), an inherent disadvantage of the post-mitotic state is that damage caused to DNA, proteins 
and organelles that is not ameliorated through cellular repair processes accumulates throughout 
the aging process, as cells are unable to dilute damaged proteins and organelles through cell 
division (Evans et al. 2004, Akbari and Krokan 2008, Barzilai et al. 2008, Martin 2008, 
McKinnon 2009, Yerbury et al. 2016). Moreover, there have been several studies 




the perineuronal net, a specialised extracellular matrix structure in the CNS) and intrinsic 
molecular programs within most neurons largely inhibit any capacity for axon regeneration 
following injury and damage accumulation (Dou and Levine 1994, Di Giovanni 2009, Liu et 
al. 2011, Schwab and Strittmatter 2014, Carulli et al. 2016, Tedeschi and Bradke 2017).  
With their specialised structures and functions, neurons have exceptionally high ATP 
requirements (Hall et al. 2012). However, dysfunction of the organelle that drives energy 
production, the mitochondria, has been found to increase with age (Kujoth et al. 2005). In 
particular, somatic mutations in mitochondrial DNA have been extensively reported to occur in 
neurons and contribute to the pathogenesis of several neurodegenerative diseases (Linnane et 
al. 1989, Corral-Debrinski et al. 1992, Corral-Debrinski et al. 1992, Corral-Debrinski et al. 
1994, Brierley et al. 1998, Michikawa et al. 1999, Lin et al. 2002, Coskun et al. 2004, 
Kraytsberg et al. 2006). ATP is crucial for the maintenance of proteostasis and ubiquitin 
homeostasis (Yerbury et al. 2016). It is required for protein synthesis, for the activity of most 
chaperones in the human chaperome, and for ubiquitylation, thus for all downstream ubiquitin-
dependent molecular processes (Hershko et al. 1980, Haas et al. 1982, Brehme et al. 2014). 
These requirements for ATP are higher in motor neurons as these processes need to be carried 
out efficiently in the far-reaching locales of the motor neuron, from the soma, along axons 
through to synaptic terminals. Hence, an age-related decline in mitochondrial function and 
subsequent disruptions in energy metabolism increase the vulnerability of motor neurons to 
proteostasis dysfunction with increasing age (Yerbury et al. 2016).  
Recently it was discovered that the proteome of spinal motor neurons is supersaturated (i.e. the 
concentration of individual proteins is high relative to their solubility) in comparison to 
oculomotor neurons, which are resistant to degeneration in ALS (Ciryam et al. 2015, Yerbury 
et al. 2019). This suggests that the metastability of the spinal motor neuron proteome may 




the expression of a sub-network of chaperones in the human chaperome, including many ATP-
dependent chaperones, has been reported to decline with age (Brehme et al. 2014). As cells age 
their ability to activate appropriate responses to proteotoxic stress deteriorates (Ben-Zvi et al. 
2009). Together, these age-related changes are potently problematic in motor neurons 
harbouring genetic mutations, as the proteostasis network is compromised in its ability to 
manage any aberrant mutant RNA or protein species that result. Mutant RNA and protein 
species are then able to further aggravate dysfunction in the proteostasis network by 
overloading key components and disrupting their functions (Matsumoto et al. 2005, Gidalevitz 
et al. 2006, Weisberg et al. 2012). For instance, it has been postulated that genetic mutations 
that increase protein aggregation-propensity may decrease the ability of the chaperone network 
to correctly fold other proteins or direct them to degradative machinery, leading to accumulation 
of misfolded proteins (Bruijn et al. 2004).  
Deterioration of the proteostasis network in aging neurons is evident in the fact that pathological 
protein inclusions are a common feature of several different age-associated neurodegenerative 
diseases. Critically, disruption of the functioning of the UPS and of molecular chaperones (e.g. 
HSP40, HSP70) is well documented to occur in these diseases, and in some cases increasing the 
levels of components of these systems has been reported to suppress pathological protein 
aggregation (Bence et al. 2001, Cleveland and Rothstein 2001, Watanabe et al. 2001, Kim et al. 
2002, Takeuchi et al. 2002, Urushitani et al. 2002, Bruijn et al. 2004, Holmberg et al. 2004, 
Kabashi et al. 2004, Bennett et al. 2005, Yerbury et al. 2013). Indeed, the affected motor neurons 
in post-mortem spinal cord tissue from individuals with sALS and fALS universally contain 
ubiquitin-positive inclusions, providing strong evidence that the proteostasis network is 
dysfunctional in ALS; in particular, the UPS and ubiquitin homeostasis (Leigh et al. 1991). As 
will be discussed in the following section, extensive evidence indicates that many of the genetic 




 A growing list of genes are associated with ALS 
Many of the ALS-associated genes encode proteins with functional roles in the maintenance of 
proteostasis in cells, or that are aggregation-prone, or that, in their mutant form, cause 
dysfunction of components of proteostasis machinery (Table 1.1). Hence, proteostasis 
dysfunction in motor neurons may be an underlying pathogenic link between the different ALS-




Table 1.1. List of some of the ALS-associated genetic mutations and the potential mechanisms by which they lead to disruptions in cellular proteome homeostasis 
(proteostasis). 
Gene; Protein Disease 
phenotype 













Catalyses the conversion 
of superoxide radicals to 
molecular oxygen and 
hydrogen peroxide.  
21q22.11 
  
> 180 mutations. 
Most common: 
G93A; D90A; A4V; I113T; 
L144F 
Impaired molecular chaperone 
activity and UPS activity. 
Shibata et al. (1996), Bruijn et al. 
(1997), Bruening et al. (1999), Johnston 
et al. (2000), Kato et al. (2000), 
Watanabe et al. (2001), Takeuchi et al. 
(2002), Urushitani et al. (2002), Wang 
et al. (2002), Cheroni et al. (2005), 
Matsumoto et al. (2005), Cheroni et al. 










to nucleus; binds DNA 
and RNA, regulates 
transcription, mRNA 
splicing and transport. 
Assembly and regulation 
of stress granules. 
1p36.22 
 
G287S; G290A; S292N; 
G294A; G298; A315T; 
E331K; R361S; D169G; 
M337V; G348C; A382T; 
N390D; N390S 
Cytoplasmic accumulation; 
disrupted stress granule 
dynamics; disruptions in 
transcription, mRNA 
processing; disruptions in 
expression of TDP-43 and 
FUS mRNA targets. 
Neumann et al. (2006), Sreedharan et 
al. (2008), Ayala et al. (2008), Belzil et 
al. (2009), Johnson et al. (2009), 
Kwiatkowski et al. (2009), Ticozzi et 
al. (2009), Vance et al. (2009), Blair et 
al. (2010), Corrado et al. (2010), 
DeJesus-Hernandez et al. (2010), Deng 
et al. (2010), Van Langenhove et al. 
(2010), Dewey et al. (2011), Lai et al. 
(2011), Polymenidou et al. (2011), 
Sephton et al. (2011), Tollervey et al. 
(2011), Colombrita et al. (2012), 
Dichmann and Harland (2012), Ishigaki 
et al. (2012), Keller et al. (2012), 
Lagier-Tourenne et al. (2012), Rogelj et 
al. (2012), Nakaya et al. (2013). 






to nucleus; binds DNA 
and RNA, regulates 
transcription, mRNA 
splicing and transport. 
Assembly and regulation 
of stress granules. 
16p11.2 
 
H517Q; R521G; insGG; 
delGG; R244C; R514S; 
G515C; R518K; R521C; 
R521G; R521H; R522G; 






Member of the ubiquilin 
protein family; ubiquitin-
like proteins involved in 
the UPS and autophagy. 
Xp11.21 
 
P497H; P497S; P506T; 
P509S; P525S 
Impaired UPS activity and 
autophagy. 
Deng et al. (2011), Fecto et al. (2012), 







Maintenance of the Golgi 
complex; membrane 
trafficking; post-Golgi 





Deletion of exon 5;  
R96L; E478G; A481V; 
Q398X; Q165X 




accumulation of OPTN.  
Sahlender et al. (2005), del Toro et al. 
(2009), Maruyama et al. (2010), Ito et 














Localised to ER 





proteins to cytosolic 
surface of ER membranes; 
homeostatic and 




P56S ER dysfunction; 
oligomerisation and 
aggregation; dominant-
negative inhibition of wild-
type VAPB. 
Skehel et al. (2000), Nishimura et al. 
(2004a), Nishimura et al. (2004b), 
Kaiser et al. (2005), Loewen and 
Levine (2005), Teuling et al. (2007), 
Ratnaparkhi et al. (2008), Suzuki et al. 
(2009), Forrest et al. (2013), Kuijpers et 











a variety of cellular 
functions: cell signalling, 
cell cycling, organelle 
biogenesis, protein 
degradation via 





R191Q; R159G; D592N; 
R155H; I151V; I114P 
 
Impaired ERAD, UPS and 
autophagy. 
Ye et al. (2001), Watts et al. (2004), 
Weihl et al. (2007), Ju et al. (2009), 
Gitcho et al. (2009), Johnson et al. 






Multifunctional; roles in 






P392L; A33V; V153I; 
S370P; K238E; K344E; 
P348L 
Impaired UPS activity and 
autophagy; aberrant 
accumulation and aggregation 
of p62. 
Fecto et al. (2011), Teyssou et al. 
















Loss of function in autophagy; 
proteotoxicity through 
production and aberrant 
activity of dipeptide-repeat 
(DPR) proteins; disruption of 
RNA metabolism through 
production and activity of 
RNA foci. 
Todd and Paulson (2010), Hernandez et 
al. (2011), Renton et al. (2011), Mori et 
al. (2013), May et al. (2014), Peters et 
al. (2015), Haeusler et al. (2016), 







ALS Predominantly localised 
to nucleus; binds DNA 
and RNA, regulates 
transcription, mRNA 
splicing and transport. 




G391E; R408C; G473E; 
M368T; D386N; R388H; 
R395Q 
Disrupted stress granule 
dynamics; disruptions in 
transcription, mRNA 
processing. 





1.4.1 SOD1 and C9ORF72; the major genetic players? 
Mutations in the gene encoding SOD1 are among the most well studied in fALS, accounting 
for a significant proportion (20-25%) of all fALS cases (Bosco et al. 2010, Chen et al. 2013) 
and 2% of sALS cases (Pasinelli and Brown 2006). The first reports of an association between 
mutant SOD1 and ALS were published in 1993 (Deng et al., 1993; Rosen et al., 1993), and 
since then at least 180 different mutations that are associated with ALS have been identified in 
this gene, located at chromosomal locus 21q22.11 (Abel et al. 2013). Disease onset and 
progression is variable among individuals with different SOD1 mutations, and even between 
people with the same SOD1 mutation (Picher-Martel et al. 2016). The propensity of SOD1 
mutants to unfold and aggregate correlates with cellular toxicity, and it has been proposed that 
this may contribute to variation in disease severity associated with different SOD1 mutations 
(McAlary et al. 2016). The Ala4Val mutation in SOD1 (SOD1A4V) has been documented to 
present as one of the more severe forms of ALS with rapid disease progression (Cudkowicz et 
al. 1997, Juneja et al. 1997). In zebrafish ALS models, it has been found that the disease 
phenotype is most aggressive in animals injected with SOD1A4V mRNA compared to SOD1G93A 
or SOD1G37R mRNA (Lemmens et al. 2007).  
In its wild-type form (SOD1WT), SOD1 is a 32 kDa soluble cytosolic homodimeric protein, with 
one copper- and one zinc-binding site per monomer (Crapo et al. 1992, Strong et al. 2005). It 
is a highly conserved antioxidant that catalyses the conversion of superoxide radicals to 
molecular oxygen and hydrogen peroxide, protecting cells from uncontrolled reactions with 
harmful oxygen free radicals (McCord and Fridovich 1969). Of all cell types in the body it is 
found in its highest concentration within motor neurons (Bergeron et al. 1996). 
Most SOD1 mutations are dominant, and it is now widely recognised that mutations contribute 
to neurodegeneration via a toxic gain-of-function mechanism as opposed to a loss of antioxidant 




et al. 1997, Nagai et al. 2001, Howland et al. 2002, Wang et al. 2003, Jonsson et al. 2004). 
Supporting this is the finding that transgenic SOD1 knockout mice do not develop ALS 
symptoms (Reaume et al. 1996). Moreover, increased expression of SOD1WT accelerates 
disease progression (Jaarsma et al. 2000, Deng et al. 2006). Studies using conformation-
specific antibodies that are selective for misfolded SOD1WT with altered post-translational 
modifications have detected misfolded SOD1WT in sALS patients, demonstrating that SOD1WT 
is able to adopt abnormal conformations (Bosco et al. 2010, Pokrishevsky et al. 2012). 
Ubiquitylated intracellular inclusions containing detergent-insoluble protein aggregates 
immunoreactive to SOD1 are a characteristic pathological feature observed in post-mortem 
spinal cord tissue samples from SOD1-fALS patients (Shibata et al. 1996, Kato et al. 2000) as 
well as in mutant SOD1 transgenic mouse models (Bruijn et al. 1997, Johnston 2000, Watanabe 
et al. 2001, Wang et al. 2003). Interestingly, Keller et al. (2012) found that SOD1-fALS patients 
possess a unique immunohistochemical signature, including the presence of C9ORF72-positive 
inclusions. In fact, the TDP-43-positive inclusions that are a hallmark of most genetic variants 
of fALS and sALS are not found in SOD1-fALS patients or transgenic mouse models 
(Mackenzie et al. 2007).  
Beyond the presence of ubiquitin in SOD1 inclusions, there is extensive evidence indicating 
that aberrant interactions occur between mutant SOD1 and other proteostasis components. The 
first report of an effect of mutant SOD1 in modulating the activity of different molecular 
chaperones was published ~20 years ago (Bruening et al. 1999). Numerous studies have since 
documented correlations between mutant SOD1 aggregation, modulation of the activity of 
chaperones and decreases in UPS activity in neuronal cell culture and in spinal cord motor 
neurons in mouse models of SOD1-fALS (Watanabe et al. 2001, Takeuchi et al. 2002, Cheroni 
et al. 2005, Matsumoto et al. 2005, Cheroni et al. 2009, Crippa et al. 2010). Critically, the 




neurons of SOD1G93A mice than in non-motor neurons (Urushitani et al. 2002). Corroborating 
this evidence that motor neurons have a distinct vulnerability to UPS dysfunction, Onesto et al. 
(2011) observed that mutant SOD1 aggregation and UPS dysfunction occurred exclusively in 
motor neuron-like NSC-34 cells, and not in C2C12 muscle cells. Given that molecular 
chaperones and the UPS are essential for the maintenance of proteostasis and for the regulation 
of normal cellular activities, these data indicate that a potential mechanism of mutant SOD1 
neurotoxicity is through decreasing the capacity of the UPS and the chaperone network (Figure 
1.4). The increased burden on proteostasis machinery likely impairs the ability of the cell to 
correctly fold or degrade other proteins, leading to drastic disruptions in diverse molecular 








Figure 1.4. Potential pathogenic mechanisms of mutant SOD1 on the UPS and chaperone activity in motor 
neurons. Compared to other cell types, motor neurons have a distinct vulnerability to mutant SOD1-mediated UPS 
dysfunction and disruptions in the activity of molecular chaperones. (A) In motor neurons, (i) misfolded mutant 
SOD1 may overload the capacity of molecular chaperone systems, e.g. the HSP70/HSP40 system, thereby 
decreasing the capacity of these chaperone systems to fold other proteins in the cell, leading to accumulation of 
aberrant protein species. (ii) Evidence indicates that mutant SOD1 may be preferentially targeted for proteasomal 
degradation, however, this conversely may cause overloading of the UPS in motor neurons, disrupting the 
proteasomal degradation of other substrate proteins in the cell. (B) In other cell types (e.g. muscle cells, non-motor 
neurons) the expression of mutant SOD1 does not lead to disruptions in the capacity of the molecular chaperone 
systems or of the UPS.  
 
 
The most common genetic cause of ALS currently identified is a (GGGGCC)n repeat expansion 
that occurs either in the first intron or the promoter of the C9ORF72 gene on chromosome 9, 
varying depending on the transcript isoform (Beck et al. 2013). In normal, healthy individuals 
the GGGGCC hexanucleotide sequence is repeated no more than 33 times, compared to up to 
hundreds and even thousands of repeats in patients with ALS, FTD and ALS/FTD (DeJesus-
Hernandez et al. 2011, Beck et al. 2013, van der Zee et al. 2013). Hernandez et al. (2011) first 
identified this hexanucleotide expansion in a large cohort of fALS patients also exhibiting a 
FTD phenotype, as well as in a smaller percentage of sALS patients. Mutant C9ORF72 accounts 
for about 40% of fALS and 7% of sALS (Majounie et al. 2012). 
The function of C9ORF72 was elucidated over several studies in the past decade. Initially, two 
independent groups identified homology of full-length C9ORF72 with DENN (Differentially 
Expressed in Normal and Neoplasia)-domain proteins (Zhang et al. 2012, Levine et al. 2013). 
DENN-domain proteins are highly conserved GDP/GTP exchange factors (GEFs) for Rab-
GTPases, which regulate many aspects of membrane trafficking. This implicated a very 
important role for C9ORF72 in key cellular processes, including the autophagic protein 
degradation pathway. It was through the work of Webster et al. (2016) that the role of C9ORF72 
in regulating the first steps of autophagy was demonstrated. One of the major theories regarding 
the pathological role of the C9ORF72 mutation in FTD and ALS is that it leads to 




Pathogenicity of C9ORF72 mutation is also believed to result from accumulation of the non-
coding repeat expansion mRNA in the cytoplasm and nucleus, forming toxic RNA foci that 
sequester RBPs (Todd and Paulson 2010, DeJesus-Hernandez et al. 2011, Renton et al. 2011). 
RNA foci are characteristic molecular hallmarks of pathogenesis in myotonic dystrophy and 
several other neurological disorders (Wojciechowska and Krzyzosiak 2011). Additionally, ALS 
patients with the C9ORF72 mutation exhibit the characteristic intracellular inclusions of 
misfolded proteins, particularly phosphorylated TDP-43 aggregates (DeJesus-Hernandez et al. 
2011). Cytoplasmic inclusions that are unique to C9ORF72-ALS, C9ORF72-ALS/FTD and 
C9ORF72-FTD have also been reported; characteristically TDP-43-negative, p62-, ubiquitin- 
and UBQLN2-positive inclusions that contain poly-(Gly-Ala), -(Gly-Pro) and –(Gly-Arg) 
dipeptide-repeat (DPR) proteins (Mori et al. 2013, May et al. 2014).  
DPR pathology is a direct consequence of the GGGGCC hexanucleotide repeat expansion, 
through repeat-associated non-ATG-initiated (RAN) translation of this intronic repeat from 
both the sense and antisense transcripts (Ash et al. 2013, Gendron et al. 2013, Mann et al. 2013, 
Mori et al. 2013, Zu et al. 2013, May et al. 2014). Poly-(Gly-Ala) DPRs are the most abundant 
DPR species in post-mortem brain tissue from individuals with repeat expansions in C9ORF72 
(Mori et al. 2013). Proteomic analysis of poly-(Gly-Ala) aggregates has detected strong 
enrichment for p62, the proteasome subunits PSMB4, PSMB5, PSMB6, PSMC6, and PSMD13, 
several ubiquitin-related proteins, including UBQLN1 and UBQLN2, and the multifunctional 
protein UNC119 (May et al. 2014). UNC119 is required for axon development and maintenance 
and has key roles in synaptic functions (Maduro and Pilgrim 1995). UNC119 mutation in 
Caenorhabditis elegans leads to motor dysfunction (Knobel et al. 2001). It is thus possible that 
DPR aggregates contribute to neuronal dysfunction and degeneration in individuals with 
C9ORF72 repeat expansions through sequestering proteins, such as UNC119, with important 




C9ORF72 haploinsufficiency and the toxic gain-of-function mechanisms of aberrant RNA foci 
and DPRs that cause the full spectrum of pathology observed in individuals with C9ORF72 
repeat expansions (Peters et al. 2015, Haeusler et al. 2016, Chitiprolu et al. 2018). 
1.4.2 Mutations in genes involved in protein degradation pathways 
1.4.2.1 UBQLN2 mutations  
Several ALS-associated genes function in protein degradation pathways. Mutations in the 
UBQLN2 gene (chromosomal locus Xp11.21) cause X-linked fALS and ALS/FTD (Deng et al. 
2011). UBQLN2 is a member of the ubiquilin protein family, ubiquitin-like proteins that are 
involved in delivering ubiquitylated proteins to the proteasome and have roles in autophagy 
(Ko et al. 2004, Rothenberg et al. 2010). UBQLN2 has an N-terminal ubiquitin-like (UBL) 
domain that binds to the proteasome and a C-terminal ubiquitin-associated (UBA) domain that 
binds to substrate proteins. Interestingly, Deng et al. (2011) found that all the UBQLN2 
mutations (P497H, P497S, P506T, P509S and P525S) detected in patients affect proline 
residues in a unique PXX repeat region, indicating that these mutations could confer a common 
pathogenic property on the UBQLN2 protein. Through work using cell culture models, these 
researchers investigated the functional consequence of mutant UBQLN2 on ubiquitin-mediated 
protein degradation and found that protein degradation via the UPS was impaired. Moreover, 
mutations in UBQLN2 have been found to cause impaired autophagy (Fecto et al. 2012, 
Teyssou et al. 2017). Such disruptions to degradative pathways, which are crucial for 
proteostasis, could contribute significantly to further proteostasis disruptions and the 
accumulation and aggregation of aberrant proteins in the cell. 
Examining post-mortem spinal cord sections from two fALS patients with a P497H or P506T 
mutation, Deng et al. (2011) observed skein-like inclusions that were immunoreactive to two 
types of UBQLN2 antibodies. These same inclusions were also immunoreactive for p62, TDP-




inclusions in other types of ALS. Of note, these inclusions were not found to contain SOD1. 
UBQLN2 was also detected in the skein-like inclusions observed in a broad spectrum of ALS 
cases; sporadic and familial forms of ALS, including those caused by either SOD1 or TARDBP 
mutations, and ALS/FTD (Deng et al. 2011).  This common association of UBQLN2 with 
inclusions indicates that it could have important roles in ALS and ALS/FTD caused by 
mutations in different genes.  
1.4.2.2 SQSTM1 mutations 
Mutations in SQSTM1, encoding another ubiquitin-binding protein, p62, have been reported in 
fALS, sALS and FTD (Fecto et al. 2011, Rubino et al. 2012, Teyssou et al. 2013). P62 is a 
multifunctional protein with particularly important roles in proteasomal and autophagic protein 
degradation (Seibenhener et al. 2004, Bjorkoy et al. 2006). The involvement of p62 in 
neurodegeneration is becoming increasingly apparent, with p62-immunoreactive inclusions a 
common pathological feature in many neurodegenerative diseases including AD, PD, HD, FTD 
as well as in the motor neurons of ALS patients (Kuusisto et al. 2002, Zatloukal et al. 2002, 
Nakaso et al. 2004, Mizuno et al. 2006, Pikkarainen et al. 2008). It is often detected co-localised 
with TDP-43 and ubiquitin in the inclusions of ALS and FTD patients (Hiji et al. 2008, Deng 
et al. 2010, Keller et al. 2012, Teyssou et al. 2013). 
The mutations that have been identified in ALS and FTD patients are distributed throughout 
the whole protein, but most affect amino acids that are highly conserved in mammals, and that 
are in different functional domains important for protein-protein interactions. For instance, 
several mutations have been found in its UBA domain, affecting the binding of p62 to ubiquitin 
and ubiquitylated proteins (Fecto et al. 2011, Teyssou et al. 2013). Both proteasomal and 
autophagic protein degradation may be severely impeded in such variants. Indeed, some 
mutations (e.g. K344E) have been detected in a region of the protein that interacts with LC3, a 




impede the autophagic pathway (Rubino et al. 2012). As well as a loss-of-function mechanism 
contributing to disease, mutations may lead to a toxic gain-of-function through dysregulation 
of the cell signalling pathways in which p62 has key roles. For example, several mutations 
affect the PEST (proline-, glutamic acid-, serine-, threonine-enriched) domain, which forms a 
signal peptide important for degradation of p62 and thus for regulating p62 protein levels (Fecto 
et al. 2011). Such altered levels of p62 may lead to both accumulation and aggregation of 
misfolded p62 and disturbance of the signalling pathways regulated by this protein. Given the 
common presence of p62 pathology in several neurodegenerative diseases, it is likely that it is 
fundamentally involved in the pathogenesis of these diseases, potentially through disruption of 
its functions in proteostasis. 
1.4.2.3 VCP mutations 
Mutations in VCP have been identified in patients suffering from a spectrum of 
neurodegenerative disorders including inclusion body myopathy with Paget disease of bone 
(PDB) and/or FTD (IBMPFD) (Weihl et al. 2009).  An exome sequencing study revealed that 
VCP mutations were causal in a cohort of fALS cases, and that mutations in this gene may 
account for ~1-2% of fALS cases (Johnson et al. 2010). Mutations in VCP lead to TDP-43-
immunoreactive, ubiquitylated cytoplasmic inclusions in muscle and frontal cortex neurons of 
patients (Watts et al. 2004, Weihl et al. 2008) and in transgenic mouse models harbouring the 
R155H and A232E mutations (Weihl et al. 2007, Badadani et al. 2010, Custer et al. 2010). A 
novel mutation in VCP, I114P, has also been detected in sALS (Koppers et al. 2012), though 
the pathogenicity of this variant is yet to be confirmed. This same study detected inclusions 
positive for p62, ubiquitin and TDP-43, and confirmed the VCP-ALS frequency of ~1-2% 
found in the exome sequencing study.  
VCP is a highly conserved AAA+-ATPase, involved in the regulation of a variety of cellular 




protein degradation via autophagy, the UPS, and the endoplasmic reticulum-associated 
degradation (ERAD) pathway; VCP provides mechanical force for extracting substrates from 
the ER membrane (Ye et al. 2001, Johnson et al. 2010, Meyer et al. 2012). In autophagy, VCP 
is essential for maturation of ubiquitin-containing autophagosomes. The VCP mutations 
identified in ALS and IBMPFD interestingly all occur in the N-terminal region of the protein, 
which functions in binding polyubiquitylated proteins (Watts et al. 2004, Johnson et al. 2010). 
Studies of mutant VCP using cell culture and transgenic mouse models has shown that loss of 
VCP activity impairs autophagy; specifically, autophagosomes fail to mature into 
autophagolysosomes, leading to the accumulation of non-degradative autophagosomes and 
aggregated proteins (Ju et al. 2009). Moreover, mutations in VCP have been found to lead to 
impaired proteasome activity, endoplasmic reticulum (ER) stress and activation of apoptosis 
signalling pathways (Gitcho et al. 2009). It is conceivable that the functions of VCP in protein 
degradation are disrupted in VCP-fALS, and that these disruptions lead to the accumulation and 
aggregation of ubiquitylated proteins in motor neurons.  
1.4.2.4 OPTN mutations 
Maruyama et al. (2010) reported the first findings of mutations in the OPTN gene in fALS 
patients, the product of which has been detected in inclusions within post-mortem spinal cord 
tissue from individuals with fALS and sALS, co-localised with ubiquitin, TDP-43, FUS and 
SOD1 in different cases (Maruyama et al. 2010, Ito and Suzuki 2011, Keller et al. 2012). OPTN 
is a multifunctional protein involved in maintenance of the Golgi apparatus and post-Golgi 
trafficking to the cell surface and to lysosomes through its interactions with huntingtin, Rab8 
and myosin VI (Sahlender et al. 2005, del Toro et al. 2009). It may also have a role in regulating 
its own expression, as an inhibitor of the activation of nuclear factor kappa B (NF-κB), which 
mediates upregulation of OPTN (Zhu et al. 2007, Mrowka et al. 2008). 




as well as in other fALS variants, such as C9ORF72 repeat expansion carriers and those with 
mutations in TARDBP, FUS and in individuals with sALS (Maruyama et al. 2010, Keller et al. 
2012), indicates a broad role for OPTN in the pathogenic mechanisms of ALS. Moreover, 
OPTN has been detected in the inclusion bodies characteristic of a wide range of 
neurodegenerative diseases including AD, PD and Creutzfeldt-Jakob disease (CJD) (Osawa et 
al. 2011) and mutations have been implicated in primary open angle glaucoma (POAG), a 
neurodegenerative eye disease (Rezaie et al. 2002). This suggests that OPTN could contribute 
to neurodegeneration in these diseases via common pathogenic pathways. Two of the mutations 
in OPTN, a Q398X nonsense mutation and a homozygous deletion of exon 5 (Ex5del), result 
in a loss-of-function phenotype, disturbing Golgi organisation and regulation, and post-Golgi 
transport. Indeed, depletion of OPTN through RNA interference has been shown to result in 
Golgi disorganisation and reduced post-Golgi transport (Sahlender et al. 2005). As with 
SQSTM1-, VCP- and UBQLN2-fALS cases, mutations in OPTN potentially cause impairment 
of autophagy; mutations in OPTN and disruptions of its functions would lead to altered 
trafficking of lysosomal proteins from the Golgi, causing disruptions in lysosomal function. 
The glutamic acid residue substituted in the E478G mutation is highly conserved among OPTN 
proteins of a wide range of species and occurs in the ubiquitin-binding domain of the protein 
that mediates its interaction with NF-κB (Maruyama et al. 2010). Consistent with the 
observation that OPTN-immunoreactivity in tissue from a patient with the E478G mutation is 
increased, the E478G mutation potentially causes upregulation of OPTN through overactive 
NF-κB activity. While the initial pathological mechanisms caused by these mutations differ, 
their downstream effects converge in disrupting proteostasis, through dysfunction of OPTN in 
protein degradation, or through increasing the levels of an aberrant mutant form of OPTN. It is 
also conceivable that aggregation of OPTN results in loss of soluble protein from the cell, and 




1.4.2.5 VAPB mutations 
In 2004 a new chromosomal locus (20q13.3) was identified for an atypical form of ALS, ALS8 
(Nishimura et al. 2004), and subsequently a novel missense mutation, P56S, was found in the 
gene encoding VAPB (Nishimura et al. 2004). VAPB belongs to a family of ubiquitously 
expressed, type II integral membrane VAP proteins that localise to the ER membrane and pre-
Golgi intermediates (Skehel et al. 2000), and are involved in non-vesicular transfer of lipids, 
membrane trafficking, regulating ER-organelle and ER-cytoskeleton interactions, transport and 
secretion, as well as homeostatic and signalling functions at the neuromuscular junction 
(Soussan et al. 1999, Foster et al. 2000, Amarilio et al. 2005, Lev et al. 2008, De Vos et al. 
2012, Han et al. 2012, Manford et al. 2012). The VAP protein family also target lipid-binding 
proteins carrying a short motif containing two phenylalanines in an acidic tract (FFAT motif). 
Recognising the FFAT motif, VAPs then recruit them to the cytosolic surface of ER membranes 
(Kaiser et al. 2005, Loewen and Levine 2005). Mammalian species have two VAP proteins; 
VAPA and VAPB (Nishimura et al. 1999). 
Several mutations in VAPB have now been identified in people with ALS, however the P56S 
mutation is the only one currently known to co-segregate with ALS (Nishimura et al. 2004, 
Kabashi et al. 2013). In vitro and in vivo this mutation causes VAPB to oligomerise, aggregate 
and accumulate in inclusions (Nishimura et al. 2004, Teuling et al. 2007, Tudor et al. 2010, 
Kuijpers et al. 2013, Qiu et al. 2013). Interestingly, Teuling et al. (2007) found that mutant 
VAPBP56S aggregates are continuous with the ER, possibly through interactions between the 
transmembrane domains of the mutant VAPB proteins with VAPBWT still anchored to the ER 
membrane. Furthermore, by trapping endogenous VAPBWT in mutant aggregates and reducing 
cytosolic VAPB levels, this interaction impairs the normal function of VAPB. The hypothesis 
of a dominant-negative mechanism of action of mutant VAPB in disease is supported by other 




(Ratnaparkhi et al. 2008, Suzuki et al. 2009, Forrest et al. 2013, Kuijpers et al. 2013). 
Moreover, Teuling et al. (2007) reported that VAPA and VAPB levels are reduced in the spinal 
cord motor neurons of ALS patients, in contrast to the normally abundant levels of these 
proteins in the CNS of healthy individuals not affected by ALS, particularly in motor neurons. 
The relatively high lipid metabolism and lipid transport requirements of large, complex motor 
neurons makes them particularly vulnerable to reduced VAP function caused by mutation. 
Golgi disassembly has been shown to result from abnormal lipid metabolism (Fukunaga et al. 
2000, Gonatas et al. 2006). The disruption of intracellular transport and membrane trafficking 
caused by reduced VAPB activity and abnormal lipid metabolism may additionally affect 
autophagy.  
Strikingly, findings made in work by Kuijpers et al. (2013) suggest a novel mechanism in motor 
neurons that may enable them to cope with mutant VAPB levels that exceed the capacity of the 
normal quality control pathways. They reported on extensive data that support a hypothesis in 
which mutant VAPB inclusions represent a specialised ER-associated protein quality control 
compartment, reminiscent of aggresomes, that isolates misfolded and aggregated VAPB from 
the rest of the ER. Moreover, these researchers showed that mutant VAPB inclusions in 
VAPBP56S transgenic mice were reversible ER-associated structures that were enriched in 
factors that operate in the ERAD pathway (VCP, Derlin-1 and BAP31), the presence of which 
was not associated with signs of motor neuron degeneration (Kuijpers et al. 2013). The lack of 
neuronal pathology in these mice may be due to effective sequestration and clearance of mutant 
VAPB in this novel protective compartment, preventing its aberrant accumulation and 
interaction with VAPBWT.  
1.4.3 DNA/RNA-binding proteins in ALS 
The role of aberrant RNA metabolism in ALS pathogenesis first came to light with the 




inclusions in sALS, which comprises the majority (~90%) of all ALS cases (Neumann et al. 
2006). It was also found to be the major constituent of inclusions in MAPT-negative FTD 
patients, providing the first biochemical evidence of a molecular link between ALS and FTD 
(Arai et al. 2006, Neumann et al. 2006). Subsequently, mutations were identified in a highly 
conserved region of the TARDBP gene in both fALS and sALS patients (Sreedharan et al. 
2008), as well as ALS/FTD and FTD patients (Borroni et al. 2009, Gitcho et al. 2009, Andersen 
and Al-Chalabi 2011). Shortly following this, mutations in FUS, encoding another D/RBP, 
were detected in ~4-5% of fALS patients (Kwiatkowski et al. 2009, Vance et al. 2009). 
Mutations in FUS have also been identified in sALS and FTD patients (Belzil et al. 2009, 
Ticozzi et al. 2009, Blair et al. 2010, Corrado et al. 2010, DeJesus-Hernandez et al. 2010, Deng 
et al. 2010, Van Langenhove et al. 2010, Lai et al. 2011), and intraneuronal inclusions 
containing FUS are reported to occur in the brain and spinal cord of both familial and sporadic 
ALS and FTD patients (Kwiatkowski et al. 2009, Neumann et al. 2009, Neumann et al. 2009, 
Vance et al. 2009, Keller et al. 2012). Moreover, TDP-43 and FUS mislocalisation and 
pathology have been observed in several neurodegenerative disorders; both are implicated in 
polyglutamine disorders (Schwab et al. 2008, Doi et al. 2010), while TDP-43 pathology is also 
observed in AD and other forms of dementia, PD and various myopathies (Forman et al. 2007, 
Chen-Plotkin et al. 2010, Lagier-Tourenne et al. 2010). 
TDP-43 and FUS are structurally and functionally related heterogeneous nuclear 
ribonucleoproteins (hnRNPs), both with roles in transcription regulation, pre-mRNA splicing, 
mRNA stabilisation and RNA transport (Buratti et al. 2001, Buratti et al. 2004, Mercado et al. 
2005, Strong et al. 2007, Colombrita et al. 2009). Indeed, TDP-43 and FUS each have several 
thousand mRNA targets (Hoell et al. 2011, Polymenidou et al. 2011, Tollervey et al. 2011). 
Both proteins contain RNA recognition motifs (RRM), a nuclear localisation signal (NLS) and 




Buratti et al. 2005, Neumann et al. 2006, Lagier-Tourenne and Cleveland 2009, Cushman et al. 
2010, Gitler and Shorter 2011, Udan and Baloh 2011). This functional and structural similarity 
led Couthouis et al. (2011) to screen for additional prion-like domain-containing D/RBPs that 
may contribute to ALS pathogenesis, through which they identified mutations in TAF15 in 
fALS patients. A separate study also detected TAF15 mutations in fALS patients (Ticozzi et al. 
2011), and TAF15-positive intraneuronal inclusions are present within TAF15-fALS patients 
(Couthouis et al. 2011), findings that underscore a role for aberrant RNA metabolism in ALS. 
Although predominantly localised to the nucleus, TDP-43 shuttles between the nucleus and 
cytoplasm in a transcription-dependent manner (Ayala et al. 2008). In the cytoplasm, TDP-43 
has been found to have distinct functions, including mRNA stabilisation and translation (Wang 
et al. 2008) and the formation and regulation of stress granules (Colombrita et al. 2009, Liu-
Yesucevitz et al. 2010, Dewey et al. 2011, McDonald et al. 2011, Bentmann et al. 2012). Stress 
granules (SGs) are punctate cytoplasmic foci, ranging in size from 0.1 to 2.0 µm, that sequester 
mRNA and ribosomal components to regulate translation and prioritise the synthesis of stress 
protective proteins in response to stressors, e.g. oxidative stress, heat shock, proteasome 
inhibition and other forms of cellular injury (Anderson and Kedersha 2009, Moisse et al. 2009, 
Moisse et al. 2009). SGs are transient structures; when the cellular stress has passed, SGs 
rapidly disaggregate, enabling their components to return to their normal localisation and 
function (Kedersha et al. 1999). 
As with TDP-43, both FUS and TAF15 are predominantly nuclear proteins that have additional 
cytoplasmic functions, such as mRNA transport, local translation and RNA decay, and they 
incorporate into SGs (Fujii et al. 2005, Yoshimura et al. 2006, Andersson et al. 2008, 
Blechingberg et al. 2012). FUS and TAF15 are part of the FET (FUS, EWS, TAF15) family of 
structurally and functionally related D/RBPs (Tan and Manley 2009). These two proteins 




domains of both proteins, which contain RGG repeats and a zinc finger domain, mediate SG 
recruitment (Bentmann et al. 2012, Marko et al. 2012). 
The key mechanisms by which these D/RBPs contribute to disease are not yet clear, although 
the fact that TDP-43 and FUS pathology occur in a wide variety of diseases is strong indication 
for an important pathogenic role of altered RNA metabolism. Nuclear import defects and 
cytoplasmic accumulation seem to be important events in both FUS- and TARDBP-linked ALS, 
and possibly in TAF15-linked disease. Most of the ALS-associated mutations in FUS are 
clustered within its C-terminal NLS, and multiple studies have shown a correlation between 
mutations that cause a severe cytoplasmic accumulation and a greater disease severity and 
progression rate (Kwiatkowski et al. 2009, Dormann et al. 2010, Gal et al. 2011, Niu et al. 
2012). Mutations in the GRR of TARDBP, which constitute the majority of disease-linked 
mutations, have been shown to cause a progressive shift of TDP-43 localisation to the 
cytoplasm (Ayala et al. 2008, Johnson et al. 2009), and the cytoplasmic accumulation of TDP-
43 has been shown to be toxic to neurons (Barmada et al. 2010). The GRR is also necessary for 
its association with SGs, and GRR mutations cause altered SG dynamics (Dewey et al. 2011).  
Increased sequestration of TDP-43, FUS, TAF15 and other D/RBPs in cytoplasmic SGs 
interferes with their dynamic nucleus-cytoplasm shuttling, reducing levels of these proteins in 
the nucleus and their functional availability in the cytoplasm. Furthermore, the accumulation of 
TDP-43 into cytoplasmic inclusions that is characteristic of ALS, FTD, AD, PD and various 
myopathies (Forman et al. 2007, Schwab et al. 2008, Chen-Plotkin et al. 2010, Doi et al. 2010, 
Lagier-Tourenne et al. 2010) further depletes the functional pool of TDP-43 in neurons. The 
aggregation of TDP-43 into cytoplasmic inclusions in ALS may be triggered by cellular insult 
resulting from defective autophagic or UPS protein degradation, suggested by the recurrent 
finding that ubiquitin and p62 are co-localised in TDP-43-positive inclusions (Mizuno et al. 




model, disease-causing mutations in VCP were found to cause significant redistribution of 
TDP-43 to the cytoplasm, and this redistribution was sufficient to cause cytotoxicity (Ritson et 
al. 2010). It is entirely possible that the key roles of VCP in autophagy and ubiquitin-dependent 
segregation of substrates from multiprotein complexes, e.g. SGs, would be hindered in cases in 
which it is mutated, thus causing impaired recycling of TDP-43 from SGs back to the nucleus.  
Many of the mRNA targets of TDP-43 and FUS are crucial for normal neuronal function 
(Polymenidou et al. 2011, Sephton et al. 2011, Tollervey et al. 2011, Colombrita et al. 2012, 
Dichmann and Harland 2012, Ishigaki et al. 2012, Lagier-Tourenne et al. 2012, Rogelj et al. 
2012, Nakaya et al. 2013). Moreover, TDP-43 deficiency has been found to affect the levels of 
mRNAs encoding CHMP2B, FIG, OPTN, VAPB and VCP, all of which are implicated in ALS 
and have key roles in protein degradation pathways (Polymenidou et al. 2011). Another target 
of TDP-43 is the mRNA encoding ATG7, an autophagy-related protein (Bose et al. 2011). FUS 
has also been reported to bind to mRNAs encoding ALS-associated OPTN, VAPB, VCP and 
UBQLN2, as well as mRNAs encoding other proteins involved in the UPS (Hoell et al. 2011, 
Colombrita et al. 2012, Lagier-Tourenne et al. 2012). It is thus conceivable that abnormalities 
in mRNA splicing and processing resulting from dysregulation of TDP-43 and/or FUS lead to 
innumerable disturbances in neurons. Indeed, both deficiency and overexpression of WT and 
mutant forms of TDP-43 promote cytotoxicity, and it is intrinsically aggregation-prone in its 
WT form (Johnson et al. 2009, Laird et al. 2010, Liachko et al. 2010, Armakola et al. 2011, 
Huang et al. 2012, Uchida et al. 2012). Cytoplasmic accumulations of TDP-43, FUS or TAF15 
may aberrantly sequester RNAs and/or other proteins (Voigt et al. 2010, Hoell et al. 2011), 
causing further dysfunction in cellular RNA metabolism and disruptions in the activities of the 
affected proteins. 
The possible role of mutant TDP-43 in the disruption of proteostasis can also be extended to 




al. (2008) found that abnormal TDP-43 cytoplasmic immunoreactivity was associated with 
impaired functioning of the Golgi apparatus, leading to Golgi fragmentation. It is unknown 
whether errors in mRNA metabolism are responsible for this impairment. The Golgi apparatus 
has numerous important functions in maintaining proteostasis, including post-translational 
modification of proteins and protein trafficking. 
 ALS gene variants may converge in proteostasis dysfunction 
Inclusion bodies containing visible accumulations of detergent-insoluble protein aggregates are 
a pathological hallmark of many neurodegenerative disorders including AD, PD, HD and CJD 
(Leigh et al. 1991, Chiti and Dobson 2006, Ticozzi et al. 2010), and ALS, in both sporadic and 
familial cases (Gurney et al. 1994, Wong et al. 1995, Bruijn et al. 1997, Bruijn et al. 1998, 
Watanabe et al. 2001, Boillee et al. 2006). Generally, specific aggregating proteins are 
implicated in each of these neurodegenerative diseases; α-synuclein in PD, huntingtin in HD, 
Aβ and tau in AD (Ilieva et al. 2009). In ALS, however, the situation appears to be more 
complex, with a multitude of different proteins being detected in the inclusion bodies inside 
affected motor neurons (Migheli et al. 1993, Okamoto et al. 1993, Buee-Scherrer et al. 1995, 
Wong et al. 2000, Arai et al. 2006, Mizuno et al. 2006, Neumann et al. 2006, Fujita et al. 2008, 
Maruyama et al. 2010, Deng et al. 2011). In fact, a number of morphologically different types 
of inclusions are found in ALS motor neurons, including: filamentous skeins, dense hyaline 
bodies, and round or conglomerate Lewy body-like forms (Leigh et al. 1991); Bunina bodies 
(Okamoto et al. 1993, Strong et al. 2005); basophilic inclusions (Nelson and Prensky 1972, 
Oda et al. 1978, Chou 1979); and spheroids (Leigh et al. 1991). Intra- and extraneuronal tau-
immunoreactive aggregates have also been detected in a subgroup of ALS patients exhibiting 
features of FTD and cognitive decline (Yang et al. 2003), although the exact prevalence of these 
aggregates is yet to be determined.  




exceeds their solubility (Chiti and Dobson 2006). Yet proteins have co-evolved with their 
cellular environments to exist at optimal functional concentrations at which their solubility is 
near compromised (Tartaglia et al. 2007, Ciryam et al. 2013, Ciryam et al. 2015), seemingly 
making them vulnerable to precipitation in the face of changes to their environment. In order 
to prevent such changes to protein solubility, the cell must be able to actively maintain 
proteostasis, keeping cellular proteins in their correct conformation, concentration and location 
(Balch et al. 2008). Proteins can accumulate in the cell and form inclusions when these 
mechanisms maintaining proteostasis are compromised, or their capacity is exceeded (Yerbury 
and Kumita 2010, Gidalevitz et al. 2011, Yerbury et al. 2013). Conversely, as mentioned in 
section 1.2.2.1, aberrant protein species can be sequestered into inclusions that function as 
protein quality control compartments when proteostasis is compromised or capacity is 
exceeded, in a cellular response to protect against abnormal interactions of aberrant proteins 
with other molecules and macromolecular complexes within the cells (Johnston et al. 1998, 
Kopito 2000, Arrasate et al. 2004, Kaganovich et al. 2008, Treusch et al. 2009, Zhang and Qian 
2011, Weisberg et al. 2012, Polling et al. 2014).  
As cells age, the efficacy of proteostasis mechanisms declines (Balch et al. 2008, Ben-Zvi et 
al. 2009, Brehme et al. 2014). It is postulated that aging, proteostasis and neurodegenerative 
disease are closely linked (Morimoto 2008, Wyatt et al. 2013, Yerbury et al. 2016), explaining 
why most neurodegenerative diseases, including ALS, are late-onset, with most forms 
developing during middle-age and in later years (Derham and Harding 1997, Zhang et al. 2004, 
Erickson et al. 2006, Massey et al. 2006). Importantly, motor neurons have been shown to be 
particularly vulnerable to disruptions in proteostasis and to other stressful stimuli, including 
proteotoxic stress induced by aggregated proteins, even in comparison with other cells of the 





The common occurrence of ubiquitylated protein inclusions inside the diseased motor neurons 
of ALS patients harbouring a multitude of different genetic mutations leads to the hypothesis 
that altered proteostasis in motor neurons is a critical underlying cause of ALS (Figure 1.5). 
Investigating how mutations in the identified ALS-associated genes lead to dysfunction of 
proteostasis and the responses of motor neurons to these events will greatly increase our 











Figure 1.5. Summary of potential mechanisms by which ALS-associated gene variants cause proteostasis 
dysfunction in motor neurons. Oligomeric or aggregated mutant SOD1 sequesters molecular chaperones, 
ubiquitin and proteasome subunits, interfering with chaperone activity and the UPS. Mutations in C9ORF72 may 
lead to haploinsufficiency and thereby disruptions in C9ORF72 function in autophagy. C9ORF72 mutations also 
result in the production of toxic RNA foci and dipeptide repeat proteins (DPRs). RNA foci sequester RNA-binding 
proteins (RBPs), disrupting their functions while DPRs may aberrantly interact with and sequester different cellular 
components, including proteasome subunits. Mutations in UBQLN2 and SQSTM1 (encoding p62) impair their 
functions in autophagy and in delivering ubiquitylated proteins to the proteasome for degradation. VCP is involved 
in protein degradation via autophagy, the UPS, and the endoplasmic reticulum-associated degradation (ERAD) 
pathway. Loss of VCP activity from ALS-associated mutations leads to impaired delivery of ubiquitylated proteins 
to the proteasome, disruptions in ERAD and failure of autophagosomes to mature into autophagolysosomes. 
Mutations in OPTN impair the functions of OPTN in Golgi organisation and post-Golgi transport, leading to Golgi 
disorganisation and fragmentation. Impaired OPTN activity potentially leads to altered delivery of ubiquitylated 
cargo to autophagosomes and disrupted trafficking of lysosomal proteins from the Golgi, causing disruptions in 
lysosomal function and autophagy. Mutations in VAPB are hypothesised to cause dominant-negative impairment 
of wild-type VAPB; aggregates formed by mutant VAPB interact aberrantly with and sequester wild-type VAPB. 
Consequently, impaired VAPB activity leads to disruptions in ER function, ER-Golgi transport and membrane 
trafficking. Mutations in the DNA/RNA-binding proteins TARDBP (encoding TDP-43), FUS and TAF15 cause 
disruptions in transcription, mRNA splicing and processing, mRNA transport and altered stress granule dynamics. 
Moreover, mutations in TARDBP and FUS lead to disruptions in the expression of the mRNA targets of TDP-43 










































 Studying dysregulation of proteostasis in ALS models: Summary and aims  
Amongst the complexity and molecular heterogeneity of ALS, previous studies have identified 
disruptions in the proteostasis network that are associated with certain ALS gene variants. 
However, there remains a need to identify the exact proteostasis disruptions that are commonly 
associated with each of the ALS-causing genetic mutations, and those that are unique to each 
gene variant. It is hypothesised that dysfunction of the proteostasis network in motor neurons 
may be an underlying link between the different ALS-associated gene variants that contributes 
to motor neuron degeneration in ALS. As such, the overall objective of this PhD research was 
to develop and employ novel experimental strategies that enable investigation of the effects of 
different ALS-associated gene variants on common proteostasis components and processes. 
Such approaches may facilitate identification of the proteostasis components that have key roles 
in ALS pathogenesis, and thereby lead to the elucidation of potential therapeutic targets. To 
achieve this objective, the specific aims of this work were to: 
1. Establish a high-throughput screening system using Saccharomyces cerevisiae to model 
pathological TDP-43 and FUS aggregation, and ALS-associated mutant SOD1. 
2.  Use this S. cerevisiae model to examine the effects of pathological TDP-43, FUS and 
SOD1 on common proteostasis components and processes. 
3. Validate the relevance of key proteostasis components identified in the S. cerevisiae 
screens using neuronal cell culture models of ALS. 
4. Establish a high-content screening (HCS) system that can be used to investigate 
proteostasis dysfunction in neuronal cell culture models of multiple different ALS-



















































This chapter outlines the general materials and methods used in the research detailed 
throughout this thesis. Additional materials and methods that pertain specifically to the work 
detailed in Chapters III – V are provided in the relevant chapters. 
 Materials and reagents  
All media and buffers used in this research were prepared using Milli-Q water (Q-POD® 
Ultrapure Water Remote Dispenser, Millipore, Billerica, MA, USA). 
Ethylenediaminetetraacetic acid (EDTA) and tryptone were from Amresco (Solon, USA). 
HyperLadder™ I and HyperLadder™ II molecular weight markers were from Bioline 
(Alexandria, NSW, Australia). Mini-PROTEAN® TGX™ Precast Protein Gels, Precision Plus 
Protein™ Dual Color protein standards and sodium dodecyl sulphate (SDS) were from Bio-
Rad (Hercules, CA, USA). Foetal Bovine Serum (heat-inactivated prior to use; FBS) was from 
Bovogen Biologicals (East Keilor, VIC, Australia). Sterile cell culture plates were from Greiner 
Bio-One (Frickenhausen, Germany). Β-mercaptoethanol, bicinchoninic acid disodium salt 
hydrate (bicinchoninic acid, BCA), bovine serum albumin (BSA), Brilliant Blue R concentrate, 
copper sulphate pentahydrate (CuSO4.5H2O), dimethyl sulfoxide (DMSO), magnesium 
chloride (MgCl2), methanol, paraformaldehyde (PFA), potassium chloride (KCl), sodium 
chloride (NaCl), Tris-hydrochloride (Tris-HCl), tris(hydroxymethyl)aminomethane, Triton X-
100, Tween® 20 (polyethylene glycol sorbitan monolaurate) and yeast extract were from 
Sigma-Aldrich (St. Louis, MO, USA). Dulbecco’s Modified Eagles Medium with nutrient 
mixture F-12 powder (DMEM/F-12) supplemented with 2.5 mM L-glutamine, DMEM/F-12 
without phenol red supplemented with 2.5 mM L-glutamine, Halt™ Protease Inhibitor Cocktail 
(100X), Lipofectamine® 2000 and 3000, OptiMEM® I (1X) reduced serum medium, 
SuperSignal™ West Pico chemiluminescent substrate, 0.05% trypsin-EDTA were all obtained 
from Thermo Fisher Scientific (Waltham, MA, USA). All other reagents were from Amresco, 





The pEGFP-N1 expression vector containing human wild-type SOD1 (SOD1WT-EGFP) and 
SOD1 altered by the disease-associated Ala4Val (A4V) mutation (SOD1A4V-EGFP) were 
kindly provided by Assoc. Prof. Bradley Turner (The Florey Institute of Neuroscience & 
Mental Health, Victoria, Australia) and had been constructed as previously described (Turner 
et al. 2005). Both the SOD1-EGFP vectors and the pCMV6-AC-tGFP vector containing human 
wild-type TARDBP (TDP-43WT-tGFP) and the disease-associated mutant M337V (TDP-
43M337V-tGFP) (OriGene, Maryland, USA) had previously been transformed into chemically 
competent Escherichia coli (E. coli) DH5-α cells and were stored in glycerol at -80 °C prior to 
plasmid DNA purification. The identity of these stocks had been confirmed by sequencing 
(Jake Matic, 2012, personal communication). Additional plasmids used in the research 
presented in Chapters III – V are detailed in the relevant chapters. 
 Transformation of E. coli and plasmid DNA purification 
The subcloning procedures used throughout the research presented in Chapters III and V used 
the DH5-α E. coli strain. Chemically-competent DH5-α cells had kindly been previously 
prepared using calcium chloride-treatment by Dr. Luke McAlary (University of Wollongong, 
NSW, Australia). To transform cells using the heat-shock protocol, 100 µL of chemically-
competent DH5-α cells were gently mixed with 10 ng of plasmid DNA and incubated on ice 
for 30 min. Cells were then heat-shocked at 42 °C for 45 sec and immediately transferred to 
ice to incubate for 5 min. Cells were then diluted with 500 µL of Super Optimal Broth with 
Catabolite repression (SOC; 0.5% (w/v) yeast extract, 2% (w/v) tryptone, 10 mM NaCl, 2.5 
mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose) and incubated for 1 h at 37 °C with 
agitation (190 rpm). Aliquots of 100 µL and 300 µL of transformation cultures were then plated 
onto pre-warmed sterile selective Luria-Bertani (LB)-agar plates (LB [1% (w/v) tryptone, 1% 




antibiotic; either 100 µg/mL ampicillin, or 50 µg/mL kanamycin) and incubated overnight at 
37 °C. Successfully transformed single bacterial colonies were selected and used to inoculate 
sterile selective LB broth containing the appropriate antibiotic, for plasmid purification using 
the CompactPrep Plasmid Maxi Kit (Qiagen, Hilden, Germany) as per the manufacturer’s 
protocol. To confirm the purity of extracted plasmid DNA following the purification procedure 
and measure its concentration, the ratio of absorbance at 260 nm and 280 nm (A260/A280 ratio) 
and concentration (A260) were measured using a NanoDrop 2000c dual-mode UV-Vis 
Spectrophotometer (Thermo Fisher Scientific, Waltham, USA).  
Samples of extracted plasmid DNA were examined using diagnostic restriction enzyme 
digestion with the appropriate restriction enzymes. Digested plasmid DNA samples were then 
prepared for agarose gel electrophoresis by mixing samples with DNA loading buffer (30% 
(v/v) glycerol, 0.25% (w/v) bromophenol blue) and resolved by electrophoresis on 1% (w/v) 
agarose gels in tris-acetate-EDTA (TAE) buffer (1 mM EDTA, 40 mM Tris and 20 mM acetic 
acid) alongside HyperLadder™ I (200 – 10037 bp) or HyperLadder™ II (50 – 2000 bp) 
molecular weight markers, as appropriate for each digested DNA sample. Following 
electrophoresis, agarose gels were stained with 0.005% (w/v) ethidium bromide solution for 20 
min and destained in dH2O for 20 min. The resulting stained DNA bands within the gels were 
visualised using UV light exposure in a Gel Logic 2200 Pro Imaging System (Carestream 
Health, Rochester, NY, USA). 
 Preparation of glycerol stocks of transformed E. coli 
Glycerol stocks of successfully transformed DH5-α E. coli were prepared for the long-term 
storage of plasmid DNA at -80 °C. Selected single colonies of DH5-α E. coli transformed with 
each respective plasmid construct were used to inoculate 5 mL aliquots of LB broth 
supplemented with the appropriate antibiotic (either 100 µg/mL ampicillin, or 50 µg/mL 




mL of each overnight culture was mixed with 1 mL of sterile glycerol in cryovials for storage 
at -80 °C. 
 Mammalian cell culture 
The M. musculus neuroblastoma × spinal cord hybrid cell line (NSC-34) was supplied by Prof. 
Neil Cashman (University of British Columbia, Vancouver, Canada) (Cashman et al. 1992). 
NSC-34 cells were maintained in a routinely serviced 37 °C Heracell 150i incubator with 
humidified air containing 5% (v/v) carbon dioxide (CO2). DMEM/F-12 supplemented with 
10% (v/v) FBS (DMEM/F-12/FBS) was used for regular culturing of cells. Cells were passaged 
once they reached ~80% confluence, usually every 3 days. This involved rinsing the adherent 
cells with a small volume of serum-free DMEM/F-12 before incubating them with 0.05% 
trypsin-EDTA for 3 min at 37 °C. Cells were then collected by centrifugation at 1,500 rpm for 
5 min at room temperature, followed by resuspension in DMEM/F-12/FBS and transfer of a 
suitable volume of resuspended cells to a sterile cell culture flask to achieve an appropriate 
dilution, usually a 1:6 dilution. Plasmid DNA transfections in NSC-34 cells performed in the 
experiments outlined in Chapters III and V are detailed in the relevant sections of each chapter. 
 Statistics 
Results presented throughout Chapters III – V are the mean ± SEM of three independent 
experiments, unless otherwise indicated. To analyse and compare differences in means in 
experiments involving multiple treatments, one-way analysis of variance (ANOVA) tests were 
used, paired with post hoc testing using Tukey’s multiple comparison test. Otherwise, Student’s 
t tests were used to evaluate differences in means. Unless stated otherwise, statistical analyses 
were performed using GraphPad Prism® (Version 5.00, GraphPad Software, Inc., La Jolla, 
CA, USA). A significance level of p < 0.05 was used to define differences between means as 
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Chapter 3: Yeast EGFP-fusion library screens 
reveal differential levels of ALS-associated proteins 
in yeast expressing TDP-43, FUS and SOD1 
 
The research in this chapter was carried out in collaboration with Professor Stephen G. 
Oliver and Dr. Giorgio Favrin as part of a 12 month stay in the S. G. Oliver laboratory at 


















The budding yeast Saccharomyces cerevisiae has become an established robust model for 
investigating mechanisms involved in several neurodegenerative diseases, including PD, HD, 
AD and ALS (Krobitsch and Lindquist 2000, Auluck et al. 2002, Outeiro and Lindquist 2003, 
Willingham et al. 2003, Cooper et al. 2006, Johnson et al. 2008, Gitler et al. 2009, Johnson et 
al. 2009, Elden et al. 2010, Sun et al. 2011, Treusch et al. 2011, Kim et al. 2014). The yeast 
genome is well characterised and many key molecular processes are conserved between yeast 
and higher eukaryotic organisms, including humans. Almost a third of yeast genes have a direct 
human orthologue (Botstein et al. 1997). Indeed, key pathways that are disrupted in 
neurodegenerative diseases, such as protein folding and other protein quality control 
mechanisms, are fundamental features of eukaryotic biology that are conserved across the 
spectrum of eukaryotic organisms. As such, yeast provide an ideal starting point to screen for 
genes and proteins that aberrantly or advantageously interact with neurodegenerative disease 
genes, with findings that can then be validated in neurologically relevant cellular and animal 
models (Elden et al. 2010, Couthouis et al. 2011, Sun et al. 2011, Kim et al. 2014). Methods 
to overexpress or knock out every yeast gene are well established. The development of 
Synthetic genetic array (SGA) methodology (Baryshnikova et al. 2010) has facilitated the study 
of genes and their associated pathways that are affected by or modify the effects of disease-
associated genes (Yuen et al. 2007, Deshpande et al. 2013, van Pel et al. 2013, Bian et al. 
2014). Such studies provide valuable insight into disease mechanisms at the genetic level. 
However, key post-transcriptional, translational and post-translational information can be 
missed without investigation at the protein level. 
For the present study, a collection of yeast EGFP-fusion strains (Huh et al. 2003) was employed 
to develop a yeast screening system to explore proteins and molecular pathways that may be 




collection was created by the integration of an EGFP at the C-terminus of the genomic locus 
of each yeast gene, preserving the natural promoter of each gene to facilitate minimal 
perturbation in the levels and activity of each encoded protein. Previously, most studies 
utilising this collection have investigated the localisation of proteins and their alterations under 
stress conditions using fluorescence microscopy (Huh et al. 2003, Breker et al. 2013, Breker 
et al. 2014). The use of a fluorescent plate reader to quantify the expression of the yeast EGFP-
fusion proteins under different conditions has only recently emerged (Lichten et al. 2014). In 
the face of extrinsic or intrinsic stimuli that disturb cellular homeostasis, cells respond by up-
regulating proteins that assist in maintaining a homeostatic state and down-regulating proteins 
that impair the cellular ability to appropriately respond to the disturbance (Beyer et al. 2004, 
Newman et al. 2006, Sigal et al. 2006, Erjavec et al. 2007, Sigal et al. 2007, Aragon et al. 
2009, Frenkel-Morgenstern et al. 2010, Eden et al. 2011, Lee et al. 2011, Tkach et al. 2012, 
Breker et al. 2013). Consequently, the measurement of protein abundance changes in cells 
exposed to different stressors, such as the overexpression of disease-causing gene variants, can 
provide insight into the proteins and molecular processes involved in the cellular response to 
the specific stress. It was thus hypothesised that proteins found to have differential levels in 
yeast expressing human TDP-43, FUS and mutant SOD1 may be critically involved in the 
response of cells to these aberrant ALS-associated proteins.  
There are no true homologues of TDP-43 and FUS in yeast (Johnson et al. 2008, Ju et al. 2011). 
In previously described yeast models, the expression of human TDP-43WT and FUSWT without 
the need for ALS specific mutation recapitulates key pathological features observed in human 
tissue, mammalian cell culture and animal models. These features include a shift from 
predominantly nuclear localisation to cytoplasmic sequestration and aggregation, and toxicity 
(Johnson et al. 2008, Johnson et al. 2009, Fushimi et al. 2011, Ju et al. 2011, Kryndushkin et 




studies of neurodegenerative disease mechanisms have gone on to be validated in 
neurologically relevant cellular and animal models, as well as in human tissue (Couthouis et 
al. 2011, Couthouis et al. 2012, Kim et al. 2014). For instance, findings from a yeast genome-
wide screen were followed up using Drosophila melanogaster and mammalian cell culture 
models of ALS and led to the discovery that dysfunction in SG dynamics contributes 
significantly to toxicity caused by a pathological interaction between TDP-43 and ataxin-2 
(Kim et al. 2014). Indeed, these findings from yeast led to the discovery of genetic association 
between ataxin-2 and ALS, clearly demonstrating the relevance of yeast as a model system.  
Furthermore, examining the findings from this yeast-based study in D. melanogaster led to the 
discovery of a protein that is critical for the pathological TDP-43-ataxin-2 interaction, 
polyadenylate-binding protein (PABP), and that this protein is present in cytoplasmic 
inclusions in post-mortem spinal cord tissue from individuals with ALS (Kim et al. 2014). 
Many of the early yeast-based studies into neurodegenerative disease mechanisms, and the 
correlation of the reported findings with those documented in mammalian cell culture and 
animal models, have been thoroughly reviewed elsewhere (Outeiro and Muchowski 2004). 
As reviewed in Chapter I, while the mechanisms that have been postulated to contribute to ALS 
pathogenesis are diverse, many of them link either directly or indirectly to disruptions in the 
proteostasis network. There remains a need to further dissect these links to proteostasis 
dysfunction and to decipher precisely how this dysfunction proceeds with regard to the cellular 
response to ALS-causing pathological proteins. One way to gain such insight is to focus on the 
molecular processes that have been implicated in ALS pathogenesis, including molecular 
processes that are part of the proteostasis network, and examine whether any specific protein 
components of these processes are differentially regulated in cells expressing ALS-causing 
gene variants. Thus, to investigate the specific proteins that are involved in the cellular response 




described in this chapter were to:  
(i) collate a list of proteins involved in molecular processes that have been previously 
implicated in ALS pathogenesis and  
(ii) using the EGFP-fusion yeast library, determine whether the levels of these proteins 
are altered by the expression of the ALS-associated proteins TDP-43WT, FUSWT, 
SOD1WT and mutant SOD1A4V.  
It was hypothesised that some of these proteostasis-associated proteins will have differential 
expression in the absence versus presence of TDP-43, FUS and mutant SOD1 and that these 
will represent proteins with key roles in the cellular response to ALS-linked pathology.  
 Materials and methods 
3.2.1 Materials and reagents 
Bacto™ agar, Bacto™ peptone, Bacto™ tryptone and Bacto™ yeast extract were from BD 
Biosciences (Becton, Dickinson and Co., San Jose, CA, USA). Sterile 384-well flat-bottom 
µclear microplates and sterile 96-well flat-bottom crystal-clear microplates were from Greiner 
Bio-One (Frickenhausen, Germany). Agarose (molecular biology grade, electrophoresis 
grade), glycine and tris(hydroxymethyl)aminomethane were from Melford (Suffolk, UK). The 
E.Z.N.A.® Plasmid DNA Mini Kit I was from Omega Bio-Tek, Inc. (Norcross, GA, USA). 
The QIAquick® Gel Extraction Kit was from Qiagen (Hilden, Germany). D-(+)-galactose, D-
(+)-glucose, D-(+)-raffinose pentahydrate, glass beads (acid-washed), L-glutamic acid 
monosodium salt hydrate, L-leucine, uracil and yeast nitrogen base without amino acids (YNB) 
were from Sigma-Aldrich (St. Louis, MO, USA). Glycerol and sodium chloride (NaCl) were 
from Thermo Fisher Scientific (Waltham, MA, USA). 
3.2.2 Advanced Gateway® Cloning, plasmids and yeast transformation 




into the pAG416GAL-ccdB-DsRed vector using the Advanced Gateway® BP and LR 
recombination reactions, as per the manufacturer’s instructions (Figure 3.1, a). In order to carry 
out the BP recombination reaction, site-specific attachment (attB) sites were first added to the 
5’ and 3’ ends of the ORFs of SOD1WT and SOD1A4V in pEGFP-N1. PCR primers were 
designed to add attB sites and isolate the SOD1WT and SOD1A4V ORFs from the backbone 
sequence (Table 3.1). Manufacturing of the primers was outsourced to Sigma-Aldrich (UK). 
The PCR procedure was carried out using VELOCITY DNA polymerase (Bioline, UK) as per 
the manufacturer’s instructions. Following PCR, each reaction mixture was digested with 5 
units of DpnI (New England BioLabs® Inc., MA, USA) at 37 °C for 1 h to remove any 
remnants of the original plasmids. 
Table 3.1. PCR primer sequences used to add attB sites to SOD1WT and SOD1A4V in pEGFP-N1. 
Gene/vector 
backbone 




To add attB1 and attB2 sites to 
the 5’ and 3’ ends of the SOD1 












To purify the PCR products from the reaction mixture, 50 µL of each reaction mixture was 
mixed with 10 µL of 6× DNA loading dye and subjected to agarose gel electrophoresis. DNA 
bands corresponding to human SOD1WT and SOD1A4V flanked with attB sites were then excised 
from the agarose gel and purified using the QIAquick® Gel Extraction Kit (Qiagen, Hilden, 
Germany). The purified attB-SOD1WT and attB-SOD1A4V PCR products were sub-cloned into 




manufacturer’s instructions but with the following modifications to scale down volumes: 0.4 
µL of 5× BP Clonase™, 0.4 µL of 5× BP Clonase™ Reaction Buffer, 30 ng of pDONR™221, 
30 ng of either attB-SOD1WT , attB-SOD1A4V PCR product or pEXP7-tet (positive control) and 
TE buffer (pH 8.0) to a final volume of 2 µL, for a 1 h reaction at 25 °C. The reaction mixtures 
were then treated with 0.2 µL of Proteinase K. The resulting pDONR™221-SOD1WT, 
pDONR™221-SOD1A4V and positive control were then transformed into chemically-
competent TOP10 E. coli using the heat-shock transformation protocol and incubated overnight 
at 37 °C on LB agar plates supplemented with 50 µg/mL kanamycin. The following day, 3 
single colonies from each transformation plate were picked and streaked onto new LB agar-
kanamycin plates followed by overnight incubation at 37 °C. Single colonies were isolated and 
used to inoculate 2.5 mL of LB broth containing 50 µg/mL kanamycin for overnight incubation 
at 37 °C with agitation. 
Since the expression of human TDP-43WT and FUSWT in yeast recapitulates key pathological 
features observed in human tissue, mammalian cell culture and animal models, these were used 
to transform yeast rather than specific ALS-associated mutant isoforms of these genes. The 
expression of SOD1WT in yeast, on the other hand, has no effect on the viability of yeast cells, 
and serves as a suitable control to yeast strains expressing ALS-associated SOD1 mutations 
(e.g. A4V and G93A) (Gunther et al. 2004, Bastow et al. 2016). Human TDP-43WT and FUSWT 
in pDONR™221 (previously prepared by Dr. Daniel Bean, University of Cambridge, UK), and 
SOD1WT and SOD1A4V in pDONR™221 were sub-cloned into the pAG416GAL-ccdB-DsRed 
vector using the Advanced Gateway® LR recombination reaction, as per the manufacturer’s 
instructions but with the following modifications to scale down volumes: 0.4 µL of 5× LR 
Clonase™ II, 30 ng of the Entry Clone (pDONR™221 containing TDP-43 or FUS) and of the 
Destination Vector (pAG416GAL-ccdB-DsRed), and TE buffer (pH 8.0) to a final volume of 




Proteinase K. The resulting pAG416GAL-TDP-43WT-DsRed, pAG416GAL-FUSWT-DsRed, 
pAG416GAL-SOD1WT-DsRed and pAG416GAL-SOD1A4V-DsRed expression clones were 
then transformed into chemically-competent TOP10 E. coli using the heat-shock 
transformation protocol. Plasmid DNA from successfully transformed single colonies was then 
extracted from bacterial cells using the E. Z. N. A. Plasmid DNA Mini Kit I (VWR 
International, Omega Bio-Tek, Inc., GA, USA) as per the manufacturer’s instructions. 
Extracted plasmid DNA was then subject to restriction enzyme digestion and agarose gel 
electrophoresis to verify that the recombinant plasmids had the correct backbone and insert 
size. Colonies identified to contain the correct plasmid DNA were then used to prepare glycerol 
stocks. Briefly, 2.5 mL aliquots of LB containing the appropriate antibiotic were inoculated 
with the selected colonies and incubated overnight at 37 °C with agitation. The following day 
these cultures were then diluted 1:1 with sterile 50% (v/v) glycerol solution and stored in sterile 
cryogenic tubes at -80 °C for long-term storage. 
3.2.3 Yeast strains, transformation, media and culturing 
Yeast were cultured at 30 °C unless otherwise indicated. The haploid MATα strain of 
Saccharomyces cerevisiae, Y7039 (MATα can1Δ::STE2pr-LEU2 lyp1Δ his3Δ1 leu2Δ0 ura3Δ0 
LYS2+), was a gift from Prof. Charles Boone (University of Toronto, Canada). Y7039 cells 
were grown in rich media (yeast extract-peptone-dextrose; YPD; 1% (w/v) yeast extract, 2% 
(w/v) peptone, 2% (w/v) glucose) or in synthetic medium lacking leucine (0.67% (w/v) yeast 
nitrogen base without amino acids, 0.0109% (w/v) adenine, 0.00725% (w/v) uracil, 0.00725% 
(w/v) inositol, 0.000725% (w/v) para-aminobenzoic acid, 0.00725% (w/v) alanine, 0.00725% 
(w/v) arginine, 0.00725% (w/v) asparagine, 0.00725% (w/v) aspartic acid, 0.00725% (w/v) 
cysteine, 0.00725% (w/v) glutamic acid, 0.00725% (w/v) glutamine, 0.00725% (w/v) glycine, 
0.00725% (w/v) histidine, 0.00725% (w/v) isoleucine, 0.00725% (w/v) lysine, 0.00725% (w/v) 




0.00725% (w/v) threonine, 0.00725% (w/v) tryptophan, 0.00725% (w/v) tyrosine and 
0.00725% (w/v) valine) containing 2% (w/v) glucose (SD/-Leu), 2% (w/v) raffinose (SRaf/-
Leu), or 2% (w/v) galactose (SGal/-Leu).  
Cultures of Y7039 were transformed with the pAG416GAL-TDP-43WT-DsRed, pAG416GAL-
FUSWT-DsRed, pAG416GAL-SOD1WT-DsRed, pAG416GAL-SOD1A4V-DsRed and 
pAG416GAL-ccdB-DsRed constructs using the PEG/lithium acetate method to create four 
query strains and a control strain (Ito et al. 1983) (Figure 3.1, b). The pAG416GAL-ccdB-
DsRed vector contains the URA3 selectable marker and enables growth of transformed cells 
on media lacking uracil. The Y7039 cultures transformed with pAG416GAL-TDP-43WT-
DsRed, pAG416GAL-FUSWT-DsRed, pAG416GAL-SOD1WT-DsRed, pAG416GAL-
SOD1A4V-DsRed or the pAG416GAL-ccdB-DsRed vector were grown in synthetic medium 
lacking leucine and uracil, supplemented with 2% (w/v) glucose (SD/-Leu/Ura), 2% (w/v) 
raffinose (SRaf/-Leu/Ura, or 2% (w/v) galactose (SGal/-Leu/Ura). 
The yeast EGFP-fusion collection (Huh et al. 2003) was grown on solid synthetic medium 
lacking histidine (0.67% (w/v) yeast nitrogen base without amino acids, 0.0109% (w/v) 
adenine, 0.00725% (w/v) uracil, 0.00725% (w/v) inositol, 0.000725% (w/v) para-
aminobenzoic acid, 0.00725% (w/v) alanine, 0.00725% (w/v) arginine, 0.00725% (w/v) 
asparagine, 0.00725% (w/v) aspartic acid, 0.00725% (w/v) cysteine, 0.00725% (w/v) glutamic 
acid, 0.00725% (w/v) glutamine, 0.00725% (w/v) glycine, 0.00725% (w/v) isoleucine, 0.036% 
(w/v) leucine, 0.00725% (w/v) lysine, 0.00725% (w/v) methionine, 0.00725% (w/v) 
phenylalanine, 0.00725% (w/v) proline, 0.00725% (w/v) serine, 0.00725% (w/v) threonine, 
0.00725% (w/v) tryptophan, 0.00725% (w/v) tyrosine and 0.00725% (w/v) valine) containing 
2% (w/v) glucose, 2% (w/v) agar and supplemented with 100 µg/mL ampicillin (SD/-His + 
Amp) in PlusPlates (Singer instruments, Somerset, UK). Single colonies from the 17× 384-




extension of the ROTOR™ High-throughput Microbial Array Pinning Robot (Singer 
Instruments, Somerset, UK) and inoculated onto new PlusPlates to prepare 4× 96-colony-dense 
plates of customised arrays. 
To prepare glycerol stocks of the full yeast EGFP-fusion collection and of the custom arrays, 
the ROTOR™ was used to pin colonies from agar plates to 96-well plates containing 140 
µL/well of SD/-His broth. Plates were incubated overnight at 30 °C with agitation. The 
following day the cultures in each well were diluted with 60 µL of sterile 80% (v/v) glycerol 
solution. Wells were sealed using pre-cut sheets of sterile multi-well plate sealing film and 
stored at -80 °C for long-term storage.  
3.2.4 Yeast mating procedure 
The yeast mating procedure is illustrated schematically in Figure 3.1, c. Single colonies of 
Y7039 transformed with either pAG416GAL-TDP-43WT-DsRed (GALTDP-43WT-DsRed), 
pAG416GAL-FUSWT-DsRed (GALFUSWT-DsRed), pAG416GAL-SOD1WT-DsRed 
(GALSOD1WT-DsRed), pAG416GAL-SOD1A4V-DsRed (GALSOD1A4V-DsRed) or 
pAG416GAL-ccdB-DsRed (GALDsRedempty; vector control) were inoculated into 10 mL of 
SD/-Leu/Ura and grown overnight at 30 °C with agitation. The following morning the 
overnight cultures were diluted into 30 mL of SD/-Leu/Ura and pinned in 96-colony density 
format to PlusPlates containing YPD using the ROTOR™, 4 plates per query strain. The pinned 
query strains were then grown for 48 h at 30 °C. 
Each query strain and the control strain were crossed to an ordered 96-colony-dense array of a 
selection of 128 haploid MATa strains from the EGFP-fusion collection of yeast strains. Each 
EGFP-fusion ORF in this collection is tagged with the S. pombe his5+ gene which allows 
growth on medium lacking histidine. The resulting heterozygous diploid strains were selected 




supplemented with 2% (w/v) glucose (SD) – His/Ura), for 48 h at 30 °C (Figure 3.1, d). 
Glycerol stocks of the diploid strains were prepared using the ROTOR™ to pin colonies from 
agar plates to 96-well plates containing 140 µL/well of SD/-His/Ura broth. Plates were 
incubated overnight at 30 °C with agitation. The following day the cultures in each well were 
diluted with 60 µL of sterile 80% (v/v) glycerol solution. Wells were sealed using pre-cut sheets 
































Figure 3.1. Schematic representation of the generation of SOD1WT-DsRed, SOD1A4V-DsRed, TDP-43WT-
DsRed and FUSWT-DsRed yeast query strains, mating with the yeast EGFP-fusion collection and diploid 
selection in preparation for screening experiments. (A) Human wild-type TDP-43 (TDP-43WT), FUSWT, 
SOD1WT and SOD1A4V were cloned from a mammalian expression vector into pAG416GAL-ccdB-DsRed using 
the Advanced Gateway® cloning system. (B) The resulting galactose-inducible pAG416GAL-TDP-43WT-DsRed, 
pAG416GAL-FUSWT-DsRed, pAG416GAL-SOD1WT-DsRed, pAG416GAL-SOD1A4V-DsRed and 
pAG416GAL-ccdB-DsRed (vector control) expression clones were transformed into the haploid MATα yeast 
strain Y7039 to create four query strains and a control strain. (C) Each query strain and the control strain were 
crossed to an ordered array of a selection of 128 haploid MATa strains from the EGFP-fusion collection of yeast 
strains (Huh et al. 2003). The EGFP-fusion strains were selected based on involvement in conserved proteostasis 
pathways, other pathways suspected to be involved in ALS pathogenesis as well as the yeast orthologues of human 
proteins that have been found colocalised in inclusions in ALS patients’ motor neurons. Each EGFP-fusion ORF 
is tagged with the S. pombe his5+ gene and allows growth on medium lacking histidine. (D) The resulting 
heterozygous diploid strains were selected by growing the cells on solid (agar) synthetic medium lacking histidine 
and uracil (synthetic dextrose (SD) – His/Ura).  
 
 
3.2.5 Spotting assays 
Single colonies of the haploid MATα yeast query strains, generated through transformation of 
Y7039 with pAG416GAL-TDP-43WT-DsRed (GALTDP-43WT-DsRed), pAG416GAL-FUSWT-
DsRed (GALFUSWT-DsRed), pAG416GAL-SOD1WT-DsRed (GALSOD1WT-DsRed), 
pAG416GAL-SOD1A4V-DsRed (GALSOD1A4V-DsRed) or pAG416GAL-ccdB-DsRed 
(GALDsRedempty; vector control) and grown on SD/-Ura agar plates, were picked and used to 
inoculate 10 mL of SD/-Ura broth. Following overnight incubation at 30 °C with agitation, 125 
µL of each culture was diluted into 2.5 mL of SRaf/-Ura broth and grown overnight at 30 °C 
with agitation. The following day this dilution procedure was repeated for a second night of 
growth in SRaf/-Ura broth. Cultures were then normalised for OD600, serial diluted, spotted 
onto SD/-Ura or SGal/-Ura and incubated at 30 °C for 48 h. The incubated plates were then 
scanned using a standard HP® scanner, and the sizes of the resulting colonies were 
qualitatively examined for the diameter and density of yeast growth. 
Spotting assays were also carried out following mating of haploid yeast query strains with 
haploid MATa strains from the EGFP fusion collection of yeast strains, and consequent diploid 
selection. The resulting diploid strains were prepared for spotting assays using the procedure 
above, with the exception that SD/-His/Ura, SRaf/-His/Ura, and SGal/-His/Ura selective media 




Query strains and diploid strains were grown in either galactose-supplemented media to induce 
expression of DsRed-tagged FUSWT, TDP-43WT, SOD1WT, SOD1A4V or DsRed alone, or in 
glucose-supplemented media to control for differences in growth between strains that were not 
caused by expression of the DsRed-fusion genes. 
3.2.6 DeltaVision OMX™ super resolution fluorescence microscopy 
To characterise the localisation of TDP-43WT-DsRed, FUSWT-DsRed, SOD1WT-DsRed and 
SOD1A4V-DsRed and the EGFP fusion proteins in diploid strains, the fluorescent proteins were 
examined in cells using a DeltaVision OMX™ super resolution microscope (GE Healthcare 
Life Sciences, Marlborough, MA, USA). Super resolution microscopy was necessary for these 
experiments due to the size of the yeast cells; conventional microscopy would not provide the 
resolution needed to examine the intracellular localisation patterns of the EGFP-fusion 
proteins. To validate the use of diploid GALDsRedempty strains as control strains and to establish 
the baseline cellular levels of the EGFP-fusion proteins screened, it was crucial to ensure that 
the localisation of the EGFP-fusion proteins in the GALDsRedempty strains were comparable to 
the localisation patterns previously reported for growth in control conditions (Huh et al. 2003, 
Breker et al. 2013, Breker et al. 2014). Time limitations prevented the microscopic examination 
of all diploid strains used in the present work, thus only several strains were selected for 
microscopy. To microscopically examine a variety of localisation patterns, strains were 
selected to include EGFP-fusion proteins that have been reported to be localised to different 
macromolecular structures, organelles and to the cytosol. Slides were prepared for microscopy 
by placing flat agarose pads of 1 cm diameter, made of SGal/-His/Ura containing 1.5% (w/v) 
agarose, into the centre of each slide. To prepare diploid strains for microscopy, individual 
colonies on 96-colony-dense SD/-His/Ura plates were picked and used to inoculate 2.5 mL of 
SRaf/-His/Ura broth to grow overnight at 30 °C with agitation. The following day, 125 µL of 




agitation. Following this second night of growth in SRaf/-His/Ura broth, 125 µL of each culture 
was diluted into 2.5 mL of SGal/-His/Ura broth and grown overnight at 30 °C with agitation to 
induce expression of GALTDP-43WT-DsRed, GALFUSWT-DsRed, GALSOD1WT-DsRed, 
GALSOD1A4V-DsRed or GALDsRedempty. In the later rounds of microscopy, in which diploid 
BMH1-EGFP, RPL40A-EGFP, RPN10-EGFP, TRS23-EGFP, MDJ1-EGFP, MGE1-EGFP, 
PUB1-EGFP, XRN1-EGFP and UFD4-EGFP strains were imaged, cells were counterstained 
with 0.8 µg/mL DAPI in PBS for 30 min at room temperature, followed by two washes in PBS 
(each wash involved centrifugation of cells at 1,000 × g followed by resuspension in 1 mL of 
PBS), centrifugation at 1,000 × g and resuspension in 1 mL of fresh SGal/-His/Ura broth. 
Resuspended cells from each culture (5 µL) was then pipetted onto SGal/-His/Ura agarose pads 
on prepared slides. Imaging was carried out using the 100× oil-immersion objective lens, with 
EGFP fluorescence excited at 488 nm and DsRed fluorescence excited at 568 nm using 
optically pumped, frequency-doubled vertical external cavity surface emitting lasers 
(VECSELs). The localisation of the EGFP-fusion yeast proteins observed through microscopy 
was compared with the localisation data documented on the Yeast GFP Fusion Localisation 
Database (YGFLD) [https://yeastgfp.yeastgenome.org/ - (Huh et al. 2003)], the LoQAtE 
database (Breker et al. 2013, Breker et al. 2014), the UniProt Database and the Saccharomyces 
Genome Database (SGD). 
It should be noted that for diploid RPL40A-EGFP, RPN10-EGFP, TRS23-EGFP, MDJ1-
EGFP, MGE1-EGFP, PUB1-EGFP, UFD4-EGFP and XRN1-EGFP strains, time restrictions 
prevented the microscopic examination of all five corresponding diploid strains 
(GALDsRedempty, GALTDP-43WT-DsRed, GALFUSWT-DsRed, GALSOD1WT-DsRed and 
GALSOD1A4V-DsRed). However, the corresponding diploid EGFP-fusion/GALDsRedempty strain 
was included as a control for microscopic examination of each diploid EGFP-fusion/GALTDP-




fusion/GALSOD1A4V-DsRed strain, for comparisons of protein localisation patterns. Time 
limitations prevented the repetition of microscopy of each diploid strain, and thus the images 
presented and the observations described in the Results section are representative of n = 1 
experiment. 
3.2.7 Measurement of EGFP-fusion protein levels in diploid yeast strains 
The methods used to measure levels of EGFP-fusion proteins in diploid strains is illustrated 
schematically in Figure 3.2. Each 96-colony-dense plate of diploid strains was pinned in 
quadruplicate to a 384-well microtitre plate containing 100 µL per well of SRaf/-His/Ura using 
the ROTOR™ and grown overnight at 30 °C with agitation (Figure 3.2, a). The following day 
the 100 µL overnight cultures were pinned to black-walled 384-well µclear plates containing 
100 µL per well of SGal/-His/Ura to induce expression of GALTDP-43WT-DsRed, GALFUSWT-
DsRed, GALSOD1WT-DsRed, GALSOD1A4V-DsRed or GALDsRedempty. The absorbance (optical 
density [OD] at 600 nm), EGFP (excitation 485/12 nm, emission collected at 510/20 nm) and 
DsRed (excitation 580/10 nm, emission collected at 612 nm) fluorescence were then measured 
in each plate of cells over 48 h using a FLUOstar® Optima plate reader (BMG LABTECH, 










Figure 3.2. Schematic representation of the analysis workflow used to identify yeast EGFP-fusion proteins 
with altered levels in yeast expressing human SOD1WT-DsRed, SOD1A4V-DsRed, TDP-43WT-DsRed and 
FUSWT-DsRed. (A) Each 96-colony-dense plate of diploid strains was pinned in quadruplicate to a 384-well 
microtitre plate containing SRaf/-His/Ura using the ROTOR™ and grown overnight at 30 °C with agitation. The 
following day the overnight cultures were pinned to black-walled 384-well µclear plates containing SGal/-His/Ura 
to induce expression of GALTDP-43WT-DsRed, GALFUSWT-DsRed, GALSOD1WT-DsRed, GALSOD1A4V-DsRed or 
GALDsRedempty (DsRed alone). (B) The absorbance (optical density [OD] at 600 nm), EGFP (excitation 485/12 nm, 
emission collected at 510/20 nm) and DsRed (excitation 580/10 nm, emission collected at 612 nm) fluorescence 
were then measured in each plate of cells over 48 h using a FLUOstar® Optima plate reader. (C) The EGFP 
fluorescence intensity (F.I.) measured at 485 nm in each well of cells was normalised to the absorbance at each 
time point to account for cell density in each well. The normalised EGFP values were used in subsequent analyses 
to calculate yield of EGFP-fusion protein levels in cells expressing GALTDP-43WT-DsRed, GALFUSWT-DsRed, 
GALSOD1WT-DsRed or GALSOD1A4V-DsRed relative to control cells expressing GALDsRedempty. Custom R scripts 
were used to analyse the normalised EGFP F.I. values over the 48 h assay period. Calculations of the yield of 
EGFP-fusion protein levels were based on the difference in normalised EGFP from mid-exponential growth phase 
to stationary phase (monitored by the OD at 600 nm), when EGFP F.I. reached a maximum. (D) T tests were 
carried out using a custom R script to determine the difference (fold change) in EGFP-fusion protein levels in 
strains expressing GALTDP-43WT-DsRed, GALFUSWT-DsRed, GALSOD1WT-DsRed or GALSOD1A4V-DsRed 
compared to strains expressing GALDsRedempty.  (E) Strains exhibiting a significant differential in EGFP-fusion 
protein levels (p < 0.05) were selected for repeat screening. EGFP-fusion proteins were ranked as having 
differential levels in GALTDP-43WT-DsRed, GALFUSWT-DsRed, GALSOD1WT-DsRed or GALSOD1A4V-DsRed strains 
based on those exhibiting both a fold change in EGFP-fusion protein levels of > 0.075 (arbitrary cut-off value) 
and p < 0.05 relative to control GALDsRedempty strains. In the case of GALSOD1A4V-DsRed, ‘hits’ were selected 
based on those exhibiting differential protein levels only in strains expressing GALSOD1A4V-DsRed but not in 
strains expressing GALSOD1WT-DsRed. 
 
 
3.2.8 Analysis of EGFP-fusion protein levels 
Analyses of EGFP-fusion protein levels measured in each diploid strain are illustrated 
schematically in Figure 3.2, c, d and e. R statistical computing software, Microsoft® Office 
Excel and Graphpad Prism 5 (GraphPad Software Inc., La Jolla, CA, USA) were used for 
subsequent data analyses. The EGFP fluorescence intensity (F.I.) (excitation 485/12 nm, 
emission collected at 510/20 nm) measured in each well was normalised to the absorbance at 
600 nm at each time point using Microsoft® Office Excel in order to account for cell density 
in each well. Normalisation involved dividing the EGFP F.I. value by the absorbance at each 
time point. The normalised EGFP values were used in subsequent analyses in R to calculate 
yield and fold change in EGFP-fusion protein levels in cells expressing GALTDP-43WT-DsRed, 
GALFUSWT-DsRed, GALSOD1WT-DsRed or GALSOD1A4V-DsRed relative to control cells 
expressing GALDsRedempty (DsRed alone). Custom R scripts (Appendix I) were originally 
written by Dr. Daniel Bean (University of Cambridge, UK) for analyses of yeast growth curves 




over the 48 h assay period. Calculations of the yield of EGFP-fusion protein levels were based 
on the difference in normalised EGFP from mid-exponential growth phase to stationary phase, 
when EGFP F.I. reached a maximum. T tests were carried out using a custom R script 
(Appendix I) originally written by Ms Anastasiya Pachyna (University of Cambridge, UK) and 
modified in the present work to determine the difference (fold change; ΔF) in EGFP-fusion 
protein levels in strains expressing GALTDP-43WT-DsRed, GALFUSWT-DsRed, GALSOD1WT-
DsRed or GALSOD1A4V-DsRed compared to strains expressing GALDsRedempty (DsRed alone), 
across two replicates per strain.  Strains exhibiting a significant change in EGFP-fusion protein 
levels (p < 0.05) were selected for repeat screening (four replicates). EGFP-fusion proteins 
were ranked as having differential levels in GALTDP-43WT-DsRed, GALFUSWT-DsRed, 
GALSOD1WT-DsRed or GALSOD1A4V-DsRed strains based on those exhibiting both a fold 
change in EGFP-fusion protein levels of > 0.075 (arbitrary cut-off value) and p < 0.05 relative 
to control GALDsRedempty strains. In the case of GALSOD1A4V-DsRed, ‘hits’ were selected based 
on those exhibiting differential protein levels only in strains expressing GALSOD1A4V-DsRed 
but not in strains expressing GALSOD1WT-DsRed. 
3.2.9 Analysis of protein-protein interaction networks 
Interactions between yeast EGFP-fusion proteins that were identified to be present at altered 
levels in diploid GALTDP-43WT-DsRed, GALFUSWT-DsRed or GALSOD1A4V-DsRed strains 
relative to diploid control GALDsRedempty strains, ‘hits’, were analysed using the STRING 
database (Szklarczyk et al. 2015, Szklarczyk et al. 2017) and Cytoscape 3.7.1 (National 
Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH), 
USA). Each set of hits for GALTDP-43WT-DsRed, GALFUSWT-DsRed and GALSOD1A4V-DsRed 
was queried in STRING to identify interactions between the hits using co-expression, published 
experiments and databases as sources of interaction data. STRING computes confidence scores 




present analyses. No more than ten secondary interacting genes/proteins of the hits were 
included in each interaction network. The resulting interaction network data was then imported 
into Cytoscape to format the network to distinguish between the primary hits for each of 
GALTDP-43WT-DsRed, GALFUSWT-DsRed and GALSOD1A4V-DsRed and the ten secondary 
interactors connecting the hits to each other. 
Although these yeast EGFP-fusion protein collection screens were pathway-focused, in that 
only a selection of 128 strains from the full EGFP-fusion collection of strains were included, 
this selection nevertheless covered a spectrum of molecular functions. It was thus useful to 
examine the gene ontology (GO) functional enrichments of the hits for each of GALTDP-43WT-
DsRed, GALFUSWT-DsRed and GALSOD1A4V-DsRed against the background pathway-focused 
selection of 128 EGFP-fusion proteins. GO analyses of each set of hits were carried out using 
PANTHER GO Enrichment Analysis (version 14) (Ashburner et al. 2000, Mi et al. 2019, The 
Gene Ontology Consortium 2019), with the pathway-focused selection of 128 EGFP-fusion 
proteins set as the background reference list.  
3.2.10 Data quality control analyses 
To ensure that growth and expression of GALTDP-43WT-DsRed, GALFUSWT-DsRed, 
GALSOD1WT-DsRed, GALSOD1A4V-DsRed and GALDsRedempty (DsRed alone) in diploid strains 
assayed on the FLUOstar® Optima plate reader were consistent between wells within each 
plate and between different plates in separate experiments, the raw absorbance (OD600) and 
DsRed fluorescence data from each well were examined in GraphPad Prism. Specifically, 
growth between strains and between replicates was evaluated by examining the distribution of 
the OD600 yield (maximum OD600 – minimum OD600) and the maximum exponential rate of 
change of OD600 (maximum growth rate; OD600/h) between wells. The expression of GALTDP-
43WT-DsRed, GALFUSWT-DsRed, GALSOD1WT-DsRed, GALSOD1A4V-DsRed or GALDsRedempty 




DsRed F.I. (Fmax; maximum DsRed F.I. – minimum DsRed F.I.; relative fluorescence units, 
RFU) and the maximum exponential rate of change of DsRed F.I. (maximum rate of DsRed 






3.3.1 Collating the list of relevant EGFP-fusion yeast proteins to screen 
The yeast EGFP-fusion collection comprises 4156 different strains (Huh et al. 2003). For the 
purposes of the work described in this chapter, it was pertinent to collate a focused selection of 
EGFP-fusion strains of relevance to human cellular biology in the context of ALS. Relevant 
proteins and the corresponding EGFP-fusion yeast strains were selected based on (i) 
involvement in conserved proteostasis pathways, (ii) other pathways suspected to be involved 
in ALS pathogenesis, or (iii) the yeast orthologues of human proteins that have been found 
colocalised in inclusions in ALS patients’ motor neurons (Ciryam et al. 2017). Literature 
searches and online databases (Ensembl genome database, BioGRID, esyN, Kyoto 
Encyclopedia of Genes and Genomes (KEGG), PubMed, Saccharomyces genome database 
(SGD) and UniProt) were used to inform selection of the proteins of interest and to analyse 
their function, localisation, expression and interaction data. It was crucial that expression of 
the EGFP-fusion yeast genes could be reliably detected and measured using a fluorescent plate 
reader. Therefore, in most cases proteins with known abundance levels greater than 1,500 
molecules per cell were included for analysis (Ghaemmaghami et al. 2003). However, some 
proteins (24) were included that had low cellular abundance (< 1,500 molecules/cell) 
(Ghaemmaghami et al. 2003) (Table S3.2, Appendix I) or did not have direct human 
orthologues (Table S3.3, Appendix I) because those proteins were particularly relevant to ALS 
pathogenesis. The final selection consisted of 128 EGFP-fusion yeast strains (Table S3.1, 
Appendix I). Of these, 19 have RNA metabolic functions, 13 have functions associated with 
ribosomes and protein translation, 21 are involved in ubiquitin homeostasis and/or the UPS, 2 
are ubiquitin-like modifier proteins, 15 are molecular chaperones, 15 are involved in regulating 
ER proteostasis and/or responding to ER stress, 11 have functions in the endomembrane 




involved in autophagy, 1 is involved in aggresome function, 9 function in protein 
phosphorylation, trafficking and signal transduction, 15 are involved in mitochondrial 
homeostasis and antioxidant activity, 1 is a glutamine synthetase and 2 have functions in energy 
metabolism. 
Following selection of EGFP-fusion strains to cross with the GALTDP-43WT-DsRed, GALFUSWT-
DsRed, GALSOD1WT-DsRed and GALSOD1A4V-DsRed query strains and the GALDsRedempty 
(DsRed alone) control strain, it was found that 2 of the strains, UBP6-EGFP (YFR010W) and 
EIF2A-EGFP (YGR054W), were unable to grow properly, even in rich YPD media. These 
strains were thus excluded from the screens. 
3.3.2 Characterisation of haploid query strains and diploid strains 
To generate yeast models of SOD1, TDP-43 and FUS pathology, yeast centromeric galactose-
inducible plasmids containing human SOD1WT, SOD1A4V, TDP-43WT and FUSWT with C-
terminal DsRed tags were constructed and transformed into the haploid MATα yeast strain 
Y7039. The resulting query strains along with a control strain transformed with the DsRed 
backbone vector were tested for toxicity caused by expression of the human genes using 
spotting assays (Figure 3.3). The untransformed Y7039 strain was included in the spotting 
assays to confirm that it had normal growth patterns (Figure 3.3, a, i and ii). To ensure that any 
differences in growth between strains were caused by expression of the DsRed-fusion human 
genes and not by unknown variables, the haploid query strains and the diploid strains were 
grown on glucose-supplemented plates (does not express DsRed-fusion human gene) in 
parallel to galactose-supplemented plates (expresses DsRed-fusion human gene). Comparison 
of the growth of each strain at each dilution on glucose-supplemented plates confirmed that 
without expression of the DsRed-tagged human genes, viability was similar between each 
haploid and diploid strain (Figure 3.3, b, ii and c, ii). Examining the growth of the haploid 




DsRed strikingly reduced yeast viability, while GALFUSWT-DsRed, GALSOD1WT-DsRed and 
GALSOD1A4V-DsRed did not affect yeast viability relative to control yeast expressing 
GALDsRedempty (DsRed alone) (Figure 3.3, b, i). The toxicity of GALTDP-43WT-DsRed 
expression was also evident in diploid yeast, as represented in the PUB1-EGFP/GALTDP-43WT-
DsRed strain, while no reduction in growth was observed in the PUB1-EGFP/GALSOD1WT-
DsRed and PUB1-EGFP/GALSOD1A4V-DsRed diploid strains relative to the diploid control 
strain PUB1-EGFP/GALDsRedempty (Figure 3.3, c, i). Interestingly, while no reductions in cell 
viability were observed for the haploid GALFUSWT-DsRed strain, a slight decrease in viability 








Figure 3.3. Viability of yeast expressing DsRed-tagged human SOD1WT, SOD1A4V, TDP-43WT, or FUSWT 
relative to yeast expressing DsRed alone. Spotting assays of (A) the haploid MATα yeast strain, Y7039, (B) 
Y7039 transformed with pAG416GAL-TDP-43WT-DsRed (GALTDP-43WT), pAG416GAL-FUSWT-DsRed 
(GALFUSWT), pAG416GAL-SOD1WT-DsRed (GALSOD1WT), pAG416GAL-SOD1A4V-DsRed (GALSOD1A4V) or 
pAG416GAL-ccdB-DsRed (GALDsRedempty; vector control (DsRed alone)) (haploid query strains) and (C) 
representative diploid strains created by mating each haploid query strain with the haploid PUB1-EGFP strain 
from the yeast EGFP fusion collection (Huh et al. 2003) and subsequent diploid selection. Yeast strains were 
grown overnight in (A) YPD, (B, i) SGal/-Ura or (B, ii) SD/-Ura, (C, i) SGal/-His/Ura or (C, ii) SD/-His/Ura broth 
at 30 °C with agitation. Cultures were then normalised for OD600, serial diluted, spotted onto solid (A) YPD, (B, 
i) SGal/-Ura or (B, ii) SD/-Ura, (C, i) SGal/-His/Ura or (C, ii) SD/-His/Ura agar plates and incubated at 30 °C for 
48 h. The incubated plates were then scanned using a standard HP® scanner, and the sizes of the resulting colonies 
were qualitatively examined for the diameter and density of yeast growth. Query strains and diploid strains were 
grown in either galactose-supplemented media to induce expression of DsRed-tagged GALFUSWT, GALTDP-43WT, 
GALSOD1WT, GALSOD1A4V or GALDsRedempty (DsRed alone), or in glucose-supplemented media to control for 
differences in growth between strains that were not caused by expression of the DsRed-tagged genes. 
 
 
Prior to screening the levels of the EGFP-fusion proteins in each diploid strain using the 
fluorescent plate reader, it was imperative to microscopically examine the localisation patterns 
of both the DsRed-fusion proteins and a selection of the EGFP-fusion yeast proteins. This was 




strains did not deviate from those documented on the UniProt and SGD databases and as 
previously reported for the EGFP-fusion strains grown in control conditions (Breker et al. 
2013, Breker et al. 2014), and thus that the GALDsRedempty strains could be used as valid 
controls. For this purpose, several strains were selected for microscopy to include EGFP-fusion 
proteins that have functions in different cellular compartments and thus diverse localisation 
patterns; CDC48, ERV25, ENO1, BMH1, RPL40A, RPN10, TRS23, MDJ1, MGE1/GRPE, 
PUB1, XRN1 and UFD4. The localisation patterns of TDP-43WT-DsRed, FUSWT-DsRed, 
SOD1WT-DsRed and SOD1A4V-DsRed were also assessed. While the spotting assays 
demonstrated that the expression of TDP-43WT-DsRed and FUSWT-DsRed was toxic in yeast, 
it was necessary to confirm that TDP-43WT-DsRed and FUSWT-DsRed shifted from a 
predominantly nuclear localisation to accumulate into cytoplasmic foci, and thus recapitulate 
the mislocalisation observed in human tissue, mammalian cell culture and animal models. The 
expression of SOD1A4V-DsRed did not impair the viability of yeast, in contrast to the toxicity 
the SOD1A4V mutant causes in neuronal cells (data presented in Chapter IV; Figure 4.1, a), in 
zebrafish, and the rapid disease progression in individuals with ALS who have this mutation 
(Cudkowicz et al. 1997, Juneja et al. 1997, Lemmens et al. 2007). Because SOD1-positive 
inclusions are a characteristic pathological feature observed in post-mortem spinal cord tissue 
samples from SOD1-fALS patients (Shibata et al. 1996, Kato et al. 2000) and mutant SOD1 
transgenic mouse models (Bruijn et al. 1997, Johnston et al. 2000, Watanabe et al. 2001, Wang 
et al. 2002) it was of interest to examine whether SOD1A4V-DsRed aggregated into inclusions 
in the diploid yeast strains. 
Across all diploid strains examined, the expression of DsRed alone was observed to be 
relatively low (Figures S3.1 to S3.12, Appendix I). In cells in which its fluorescence was 
detectable, DsRed appeared to be localised to focal regions of the cell rather than more diffusely 




vector (EGFP alone) (data presented in Chapters IV and V). Both TDP-43WT-DsRed and 
FUSWT-DsRed were predominantly localised to small cytoplasmic foci in most cells. In 
contrast, SOD1WT-DsRed and SOD1A4V-DsRed exhibited a uniform distribution throughout 
the cytoplasm and nucleus of all cells. Interestingly, SOD1A4V-DsRed was not observed to 
aggregate into inclusions but had a similar localisation pattern to that of SOD1WT-DsRed. 
The localisation patterns of the examined EGFP-fusion proteins (Figures S3.1 to S3.12, 
Appendix I) are summarised in Table 3.2. Importantly, examination of the EGFP-fusion 
proteins localisation patterns in diploid GALDsRedempty strains confirmed that there was no 
deviation from the localisation patterns that had previously been reported for the EGFP-fusion 
strains grown under control conditions (Breker et al. 2013, Breker et al. 2014) and as 
documented on the UniProt and SGD databases. Across the examined diploid strains 
expressing TDP-43WT-DsRed, FUSWT-DsRed, SOD1WT-DsRed or SOD1A4V-DsRed, several of 
the EGFP-fusion proteins exhibited differential localisation patterns. Although evaluation of 
the localisation patterns of the EGFP-fusion proteins across the different diploid strains was 
not a primary objective of the present study, and only a sub-selection of diploid strains were 
examined out of the full selection screened in the plate reader-based assays, it is worth noting 
the localisation changes that were observed in the microscopically examined diploid strains.  
The localisation patterns of CDC48-EGFP, RPL40A-EGFP, RPN10-EGFP and PUB1-EGFP 
were observed to be altered in yeast expressing TDP-43WT-DsRed compared to yeast 
expressing DsRed alone. The localisation patterns of RPN10-EGFP and PUB1-EGFP were also 
altered in yeast expressing FUSWT-DsRed. In diploid CDC48-EGFP/GALTDP-43WT-DsRed 
yeast, CDC48-EGFP appeared to colocalise to the cytoplasmic foci formed by TDP-43WT-
DsRed (Figure S3.1, Appendix I). In diploid RPL40A-EGFP/GALDsRedempty and RPL40A-
EGFP/GALSOD1A4V-DsRed strains the EGFP-fusion protein was predominantly localised to 




distributed more evenly throughout the cytoplasm of cells (Figure S3.5, Appendix I). RPL40A 
is a fusion protein that is proteolytically cleaved to produce ubiquitin and the L40 ribosomal 
subunit protein (Finley et al. 1989). After cleavage, the L40 protein predominantly assembles 
into mature cytoplasmic pre-60 S ribosomal subunits (Fernández-Pevida et al. 2012). The 
cleaved ubiquitin forms a complex with ribosomal proteins and helps regulate translation 
(Kobayashi et al. 2016). The ribosomal subunit protein is in the C terminal region of RPL40A, 
to which EGFP is fused. It is unclear whether the pattern of EGFP fluorescence seen in cells 
may reflect the localisation of uncleaved RPL40A or cleaved L40 protein. For instance, the 
increased EGFP fluorescence intensity observed in the cytoplasm of RPL40A-EGFP/GALTDP-
43WT-DsRed cells could be due to increased association of L40 with cytoplasmic ribosomal 
subunits.  
In diploid RPN10-EGFP/GALTDP-43WT-EGFP and RPN10-EGFP/GALFUSWT-EGFP yeast, 
cytoplasmic foci formed by TDP-43WT-DsRed and FUSWT-DsRed appeared to colocalise with 
areas of increased cytoplasmic RPN10-EGFP fluorescence intensity (Figure S3.6, Appendix 
I). RPN10 is one of the non-ATPase base subunits of the 19S regulatory particle of the 
proteasome (Glickman et al. 1998, Verma et al. 2004). The observed regions of increased 
RPN10-EGFP fluorescence intensity may indicate areas of higher concentration of assembled 
proteasomes. The localisation of TDP-43WT-DsRed and FUSWT-DsRed foci to these regions 
could be due to targeting of the foci for proteasomal degradation.  
PUB1 is a poly (A)+ RBP involved in the regulation of translation and is an important 
component of SGs (reviewed in Buchan and Parker (2009)). In both PUB1-EGFP/GALTDP-
43WT-DsRed and PUB1-EGFP/GALFUSWT-DsRed cells, a proportion of the cytosolic foci 
formed by TDP-43WT-DsRed and FUSWT-DsRed colocalised with foci formed by PUB1-EGFP 
(Figure S3.10, Appendix I). This is likely due to the association of these proteins in SGs. It is 




colocalised with PUB1-EGFP were cytosolic accumulations of the proteins into inclusions that 
were distinct from SGs. 
TRS23 is one of the core subunits of transport protein particle (TRAPP) complexes I-III and is 
involved in ER-Golgi transport and autophagy (Sacher et al. 2001, Lynch-Day et al. 2010, Yip 
et al. 2010). As such, it localises to the ER and Golgi apparatus in the cytoplasm of cells. In 
diploid TRS23-EGFP/GALDsRedempty and TRS23-EGFP/GALTDP-43WT-DsRed cells, the 
fluorescence of TRS23-EGFP was diffuse throughout the cytoplasm of cells, excluded from 
cell nuclei and structures likely corresponding to vacuoles (Figure S3.7, Appendix I). There 
were also small regions of increased EGFP fluorescence intensity surrounding cell nuclei and 
the vacuoles. This was likely due to increased localisation of TRS23-EGFP to the ER, the Golgi 
apparatus and to vacuoles that may be involved in autophagy. Interestingly, the pattern of 
TRS23-EGFP fluorescence was strikingly different in TRS23-EGFP/GALSOD1A4V-DsRed 
yeast. The overall fluorescence intensity of TRS23-EGFP was markedly reduced, there did not 
appear to be vacuole-like structures excluding TRS23-EGFP, and in some cells there were 
small EGFP fluorescent puncta.  
In diploid UFD4-EGFP/GALFUSWT-DsRed, UFD4-EGFP/GALSOD1A4V-DsRed and UFD4-
EGFP/GALDsRedempty yeast cells, UFD4-EGFP was localised to distinct foci throughout the 
cytoplasm (Figure S3.12, Appendix I). In UFD4-EGFP/GALFUSWT-DsRed yeast there were 
numerous larger UFD4-EGFP foci than were observed in UFD4-EGFP/GALSOD1A4V-DsRed 
and UFD4-EGFP/GALDsRedempty yeast cells, and these foci were colocalised with foci formed 
by FUSWT-DsRed. UFD4 is an E3 ubiquitin ligase and has been reported to interact with 
subunits of the 19S regulatory particle of the proteasome (Xie and Varshavsky 2000). Proteins 
that have been conjugated to a few ubiquitin molecules by UFD4 are detected by the CDC48-
UFD1-NPL4 complex, which subsequently recruits the ubiquitin chain elongation factor (E4), 




proteasome (Koegl et al. 1999). The UFD4-EGFP foci observed in diploid cells may be sites 
of ubiquitylation of proteins targeted for proteasomal degradation. This would suggest that 
colocalisation of FUSWT-DsRed and UFD4-EGFP foci may be due to ubiquitylation and 




Table 3.2. Localisation patterns of selected EGFP-fusion proteins as observed through super-resolution fluorescence microscopy. Diploid strains were grown for 2 
nights in SRaf/-His/Ura broth before being diluted 20× into SGal/-His/Ura broth and grown overnight at 30 °C with agitation to induce expression of GALTDP-43WT-DsRed, 
GALFUSWT-DsRed, GALSOD1WT-DsRed, GALSOD1A4V-DsRed or GALDsRedempty (vector control; DsRed alone). The fluorescent proteins were examined in cells using the 100× 
oil-immersion objective lens of a DeltaVision OMX™ super resolution microscope. Localisation patterns were compared with those documented on the UniProt and SGD 




















(Breker et al. 


























Cytosol AAA ATPase; subunit of 
polyubiquitin-selective 
segregase complex 
involved in ERAD; 
subunit of complex 
involved in mitochondria-
associated degradation, in 
macroautophagy, PMN, 
RAD, ribophagy (Ye et al. 
2003, Heo et al. 2010). 
YML012W ERV25 S3.2 ER; reduced 
F.I. 
ER ER ER ER ER Transport between the ER 
and the Golgi apparatus as 
a component of COPII-
coated ER-derived 
transport vesicles (Belden 


























hydratase; involved in 
glycolysis and 
gluconeogenesis (Cohen et 
al. 1987).  


























Cytosol 14-3-3 protein; diverse 
functions including vesicle 
transport and aggresome 
formation (van Heusden et 
al. 1992, Xu et al. 2013).  


















Fusion protein that is 
proteolytically cleaved to 
produce ubiquitin and the 
L40 ribosomal subunit 
protein (Finley et al. 
1989). 




























Cytosol Non-ATPase base subunit 
of the 19S regulatory 
particle of the proteasome 
(Glickman et al. 1998). 








cell nuclei and 
vacuole-like 
structures 


























Core subunit of transport 
protein particle (TRAPP) 
complexes I-III involved 
in ER-Golgi transport and 





YFL016C MDJ1 S3.8 Not examined Mitochondria Not 
examined 
Mitochondria Mitochondria Mitochondria HSP40 chaperone; 
involved in protein folding 
and refolding in the 
mitochondrial matrix 
(Rowley et al. 1994). 
YOR232W MGE1/ 
GRPE 


















cochaperone (Deloche et 
al. 1997). 


























Cytosol Poly (A)+ RBP involved 
in translation regulation; 
key component of SGs 
(Matunis et al. 1993).  






Not examined Cytosolic foci Cytosol and 
cytosolic foci 
(P-bodies) 
5’ – 3’ exonuclease 
involved in mRNA decay 
(Larimer et al. 1992, Sheth 
and Parker 2003).  






Cytosolic foci Cytosolic foci Nucleus, 
cytosol and 
mitochondria 
E3 ubiquitin ligase (Koegl 




As noted above, the main objective of the work presented in this chapter was to screen for 
alterations in the cellular levels of the ALS-relevant selection of 128 EGFP-fusion proteins, 
rather than to examine whether the localisation patterns of this set of proteins were altered in 
the presence of TDP-43, FUS and mutant SOD1. However, the documentation of the EGFP-
fusion proteins observed here to have altered localisation in response to TDP-43, FUS or 
mutant SOD1 demonstrates that systematic evaluation of the localisation patterns of the full set 
of 128 EGFP-fusion proteins across strains expressing TDP-43WT-DsRed, FUSWT-DsRed and 
SOD1A4V-DsRed could provide valuable information about the cellular responses to the 
expression of these ALS-linked genes. 
3.3.3 Quality control analyses of FLUOstar® Optima plate reader data 
There are various environmental and biological factors that can impact the growth of yeast 
strains and result in growth variation between individual cultures of the same strain. This is 
particularly important to consider for experiments involving the growth of yeast in 96- and 
384-well microtitre plates, in which culture volumes are very small (< 200 µL). Variation in 
temperature and aeration between wells across each multi-well plate can significantly affect 
the activity and metabolism of yeast cells, as well as cause variation in rates of evaporation of 
culture medium, leading to differences in culture volumes and further impacting yeast growth. 
It was important to test that the expression of GALTDP-43WT-DsRed, GALFUSWT-DsRed, 
GALSOD1WT-DsRed, GALSOD1A4V-DsRed or GALDsRedempty (DsRed alone) in diploid strains, 
and that the growth of the strains, was consistent between wells within each plate and between 
different plates in separate experiments. This was done by examining the distribution of the 
raw absorbance (OD600) and DsRed F.I. data from each well in all plates of yeast that were 
assayed for measurements of EGFP-fusion protein levels. 
In diploid GALTDP-43WT-DsRed strains and the corresponding GALDsRedempty control strains, 




between the majority of the strains (Figure 3.4, a and b). A clear difference in the maximum 
exponential rate of change of OD600 (maximum growth rate) between diploid GALTDP-43WT-
DsRed strains and the corresponding GALDsRedempty control strains was evident, with GALTDP-
43WT-DsRed strains growing at a slower rate (Figure 3.4, c and d). This is consistent with the 
reduced growth of haploid and diploid GALTDP-43WT-DsRed strains observed in the spotting 
assays (Figure 3.3, section 3.3.2). Several strains exhibited lower OD600 yields and/or 
maximum growth rates than the majority of diploid GALTDP-43WT-DsRed and GALDsRedempty 
strains. Accordingly, the lower numbers of cells and slower growth rates of these strains 
corresponded with most of them exhibiting lower DsRed Fmax and slower rates of exponential 
increase of DsRed F.I. (Figure 3.4, e, f, g and h). However, the DsRed Fmax and rates of 
exponential increase of DsRed F.I. were also altered in individual replicates of several strains 











Figure 3.4. Distribution of raw OD600 and DsRed fluorescence intensity data from FLUOstar® Optima plate 
reader assays of diploid yeast EGFP-fusion strains expressing DsRed-fusion human TDP-43WT or DsRed 
alone. Diploid strains were created by mating haploid Y7039 transformed with pAG416GAL-TDP-43WT-DsRed 
(GALTDP-43WT) or pAG416GAL-ccdB-DsRed (GALDsRedempty; vector control) with haploid strains from the yeast 
EGFP fusion collection (Huh et al. 2003). Duplicates of each diploid strain were grown in 384-well µclear plates 
containing 100 µL per well of SGal/-His/Ura to induce expression of GALTDP-43WT or GALDsRedempty in a 
FLUOstar® Optima plate reader. The absorbance (optical density [OD] at 600 nm), EGFP (excitation 485/12 nm, 
emission collected at 510/20 nm) and DsRed (excitation 580/10 nm, emission collected at 612 nm) fluorescence 
were measured over 48 h of yeast incubation at 30 °C. Raw data collected for each replicate were analysed to 
calculate the OD600 yield (maximum OD600 – minimum OD600), the maximum exponential rate of change of OD600 
(maximum growth rate; OD600/h), the maximum DsRed fluorescence intensity (Fmax) (maximum DsRed F.I. – 
minimum DsRed F.I.; relative fluorescence units, R.F.U.) and the maximum exponential rate of change of DsRed 
F.I. (maximum rate of DsRed F.I. increase; R.F.U./h). These data per replicate are presented as follows: (A) scatter 
plot and (B) histogram displaying the OD600 yield; (C) scatter plot and (D) histogram showing the maximum 
exponential rate of change of OD600 (maximum growth rate); (E) scatter plot and (F) histogram displaying the 
DsRed Fmax; (G) scatter plot and (H) histogram displaying the maximum exponential rate of change of DsRed F.I. 
(maximum rate of DsRed F.I. increase; R.F.U./h). 
 
In diploid GALFUSWT-DsRed strains and the corresponding GALDsRedempty control strains, the 
OD600 yield was reasonably consistent between replicates of the same strains as well as between 
the majority of strains (Figure 3.5, a and b). Unlike the diploid GALTDP-43WT-DsRed strains, 
there were no differences in the maximum exponential rate of change of OD600 (maximum 
growth rate) between diploid GALFUSWT-DsRed strains and the corresponding GALDsRedempty 
control strains (Figure 3.5, c and d). Several diploid strains were observed to have reduced 
growth compared to the majority of diploid strains. As was observed for the corresponding 
diploid STI1-EGFP/GALTDP-43WT-DsRed strain, growth was much reduced in all replicates of 
STI1-EGFP/GALFUSWT-DsRed and STI1-EGFP/GALDsRedempty. The DsRed Fmax and rate of 
exponential increase of DsRed F.I. were reduced in all replicates of STI1-EGFP/GALFUSWT-
DsRed and STI1-EGFP/GALDsRedempty, and is in accordance with their reduced growth and 
lower culture density (Figure 3.5, e, f, g and h). Several other diploid strains exhibited markedly 
different DsRed Fmax and/or rate of exponential increase of DsRed F.I. compared to the majority 
of diploid GALFUSWT-DsRed and GALDsRedempty strains. Notably, all replicates of the PRE3-
EGFP/GALFUSWT-DsRed and PRE3-EGFP/GALDsRedempty strains exhibited greater DsRed Fmax 
and rates of exponential increase of DsRed F.I., as was observed for all replicates of the 










Figure 3.5. Distribution of raw OD600 and DsRed fluorescence intensity data from FLUOstar® Optima 
plate reader assays of diploid yeast EGFP-fusion strains expressing DsRed-fusion human FUSWT or DsRed 
alone. Diploid strains were created by mating haploid Y7039 transformed with pAG416GAL-FUSWT-DsRed 
(GALFUSWT) or pAG416GAL-ccdB-DsRed (GALDsRedempty; vector control) with haploid strains from the yeast 
EGFP fusion collection (Huh et al. 2003). Duplicates of each diploid strain were grown in 384-well µclear plates 
containing 100 µL per well of SGal/-His/Ura to induce expression of GALFUSWT or GALDsRedempty in a FLUOstar® 
Optima plate reader. The absorbance (optical density [OD] at 600 nm), EGFP (excitation 485/12 nm, emission 
collected at 510/20 nm) and DsRed (excitation 580/10 nm, emission collected at 612 nm) fluorescence were 
measured over 48 h of yeast incubation at 30 °C. Raw data collected for each replicate were analysed to calculate 
the OD600 yield (maximum OD600 – minimum OD600), the maximum exponential rate of change of OD600 
(maximum growth rate; OD600/h), the maximum DsRed fluorescence intensity (Fmax) (maximum DsRed F.I. – 
minimum DsRed F.I.; relative fluorescence units, R.F.U.) and the maximum exponential rate of change of DsRed 
F.I. (maximum rate of DsRed F.I. increase; R.F.U./h). These data per replicate are presented as follows: (A) scatter 
plot and (B) histogram displaying the OD600 yield; (C) scatter plot and (D) histogram showing the maximum 
exponential rate of change of OD600 (maximum growth rate); (E) scatter plot and (F) histogram displaying the 
DsRed Fmax; (G) scatter plot and (H) histogram displaying the maximum exponential rate of change of DsRed F.I. 
(maximum rate of DsRed F.I. increase; R.F.U./h). 
 
The OD600 yield and maximum exponential rate of change of OD600 were similar amongst 
replicates of diploid GALSOD1WT-DsRed, GALSOD1A4V-DsRed and the corresponding 
GALDsRedempty control strains (Figure 3.6, a, b, c and d). However, several diploid strains were 
observed to have variation in their growth relative to most of the diploid strains (Figure 3.6, a, 
b, c and d). Across the plate reader assays of diploid EGFP-fusion/GALTDP-43WT-DsRed, 
/GALFUSWT-DsRed, /GALSOD1WT-DsRed, /GALSOD1A4V-DsRed or /GALDsRedempty, several 
EGFP-fusion strains were repeatedly observed to have variable growth amongst replicates; 
HRP1-EGFP, UBC4-EGFP, BET3-EGFP, STI1-EGFP, YDJ1-EGFP, PUP1-EGFP, HSP82-
EGFP, ASC1-EGFP, SIL1-EGFP, HUL5-EGFP and TSA1-EGFP. Diploid GALSOD1WT-
DsRed and GALSOD1A4V-DsRed strains exhibiting variable growth also, accordingly, exhibited 
variable DsRed Fmax and differing rates of exponential increase of DsRed F.I. to the majority 
of diploid strains (Figure 3.6, e, f, g, h). However, the DsRed Fmax and rate of exponential 
increase of DsRed F.I. measured in some strains did not correlate with the yield of their growth 
or with their growth rate, showing either increased or decreased DsRed Fmax or rates of increase 











Figure 3.6. Distribution of raw OD600 and DsRed fluorescence intensity data from FLUOstar® Optima 
plate reader assays of diploid yeast EGFP-fusion strains expressing DsRed-fusion human SOD1WT, 
SOD1A4V or DsRed alone. Diploid strains were created by mating haploid Y7039 transformed with 
pAG416GAL-SOD1WT-DsRed (GALSOD1WT), pAG416GAL-SOD1A4V-DsRed (GALSOD1A4V), or pAG416GAL-
ccdB-DsRed (GALDsRedempty; vector control) with haploid strains from the yeast EGFP fusion collection (Huh et 
al. 2003). Duplicates of each diploid strain were grown in 384-well µclear plates containing 100 µL per well of 
SGal/-His/Ura to induce expression of GALSOD1WT, GALSOD1A4V or GALDsRedempty in a FLUOstar® Optima plate 
reader. The absorbance (optical density [OD] at 600 nm), EGFP (excitation 485/12 nm, emission collected at 
510/20 nm) and DsRed (excitation 580/10 nm, emission collected at 612 nm) fluorescence were measured over 
48 h of yeast incubation at 30 °C. Raw data collected for each replicate were analysed to calculate the OD600 yield 
(maximum OD600 – minimum OD600), the maximum exponential rate of change of OD600 (maximum growth rate; 
OD600/h), the maximum DsRed fluorescence intensity (Fmax) (maximum DsRed F.I. – minimum DsRed F.I.; 
relative fluorescence units, R.F.U.) and the maximum exponential rate of change of DsRed F.I. (maximum rate of 
DsRed F.I. increase; R.F.U./h). These data per replicate are presented as follows: (A) scatter plot and (B) 
histogram displaying the OD600 yield; (C) scatter plot and (D) histogram showing the maximum exponential rate 
of change of OD600 (maximum growth rate); (E) scatter plot and (F) histogram displaying the DsRed Fmax; (G) 
scatter plot and (H) histogram displaying the maximum exponential rate of change of DsRed F.I. (maximum rate 
of DsRed F.I. increase; R.F.U./h). 
 
There are various factors that could have affected the expression of the galactose-inducible 
DsRed-fusion genes carried in the centromeric plasmids. For instance, the CEN/ARS elements 
in the plasmids may have interacted with DNA replication factors that were perhaps 
differentially active in the specific EGFP-fusion strains listed above. However, the combination 
of CEN and ARS sequences in yeast expression vectors are designed to provide greater stability 
of plasmid copy numbers in yeast cells (Duina et al. 2014). The varied levels of the DsRed-
fusion proteins may also have been influenced by variation in the volume of growth media in 
the wells, differential rates of evaporation of the media, or slight variations in temperature 
across the 384-well plate. Each EGFP-fusion strain crossed with each different DsRed-fusion 
gene plasmid had the same position in each plate between replicates. Thus, there may have 
existed particular positions in the plates that resulted in a given well(s) being subject to 
conditions that varied from other wells in the plate. This may account for the repeated 
variability observed for some diploid strains.  
Following analyses of EGFP-fusion protein levels and identification of EGFP-fusion proteins 
showing altered levels in diploid GALTDP-43WT-DsRed, GALFUSWT-DsRed, GALSOD1WT-
DsRed or GALSOD1A4V-DsRed strains relative to control diploid GALDsRedempty strains 




repeated assays to confirm the observed alterations in EGFP-fusion protein levels. In these 
repeated assays, the array of strains in each plate was changed to exclude strains that had not 
exhibited alterations in EGFP-fusion protein levels, and strains, including the diploid STI1-
EGFP strains, that had consistently shown highly variable viability and growth. Each strain 
was arrayed in quadruplicate wells of 384-well plates and a total of 8 plates were arrayed and 
monitored using the FLUOstar® Optima. Examining the distribution of OD600 yield and the 
maximum exponential rate of change of OD600 (maximum growth rate) across the 8 plates, 
plate-to-plate variation in yeast growth was evident, including for the control GALDsRedempty 
strains (Figure S3.13, a, b, c and d, Appendix I). As was observed in the first round of assays 
of diploid GALTDP-43WT strains, there were clear differences in maximum growth rates 
between GALTDP-43WT strains and their corresponding GALDsRedempty strains, again 
highlighting the reduction in cell viability caused by expression of human TDP-43WT observed 
in spotting assays (section 3.3.2.). In contrast, GALFUSWT-DsRed, GALSOD1WT-DsRed and 
GALSOD1A4V-DsRed strains showed less deviation in growth relative to their corresponding 
GALDsRedempty strains. The DsRed Fmax and the maximum exponential rate of change of DsRed 
F.I. (maximum rate of DsRed F.I. increase) measured in diploid GALTDP-43WT strains was 
greater than in the corresponding GALDsRedempty strains, despite the relatively greater growth 
of the GALDsRedempty strains (Figure S3.13, e, f, g and h, Appendix I). The DsRed Fmax and the 
maximum rate of DsRed F.I. increase was also greater in diploid GALSOD1A4V-DsRed strains 
relative to the corresponding GALDsRedempty strains. The expression of the GALDsRedempty 
plasmid (DsRed alone) resulted in a much lower DsRed F.I. than was seen in GALTDP-43WT-
DsRed, GALFUSWT-DsRed, GALSOD1WT-DsRed and GALSOD1A4V-DsRed strains when viewed 
using a fluorescence microscope (section 3.3.2). Thus, the lower DsRed F.I. signal measured 





In the following section 3.3.4, the analyses of EGFP-fusion protein levels amongst the diploid 
strains, it should be noted that any variation in growth between replicates of strains were 
accounted for by normalising the EGFP F.I. of the EGFP-fusion proteins to the OD600 at each 
measured time-point. Significant variations in normalised EGFP F.I. between replicates were 
accounted for in statistical analyses, ensuring that strains exhibiting variation between 
replicates would not be calculated to reach significance below the p value cut-off of 0.05. 
3.3.4 Identification of yeast proteins with altered levels associated with the expression 
of human TDP-43WT, FUSWT and mutant SOD1A4V 
3.3.4.1 Expression of human TDP-43WT-DsRed is associated with alterations in the 
levels of 24 yeast EGFP-fusion proteins 
Out of the 128 diploid EGFP-fusion protein/GALTDP-43WT-DsRed strains screened, differential 
levels of the EGFP-fusion proteins were observed in 24 strains (Figure 3.7 and Table 3.3). Of 
these, 20 proteins had decreased levels compared to control diploid GALDsRedempty strains while 






Figure 3.7. Expression of human TDP-43WT-DsRed in yeast causes alterations in the levels of 24 yeast 
EGFP-fusion proteins. The absorbance and EGFP fluorescence of diploid EGFP-fusion protein/GALTDP-43WT-
DsRed strains grown in SGal/-His/Ura were measured over 48 h using a FLUOstar® Optima plate reader set to 
incubate plates at 30 °C. Alterations in EGFP-fusion protein levels in diploid EGFP-fusion protein/GALTDP-43WT-
DsRed strains were identified based on a fold change of > ±0.075 (arbitrary cut-off) and p < 0.05 from t tests 
comparing the mean normalised EGFP fluorescence intensity yield (yield from 0 to 48 h) relative to control diploid 
EGFP-fusion protein/GALDsRedempty strains. These cut-offs are highlighted by dashed lines. Note that the y axis 
displays the -log10 of the p values. Data points represent the ΔEGFP fluorescence and -log10 of the p value from t 
tests comparing the differences in the means calculated from the average of quadruplicate samples. EGFP-fusion 




























Description of yeast orthologue 
(Saccharomyces Genome Database; SGD, 
UniProt) 
ΔF p value Connection to 
ALS/Proteostasis 
function(s)/Interaction with 












Enolase I, a phosphopyruvate hydratase; 
catalyses conversion of 2-phosphoglycerate to 
phosphoenolpyruvate during glycolysis and the 
reverse reaction during gluconeogenesis. 0.204 0.0416 
ENO2 has been detected in 
ubiquitin-immunoreactive 
inclusions in SOD1-linked 
fALS. Involved in glycolysis. 
Kato et al. 
1997 
TDH3 GAPDHS Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), isozyme 3; involved in glycolysis and 
gluconeogenesis; tetramer that catalyses the 
reaction of glyceraldehyde-3-phosphate to 1,3 
bis-phosphoglycerate; detected in the cytoplasm 
and cell wall. 
0.126 0.0486 
Transcription, RNA transport, 









RPN10 PSMD4 Non-ATPase base subunit of the 19S regulatory 
particle of the 26S proteasome; N-terminus plays 
a role in maintaining the structural integrity of 




degradation; components of the 
19S regulatory particle have 
been detected in nuclear 






TIF4631 EIF4G1 Translation initiation factor eIF4G; subunit of 
the mRNA cap-binding protein complex (eIF4F) 
that also contains eIF4E (CDC33); interacts with 
PAB1 and with eIF4A (TIF1); also has a role in 
biogenesis of the large ribosomal subunit. 
Interacts with CDC48.  
0.102 0.0293 
Present in ubiquitin-













ADA2 TADA2A/B Transcription coactivator, component of the 
ADA and SAGA transcriptional adaptor/HAT 
(histone acetyltransferase) complexes. -0.079 0.0392 
Involved in chromatin 








Catalytic subunit of ADA and SAGA histone 
acetyltransferase complexes; modifies N-
terminal lysines on histones H2B and H3; 
acetylates RSC4, a subunit of the RSC 
chromatin-remodelling complex, altering 
replication stress tolerance; relocalises to the 
cytosol in response to hypoxia. 
-0.089 0.0382 
Involved in chromatin 
remodelling, transcription and 
the UPR. 
  
PBP1 ATXN2 Component of glucose deprivation induced stress 
granules; involved in P-body-dependent granule 
assembly; similar to human ataxin-2; interacts 
with PAB1 to regulate mRNA polyadenylation. -0.126 0.0339 
PBP1 enhances TDP-43 
toxicity; ATXN2 is present in 
ubiquitin-immunoreactive 
inclusions in sALS and FUS-
linked fALS. 
Elden et al. 
2010; Farg et 
al. 2013; 





Poly(A) binding protein; part of the 3'-end RNA-
processing complex, mediates interactions 
between the 5' cap structure and the 3' mRNA 
poly(A) tail, involved in control of poly(A) tail 
length, interacts with translation factor eIF-4G. 
-0.124 3.10E-05 
PAB1 suppresses FUS toxicity; 
PABPC1 is present in 
basophilic ubiquitin-
immunoreactive inclusions in 
sALS and FUS-linked fALS; 
PABP is required for TDP-43 
toxicity in Saccharomyces 
cerevisiae; PABP mediates 
interaction between TDP-43 and 
ATXN2 in Drosophila 
melanogaster. 
Sun et al. 





PUB1 TIA-1 Poly (A)+ RNA-binding protein; abundant 
mRNP-component protein that binds mRNA and 
is required for stability of many mRNAs; 
component of glucose deprivation induced stress 
granules, involved in P-body-dependent granule 
assembly; implicated in regulation of translation; 
carries Q/N-rich domain at C- terminus, 
identified as candidate prion; human homologue 
TIA-1 is critical for normal synaptic plasticity. 
-0.09 0.0022 
Stress granule marker; 
colocalises with TDP-43 in 
stress granules. 





SSB1 HSPA13 Cytoplasmic ATPase that is a ribosome-
associated molecular chaperone; functions with 
J-protein partner ZUO1; may be involved in 
folding of newly-made polypeptide chains; 
member of the HSP70 family. 
-0.231 0.0023 











DSK2 UBQLN2 Nuclear-enriched ubiquitin-like polyubiquitin-
binding protein, required for spindle pole body 
(SPB) duplication and for transit through the 
G2/M phase of the cell cycle, involved in 
proteolysis, interacts with the proteasome. -0.174 0.0148 
Present in ubiquitin-
immunoreactive inclusions in 
sALS and SOD1-, TARDBP-, 
FUS-, OPTN-, UBQLN2- and 
C9ORF72-linked fALS. 
Mutations in UBQLN2 cause 
some forms of fALS. 
Deng et al. 
2011; Mori 
et al. 2013; 





CPR1 PPIE, PPIF Cytoplasmic peptidyl-prolyl cis-trans isomerase 
(cyclophilin); catalyses the cis-trans 
isomerisation of peptide bonds N-terminal to 
proline residues. -0.264 0.0018 
Member of the peptidyl-prolyl 
cis-trans isomerase (PPIase; 
cyclophilin) family. PPIases 
have been detected in ubiquitin-
immunoreactive inclusions in 
SOD1-linked fALS.  




HSP90 chaperone; required for pheromone 
signalling, negative regulation of HSF1; docks 
with TOM70 for mitochondrial preprotein 
delivery; promotes telomerase DNA binding, 
nucleotide addition; contains two acid-rich 




immunoreactive inclusions in 
SOD1-linked fALS.  





ER stress, UPR, 
ERAD 
DER1 DERL1 ER membrane protein that promotes export of 
misfolded polypeptides; required for ERAD of 
misfolded or unassembled proteins; initiates 
export of aberrant polypeptides from ER lumen 
by threading them into ER membrane and 
routing them to HRD1 for ubiquitylation. -0.121 
3.51E-
05 
Involved in ERAD.   
CDC48 VCP AAA ATPase; subunit of polyubiquitin-selective 
segregase complex involved in ERAD, cell wall 
integrity during heat stress, mitotic spindle 
disassembly; subunit of complex involved in 
mitochondria-associated degradation; role in 
mobilising membrane bound transcription factors 
by regulated ubiquitin/proteasome-dependent 
processing, in macroautophagy, PMN, RAD, 
ribophagy, homotypic ER membrane fusion, 
disassembly of MET30 from SCF complex, 
functional orthologue of human p97/VCP. 
-0.162 9.28E-05 
VCP mutations cause some 
forms of ALS. VCP is present 
in ubiquitin-immunoreactive 








HAC1 XBP1 Basic leucine zipper (bZIP) transcription factor 
(ATF/CREB1 homolog); regulates the UPR. ER 
stress-induced splicing pathway facilitates 
efficient HAC1 synthesis; translation initiation is 
repressed under non-stress conditions; protein 
abundance increases in response to DNA 
replication stress. 
-0.173 0.0086 






Serine protease and general molecular 
chaperone; cleaves ROQ1, which modifies the 
substrate specificity of the UBR1 ubiquitin 
ligase, promoting the stress-induced 
homeostatically-regulated protein degradation 
(SHRED) of misfolded and native ER-membrane 
and cytosolic proteins; chaperone activity 
involved in the heat stress response; promotes 
apoptosis through proteolysis of BIR1; role in 
lipid homeostasis; mammalian Omi/HtrA2 serine 
protease family member. 
-0.168 0.0197 
Present in ubiquitin-
immunoreactive inclusions in 
sALS and SOD1-linked fALS. 
Kawamoto 




ERV25 TMED10 Member of the p24 family involved in ER to 
Golgi transport; role in misfolded protein quality 
control. -0.155 0.026 
ER to Golgi transport; role in 
misfolded protein quality 
control. 
  
GEA2 GBF1 Guanine nucleotide exchange factor for ADP 
ribosylation factors (ARFs); involved in 
vesicular transport between the Golgi and ER, 
Golgi organisation, and actin cytoskeleton 
organisation. 
-0.118 0.0228 
Vesicular transport between the 








Component of autophagosomes and Cvt vesicles; 
regulator of ATG1, targets it to autophagosomes; 
binds the ATG1-ATG13 complex, triggering its 
vacuolar degradation; unique ubiquitin-like 
protein whose conjugation target is lipid 
phosphatidylethanolamine (PE); ATG8-PE is 
anchored to membranes, is involved in 
phagophore expansion, and may mediate 
membrane fusion during autophagosome 
formation; deconjugation of ATG8-PE is 
required for efficient autophagosome biogenesis. 
-0.103 0.0078 









SLT2 MAPK15 Serine/threonine MAP kinase; coordinates 
expression of all 19S regulatory particle 
assembly-chaperones (RACs) to control 
proteasome abundance; involved in regulating 
maintenance of cell wall integrity, cell cycle 
progression, nuclear mRNA retention in heat 
shock, septum assembly; required for mitophagy, 
pexophagy; affects recruitment of mitochondria 
to phagophore assembly site; regulated by the 
PKC1-mediated signalling pathway. 
-0.142 0.0349 
Regulates proteasome 
abundance. MAP kinases have 
been detected in ubiquitin-
immunoreactive inclusions in 
SOD1-linked fALS and sALS. 
Bendotti et 
al. 2004; 






SOD2 SOD2 Mitochondrial manganese superoxide dismutase; 
protects cells against oxygen toxicity and 
oxidative stress; human mitochondrial SOD2 can 
complement a yeast null mutant and human 
cytoplasmic SOD1 can also complement when 
targeted to the mitochondrial matrix.  
-0.229 0.0169 
Mitochondrial manganese 
superoxide dismutase; involved 






Thioredoxin peroxidase; acts as both ribosome-
associated and free cytoplasmic antioxidant; self-
associates to form high-molecular weight 
chaperone complex under oxidative stress; 
chaperone activity essential for growth in zinc 
deficiency; required for telomere length 
maintenance; binds and modulates CDC19 
activity; protein abundance increases, forms 
cytoplasmic foci during DNA replication stress. 
-0.502 0.0015 
PRDX2 has been detected in 
ubiquitin-immunoreactive 
inclusions in SOD1-linked 
fALS. Involved in antioxidant 
activity. 
Kato et al. 
2004 
TSA2 PRDX2 Stress inducible cytoplasmic thioredoxin 
peroxidase; cooperates with TSA1 in the 
removal of reactive oxygen, nitrogen and sulphur 
species using thioredoxin as hydrogen donor. 
-0.125 0.0223 
Detected in ubiquitin-
immunoreactive inclusions in 
SOD1-linked fALS. Involved in 
antioxidant activity. 









STRING network analysis of protein-protein interactions amongst the hits identified several 
interactions (Figure 3.8). Noticeably, CDC48 was a hub for several interacting proteins; DER1, 
HSP82 and TIF4631 with its shared interactions with SSB1 and PAB1. Ten additional 
interacting proteins connected CDC48 indirectly with DSK2 and RPN10; PRE4, PRE5, PRE8, 
PRE9, RPT3, RPT4, RPT6, RPN5, RPN11 and RPN12.  
 
Figure 3.8. Protein-protein interaction network for EGFP-fusion protein/GALTDP-43WT-DsRed screen hits. 
The twenty-four yeast EGFP-fusion proteins with altered levels in diploid EGFP-fusion protein/GALTDP-43WT-
DsRed strains were queried in the STRING protein-protein interaction database (Szklarczyk et al. 2015, 
Szklarczyk et al. 2017). Interactions between the hits were queried using co-expression, published experiments 
and databases as sources of interaction data, and only interactions scored with high confidence were included. It 
was selected that ten secondary interacting proteins would be included in the network analysis. The four up-
regulated proteins are displayed as pink circles, while the twenty down-regulated proteins are displayed as blue 
circles. CDC48 is indirectly linked with DSK2 and RPN10 via a sub-network of ten secondary interactors, 
displayed as pale grey/purple circles. 
 
 
Analysis of the 24 primary hits and the 10 secondary interactors was carried out to identify any 
GO term enrichment amongst the hits and interactors above the background pathway-focused 
selection of 128 EGFP-fusion proteins. The specific functions that have been documented for 
each of the 24 hits were additionally evaluated as collated in Table 3.3. GO term analysis 
identified that there was no enrichment in any one biological process amongst the hits out of 




been reported for each of the 24 hits (Table 3.3) reveal specific molecular alterations caused 
by the expression of TDP-43WT-DsRed.  
TDH3 and ENO1, two of the four yeast EGFP-fusion proteins measured to have increased 
levels in diploid GALTDP-43WT-DsRed yeast, interact with each other and are both involved in 
glycolysis. Seven of the hits have functions that are involved in gene expression regulation; 
CPR1, ADA2, GCN5, PAB1, PBP1, PUB1 and TIF4631. With the exception of TIF4631, the 
levels of each of these proteins were found to be decreased in diploid GALTDP-43WT-DsRed 
yeast (Table 3.3). In a study identifying the composition of RNA-processing complexes in 
yeast, Krogan et al. (2004) detected an interaction between TIF4631 and CDC48. The levels 
of CDC48 were decreased in diploid GALTDP-43WT-DsRed yeast (p = 9.28E-05). CDC48 was 
indirectly linked with the hits DSK2 and RPN10 via ten additional interacting proteins. Each 
of these secondary interactors are subunits of the 26S proteasome. In total, 13 of the primary 
hits and all 10 secondary interactors have functions in misfolded protein quality control and 
protein degradation mechanisms in different cellular compartments (Table 3.3).  CDC48 and 
DER1 are both required for the export of misfolded proteins from the ER for ERAD (Knop et 
al. 1996, Ye et al. 2001). ADA2 and GCN5 are catalytic subunits of the SAGA histone 
acetyltransferase complex that is involved in the transcriptional activation of ER-associated 
molecular chaperones in the IRE1-mediated UPR signalling pathway (Welihinda et al. 1997, 
Welihinda et al. 2000, Lew et al. 2015). HAC1 is essential in this pathway; the splicing of 
HAC1 mRNA, mediated by IRE1 in response to an accumulation of unfolded or misfolded 
proteins in the ER lumen, is necessary for transcriptional activation of ER-associated molecular 
chaperones (Cox and Walter 1996, Mori et al. 1996, Ron and Walter 2007). SSB1, CPR1, 
HSP82 and NMA111 are molecular chaperones with diverse functions in protein folding and 
targeting substrate proteins for degradation (Borkovich et al. 1989, Haendler et al. 1989, 




Lopez-Buesa et al. 1998, Pfund et al. 1998, Pfund et al. 2001, Gautschi et al. 2002, Picard 
2002, Padmanabhan et al. 2009, Szoradi et al. 2018). SLT2, DSK2, RPN10, CDC48 and the 
10 secondary interactors are required for functionality of the UPS (Funakoshi et al. 2002, Rao 
and Sastry 2002, Saeki et al. 2002, Carmody et al. 2010, Stolz et al. 2011, Rousseau and 
Bertolotti 2016). With the exception of RPN10, the levels of each of these proteins were found 
to be decreased in diploid TDP-43WT-DsRed yeast. As well as their functions in proteasomal 
degradation,  DSK2 and CDC48 are also important in the autophagy pathway, in which another 
hit, ATG8, has a key role (Kim and Klionsky 2000, Klionsky et al. 2003, Xie et al. 2008). 
3.3.4.2 Alterations in the levels of 10 yeast EGFP-fusion proteins are associated with 
the expression of human FUSWT-DsRed 
In diploid EGFP-fusion protein/GALFUSWT-DsRed strains, 10 yeast EGFP-fusion proteins had 
altered levels relative to their levels in control diploid EGFP-fusion protein/GALDsRedempty 
strains (Figure 3.9 and Table 3.4). Of these, the levels of 9 proteins were increased, whilst 1 





Figure 3.9. Expression of human FUSWT-DsRed in yeast causes alterations in the levels of 10 yeast EGFP-
fusion proteins. The absorbance and EGFP fluorescence of diploid EGFP-fusion protein/GALFUSWT-DsRed 
strains grown in SGal/-His/Ura were measured over 48 h using a FLUOstar® Optima plate reader set to incubate 
plates at 30 °C. Alterations in EGFP-fusion protein levels in diploid EGFP-fusion protein/GALFUSWT-DsRed 
strains were identified based on a fold change of > ±0.075 (arbitrary cut-off) and p < 0.05 from t tests comparing 
the mean normalised EGFP fluorescence intensity yield (yield from 0 to 48 h) relative to control diploid EGFP-
fusion protein/GALDsRedempty strains. These cut-offs are highlighted by dashed lines. Note that the y axis displays 
the -log10 of the p values. Data points represent the ΔEGFP fluorescence and -log10 of the p value from t tests 
comparing the differences in the means calculated from the average of quadruplicate samples. EGFP-fusion 











Description of yeast orthologue (Saccharomyces 
Genome Database; SGD, UniProt) 
ΔF p value Connection to 
ALS/Proteostasis 
function(s)/Interaction 













PBP1 ATXN2 Component of glucose deprivation induced stress 
granules; involved in P-body-dependent granule 
assembly; similar to human ataxin-2; interacts with 
PAB1 to regulate mRNA polyadenylation. 0.3332407 0.0115777 
PBP1 enhances TDP-43 
toxicity; ATXN2 is present 
in ubiquitin-immunoreactive 
inclusions in sALS and 
FUS-linked fALS. 
Elden et al. 
2010; Farg et 
al. 2013; Kim 






DSK2 UBQLN2 Nuclear-enriched ubiquitin-like polyubiquitin-binding 
protein, required for spindle pole body (SPB) duplication 
and for transit through the G2/M phase of the cell cycle, 
involved in proteolysis, interacts with the proteasome. 0.1084386 0.0494203 
Present in ubiquitin-
immunoreactive inclusions 
in sALS and SOD1-, 
TARDBP-, FUS-, OPTN-, 
UBQLN2- and C9ORF72-
linked fALS. Mutations in 
UBQLN2 cause some forms 
of fALS. 
Deng et al. 
2011; Mori et 
al. 2013; May 




HSF1 HSF1 Trimeric heat shock transcription factor; activates 
multiple genes in response to highly diverse stresses, 
including hyperthermia; recognises variable heat shock 
elements (HSEs); monitors translational status of cell at 
the ribosome through an RQC (Ribosomal Quality 
Control)-mediated translation-stress signal; involved in 
diauxic shift; posttranslationally regulated. 
0.1105651 0.0489443 




ER stress, UPR, 
ERAD 
UFD1 UFD1L Substrate-recruiting cofactor of the CDC48-NPL4-UFD1 
segregase; polyubiquitin binding protein that assists in 
the dislocation of misfolded, ERAD substrates that are 
subsequently delivered to the proteasome for 
degradation; involved in regulated destruction of ER 
membrane proteins such as HMG-CoA reductase 
(HMG1/2) and cytoplasmic proteins (FBP1); involved in 
mobilising membrane bound transcription factors by 
regulated Ub/proteasome-dependent processing. 
0.2240214 0.0489068 
ERAD pathway.   
HAC1 XBP1 Basic leucine zipper (bZIP) transcription factor 
(ATF/CREB1 homologue); regulates the unfolded 
protein response, via UPRE binding, and membrane 
biogenesis; ER stress-induced splicing pathway 
facilitates efficient HAC1 synthesis; two functional 
forms of HAC1 are produced; translation initiation is 
repressed under non-stress conditions; protein abundance 
increases in response to DNA replication stress. 
0.127716 0.0222142 






PHO85 CDK5 Cyclin-dependent kinase; has ten cyclin partners; 
involved in regulating the cellular response to nutrient 
levels and environmental conditions and progression 
through the cell cycle; human lissencephaly-associated 










MDJ1 DNAJA3 Co-chaperone that stimulates HSP70 protein SSC1 
ATPase activity; involved in protein folding/refolding in 
the mitochondrial matrix; required for proteolysis of 
misfolded proteins; member of the HSP40 (DNAJ) 






RUB1 NEDD8 Ubiquitin-like protein with similarity to mammalian 
NEDD8; conjugation (neddylation) substrates include 
the cullins CDC53, RTT101, and CUL3; activated by 
ULA1 and UBA3 (E1 enzyme pair); conjugation 




in sALS and SOD1-linked 
fALS. 





SMT3 SUMO1 Ubiquitin-like protein of the SUMO family; conjugated 
to lysine residues of target proteins; associates with 
transcriptionally active genes; regulates chromatid 
cohesion, chromosome segregation, APC-mediated 
proteolysis, DNA replication and septin ring dynamics; 
human homologue SUMO1 can complement yeast null 
mutant. 
0.1283347 0.0177666 
Sumoylation of Lys-75 in 
SOD1 modulates SOD1 
aggregation; aggregates 
containing a spliced mutant 
of TDP-43 have been found 
to contain SUMO2/3; FUS 
can function as a SUMO E3 
ligase, and can itself be 
sumoylated. 
Fei et al. 
2006; Oh et 
al. 2010; 









GRPEL1 Mitochondrial matrix cochaperone; nucleotide release 
factor for SSC1 in protein translocation and folding; also 
acts as cochaperone for SSQ1 in folding of Fe-S cluster 
proteins; acts as oxidative sensor to regulate 
mitochondrial SSC1; in presence of oxidative stress, 
dimeric MGE1 becomes a monomer and unable to 
regulate SSC1 function; homologue of E. coli GRPE and 













GO term enrichment analysis of the hits against the background set of 128 EGFP-fusion 
proteins showed that there was no enrichment in any of the biological process terms annotated 
amongst the background set of proteins. However, evaluation of the specific functions reported 
for the hits, as collated in Table 3.4, was important to identify the molecular processes that 
were altered in cells expressing FUSWT-DsRed. Moreover, STRING network analysis revealed 
interactions amongst the hits (Figure 3.10). Ten secondary interacting proteins link several of 
the hits with each other in sub-networks that highlight their shared molecular pathways. A sub-
network linking HSF1, UFD1 and RUB1, each of which were up-regulated in diploid FUSWT-
DsRed yeast, included two secondary interactors; CDC48 and NPL4. CDC48, NPL4 and UFD1 
form a polyubiquitin-selective segregase complex involved in ERAD (Ye et al. 2001). 
STRING analysis inferred a functional interaction between NPL4 and RUB1 from interactions 
that have been identified experimentally between their mammalian orthologues, rather than 
directly between these proteins in Saccharomyces cerevisiae. HSF1 linked into this sub-
network via its interaction with CDC48. CDC48 has diverse functions in cells, one of which is 
in the ribosome quality control (RQC) complex (Brandman et al. 2012). In this complex, 
CDC48 signals to HSF1 under conditions of stress resulting from disruptions in protein 
translation to elicit transcriptional activation of the heat shock response (HSR), leading to the 
expression of diverse molecular chaperones. It is interesting to note that CDC48 was found to 
be down-regulated in diploid GALTDP-43WT-DsRed yeast (section 3.3.4.1).  
A sub-network linked MDJ1 and MGE1 with 2 secondary interactors, SSC1 and TIM44. MDJ1 
is a HSP40 co-chaperone that activates the HSP70 ATPase, SSC1, which is involved in protein 
folding and refolding in the mitochondrial matrix (Deloche et al. 1997, Kubo et al. 1999). 
MGE1 is another mitochondrial matrix co-chaperone that assists SSC1 in its protein 
translocation and folding functions. Interestingly, while the levels of MDJ1 were increased in 




the only protein measured to have decreased levels in diploid FUSWT-DsRed yeast. 
Three proteins that had been measured to have decreased levels in diploid GALTDP-43WT-
DsRed yeast, HAC1, PBP1 and DSK2, were observed to have increased levels in diploid 
GALFUSWT-DsRed yeast. Through STRING analysis, no interactions were identified between 
these proteins and the other hits. The cyclin-dependent kinase, PHO85, and the ubiquitin-like 
protein, SMT3, were also not identified to share interactions with the other hits. However, they 
were connected to secondary interactors in their own distinct sub-networks.  
 
 
Figure 3.10. Protein-protein interaction network for EGFP-fusion protein/GALFUSWT-DsRed screen hits. 
The ten yeast EGFP-fusion proteins with altered levels in diploid EGFP-fusion protein/GALFUSWT-DsRed strains 
were queried in the STRING protein-protein interaction database (Szklarczyk et al. 2015, Szklarczyk et al. 2017). 
Interactions between the hits were queried using co-expression, published experiments and databases as sources 
of interaction data, and only interactions scored with high confidence were included. It was selected that ten 
secondary interacting proteins would be included in the network analysis. The nine up-regulated proteins are 
displayed as pink circles, while the one down-regulated protein is displayed as a blue circle. The ten secondary 
interacting proteins of the hits are displayed as pale grey/purple circles, showing sub-networks that link several 










3.3.4.3 Expression of human SOD1A4V-DsRed is associated with changes in the levels of 
7 yeast EGFP-fusion proteins 
In the set of 128 diploid EGFP-fusion protein/GALSOD1A4V-DsRed yeast strains that were 
examined, altered levels of the EGFP-fusion proteins were measured in 7 strains (Figure 3.11 
and Table 3.5). Out of these, the levels of 5 proteins were increased relative to the 
corresponding control diploid EGFP-fusion protein/GALDsRedempty strains and EGFP-fusion 











Figure 3.11. Expression of human SOD1A4V-DsRed in yeast causes alterations in the levels of 7 yeast EGFP-
fusion proteins. The absorbance and EGFP fluorescence of diploid EGFP-fusion protein/GALSOD1A4V-DsRed 
strains grown in SGal/-His/Ura were measured over 48 h using a FLUOstar® Optima plate reader set to incubate 
plates at 30 °C. Alterations in EGFP-fusion protein levels in diploid EGFP-fusion protein/GALSOD1A4V-DsRed 
strains were identified based on a fold change of > ±0.075 (arbitrary cut-off) and p < 0.05 from t tests comparing 
the mean normalised EGFP fluorescence intensity yield (yield from 0 to 48 h) relative to control diploid EGFP-
fusion protein/GALDsRedempty strains. These cut-offs are highlighted by dashed lines. Note that the y axis displays 
the -log10 of the p values. Data points represent the ΔEGFP fluorescence and -log10 of the p value from t tests 
comparing the differences in the means calculated from quadruplicate samples. Only EGFP-fusion proteins 
exhibiting altered levels in diploid EGFP-fusion protein/GALSOD1A4V-DsRed strains but not in the corresponding 





























Description of yeast orthologue (Saccharomyces 
Genome Database; SGD, UniProt) 

















DCP2 DCP2 Catalytic subunit of the DCP1-DCP2 decapping enzyme 
complex; removes the 5' cap structure from mRNAs 
prior to their degradation; also enters the nucleus and 
positively regulates transcription initiation; forms 
cytoplasmic foci upon DNA replication stress; human 
homologue DCP2 complements yeast DCP2 
thermosensitive mutant. 
0.135671 0.0092441 
Reported to co-localise with 
FUS in stress granules. 
Native interactor of CDC48 
(VCP). Involved in mRNA 
degradation. 





ASC1 RACK1 An integral ribosomal protein; G-protein beta subunit 
and guanine dissociation inhibitor for GPA2; orthologue 
of RACK1 that inhibits translation; core component of 
the small (40S) ribosomal subunit; regulates P-body 
formation induced by replication stress. 
0.1649825 0.0188575 
Involved in protein quality 














Beta 5 subunit of the 20S proteasome; responsible for the 





UBA1 UBA1 Ubiquitin activating enzyme (E1); catalyses the first step 
in ubiquitin conjugation to mark cellular proteins for 











UFD1 UFD1L Substrate-recruiting cofactor of the CDC48-NPL4-UFD1 
segregase; polyubiquitin binding protein that assists in 
the dislocation of misfolded, ERAD substrates that are 
subsequently delivered to the proteasome for 
degradation; involved in regulated destruction of ER 
membrane proteins such as HMG-CoA reductase 
(HMG1/2) and cytoplasmic proteins (FBP1); involved in 
mobilising membrane bound transcription factors by 














Beta 1 subunit of the 20S proteasome; responsible for 











Cytosolic copper-zinc superoxide dismutase; detoxifies 
superoxide; stabilizes YCK1 and YCK2 kinases in 
glucose to repress respiration; phosphorylated by DUN1, 
enters nucleus under oxidative stress to promote 
transcription of stress response genes; human orthologue 
SOD1 implicated in ALS complements a null allele; 
localisation to mitochondrial intermembrane space is 
modulated by MICOS complex. 
-0.081141 0.0081055 
Mutations in SOD1 cause 
~20% of fALS cases. SOD1 
is present in ubiquitin-
immunoreactive inclusions in 
SOD1-linked fALS. Involved 
in antioxidant activity; 
scavenges free radicals in 
cells. 
Shibata et al. 
1994; Kato et 
al. 1997; 







GO term enrichment analysis of the hits against the background set of 128 EGFP-fusion 
proteins showed that there was no enrichment in any biological process terms. STRING 
network analysis, however, identified that several of the hits were connected in interaction sub-
networks, linked through ten secondary interacting proteins (Figure 3.12). This revealed that 
several of the hits and the majority of the secondary interactors shared a common interactor; 
RPS31. RPS31 and eight of the ten secondary interactors are ribosomal subunits (RPS12, 
RPS13, RPS15, RPS2, RPS20, RPS3, RPS31 and RPS5). RPS31 is one of two fusion proteins 
that are proteolytically cleaved to yield ubiquitin and the S31 ribosomal subunit (Finley et al. 
1989, Oh et al. 2013). Of the primary hits, ASC1, PRE3, UBA1 and UFD1 directly interact 
with RPS31. ASC1 is a core component of the small (40S) ribosomal subunit. The levels of 
ASC1 were increased in diploid GALSOD1A4V-DsRed yeast (p = 0.0189). UFD1, which had 
increased levels in yeast expressing SOD1A4V-DsRed (p = 0.0353), also had increased levels in 
yeast expressing FUSWT-DsRed (see section 3.3.4.2). As described in section 3.3.4.2, UFD1 
forms a polyubiquitin-selective segregase complex, together with NPL4 and CDC48, that is 
involved in ERAD (Ye et al. 2001). UBA1 is the primary E1 ubiquitin-activating enzyme in 
yeast, as is its orthologue in humans (Chiu et al. 2007, Jin et al. 2007, Pelzer et al. 2007). UBA1 
levels were found to be increased in diploid GALSOD1A4V-DsRed yeast (p = 0.048). PRE3, the 
levels of which were decreased in yeast expressing SOD1A4V-DsRed (p = 0.0008), is a β-subunit 
of the 20S proteasome that catalyses cleavage after acidic residues in peptides. PRE3 interacts 
with PRE2, another β-subunit of the 20S proteasome that is responsible for the chymotryptic 
activity of the proteasome. The secondary interactors of these two proteins, PRE7 and PUP1, 
are the β6 and β2 subunits of the 20S proteasome. Out of the 17 total primary hits and secondary 
interactors, 6 are involved in ubiquitin-dependent protein degradation (PRE2, PRE3, UBA1, 
UFD1, PRE7 and PUP1).  




and SOD1. Yeast SOD1 was found to be down-regulated in yeast expressing human SOD1A4V-
DsRed (p = 0.0081). The heterologous expression of human SOD1 containing ALS-associated 
mutations (G93A, G85R and K100G) in yeast has been shown to complement a null yeast SOD1 
allele (Nishida et al. 1994). It is possible that the overexpression of human SOD1A4V-DsRed 
was complementary to the activity of yeast SOD1, causing a decrease in the expression of yeast 
SOD1. DCP2, which had increased levels in diploid GALSOD1A4V-DsRed yeast (p = 0.0092), is 
a catalytic subunit of the DCP1-DCP2 decapping enzyme complex that removes the 5’ cap from 
mRNAs before they are degraded (Dunckley and Parker 1999).  
 
 
Figure 3.12. Protein-protein interaction network for EGFP-fusion protein/GALSOD1A4V-DsRed screen hits. 
The seven yeast EGFP-fusion proteins with altered levels in diploid EGFP-fusion protein/GALSOD1A4V-DsRed 
strains were queried in the STRING protein-protein interaction database (Szklarczyk et al. 2015, Szklarczyk et al. 
2017). Interactions between the hits were queried using co-expression, published experiments and databases as 
sources of interaction data, and only interactions scored with high confidence were included. It was selected that 
ten secondary interacting proteins would be included in the network analysis. The five up-regulated proteins are 
displayed as pink circles, while the two down-regulated proteins are displayed as blue circles. The ten secondary 
interacting proteins of the hits are displayed as pale grey/purple circles, showing sub-networks that link several of 









3.3.4.4 Common hits and pathways differentially expressed in diploid EGFP-fusion 
strains expressing human TDP-43WT, FUSWT or SOD1A4V 
While there were no common hits between all three screens against TDP43, FUS and SOD1, 
three hits (PBP1, HAC1 and DSK2) were common between the TDP-43 and FUS screens and 
one hit (UFD1) was common between the FUS and SOD1 screens (Figure 3.13). The levels of 
UFD1 were found to be increased both in yeast expressing SOD1A4V-DsRed and in yeast 
expressing FUSWT-DsRed. As described in sections 3.3.4.2 and 3.3.4.3, UFD1 is one of the 
three proteins that form a polyubiquitin-selective segregase complex, together with NPL4 and 
CDC48, that is involved in ERAD (Ye et al. 2001). While the levels of HAC1, PBP1 and DSK2 
were decreased in yeast expressing TDP-43WT-DsRed, their levels were increased in yeast 
expressing FUSWT-DsRed. These three proteins are not reported to directly interact with one 
another. DSK2 has several functions in proteolysis. It is a ubiquitin-like polyubiquitin-binding 
protein involved in the UPS, autophagy as well as in the ERAD pathway (Funakoshi et al. 2002, 
Saeki et al. 2002, Medicherla et al. 2004, Nolan et al. 2017). HAC1 is involved in the IRE1-
mediated UPR signalling pathway. It is a transcription factor that promotes the expression of 
proteins important for ER quality control (Cox and Walter 1996, Mori et al. 1996, Ron and 
Walter 2007). PBP1 also has roles in regulating gene expression, however it is specifically 
involved in the maturation of pre-mRNAs for translation, mediating their polyadenylation 











Figure 3.13. Venn diagram illustrating the yeast EGFP-fusion proteins that were commonly altered by the 
expression of human TDP-43WT-DsRed, FUSWT-DsRed and/or SOD1A4V-DsRed in diploid yeast strains. 
Three proteins were altered both in yeast expressing TDP-43WT-DsRed and in yeast expressing FUSWT-DsRed; 
PBP1, HAC1 and DSK2. The levels of UFD1 were increased both in yeast expressing FUSWT-DsRed and in yeast 
expressing SOD1A4V-DsRed. PBP1 is involved in mRNA processing and stress granule dynamics and is the yeast 
orthologue of ATXN2, polyglutamine repeat expansions in which are a genetic risk factor for ALS (Elden et al. 
2010, Farg et al. 2013, Tazen et al. 2013). HAC1 is the major regulator of the unfolded protein response. DSK2 is 
the yeast orthologue of UBQLN2, mutations in which are associated with ALS (Deng et al. 2011). UFD1 has 




GO term enrichment analysis for the primary hits identified in each screen against the 
background set of 128 EGFP-fusion proteins showed that there was no enrichment in any of the 
biological processes that have been annotated for the background set of proteins. However, 
several of the hits and secondary interactors identified in the screens of yeast expressing human 
TDP-43WT-DsRed, FUSWT-DsRed and SOD1A4V-DsRed have functions in gene expression, SG 
assembly and dynamics, ERAD and the UPS (Table 3.6). In the screens of yeast expressing 
human TDP-43WT-DsRed or FUSWT-DsRed there were hits and interactors with molecular 







Table 3.6. The common major categories of molecular processes that have been reported for the primary 
hits and secondary interactors identified in the screens of diploid yeast EGFP-fusion strains expressing 








ADA2, GCN5, HAC1, 
PAB1, PBP1, PUB1, 
RPT3, RPT4, RPT6, 
SLT2, TIF4631 
PBP1, CKS1, HAC1, 
HSF1, PHO80, 
PHO85 
DCP2, RPS12, RPS13, 
RPS15, RPS2, RPS20, 
RPS3, RPS31, RPS5 
Stress granules PBP1, PUB1, TIF4631 PBP1 DCP2 
Molecular 
chaperone activity 
CPR1, HSP82, SSB1, 
TSA1, TSA2 
MDJ1, MGE1, SSC1   
Transport between 
ER and Golgi 
ATG8, ERV25, GEA2     
ER stress, UPR, 
ERAD 
CDC48, DER1, DSK2, 
HAC1, RPT3, RPT4, 
RPT6, SLT2 
CDC48, DSK2, 




CDC48, HSP82, DSK2, 
PRE4, PRE9, RPN10, 
RPN11, RPN12, RPT3, 




PRE2, PRE3, PRE7, PUP1, 
UBA1, UFD1 
Autophagy 







  MDJ1, MGE1, SSC1, 
TIM44 
  
Antioxidant activity SOD2, TSA1, TSA2   SOD1 
Calcium-mediated 
signalling 




Over the last two decades, the study of different neurodegenerative diseases, including PD, HD, 
AD and ALS, has benefited from the use of Saccharomyces cerevisiae as a model organism 
(Krobitsch and Lindquist 2000, Auluck et al. 2002, Outeiro and Lindquist 2003, Willingham et 
al. 2003, Cooper et al. 2006, Johnson et al. 2008, Gitler et al. 2009, Johnson et al. 2009, Elden 
et al. 2010, Sun et al. 2011, Treusch et al. 2011, Kim et al. 2014). Many conserved, fundamental 
biological processes that are affected by the expression of disease-causing genes in humans can 
be identified using yeast as a model system. In the present study, the effect of the heterologous 




different yeast proteins was investigated. It was hypothesised that any proteins in this selection 
that were found to have altered expression in the presence of TDP-43, FUS and mutant SOD1 
may play a key role(s) in the cellular response to ALS-associated pathology. A comprehensive 
list of conserved yeast proteins to include for screening was compiled, including proteins 
involved in proteostasis mechanisms, other pathways suspected to be involved in ALS 
pathogenesis (e.g. mitochondrial dysfunction, disruptions in energy metabolism), and 
orthologues of human proteins that have been found colocalised in inclusions in post-mortem 
spinal cord tissue from ALS patients (Ciryam et al. 2017). The result of this yeast screen was 
the identification of 24, 10 and 7 yeast proteins found to have altered levels in yeast expressing 
TDP-43WT-DsRed, FUSWT-DsRed and SOD1A4V-DsRed, respectively. 
In future work it will be necessary to validate the hits from this yeast screen. The hits will first 
need to be validated biochemically through immunoblotting of lysates prepared from each 
diploid yeast strain. This could be done using an anti-EGFP antibody to probe for the EGFP-
fusion yeast protein in each diploid strain, to then compare the levels of each EGFP-fusion 
protein between each diploid strain expressing the ALS gene relative to the corresponding 
control strain expressing DsRed alone. It will also be important to confirm that the changes in 
EGFP-fusion protein levels measured in the present study were of a magnitude that would have 
functional effects. There is no available method or formula to calibrate the measured changes 
in EGFP-fusion protein levels to an absolute quantity of the protein levels. This limits us from 
comparing the changes in EGFP-fusion protein levels that were observed with data published 
in the literature on protein expression level changes that would be sizeable enough to impact 
molecular and cellular function. One approach to investigate this experimentally would involve 
measuring the activity of molecular processes that are downstream from each hit, and 
comparing between each diploid yeast strain expressing the ALS gene and the corresponding 




process in cells expressing the ALS gene relative to control cells expressing DsRed alone would 
provide evidence that the alterations in EGFP-fusion protein levels measured in the present 
study were of an amplitude great enough to have functional effects. 
All biochemically confirmed hits would then need to be validated using mammalian cell culture 
models of SOD1, TDP-43 and FUS. Validation in these models would involve preparing cell 
lysates from each cell culture model and using these to immunoblot for the endogenous 
mammalian orthologue of each hit. As would be done for the yeast strains, the endogenous 
levels of the protein hit that was probed for would be compared between cells expressing the 
ALS gene mutant and corresponding control cells expressing GFP alone.  
Beyond these proposed validation studies, it would be important to carry out knockdown studies 
using siRNA targeted to each hit. Conversely, it would also be important to carry out studies to 
examine the effects of overexpression of each hit. In these knockdown and overexpression 
studies, measurement of the effect on the activity of known downstream targets of the hit, cell 
viability, localisation of the ALS mutant and/or aggregation of the ALS mutant would provide 
valuable mechanistic information on the role that the hit may play in the cellular response to 
the expression of the ALS mutant. 
3.4.1 Alterations in gene expression regulation may be common to ALS associated with 
SOD1, TDP-43 and FUS  
In the past decade, studies to characterise alterations in protein levels resulting from factors that 
cause cellular stress have emerged as a way to gain insight into the molecular pathways involved 
in disease and in the cellular response to harmful stimuli (Breker et al. 2013, D'Souza et al. 
2014, Fesenko et al. 2016, Tangsongcharoen et al. 2019). Between all three screens conducted 
as part of this work, the primary hits and secondary interactors identified have functions in 
several common molecular processes of the proteostasis network; gene expression, ERAD and 




selected based on their relevance to the molecular mechanisms suspected to be involved in 
motor neuron dysfunction in ALS, particularly proteostasis. Thus, it is not surprising that 
processes related to proteostasis were identified to be affected; however, it is important to gain 
insight into commonly altered molecular processes in all three genetic screens, as well as any 
changes that are unique to each. For instance, gene expression alterations and changes in SG 
dynamics have been comprehensively investigated in the context of mutations in TARDBP and 
FUS, both of which are involved in RNA metabolism. Up until very recently, these molecular 
alterations had not received attention in relation to their association with mutations in SOD1. 
However, a 2016 study revealed an interaction between mutant SOD1 and G3BP1, a protein 
involved in SG dynamics (Gal et al. 2016). In the present work, the levels of the P-body and 
SG-associated protein, DCP2, were up-regulated in yeast expressing SOD1A4V-DsRed. DCP2 
is involved in gene expression through its function in mRNA degradation (Dunckley and Parker 
1999). Some of the proteins identified in the SOD1A4V screen, ASC1 and its secondary 
interactors, are components of the small 40S ribosomal subunit and therefore essential for 
translation. One of these interactors, RPS31, was a central interactor linking ASC1 and the other 
primary hits UFD1, UBA1 and PRE3. The up-regulation of DCP2 and ASC1 and the connection 
between all seven primary hits of a ribosome subunit fusion protein, RPS31, suggest that there 
may have been an increased need for gene expression regulation in yeast expressing SOD1A4V. 
Gene expression alterations may thus not only be associated with TDP-43 and FUS in ALS, but 
also altered in the presence of mutant SOD1. 
Further to identifying that gene expression regulation, ERAD and the UPS were commonly 
affected molecular processes in yeast modelling TDP-43, FUS and SOD1 pathology, three 
specific proteins (PBP1, HAC1 and DSK2) were found to be commonly altered between the 
TDP-43 and FUS yeast screens, and one common hit (UFD1) was identified between the FUS 




3.4.2 The expression of TDP-43WT and FUSWT cause alterations in the IRE1-mediated 
UPR signalling pathway in yeast 
The expression of human TDP-43WT-DsRed was clearly toxic in yeast, as demonstrated through 
spotting assays (see section 3.3.2), showing that critical processes were perturbed in these cells. 
Several proteins involved in ER protein quality control and the ER stress response were found 
to have decreased levels in yeast expressing TDP-43WT-DsRed; ERV25 has functions in 
misfolded protein quality control in the ER (Copic et al. 2009), DER1 promotes the export of 
misfolded proteins from the ER for ERAD (Knop et al. 1996, Hitt and Wolf 2004), CDC48 is 
one of the three members of the polyubiquitin-selective segregase complex involved in ERAD 
(Ye et al. 2001, Ye et al. 2003), and NMA111 promotes stress-induced homeostatically-
regulated protein degradation (SHRED) of misfolded and native ER-membrane proteins 
(Szoradi et al. 2018). Potentially, the presence of human TDP-43WT-DsRed in yeast caused a 
widespread dysregulation of ER proteostasis. Reduction in the capacity of cells to ameliorate 
ER stress has previously been implicated to be involved in the pathogenic mechanisms of 
mutant TDP-43 (Walker et al. 2013, Wang et al. 2015). Compounding this, the decreased levels 
of HAC1 suggest that TDP-43WT-DsRed further caused disruption of the pathway that regulates 
HAC1 translation, impairing the IRE1-mediated UPR signalling pathway that is triggered by 
ER stress (Cox and Walter 1996, Sidrauski and Walter 1997, Ron and Walter 2007).  
The increased levels of HAC1 in yeast expressing FUSWT-DsRed indicate that proteostasis in 
the ER of cells was compromised, causing ER stress, leading to increased splicing of HAC1 
mRNA and consequently up-regulation of HAC1. In line with this, there is evidence that the 
expression of mutant FUS in NSC-34 cells causes ER stress (Farg et al. 2012).  
Importantly, these findings suggest that functionality of the IRE1-mediated UPR signalling 
pathway may be a key determinant of the cellular ability to respond to ER stress caused by 




key mechanism of TDP-43 toxicity, impairing cellular ability to restore ER proteostasis that is 
initially disrupted through the aberrant activity of mislocalised TDP-43. 
3.4.3 Differential regulation of PBP1 reveals differences in the cellular response to 
mislocalised, toxic TDP-43WT and FUSWT 
PBP1 is the yeast orthologue of ATXN2. Intermediate expansions of a CAG trinucleotide repeat 
in ATXN2 are correlated with an increased risk for ALS (Elden et al. 2010, Tazen et al. 2013). 
ATXN2 has further been associated with ALS through discovery of its presence in ubiquitin-
immunoreactive inclusions in tissue from patients with sALS and FUS-linked fALS (Farg et al. 
2013, Tazen et al. 2013). In yeast expressing TDP-43WT-DsRed it was found that PBP1 was 
down-regulated, whereas it was up-regulated in yeast expressing FUSWT-DsRed. Findings from 
previous work investigating modifiers of TDP-43WT toxicity indicated that increased levels of 
PBP1 enhance the toxicity caused by TDP-43WT (Kim et al. 2014). It was further identified that 
polyadenylate-binding protein (PAB1) mediated interactions between TDP-43 and 
ATXN2/PBP1 that resulted in toxicity (Kim et al. 2014). In the present work, PAB1 was found 
to be down-regulated in yeast expressing TDP-43WT-DsRed. The expression of human TDP-
43WT-DsRed caused striking toxicity in yeast. If, as reported by Kim et al. (2014), increased 
levels of PBP1 enhance the toxicity caused by TDP-43WT in yeast, and PAB1 is involved in an 
aberrant interaction between PBP1 and TDP-43, then down-regulation of these proteins may 
improve the fitness of yeast expressing TDP-43WT. The decreased levels of PBP1 and PAB1 in 
yeast expressing TDP-43WT may thus be the result of selection for TDP-43WT-DsRed-
expressing cells that expressed lower levels of these proteins over successive cell divisions.  
PBP1 is involved in diverse RNA processing pathways that control gene expression, including 
P-body-dependent SG assembly and the regulation of mRNA polyadenylation (Mangus et al. 
1998, Buchan et al. 2008). The up-regulation of PBP1 in yeast expressing FUSWT-DsRed may 




toxicity of mislocalised FUSWT-DsRed. Indeed, as well as up-regulation of PBP1 in yeast 
expressing FUSWT-DsRed, several other proteins with key functions in responding to 
proteotoxic stress were up-regulated, including HAC1 (as discussed above), DSK2, UFD1, 
SMT3, HSF1 and MDJ1.  
3.4.4 Yeast differentially regulate DSK2 in response to proteotoxic stress caused by 
mislocalised TDP-43WT and FUSWT 
The third common hit identified in the TDP-43WT-DsRed and FUSWT-DsRed screens, DSK2, is 
particularly interesting as it is the yeast orthologue of a protein that is closely associated with 
ALS; UBQLN2. Mutations in UBQLN2 cause X-linked ALS and ALS/FTD (Deng et al. 2011, 
Teyssou et al. 2017). It is a commonly detected protein component of several different types of 
inclusions detected in ALS patients’ motor neurons. It is detected in skein-like p62-, TDP-43-, 
FUS- and OPTN-positive inclusions in ALS patients with P497H or P506T mutations in 
UBQLN2 and in patients with sALS and fALS patients with mutations in SOD1, TARDBP and 
FUS (Deng et al. 2011). It is also detected in TDP-43-negative, poly-(Gly-Ala), -(Gly-Pro), -
(Gly-Arg) DPR-, p62- and ubiquitin-positive inclusions in patients with pathological 
hexanucleotide repeat expansions in C9ORF72 (Mori et al. 2013, May et al. 2014). Both DSK2 
and its mammalian orthologue have several functions in proteolysis. It is a ubiquitin-like 
polyubiquitin-binding protein involved in the UPS, autophagy and ERAD (Funakoshi et al. 
2002, Saeki et al. 2002, Medicherla et al. 2004, Nolan et al. 2017). Interestingly, as was the 
case for the other two common hits, HAC1 and PBP1, DSK2 was down-regulated in yeast 
expressing TDP-43WT-DsRed but up-regulated in yeast expressing FUSWT-DsRed. Alterations 
in the levels of DSK2 indicate that downstream ubiquitin-dependent degradation pathways, 
namely the UPS, autophagy and ERAD, may be implicated in the cellular response to TDP-
43WT-DsRed and FUSWT-DsRed. Indeed, as well as up-regulation of DSK2 in yeast expressing 




cells in responding to proteotoxic stress. Apart from PBP1 (discussed above) the up-regulation 
of proteins involved in mitochondrial proteostasis (MDJ1), ERAD (DSK2, UFD1), the UPR 
(HAC1), the UPS and autophagy (DSK2) and, critically, the major regulator of the cellular 
response to proteotoxic stress (HSF1), indicate that the expression of FUSWT-DsRed caused 
widespread proteostasis dysfunction in cells. Potentially, these proteins were up-regulated in an 
attempt by the cell to deal with proteostasis disruption caused by mislocalised FUSWT-DsRed.  
In yeast expressing TDP-43WT-DsRed, as well as decreased levels of DSK2, the levels of ATG8, 
required for autophagosome membrane formation, and proteins involved in ERAD (CDC48, 
DER1, HAC1 and NMA111) were similarly decreased. Regarding the UPS, the primary 
proteasome-associated ubiquitin receptor, RPN10, was up-regulated in yeast expressing TDP-
43WT-DsRed. Moreover, the localisation of RPN10-EGFP was altered in yeast expressing TDP-
43WT-DsRed, observed to be colocalised with cytosolic TDP-43WT-DsRed foci (Table 3.2, 
section 3.3.2 and Figure S3.6, Appendix I). RPN10 is an atypical component of the proteasome, 
as a large proportion of it exists in a proteasome-unassociated pool in which it functions, 
similarly to DSK2, as a ubiquitin/polyubiquitin shuttle factor (Fu et al. 1998). In a landmark 
study, Matiuhin et al. (2008) discovered a unique interaction between DSK2 and RPN10: 
through demonstrating that overexpression of DSK2 was toxic in yeast, they unravelled a 
complex mechanism by which RPN10 competes with DSK2 for binding to the proteasome, and 
that RPN10 attenuates the toxicity associated with dysregulated DSK2. The toxicity mediated 
by dysregulated DSK2 results from its interference with the normal functioning of the UPS, 
altering the ratio of Lys48 to Lys63 polyubiquitin chains in the cellular ubiquitin pool (Matiuhin 
et al. 2008). The data reported by Matiuhin et al. (2008) suggests that the delivery of substrate 
polyubiquitylated proteins to the proteasome requires stringent regulation by the polyubiquitin 
shuttle proteins, particularly DSK2 and RPN10, for efficient proteolysis and prevention of 




of RPN10 may be due to an increased demand for RPN10 in shuttling proteasomal substrates 
for degradation. In this case, DSK2 may be down-regulated to prevent its interference with the 
ubiquitin/polyubiquitin shuttling activity of RPN10. Moreover, the colocalisation of RPN10 
with cytosolic TDP-43WT-DsRed foci may indicate an attempt to direct mislocalised, toxic 
TDP-43WT-DsRed for proteasomal degradation. However, in the present work it was not 
investigated whether the cytosolic TDP-43WT-DsRed foci were ubiquitylated. Microscopy of 
diploid RPN10-EGFP/TDP-43WT-DsRed yeast immunostained for ubiquitin would be needed 
to examine whether the cytosolic RPN10-EGFP/TDP-43WT-DsRed foci are ubiquitin-positive, 
and thus whether the colocalisation of RPN10-EGFP to these foci may be due to its 
ubiquitin/polyubiquitin shuttling activity.  
3.4.5 UFD1 is up-regulated in the presence of mutant SOD1A4V and mislocalised 
FUSWT in yeast 
In both yeast expressing FUSWT-DsRed and yeast expressing SOD1A4V-DsRed, the levels of 
UFD1 were found to be increased. UFD1 is a polyubiquitin binding protein that has a crucial 
role in ERAD, forming a segregase complex with CDC48 and NPL4 that extracts misfolded 
proteins from the ER and directs them to the proteasome for degradation (Ye et al. 2001). Three 
different ALS-causing mutations in SOD1, A4V, G85R and G93A, have been shown to cause 
disruptions in ER-Golgi trafficking and the secretory pathway, leading to ER stress (Atkin et 
al. 2014). The up-regulation of UFD1 in yeast expressing SOD1A4V-DsRed may thus be due to 
augmentation of the ERAD pathway in an attempt to ameliorate ER stress caused by SOD1A4V-
DsRed-mediated disruption of ER proteostasis.  
Interestingly, UFD1 and the CDC48-NPL4-UFD1 complex have been implicated in the DNA 
damage response (DDR) pathway. Nie et al. (2012) investigated SUMO-targeted ubiquitin 
ligases (STUbLs) and SUMOylation of target proteins in the context of toxicity caused by the 




ubiquitylation of target proteins are important modulators of the DDR pathway (reviewed in 
Jackson and Durocher (2013)). Using a proteomics approach Nie et al. (2012) discovered that 
the CDC48-NPL4-UFD1 complex was highly enriched among SUMO-binding proteins in the 
fission yeast Schizosaccharomyces pombe, revealing a role for the CDC48-NPL4-UFD1 
complex as a STUbL cofactor which protects cells against SUMO chain-mediated toxicity. 
Furthermore, a combination of ubiquitin and SUMO recognition motifs within UFD1 appear to 
mediate the targeting of the CDC48-NPL4-UFD1 complex to SUMOylated and ubiquitylated 
substrates (Nie et al. 2012). Intriguingly, in the present work SMT3, a protein of the SUMO 
family, was also up-regulated in yeast expressing FUSWT-DsRed. In another study, in cells in 
which the DDR pathway was activated, a mutation in UFD1 lead to an accumulation of 
SUMOylated species in nuclear foci (Køhler et al. 2013). This supports a direct role for UFD1 
in regulating SUMOylated species in the DDR pathway. The up-regulation of UFD1 and SMT3 
in yeast expressing FUSWT-DsRed observed here may be indicative of dysregulation of the 
DDR pathway. Indeed, several studies have demonstrated that FUS has important functions in 
the DDR pathway, and that mutations in the NLS of FUS result in impairment of this pathway 
(Wang et al. 2013, Higelin et al. 2016, Gong et al. 2017, Naumann et al. 2018). Further 
investigation of changes in the activity of UFD1 and its downstream effects in neuronal cell 
models of disease-associated FUS mutations may help elucidate a role for UFD1 in the DDR 
in the context of FUS-linked ALS. 
3.4.6 Expression of TDP-43WT in yeast is associated with decreased levels of two key 
autophagy proteins 
CDC48 is a particularly intriguing hit from the TDP-43WT-DsRed screen given that mutations 
in the human orthologue of CDC48, VCP, account for 1-2% of fALS and <1% of sALS cases 
(Johnson et al. 2010, Abramzon et al. 2012). Mutations in VCP also cause IBMPFD (Watts et 




patients’ muscle and brain tissue (Watts et al. 2004, Kimonis et al. 2008) and in diseased motor 
neurons in ALS patients. It was previously hypothesised that SGs that persist abnormally in 
diseased cells seed the formation of inclusions, including TDP-43 inclusions (Dewey et al. 
2012, Parker et al. 2012). More recent work has demonstrated that SGs do not seed the 
aggregation of TDP-43 into inclusions (Chen and Cohen 2019, Gasset-Rosa et al. 2019, Mann 
et al. 2019), however they may indirectly promote the pathological accumulation of TDP-43 
into inclusions by interfering with the autophagic clearance of TDP-43 aggregates (Chen and 
Cohen 2019).  
Importantly, CDC48/VCP has been reported to mediate the clearance of SGs through selective 
autophagy (Buchan et al. 2013). This provides a key link in diseases that are associated with 
VCP mutations between impaired VCP function and the occurrence of TDP-43-positive 
inclusions, with impairment in the autophagy pathway perhaps playing an important pathogenic 
role. Loss of VCP function may impair the autophagic clearance of TDP-43, and potentially 
further promote the accumulation of aggregated TDP-43 into inclusions due to impaired 
autophagic clearance of SGs. SGs that have escaped clearance may sequester proteins that have 
key functions in autophagy (Chen and Cohen 2019), further impairing the ability of cells to 
eliminate TDP-43 inclusions through autophagy. In the present work, the levels of CDC48 were 
reduced in yeast expressing TDP-43WT-DsRed, as were the levels of the key autophagy-related 
protein ATG8. Through confocal microscopy, TDP-43WT-DsRed was observed to form 
cytosolic foci in yeast cells, and there was minimal colocalisation with the SG protein PUB1, 
indicating that these TDP-43 foci likely represented pathological inclusions that were distinct 
from SGs (Table 3.2, section 3.3.2 and Figure S3.10, Appendix I). The localisation of CDC48-
EGFP was unique in yeast expressing TDP-43WT-DsRed compared to control diploid CDC48-
EGFP/GALDsRedempty yeast; it was observed to colocalise with cytosolic TDP-43WT-DsRed foci. 




43 inclusions. Pathologically mislocalised, aggregated TDP-43WT-DsRed may thus have 
impaired CDC48 function by depleting its functional levels in cells. Moreover, the decreased 
levels of CDC48 and ATG8 in yeast expressing TDP-43WT-DsRed further suggest that 
pathological TDP-43WT-DsRed may have aberrantly interacted with these proteins, 
consequently impairing their functions in autophagy. Potentially, TDP-43-mediated 
impairment of the functions of CDC48 and ATG8 in autophagy may have further enabled 
aggregated TDP-43WT-DsRed to escape autophagic clearance and to accumulate in cells. To 
explore this hypothesis, immunocytochemistry to probe for ATG8 and other autophagy 
markers, including the yeast orthologue of beclin-1, VPS30, in CDC48-EGFP/GALTDP-43WT-
DsRed yeast at several time points is required in order to measure autophagic flux and determine 
if  autophagy is impaired in yeast expressing TDP-43WT-DsRed. 
3.4.7 Up-regulation of key UPS proteins is associated with an absence of SOD1A4V 
toxicity in yeast 
An intriguing observation in the work presented in this chapter is that the expression of human 
SOD1 containing the ALS-causing A4V mutation did not cause toxicity in yeast, whereas this 
mutation is associated with a rapidly progressive disease course in humans (Cudkowicz et al. 
1997, Juneja et al. 1997). Coinciding with this distinct lack of toxicity in each of the diploid 
EGFP-fusion/GALSOD1A4V-DsRed strains was up-regulation of three proteins with important 
roles in ubiquitin-dependent protein degradation; UBA1, PRE2 and UFD1. The secondary 
interactors of these proteins, PRE7 and PUP1, are β-subunits of the 20S proteasome complex, 
as is the primary hit PRE2. Interestingly, another β-subunit of the 20S proteasome complex, 
PRE3, was down-regulated in yeast expressing SOD1A4V-DsRed.  
The down-regulation of PRE3 is surprising given the up-regulation of UBA1, PRE2 and UFD1 
as each of these proteins have functions in the UPS. Specifically, this raises the question as to 




catalytic β-subunit was down-regulated (PRE3). Differential regulation of proteasome subunits 
has been investigated in relation to the changes that occur throughout diverse processes 
including neonatal development, aging, cellular stress responses, cellular replicative 
senescence, and in response to targeted RNAi of specific proteasome subunits (Shibatani et al. 
1996, Keller et al. 2000, Wójcik and DeMartino 2002, Chondrogianni et al. 2003, Claud et al. 
2014). These findings demonstrate that differential regulation of specific proteasome subunits 
can enable cells to fine-tune their responses to changes in the intracellular environment, 
increasing their capacity to adapt. For instance, overexpression of catalytic β-subunits of the 
20S proteasome complex can lead to augmentation of the specific catalytic activity of the 
overexpressed β-subunit (Gaczynska et al. 1994, Gaczynska et al. 1996). Overexpression of the 
β5 subunit in human fibroblasts has been reported to increase the replicative potential of cells 
(Chondrogianni et al. 2005). In the present work, the increased levels of PRE2, the β5 subunit 
of the 20S proteasome complex, in yeast expressing SOD1A4V-DsRed may indicate that cells 
had an increased requirement for the catalytic chymotryptic activity of this subunit. Moreover, 
there may be decreased demand for the catalytic activity of the PRE3 β-subunit in these cells, 
and thus it was consequently down-regulated to further enable the up-regulation of PRE2. In 
this case, the cellular levels of PRE2 β5 subunits may even be a critical determinant of 
proteasome activity in cells expressing SOD1A4V-DsRed. It has been hypothesised that reduced 
availability of β-subunits in cells is a rate-limiting factor in proteasome activity (Chondrogianni 
et al. 2005). In the present work, as yeast expressing SOD1A4V-DsRed did not exhibit reduced 
cellular viability, down-regulation of PRE3 in the context of up-regulated PRE2 was not 
detrimental to the viability of yeast.  
The up-regulation of UBA1, UFD1 and PRE2 suggest that UPS activity was increased in cells 
expressing SOD1A4V-DsRed. Moreover, the common, central interactor of the primary hits and 




are conserved in eukaryotes (Finley et al. 1989, Oh et al. 2013). As such, it is one of four genes 
that encode ubiquitin in yeast, as is its mammalian orthologue. Common between these primary 
hits and secondary interactors (PRE7, PUP1 and RPS31) is that through their functions in cells 
they influence the distribution of ubiquitin in the cellular ubiquitin pools. In particular, UBA1 
is a key enzyme that modulates the activated ubiquitin pool. It functions at the apex of the UPS, 
mediating ATP- and Mg2+-dependent activation of ubiquitin before it is transferred to one of 
∼40 E2 enzymes which work in co-operation with one of > 600 E3 ligases to conjugate 
ubiquitin to target proteins (Ayusawa et al. 1992, Cook and Chock 1992, Clague et al. 2015). 
It is thus the key driver of the UPS. The increased levels of UBA1 and the other proteins of the 
UPS, and the lack of toxicity of SOD1A4V-DsRed, suggest that yeast effected these changes in 
response to SOD1A4V and this protected against the toxicity of SOD1A4V. Indeed, extensive 
evidence suggests that dysfunction of the UPS contributes to motor neuron degeneration in 
ALS. This includes, but is not limited to, the universal presence of ubiquitin and the frequent 
detection of proteasome subunits in inclusions in ALS patients’ motor neurons (Leigh et al. 
1991, Seilhean et al. 2004). It is thus warranted that the effect of increased levels and activity 
of key UPS proteins be investigated in neuronal cell culture models to gain an understanding as 
to whether increased UPS functionality can afford protection in neurons expressing ALS-
causing mutations. 
3.4.8 Concluding statements 
The complexity of molecular mechanisms that underlie ALS and other neurodegenerative 
diseases make for an exceedingly challenging task in elucidating potential proteins and 
molecular processes that could be targeted for the development of a therapy. However, yeast 
represent a good model system to explore the fundamental molecular changes that are involved 
in neurodegenerative diseases. This is because many of the molecular disturbances involved in 




amongst eukaryotic organisms. In the work presented in this chapter, the heterologous 
expression of human TDP-43, FUS and SOD1A4V in 128 yeast strains from the EGFP-fusion 
collection (Huh et al. 2003) led to the identification of processes that are potentially involved 
in cellular responses to the pathogenic mechanisms that underlie ALS. Moreover, each of these 
three ALS-associated proteins were found to have their own unique ‘fingerprint’ in terms of the 
specific cellular response they elicited. Indeed, the pathways by which these three ALS-
associated proteins aggregate in cells are distinct to each (Farrawell et al. 2015). Validation of 
these findings in neuronal cell culture models will provide the basis for further studies into the 
specific roles of the differentially-regulated proteins, and the pathways in which they function, 
in ALS. Potentially, ALS linked to mutations in TARDBP, FUS and SOD1 may benefit from, 





































Chapter 4: Increased levels of UBA1 protect against 






Ubiquitin is essential for the regulation of many aspects of cell biology. In the 
neurodegeneration field, it is well known for its role in the degradation of misfolded proteins. 
However, beyond tagging proteins for degradation, ubiquitylation is one of the most abundant 
protein modifications in cellular signalling, controlling numerous cellular pathways such as 
transcription, translation, vesicle transport and apoptosis (Winston et al. 1999, Deng et al. 2000, 
Hoppe et al. 2000, Spence et al. 2000, Hoege et al. 2002, Haglund et al. 2003, Li et al. 2003, 
Margottin-Goguet et al. 2003, Wertz et al. 2004, Carter et al. 2007, Kravtsova-Ivantsiv et al. 
2009, Raiborg and Stenmark 2009, Boname et al. 2010, Dynek et al. 2010, Goto et al. 2010, 
Ren and Hurley 2010, Gerlach et al. 2011, Ikeda et al. 2011). Ubiquitin labels substrate proteins 
via a highly ordered multi-step enzymatic cascade, with specific differences in the length and 
topology of poly-ubiquitin chains determining a range of signalling outcomes or proteolytic 
degradation via the proteasome. In the nervous system, the UPS contributes to the regulation of 
many aspects of neural function, such as neuronal growth and development, neuronal 
excitability, neurotransmission, long-term potentiation (LTP) and synapse formation and 
elimination (Mabb and Ehlers 2010, Kawabe and Brose 2011). Many factors can influence 
ubiquitin homeostasis, and accumulation of ubiquitin in large misfolded protein deposits found 
in ALS pathology may indirectly interfere with other essential ubiquitin-dependent cellular 
processes (Farrawell et al. 2018). Indeed, neurons are sensitive to ubiquitin dyshomeostasis, 
which if prolonged may lead to cell death (Tan et al. 2000, Tan et al. 2001). UPS function is 
therefore central to neuronal health and neurodegenerative disease, and ubiquitylation is 
emerging as a highly promising target for human therapy that remains to be fully exploited 
(Jankowska et al. 2013). However, ubiquitin-dependent cellular processes are highly 
interconnected, and there is a lack of systematic data on disease-related perturbations in these 




in affected neurons and in response to therapeutic intervention. 
Several of the genes implicated in fALS cohorts encode components and regulators of the UPS, 
including VCP (Johnson et al. 2010, Abramzon et al. 2012), SQSTM1 (Fecto et al. 2011), 
UBQLN2 (Deng et al. 2011, Teyssou et al. 2017), OPTN (Maruyama et al. 2010), CCNF 
(Williams et al. 2016) and TBK1 (Cirulli et al. 2015). Defects in these genes are likely to lead 
to perturbations in ubiquitin homeostasis, but the precise effect of these mutations on the 
maintenance of ubiquitin homeostasis is currently unknown. Recent work using proteomics to 
map the ubiquitin-modified proteome in NSC-34 cells showed significant changes in the 
distribution of ubiquitin in mutant SOD1-expressing cells (Farrawell et al. 2018). Mutations in 
genes such as TARDBP also lead to disruption of ubiquitin homeostasis. For example, 
knockdown of the DUB, UBPY, exacerbated the toxicity of TDP-43 in Drosophila 
melanogaster (Hans et al. 2014).  
Ubiquitin regulates cellular concentrations of TDP-43 and SOD1 (Miyazaki et al. 2004, Scotter 
et al. 2014) and their aberrant accumulation can be triggered by inhibition of the proteasome. 
In human skin fibroblasts, significantly higher accumulation of a UPS reporter was observed in 
ALS patient-derived cells compared to those from controls (Yang et al. 2015). Cell models of 
CCNF-linked fALS were also found to have higher levels of the reporter compared to controls 
(Williams et al. 2016), consistent with a compromised UPS in ALS. Similar reporters of UPS 
function demonstrated UPS dysfunction in cultures of NSC-34 cells expressing mutant SOD1 
(Crippa et al. 2010) and in the spinal motor neurons of mice with ALS caused by a SOD1 
mutation (Basso et al. 2009). Indeed, proteasomal clearance of mutant SOD1 was reported to 
be impaired uniquely in NSC-34 cells in contrast to muscle cells, which exhibited efficient 
degradation of mutant SOD1 (Onesto et al. 2011). Recent work has shown that C9ORF72 poly-
(Gly-Ala) aggregates sequester a large proportion of the cell’s proteasomes and functionally 




subunit RPT3 in the absence of an ALS genetic background can result in an ALS phenotype in 
mice, including locomotor dysfunction, progressive motor neuron loss and mislocalisation of 
TDP-43, FUS, UBQLN2, and OPTN (Tashiro et al. 2012). These data are consistent with a 
reduction in UPS capacity being sufficient to drive ALS pathology in mice. Indeed, not even 
overexpression of human mutant TDP-43 gives such an accurate reproduction of a human ALS-
like phenotype in mice. The increased expression of components of the ubiquitin-dependent 
proteolysis machinery were identified as a significant distinguishing factor in the transcriptome 
of microdissected resistant oculomotor neurons compared to vulnerable motor neurons from 
the human spinal cord (Brockington et al. 2013), suggesting increased UPS capacity is 
protective in ALS. 
In a screen for responses in the proteome to expression of SOD1A4V in yeast (Chapter III), the 
E1 ubiquitin-activating enzyme UBA1 was found to be up-regulated relative to control cells. 
The increased levels of UBA1 correlated with a distinct lack of SOD1A4V toxicity, which is in 
contrast to the toxicity this SOD1 mutation causes in humans (Cudkowicz et al. 1997, Juneja et 
al. 1997). UBA1 is the primary initiator of the UPS cascade, mediating ATP- and Mg2+- 
dependent activation of ubiquitin before it is transferred to one of ∼40 E2 enzymes which work 
in co-operation with one of > 600 E3 ligases to conjugate ubiquitin to target proteins. UBA1 is 
fundamental to the UPS, and its downregulation attenuates UPS activity (Ciechanover et al. 
1984, Ghaboosi and Deshaies 2007, Qin et al. 2016). It is known to be vital for motor neuron 
health as mutations in UBA1 result in an infant onset motor neuron disease, X-linked spinal 
muscular atrophy (XL-SMA; (Ramser et al. 2008)). XL-SMA represents a rare form of SMA, 
however, notably, UBA1 is present at decreased levels in the majority of SMA cases caused by 
mutations in SMN1 (Wishart et al. 2014, Powis et al. 2016). Increasing the levels of UBA1 
restored motor performance and increased lifespan in mouse and zebrafish models of SMA 




hypothesis that increased UBA1 expression is protective against cellular toxicity induced by 
SOD1A4V. To investigate this hypothesis, the murine NSC-34 cell line was used as a mammalian 
neuronal cellular model of SOD1A4V-ALS. The specific aims of the work presented in this 
chapter were to:  
(i) compare the levels of endogenous UBA1 in mammalian neuronal cells 
overexpressing SOD1A4V with cells overexpressing SOD1WT,  
(ii) determine the effect of increased UBA1 expression on SOD1A4V-induced toxicity in 
NSC-34 cells and  
(iii) investigate the effect of increased UBA1 expression on SOD1A4V aggregation in 
cells. 
 Materials and methods 
Saponin (Saponin from Quillaja bark, Cat. No. S4521-10G) was from Sigma-Aldrich (St. Louis, 
MO, USA). 
4.2.1 Plasmid constructs for NSC-34 cells 
The pEGFP-N1 vectors containing human SOD1WT (SOD1WT-EGFP) and SOD1A4V (SOD1A4V-
EGFP) were described in Chapter II. The pEGFP-N1 vector, which encodes for EGFP alone, 
was used as a control for EGFP-tagged SOD1 expression. pCDNA3.1(+) constructs containing 
murine wild-type UBA1 (UBA1WT) or a catalytically-inactive mutant C632S UBA1 
(UBA1C632S) isoform were generated by sub-cloning murine UBA1WT from pET28-mE1 
(Addgene plasmid 32534, provided by Jorge Eduardo Azevedo (Carvalho et al. 2012)) into 
pCDNA3.1(+) and replacing Cys-632 with Ser, via GenScript’s customised cloning and site-
directed mutagenesis services. The pmCherry-C1 vector, which encodes mCherry alone, was 
used as a control in place of UBA1WT and UBA1C632S in co-transfections with SOD1WT-EGFP 




measure co-transfection efficiency and to account for cell viability in the absence of UBA1WT 
and UBA1C632S. 
4.2.2 Mammalian cell culture and transfections 
NSC-34 cells (neuroblastoma × spinal cord hybrid) were maintained as described in Chapter II. 
Cells were seeded at 1 × 105 cells/mL in DMEM/F-12/FBS into 6-well plates to prepare cell 
lysates for immunoblot analyses, 8-well µ-Slides (Ibidi, Planegg-Martinsried, Germany) for 
confocal microscopy, or 24-well plates for flow cytometry or IncuCyte® ZOOM imaging. Cells 
were transfected 24 h later using Lipofectamine® 3000 (Invitrogen, USA) according to the 
manufacturer’s instructions, with 0.2 µg DNA per well for 8-well µ-Slides, 0.5 μg DNA per 
well for 24-well plates or 2.5 μg DNA per well for 6-well plates. For co-transfections the 
amount of DNA was divided equally between constructs. Non-transfected cells were included 
as controls in all experiments. For all experiments, a time-point of 48 h post-transfection was 
used for cell lysis or fixing for confocal microscopy. 
4.2.3 IncuCyte® ZOOM live cell imaging 
IncuCyte® ZOOM live cell imaging and analysis was used to carry out two different measures 
in NSC-34 cells transiently transfected with SOD1WT-EGFP, SOD1A4V-EGFP or EGFP alone, 
or co-transfected with these constructs together with either UBA1WT, UBA1C632S or mCherry 
alone. One of the experiments involved monitoring the relative population growth of transfected 
cells (EGFP-positive cells) over 80 h. The net cell population growth (rate of cell division – 
rate of cell death) was used as a measure of cell viability, on the basis that toxicity caused by 
the overexpression of SOD1A4V-EGFP would impair cellular ability to proliferate and/or result 
in the loss of cells relative to control cells overexpressing SOD1WT-EGFP or EGFP alone. NSC-
34 cells were transfected in 6-well plates and were re-plated at 24 h post-transfection at uniform 
cell density (5 × 104 cells/mL) in 200 µL/well DMEM/F-12/FBS into 96-well plates and imaged 




viable transfected cells, a processing definition in the IncuCyte® ZOOM software was 
optimised to identify and count transfected cells based on a minimum level of EGFP 
fluorescence, and viable cells based on a minimum size. Non-transfected controls were used to 
account for and exclude background fluorescence and fluorescent artefacts, cell debris and 
dying cells. 
The second experiment quantified cells containing inclusions using a modification of a saponin-
permeabilisation protocol described by Pokrishevsky et al. (2018). Saponin is a mild, 
cholesterol-chelating detergent that creates pores in the plasma membrane of cells (Symons and 
Mitchison 1991). These pores allow soluble intracellular proteins to diffuse out of the cell, while 
trapping insoluble proteinaceous structures. NSC-34 cells were transfected with each 
expression construct in quadruplicate in 96-well plates, and after 48 h were imaged using an 
IncuCyte® ZOOM. These pre-permeabilisation images were used to measure the numbers of 
cells that were transfected (EGFP-positive) in each well. After imaging, cells were incubated 
with 0.03% (w/v) saponin in PBS for 10 min at RT to create pores in the cells’ plasma 
membranes. Saponin-treated cells were then imaged again to measure the numbers of cells in 
which non-diffusable, insoluble EGFP-positive material remained following permeabilisation. 
The percentage of transfected cells containing insoluble EGFP-fusion proteins were then 
calculated using the following formula: 
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Equation 4.1. 
For all IncuCyte® experiments, the mean ± SEM was calculated across quadruplicate 





4.2.4 Treatment with MG132 
To test the susceptibility of cells to proteasome inhibition, NSC-34 cells transfected with each 
of SOD1WT-EGFP, SOD1A4V-EGFP or EGFP alone were first replated at 24 h post-transfection 
at uniform cell density and imaged in an IncuCyte® ZOOM. At 36 h post-transfection cells 
were treated with 0, 0.5, 1, 1.5, 2, 2.5, 3.5 or 5 µM of the proteasome inhibitor MG132 and 
imaging was continued for the next 50 h. Out of two independent experiments, for each 
concentration of MG132, the numbers of cells at 48 h post-transfection were quantified and the 
IC50 was calculated for cells transfected with SOD1WT-EGFP, SOD1A4V-EGFP or EGFP alone. 
To compare the IC50 for cells expressing SOD1WT-EGFP, SOD1A4V-EGFP or EGFP alone, the 
numbers of cells expressing SOD1A4V-EGFP or EGFP alone were normalised to the numbers 
of cells expressing SOD1WT-EGFP. 
4.2.5 Cell lysis, protein extraction and quantification 
NSC-34 cells transfected with SOD1WT-EGFP, SOD1A4V-EGFP or EGFP alone and grown in 
6-well plates were harvested at 48 h post-transfection using 0.05% trypsin-EDTA. Cells were 
washed with PBS before being resuspended in RIPA buffer (50 mM Tris-HCl, pH 7.4 
containing 0.5% (w/v) sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1% (v/v) Triton X-
100, 0.1% (w/v) SDS and Halt™ Protease Inhibitor Cocktail (Thermo Fisher Scientific, 
Sydney, Australia)) and incubated overnight at 4 °C to promote cell lysis. Using 23 G needles, 
each cell suspension was drawn up and down twelve times to ensure the nuclear membrane was 
broken and the chromosomal DNA sheared. An aliquot was taken for total protein quantitation 
by bicinchoninic acid (BCA) assay and the remainder of the samples stored at -80 °C. 
4.2.6 Immunoblotting 
The UBA1 antibody used in this study was a rabbit monoclonal to human UBA1, and had been 




antibody, it should have high specificity and minimal cross-reactivity, recognising a single 
epitope at the C-terminus of UBA1. As this epitope is at the C-terminus of UBA1, this antibody 
should react with both of the isoforms of UBA1 (UBA1a and UBA1b), which differ only at the 
N-terminus (there are an additional 40 amino acids at the N-terminus of UBA1a) (Stephen et 
al. 1997). For SDS-PAGE and immunoblotting, 100 µg of total cellular protein from NSC-34 
lysates were prepared in appropriate volumes of 2× loading buffer (final concentrations: 2% 
(w/v) SDS, 0.5 M Tris-HCl, 25% (w/v) glycerol, 0.01% (w/v) bromophenol blue, 5% (v/v) β-
mercaptoethanol). Samples were reduced and denatured by heating at 95 °C for 5 min before 
being electrophoresed on a Mini-PROTEAN TGX Stain-Free Gel (Bio-Rad, USA) for 1.5 h at 
100 V. Prior to transfer, the total protein loaded per lane on each gel was imaged using a 
Criterion Stain-Free Imager (Bio-Rad, USA). Proteins were transferred onto a nitrocellulose 
membrane (Pall Corporation, USA) at 20 V overnight at 4 °C. The membrane was blocked in 
5% (w/v) skim milk powder in Tris-buffered saline (TBS) supplemented with 0.05% (v/v) 
Tween-20 (TBS-T) overnight at 4 °C, followed by overnight incubation with rabbit monoclonal 
antibody to E1 ubiquitin activating enzyme (ab181225, Abcam) at 1:10,000 dilution in 5% 
(w/v) skim milk powder in TBS-T. The following day the membrane was washed three times 
with TBS-T over 30 min before being incubated overnight at 4 °C with horseradish peroxidise 
(HRP)-conjugated goat anti-rabbit antibody (A16104, Invitrogen) at 1:2,000 dilution in 5% 
skim milk powder in TBS-T. The membrane was then washed three times with TBS-T over 45 
min and visualised with WesternBright™ Sirius chemiluminescent HRP substrate (Advansta) 
on an Amersham Imager 6600RGB. Four separate SDS-PAGE and immunoblotting 
experiments were carried out on cell lysates prepared in four separate transfection experiments. 
To measure the relative density of protein bands resolved in each immunoblotting experiment, 
the density of each band and of the total protein loaded in the respective lane of the gel were 




of each band was then normalised to the calculated total protein density in the respective gel 
lane as is standard practice for immunoblots. The mean normalised relative band densities from 
the four biological repeats were compared using one-way ANOVA with Tukey’s multiple 
comparisons post-hoc test.  
4.2.7 Fixing, permeabilising, immunolabelling and confocal microscopy 
At 48 h post-transfection, NSC-34 cells transfected with SOD1WT-EGFP, SOD1A4V-EGFP or 
EGFP alone, or co-transfected with these constructs as well as UBA1WT, UBA1C632S or mCherry 
alone, were fixed in 4% (w/v) paraformaldehyde in PBS for 20 min at room temperature in 
monolayers in 8-well µ-Slides for confocal microscopy. Cells were then washed three times 
over 15 min with PBS (pH 7.4), and permeabilised with 1% (v/v) Triton X-100 in PBS for 30 
min on crushed ice. Following permeabilisation, cells were washed twice over 10 min with PBS 
and blocked for 1 h at room temperature with 5% (v/v) FBS, 1% (w/v) bovine serum albumin, 
0.3% (v/v) Triton X-100 in PBS. After blocking, cells were washed twice over 10 min with 
PBS and incubated for 16 h at 4 °C with rabbit monoclonal antibody to E1 ubiquitin activating 
enzyme (ab181225, Abcam) or rabbit IgG monoclonal isotype control (ab172730, Abcam) at 
1:200 dilution. Primary antibodies were diluted in 1% (w/v) bovine serum albumin, 0.1% (v/v) 
Triton X-100 in PBS. The following day, cells were washed twice over 10 min with PBS and 
incubated for 5 h at room temperature with Alexa Fluor™ 647 goat anti-rabbit IgG (H+L) 
secondary antibody (ab150079, Abcam) at 1:500 dilution. Secondary antibodies were diluted 
in 1% (w/v) bovine serum albumin, 0.1% (v/v) Triton X-100 in PBS. Cells were then washed 
three times over 15 min in PBS.  
Cells were imaged using a Leica TCS SP5 II confocal microscope with a 63× oil-immersion 
objective lens (Leica Microsystems, Wetzlar, Germany). EGFP fluorescence was excited at 488 
nm by an argon laser; mCherry fluorescence was excited at 561 nm by a DPS 561 laser. 




– Advanced Fluorescence (LAS-AF) software (version 3, Leica Microsystems, Wetzlar, 
Germany). 
 Results 
4.3.1 Endogenous UBA1 levels are unaffected by overexpression of SOD1A4V-EGFP in 
NSC-34 cells 
The A4V mutation in SOD1 causes one of the most aggressive forms of ALS (Cudkowicz et al. 
1997, Juneja et al. 1997, Lemmens et al. 2007). In order to measure the effects of SOD1A4V-
EGFP overexpression on the viability of NSC-34 cells, live cell imaging on an IncuCyte® 
ZOOM was used to monitor cells over a 70 h time period. In this assay, reduced net population 
growth of cells overexpressing SOD1A4V-EGFP relative to control cells overexpressing 
SOD1WT-EGFP or EGFP alone was considered to be a toxic effect of SOD1A4V-EGFP. Over the 
imaging period the numbers of cells expressing SOD1WT-EGFP and EGFP alone steadily 
increased, while the numbers of cells expressing SOD1A4V-EGFP increased at a slower rate 
(Figure 4.1, a). At 48 h post-replating there were significantly lower numbers of cells expressing 
SOD1A4V-EGFP than cells expressing SOD1WT-EGFP (p = 0.0151) or EGFP alone (p = 0.0435) 
(Figure 4.1, b). This indicates that the overexpression of SOD1A4V-EGFP caused toxicity. 
To characterise the appearance of transfected cells and the intracellular localisation of the 
EGFP-fusion proteins, cells were imaged 48 h post-transfection using confocal microscopy. 
While SOD1WT-EGFP was observed to have a relatively even distribution throughout the 
cytoplasm and within nuclei, in a proportion of cells SOD1A4V-EGFP formed multiple large 
inclusions in the cytoplasm (Figure 4.1, c). 
Given that the heterologous expression of human SOD1A4V in yeast did not cause toxicity, that 
there was an absence of SOD1A4V aggregation in yeast cells, and that these observations 




UBA1 in NSC-34 cells expressing SOD1A4V-EGFP, SOD1WT-EGFP or EGFP alone was 
investigated. Immunoblot analysis showed that there were no differences in the levels of UBA1 
(~118 kDa) between NSC-34 cells overexpressing SOD1A4V-EGFP, SOD1WT-EGFP and EGFP 
alone (Figure 4.1, d). 
Considerable evidence supports impaired proteasome activity as one of the downstream toxic 
effects of mutant SOD1 expression in motor neurons (Urushitani et al. 2002, Allen et al. 2003, 
Kabashi et al. 2004, Cheroni et al. 2009, Crippa et al. 2010, Onesto et al. 2011). In yeast 
expressing human SOD1A4V the levels of PRE2, a key proteasome subunit, and UFD1, a protein 
with important functions in ubiquitin-dependent protein degradation, were both increased 
(Chapter III). Given these data, the susceptibility of NSC-34 cells expressing SOD1A4V-EGFP 
to proteasome inhibition were tested. Cells overexpressing SOD1A4V-EGFP were more 
sensitive to proteasome inhibition by MG132 than cells overexpressing SOD1WT-EGFP or 
EGFP alone. This was evident through the IC50 for cells overexpressing SOD1A4V-EGFP being 

















Figure 4.1.  Endogenous UBA1 levels are unaffected by overexpression of SOD1A4V-EGFP in NSC-34 cells. 
(A) Representative time-resolved plot from one of three experiments showing the numbers of NSC-34 cells 
transiently transfected with either SOD1WT-EGFP, SOD1A4V-EGFP or EGFP alone. Over time, cells 
overexpressing SOD1WT-EGFP or EGFP alone continued to proliferate while the numbers of cells overexpressing 
SOD1A4V steadily plateaued after the initial imaging period. Cells were replated at 24 h post-transfection at uniform 
cell density, before being imaged in an IncuCyte® ZOOM over 70 hours. (B) Comparison of the numbers of cells 
expressing SOD1WT-EGFP, SOD1A4V-EGFP or EGFP alone 48 h after replating and imaging in the IncuCyte® 
ZOOM. Graph represents the mean ± SEM from three independent experiments. Differences between the means 
were determined using a one-Way ANOVA followed by Tukey’s multiple comparison test. * indicates p < 0.05. 
(C) SOD1A4V-EGFP forms cytoplasmic aggregates in NSC-34 cells, while SOD1WT-EGFP is diffusely distributed 
throughout the cell. Cells were imaged at 48 h post-transfection on a Leica TCS SP5 II confocal microscope. Scale 
bar represents 10 µm. (D) The levels of endogenous UBA1 in NSC-34 cells are not altered in cells overexpressing 
SOD1A4V. NSC-34 cells overexpressing SOD1WT-EGFP, SOD1A4V-EGFP or EGFP alone were lysed at 48 h post-
transfection. 100 µg total protein from each lysate were run on a SDS-PAGE gel and immunoblotted for UBA1. 
UBA1 band densities were normalised to total protein loaded in each gel lane. Total protein loading was assessed 
by imaging stain-free gels prior to transfer. Representative immunoblot showing bands corresponding to UBA1 
(~118 kDa). Graph represents the mean ± SEM from four immunoblots of four independent transfection 
experiments. (E) NSC-34 cells overexpressing SOD1A4V-EGFP are more susceptible to proteasome inhibition than 
cells overexpressing SOD1WT-EGFP or EGFP alone. Cells were replated at 24 h post-transfection at uniform cell 
density, then treated with different concentrations (0, 0.5, 1, 1.5, 2, 2.5, 3.5 or 5 µM) of the proteasome inhibitor 
MG132 at 36 h post-transfection and imaged in an IncuCyte® ZOOM over 50 hours. 48 h after MG132 treatment, 
the concentration of MG132 required to cause half the number of cells overexpressing SOD1A4V-EGFP to die (IC50) 
was lower than that of cells overexpressing SOD1WT-EGFP or EGFP alone. Graph represents the mean ± SEM 
from two independent experiments. 
 
 
4.3.2 UBA1 expression is similar in NSC-34 cells transfected with either pcDNA3.1(+)-
UBA1WT or pcDNA3.1(+)-UBA1C632S plasmids 
To explore the effect of increasing the levels of UBA1 in NSC-34 cells overexpressing 
SOD1A4V-EGFP, two plasmid constructs were generated; pcDNA3.1(+) containing murine 
UBA1WT or UBA1C632S (UBA1 with mutation of Cys-632, the residue responsible for its E1 
catalytic activity) (Hatfield and Vierstra 1992, Forrester et al. 2011, Yang et al. 2012). To 
ensure that any effects observed in cells overexpressing UBA1WT were due to the enzymatic 
capacity of UBA1 and not from differences in expression levels between pcDNA3.1(+)-
UBA1WT and pcDNA3.1(+)-UBA1C632S, endogenous and overexpressed UBA1 levels were 
examined by immunocytochemistry and confocal microscopy. Visual inspection of the confocal 
images showed that the anti-UBA1 immunostaining was stronger in cells transfected with 
pcDNA3.1(+)-UBA1WT or pcDNA3.1(+)-UBA1C632S than in cells that were not transfected with 
these constructs (Figure 4.2, a). UBA1 appeared to be localised throughout the cytoplasm and 




cytoplasm. This localisation pattern aligns with findings from other studies showing that UBA1 
is present in nuclei and throughout the cytoplasm, including localising at high concentrations 
to several organelles (Schwartz et al. 1992, Moudry et al. 2012). Quantification of anti-UBA1 
Alexa Fluor™ 647 fluorescence intensity confirmed that there were greater levels of UBA1 in 
cells transfected with either of the two UBA1 constructs than in non-transfected cells 
(pcDNA3.1(+)-UBA1WT, p = 0.0062; pcDNA3.1(+)-UBA1C632S, p = 0.0036) (Figure 4.2, b). 
Importantly, UBA1WT and UBA1C632S were expressed at comparable levels in transfected cells, 
with no significant differences calculated in the mean anti-UBA1 Alexa Fluor™ 647 





Figure 4.2. UBA1WT and UBA1C632S are expressed at the same levels in transfected NSC-34 cells. (A) 
Representative images showing immunostaining for UBA1 in NSC-34 cells transiently co-transfected with 
SOD1A4V-EGFP and to express either mCherry alone (‘control’), UBA1WT or UBA1C632S. Cells were fixed, 
permeabilised and stained for UBA1 (Alexa Fluor™ 647) 48 h post-transfection. Scale bar represents 10 µm. (B) 
Confocal images of the cells were analysed using a macro in Image J to quantify the fluorescence intensity (F.I.) 
of the Alexa Fluor™ 647 α-UBA1 staining. Graph represents the mean ± SEM from 3 wells of cells prepared in 3 
separate transfection experiments. Means were compared using one-way ANOVA with Tukey’s multiple 





4.3.3 Overexpression of UBA1WT reduces the toxicity of SOD1A4V-EGFP in NSC-34 
cells 
To test the hypothesis that increased UBA1 expression protects the viability of cells 
overexpressing mutant SOD1, NSC-34 cells were co-transfected with SOD1WT-EGFP, 
SOD1A4V-EGFP or EGFP alone and either UBA1WT, UBA1C632S or mCherry alone, and the net 
population growth of EGFP-positive cells monitored over 90 h using an IncuCyte® ZOOM. As 
was observed for cells transfected with just SOD1WT-EGFP or SOD1A4V-EGFP (Figure 4.1, a), 
the numbers of cells overexpressing SOD1WT-EGFP and either UBA1WT, UBA1C632S or 
mCherry alone continued to increase over the 90 h of imaging (Figure 4.3, a). Within the first 
~32 h of imaging, the population growth rate of cells co-expressing SOD1A4V-EGFP and 
UBA1WT was greater than that of cells co-expressing SOD1A4V-EGFP and UBA1C632S or 
mCherry alone, such that, 48 h post-transfection, the numbers of cells co-expressing SOD1A4V-
EGFP and UBA1WT were significantly greater than the numbers of cells co-expressing 
SOD1A4V-EGFP and UBA1C632S (p = 0.0020) or mCherry alone (p = 0.0003) (Figure 4.3, b). 
This suggests that the increased levels of catalytically active UBA1WT buffered against the 
toxicity caused by SOD1A4V-EGFP overexpression. The sudden decrease in cell numbers after 
the first 32 h of imaging may be due to a decrease in the availability of UBA1WT in the cells 
over time, either due to dilution or degradation of the UBA1WT plasmid DNA, or to functional 
saturation of the exogenous UBA1WT molecules in activating ubiquitin and initiating the 















Figure 4.3. UBA1WT overexpression increases viability of NSC-34 cells overexpressing SOD1A4V-EGFP.(A) 
Representative graph showing numbers of NSC-34 cells transiently co-transfected to express either SOD1WT-
EGFP, SOD1A4V-EGFP or EGFP and UBA1WT, the catalytically inactive mutant UBA1C632S or mCherry. Cells 
were replated at 24 h post-transfection at uniform cell density, before being imaged in an IncuCyte® ZOOM over 
90 h. (B) Numbers of co-transfected NSC-34 cells at 48 h post-transfection, normalised to cells co-transfected with 
SOD1WT-EGFP and UBA1WT. Experiment was performed three times and the bar chart represents mean ± SEM. 
Differences between the means were determined using one-Way ANOVA followed by Tukey’s multiple 











4.3.4 SOD1A4V-EGFP aggregation is unaffected by UBA1WT overexpression 
After discovering that increased UBA1WT expression protected against the toxicity caused by 
SOD1A4V-EGFP in NSC-34 cells, it was next explored whether this effect may be mediated by 
inhibiting the accumulation of SOD1A4V-EGFP aggregates. To quantify the numbers of 
transfected cells containing SOD1A4V-EGFP aggregates, an assay was used in which the plasma 
membrane of transfected cells was permeabilised using saponin, allowing soluble intracellular 
proteins to diffuse out of the cell while trapping insoluble protein material. Cells were imaged 
pre- and post-permeabilisation with saponin, using an IncuCyte® ZOOM, to quantify numbers 
of transfected cells and numbers of cells containing insoluble EGFP-fusion proteins.  
Saponin-permeabilisation and imaging of NSC-34 cells co-transfected with SOD1WT-EGFP 
and either UBA1WT, UBA1C632S or mCherry alone showed that there was no fluorescent signal 
from cells overexpressing SOD1WT-EGFP or EGFP alone following plasma membrane 
permeabilisation (Figure 4.4). In contrast, after permeabilisation, SOD1A4V-EGFP protein 
remained in 8.82 ± 1.47%, 13.03 ± 2.31% and 14.3 ± 3.01% of SOD1A4V-EGFP cells co-
expressing mCherry alone, UBA1WT and UBA1C632S, respectively, indicating that similar 
amounts of insoluble, non-diffusable SOD1A4V-EGFP were present in cells under each 
condition. These results indicate that increased levels of UBA1WT had no impact on the overall 








Figure 4.4. UBA1WT overexpression does not affect SOD1A4V-EGFP aggregation in NSC-34 cells. Percentages 
of transfected cells containing insoluble EGFP-positive inclusions. NSC-34 cells were transiently co-transfected 
to express either SOD1WT-EGFP, SOD1A4V-EGFP or EGFP alone and UBA1WT, the catalytically inactive mutant 
UBA1C632S or mCherry alone. After 48 h, cells were imaged on an IncuCyte® ZOOM, followed by incubation with 
0.03% (w/v) saponin in PBS for 10 min at room temperature, before being imaged again. Cells were transfected 
in triplicate, and the experiment was performed three times. The data presented is the mean ± SEM of the 
percentage of transfected NSC-34 cells containing insoluble EGFP-positive protein following permeabilisation 
with saponin. The means were compared using one-Way ANOVA followed by Tukey’s multiple comparison test. 
 
 
As well as the toxicity associated with the aggregation of SOD1A4V into insoluble inclusions, 
several studies have also reported that soluble oligomeric species formed by SOD1A4V potently 
reduce cell viability (Redler et al. 2014, Proctor et al. 2016, Zhu et al. 2018). Thus, it was 
examined whether the protective effect of increased UBA1WT expression against SOD1A4V-
EGFP toxicity was associated with it reducing the levels of SOD1A4V-EGFP in cells. 
Comparison of the mean EGFP fluorescence intensity of cells co-expressing SOD1A4V-EGFP 
and UBA1WT, UBA1C632S or mCherry alone prior to permeabilisation by saponin showed that 
there were no differences in SOD1A4V-EGFP levels in cells co-expressing UBA1WT relative to 
cells co-expressing UBA1C632S or mCherry alone (Figure 4.5). Similarly, there were no 
differences in the levels of SOD1WT-EGFP in cells co-expressing UBA1WT, UBA1C632S or 
mCherry alone. These data demonstrate that increased expression of UBA1WT did not protect 






Figure 4.5. UBA1WT overexpression has no effect on the total levels of SOD1A4V-EGFP in NSC-34 cells. The 
mean EGFP F.I. of SOD1A4V-EGFP and SOD1WT-EGFP in NSC-34 cells co-expressing UBA1WT, the catalytically 
inactive mutant UBA1C632S or mCherry alone. NSC-34 cells were transiently co-transfected with either SOD1WT-
EGFP or SOD1A4V-EGFP and UBA1WT, UBA1C632S or mCherry alone. After 48 h, cells were imaged on an 
IncuCyte® ZOOM, and the EGFP F.I. in cells was measured. Cells were transfected in triplicate, and the 
experiment was performed three times. The data presented are the mean ± SEM of the EGFP F.I. in transfected 










 Extensive evidence implicates dysregulation of the UPS and ubiquitin homeostasis in the 
pathogenesis of ALS. One of the strongest connections is that the hallmark pathological feature 
of ALS-affected motor neurons is the presence of inclusions comprised of misfolded proteins 
and ubiquitin (Leigh et al. 1991). This sequestration of ubiquitin likely influences its 
distribution in the cellular pools in which it resides (Kaiser et al. 2011). In the pool comprised 
of polyubiquitin chains, the function of ubiquitin in tagging and directing target proteins for 
degradation through autophagy and through the UPS requires its activation by the E1 enzyme, 
UBA1 (Ayusawa et al. 1992, Cook and Chock 1992, Clague et al. 2015). In screening the levels 
of yeast proteins in response to the heterologous expression of human SOD1A4V (Chapter III), 
the levels of UBA1 were found to be increased, coinciding with a distinct lack of SOD1A4V 
toxicity. Because the A4V mutation in SOD1 results in rapid motor neuron degeneration and 
ALS disease progression in humans (Cudkowicz et al. 1997, Juneja et al. 1997), it was 
hypothesised that the increased levels of UBA1 in yeast enabled cells to respond to the toxic 
mechanisms usually induced by the SOD1A4V protein, and thereby cell viability was not 
impaired. To test this hypothesis, in the present chapter the NSC-34 cell line was used to 
examine whether UBA1 was differentially regulated in NSC-34 cells overexpressing SOD1A4V 
or SOD1WT, and to determine whether increased UBA1 expression was associated with 
modulation of SOD1A4V aggregation and toxicity. 
4.4.1 Increased UBA1WT expression protects against SOD1A4V toxicity 
In the work presented in this chapter it was found that SOD1A4V-EGFP expression caused 
striking toxicity in NSC-34 cells, consistent with the toxicity the A4V SOD1 mutation causes 
in human motor neurons (Cudkowicz et al. 1997, Juneja et al. 1997). Importantly, in contrast 
to yeast expressing SOD1A4V, there were no differences in the levels of endogenous murine 




SOD1WT-EGFP or EGFP alone. It should be noted that the levels of UBA1 were not normalised 
to the transfection efficiency of SOD1, they were normalised to the total amount of protein 
loaded into each lane of the gel as is standard practice for immunoblots. The transfection 
efficiency of SOD1 was on average ~20%, thus, there would be a negligible effect on UBA1 
levels as measured by immunoblot. Immunofluorescence, however, would be a suitable 
alternative technique to use as a read-out.  
Through confocal microscopy it was observed that SOD1A4V-EGFP formed multiple large 
aggregates in NSC-34 cells. Furthermore, NSC-34 cells expressing SOD1A4V-EGFP were more 
vulnerable to proteasome inhibition using MG132 compared to cells expressing SOD1WT-EGFP 
or EGFP alone, suggesting that there was disruption of normal UPS activity in cells expressing 
SOD1A4V-EGFP before cells were exposed to MG132-mediated proteasome inhibition. Indeed, 
dysfunction of the UPS in motor neurons expressing mutant SOD1 has been reported in several 
studies (Urushitani et al. 2002, Cheroni et al. 2009, Crippa et al. 2010, Onesto et al. 2011). 
Moreover, impaired proteasome activity in cultured cells expressing mutant SOD1 has been 
correlated with cellular toxicity (Matsumoto et al. 2005, Kitamura et al. 2014). Vulnerability 
to mutant SOD1-mediated UPS dysfunction is potentially greater in spinal cord motor neurons 
than in other cell types. Spinal cord motor neurons from mice have been found to be more 
vulnerable to proteasome inhibition than non-motor neurons (Urushitani et al. 2002). A 
transcriptomic study of populations of spinal motor neurons that succumb to degeneration in 
ALS compared to resistant oculomotor neurons discovered that UPS genes were downregulated 
in the spinal motor neurons (Brockington et al. 2013). Thus, it is logical to hypothesise that 
increasing UPS capacity in motor neurons expressing ALS-causing mutations in SOD1 could 
provide cellular protection.  
When the levels of UBA1WT were increased through overexpression in NSC-34 cells expressing 




the catalytic activity of UBA1, as the expression of UBA1C632S, an isoform with a mutation of 
the catalytic cysteine residue, did not improve cell viability. UBA1 is the primary E1 ubiquitin-
activating enzyme in mammalian cells (Schulman and Harper 2009, Ye and Rape 2009). It is 
crucial for proper UPS functioning in eukaryotes. Severe UPS inhibition has been reported in 
yeast cells harbouring a temperature-sensitive UBA1 allele, causing depletion of ubiquitin 
conjugates (Ghaboosi and Deshaies 2007). Thus, in the present work, the increased levels of 
UBA1 in NSC-34 cells may have led to augmented UPS activity. 
4.4.2 UBA1WT-mediated protection against SOD1A4V toxicity is not associated with 
suppression of SOD1A4V aggregation 
With the improved viability of NSC-34 cells expressing SOD1A4V-EGFP resulting from 
UBA1WT overexpression, it was hypothesised that this may have been mediated by improved 
UPS function and therefore suppression of SOD1A4V-EGFP aggregation. It has long been 
debated whether the accumulation of misfolded, aggregated proteins into inclusions is a cause 
of cellular toxicity, a by-product of widespread proteostasis dysfunction in cells, or a protective 
mechanism used to sequester toxic intermediate oligomeric protein species into isolated 
compartments. Notably, mounting evidence shows that certain types of inclusions, such as the 
JUNQ compartment, can serve protective functions in the cell by sequestering toxic misfolded 
proteins, oligomeric species and aggregates (Kaganovich et al. 2008, Weisberg et al. 2012). 
Through a saponin-permeabilisation assay the results presented in the present work indicate 
that the overexpression of UBA1WT did not lead to suppression of SOD1A4V-EGFP aggregation. 
Moreover, the total cellular levels of SOD1A4V-EGFP were not reduced in cells overexpressing 
UBA1WT. Evidence from previous work has demonstrated that mutant SOD1G93A aggregates 
can be toxic or nontoxic depending on whether they are localised to an active JUNQ (Weisberg 
et al. 2012). Weisberg et al. (2012) found that SOD1G93A aggregates compartmentalised within 




factors that reside inside the JUNQ. By sequestering and depleting the pool of chaperones, other 
quality control substrates that required degradation could not be delivered to JUNQ-localised 
proteasomes for degradation. Importantly, Weisberg et al. (2012) also showed that 
overexpression of HSP70 significantly reduced SOD1G93A-mediated toxicity, thus 
demonstrating that up-regulation of quality control components that have been sequestered by 
aggregated SOD1G93A in the JUNQ can reverse this effect by increasing quality control capacity. 
More recently it has been reported that aggregates formed by SOD1A4V-EGFP in NSC-34 cells 
sequester free monomeric ubiquitin from the cytoplasm, depleting the free ubiquitin pool in 
cells (Farrawell et al. 2018). Moreover, when the ubiquitin-modified proteome (the 
‘ubiquitome’) was analysed and compared between NSC-34 cells expressing SOD1A4V-EGFP 
and those expressing SOD1WT-EGFP, it was revealed that the expression of SOD1A4V-EGFP 
caused widespread ubiquitin redistribution and consequent ubiquitin dyshomeostasis (Farrawell 
et al. 2018).  
As the primary ubiquitin-activating enzyme, disruption of the normal activity of UBA1 results 
in ubiquitin dyshomeostasis in cells. In SMA linked to disruption of normal UBA1 activity, 
ubiquitin homeostasis disturbances have been well documented (Aghamaleky Sarvestany et al. 
2014, Powis et al. 2014, Wishart et al. 2014). In a mouse model of SMA, increasing the levels 
of UBA1 through AAV9-mediated delivery led to increases in the levels of monoubiquitin and 
polyubiquitin, restoration of ubiquitin homeostasis and amelioration of impaired UPS activity 
(Powis et al. 2016). Moreover, AAV9-UBA1 treatment in these mice led to body weight 
stabilisation, improved motor performance and increased survival (Powis et al. 2016). The 
toxicity caused by SOD1A4V-EGFP expression in NSC-34 cells observed in the present work 
may have been due, at least in part, to sequestration of free monomeric ubiquitin and depletion 
of the free ubiquitin pool in NSC-34 cells. This, in turn, may have contributed to 




dependent molecular processes. Indeed, it was found that UPS activity was impaired in NSC-
34 cells expressing SOD1A4V-EGFP. Furthermore, if the SOD1A4V-EGFP inclusions observed 
in NSC-34 cells represented localisation of SOD1A4V-EGFP to JUNQ compartments, this may 
have disrupted the intra-JUNQ proteasomal degradation of ubiquitylated proteins. Thus, 
increasing the levels of UBA1WT may have contributed to enhancement in the capacity of cells 
to ubiquitylate other proteins that critically need to be degraded by the proteasome. This 
hypothesised mechanistic pathway, however, remains to be explored through further 
investigation. This could be tested by measuring free ubiquitin levels as described in Farrawell 
et al. (2018). 
Inhibiting UBA1 activity leads to interference of both excitatory and inhibitory synapses in 
hippocampal neurons (Rinetti and Schweizer 2010). Similarly, loss of UBA1 in Drosophila 
melanogaster causes defects in axon development (Watts et al. 2003). Additional work in 
Drosophila melanogaster has shown that mutations that cause modest impairment of UBA1 
expression and function cause a neurodegeneration phenotype (Pfleger et al. 2007), while yet 
others have demonstrated that a UBA1 mutation causing partial loss of function is associated 
with severe locomotion impairment and reduction in lifespan (Liu and Pfleger 2013). Of note, 
increased UBA1 levels have been implicated in the mechanism of action of the slow Wallerian 
degeneration mutation, which confers protection to synapses and axons in a range of traumatic 
and disease-related degeneration contexts (Wishart et al. 2007, Wishart et al. 2008).  
4.4.3 Concluding statements 
Importantly, the work presented in this chapter adds to previous efforts implicating the 
beneficial effects of increased UBA1 activity in neuronal cells. Moreover, the data from the 
present study extends on findings reported by others to demonstrate that augmented UBA1 
activity may have the capacity to ameliorate ubiquitin dyshomeostasis and UPS dysfunction 




together with the work presented in this chapter, it is hypothesised that increasing the levels of 
UBA1 in motor neurons may be able to improve cell viability by restoring ubiquitin 
homeostasis. This may enable reestablishment of normal activity of the downstream ubiquitin-
dependent molecular processes discussed above, including the UPS, that become dysfunctional 
in motor neurons as a result of the expression of ALS-causing mutations in SOD1 and other 
genes implicated in ALS. 
 
 
5. Chapter V 



























Chapter 5: A high-content screening system to 
evaluate protein aggregation and proteostasis 






Post-mortem examination of spinal cord tissue from ALS patients consistently reveal the 
presence of TDP-43-, FUS- or SOD1- and ubiquitin-positive inclusions comprised of insoluble 
proteinaceous material. Extensive research suggests that misfolded proteins, as abnormal 
monomers and/or oligomeric precursors, possess cytotoxic properties (Bolognesi et al. 2010, 
Proctor et al. 2016, Zhu et al. 2018) and that their aggregation into certain kinds of inclusions 
may serve to protect cells and to assist in the clearance of these toxic species (Johnston et al. 
1998, Kopito 2000, Kawaguchi et al. 2003, Arrasate et al. 2004, Kaganovich et al. 2008, Tan 
et al. 2008, Treusch et al. 2009, Zhang and Qian 2011, Weisberg et al. 2012, Polling et al. 
2014). However, the formation of protein inclusions is also indicative of dysregulated 
proteostasis and the inability of the cell to properly monitor, refold or degrade non-native 
proteins. Further, it has been suggested that the progressive spread of pathology in patients 
could be due to the cell-to-cell propagation of protein misfolding and aggregation (Shaw 2002, 
Brettschneider et al. 2014). Indeed, the uptake of preformed SOD1 aggregates into neuronal 
cells from the surrounding cell culture media has been demonstrated in several studies (Munch 
et al. 2011, Sundaramoorthy et al. 2013, Grad et al. 2014, Zeineddine et al. 2015). Inclusions 
with distinct characteristics, and that have been formed through diverse pathways, are observed 
in cellular models of ALS and human post-mortem tissue from patients with ALS and other 
neurodegenerative disorders (Krobitsch and Lindquist 2000, Kamhi-Nesher et al. 2001, Huyer 
et al. 2004, Matsumoto et al. 2005, Matsumoto et al. 2006, Kaganovich et al. 2008, Farrawell 
et al. 2015); including aggresomes, JUNQ and IPOD inclusions. Aggresome-, JUNQ- and 
IPOD-like inclusions can be distinguished based on their mobility, microtubule-dependence 
and colocalisation with different components of protein quality control pathways, most notably 
ubiquitin, but also with 26S proteasomes, molecular chaperones, and markers of autophagy and 




the majority of the inclusions examined in ALS patient tissue are ubiquitin-positive, additional 
types of inclusions that are ubiquitin-negative have also been reported (Forsberg et al. 2010). 
The ubiquitylation dynamics of misfolded proteins plays a key role in determining the type of 
inclusion they partition to (Kaganovich et al. 2008), however, the ubiquitylation dynamics of 
ALS-associated proteins have largely remained unclear. Also remaining to be characterised are 
the proteostasis disturbances that occur in motor neurons harbouring mutations in different 
ALS-associated genes. 
There is a vital need for the development of effective diagnostic tools and therapeutic strategies 
for ALS. Given the heterogeneity of ALS, the ALS research field would benefit greatly from 
the development of assays that can measure multiple phenotypic features in cellular ALS 
models and extract rich, descriptive information of responses to candidate therapeutic 
compounds and modifiers of ALS gene toxicity. Assays that utilise the principles of high 
content screening (HCS) could help to address this investigative gap. In the past 20 years HCS 
approaches have evolved to emerge as attractive options for researchers interested in obtaining 
extensively descriptive phenotypic data through automated microscopy. 
The overarching objective of the work presented in this chapter was to develop an experimental 
system with HCS capacity that could be used to extract multiplexed phenotypic data from 
cellular ALS models. The specific aims of this work were thus to: 
(i) generate cellular models of SOD1-, TDP-43-, FUS-, CCNF-, VAPB-, VCP-, OPTN- 
and UBQLN2-associated ALS 
(ii) develop a HCS method with the potential to examine pathological features in cellular 
ALS models 





 Materials and methods 
5.2.1 Plasmids 
In addition to SOD1WT-EGFP, SOD1A4V-EGFP, TDP-43WT-tGFP and TDP-43M337V-tGFP 
(described in section 2.2, Chapter II), the plasmids used in the present work are detailed in Table 
5.1. OPTNWT-EGFP, OPTNQ398X-EGFP and OPTNE478G-EGFP had previously been 
transformed into chemically competent E. coli DH5-α cells, and were stored in glycerol at -
80°C prior to plasmid DNA purification. Mammalian expression constructs comprised of the 
pCMV6-AC-tGFP vector containing human WT FUS, VAPB, UBQLN2 and VCP were obtained 
from OriGene Technologies (MD, USA). To obtain constructs containing ALS-associated 
mutations in each gene, sequences were designed in-house according to mutant sequences 
described in the literature, and site-directed mutagenesis was outsourced to GenScript. 
Sequencing was carried out by GenScript as part of their service to confirm the correct full 
sequence of each construct. 
The pCIneo mammalian expression construct containing sequences encoding C-terminally 
EGFP-tagged WT firefly luciferase (FlucWT-EGFP) and two conformationally destabilised 
mutants (containing a single mutation (SM), FlucSM-EGFP or two mutations (double mutant; 
DM), FlucDM-EGFP) were generously provided by Prof. Franz-Ulrich Hartl (Max Planck 
Institute of Biochemistry, Planegg, Germany). For detailed information on the design and 
construction of the destabilised Fluc-EGFP mutant plasmids see Gupta et al. (2011). Briefly, 
WT luciferase from the American firefly (Photinus pyralis) was mutationally optimised, PCR-
amplified and sub-cloned into the pCIneo expression vector. Site-directed mutagenesis was 
used to introduce either a single mutation (R188Q) or two mutations (R188Q and R261Q) to 
generate increasingly destabilised forms of the protein. EGFP from pEGFP-N2 (Clontech) was 





Table 5.1. List of plasmids used in the present chapter. The backbone vector, insert gene, any custom 
modifications made, the in-text nomenclature used for each plasmid, the source of each plasmid and reference 


















FUSWT   FUSWT-tGFP 





FUSR495X Site-directed mutagenesis FUS
R495X-tGFP GenScript 
FUSR521G Site-directed mutagenesis FUS
R521G-tGFP GenScript 
VAPBWT   VAPBWT-tGFP 




VAPBP56S Site-directed mutagenesis VAPB
P56S-tGFP GenScript 
UBQLN2WT   UBQLN2WT-tGFP 




UBQLN2P497H Site-directed mutagenesis 
UBQLN2P497H-
tGFP GenScript 
UBQLN2P525S Site-directed mutagenesis 
UBQLN2P525S-
tGFP GenScript 
VCPWT   VCPWT-tGFP 




VCPR159H Site-directed mutagenesis VCP
R159H-tGFP GenScript 


















SOD1WT-tdT Custom cloned using 
GenScript   SOD1A4V SOD1A4V-tdT 
pmRFP-ubiquitin (see 
reference)   
mRFPubiquitin 



















reference)   TDP-43
WT-tdT 




plasmid no. 28205) 































reference)     
Prof. Angus Lamond, 
University of 
Dundee, UK 
Leung et al. 
2004 
 
5.2.2 Transient transfections and treatment with proteasome inhibitor 
NSC-34 cells were seeded at 100,000 cells/mL in 10% (v/v) FBS in DMEM/F-12 into either 8-
well µ-Slides (Ibidi, Planegg-Martinsried, Germany) for confocal microscopy or 96-well plates 
(Greiner Bio-One, Frickenhausen, Germany) for imaging using the Thermo Scientific™ 
Cellomics® ArrayScan™ VTI High Content Screening microscope. After overnight incubation 
at 37 °C under 5% CO2/95% air, cells were either single-transfected, dual-transfected or triple-
transfected using Lipofectamine® 2000 (Invitrogen, Waltham, USA) according to 
manufacturer’s instructions. Briefly, per well, 0.3 µL or 0.6 µL of Lipofectamine® 2000 and a 
total of 0.1 µg or 0.2 µg of plasmid DNA for the 96-well plate format or 8-well µ-Slide format, 
respectively, were used to transfect NSC-34 cells. For dual and triple transfections, plasmids 




quadruplicate. For confocal microscopy experiments, NSC-34 cells were single-transfected or 
dual-transfected. NSC-34 cells were single-transfected with SOD1WT-EGFP, SOD1A4V-EGFP, 
TDP-43WT-tGFP, TDP-43M337V-tGFP, FUSWT-tGFP, FUSR495X-tGFP, FUSR521G-tGFP, 
CCNFWT-mCherry, CCNFS621G-mCherry, the pEGFP-N1 vector (EGFP alone) or the 
pmCherry-C1 vector (mCherry alone). NSC-34 cells were dual-transfected as detailed in Table 
5.2. An additional dual transfection experiment was carried out with transfection of NSC-34 
cells with (1) VCPWT-tGFP, VCPR159H-tGFP or VCPR191Q-tGFP and (2) TDP-43WT-tdTomato. 
For these dual transfection experiments, mCherry alone was used as a control for the expression 
of a RFP only, to ensure that the localisation patterns observed for mRFPLC3, mRFPubiquitin and 




























Table 5.2. Plasmid combinations used in dual transfections. The localisation patterns of the EGFP-/tGFP 
proteins, mRFPLC3, mRFPubiquitin and TDP-43WT-tdT, encoded in the plasmids listed here, were examined in dual-
transfected NSC-34 cells using confocal microscopy. 
mRFPLC3 localisation microscopy 








EGFP alone mRFPLC3 
mRFPubiquitin localisation microscopy 










EGFP alone mRFPubiquitin 
TDP-43WT-tdT localisation 










For optimisation of the parameters used for automated imaging and image analysis using the 
Thermo Scientific™ Cellomics® ArrayScan™ VTI High Content Screening microscope, NSC-
34 cells were triple-transfected as detailed in Table 5.3.  
Table 5.3. Plasmid combinations used in triple transfections in preparation for HCS microscopy 
optimisation. Triple-transfected NSC-34 cells were used for preliminary experiments to optimise the parameters 
used for automated imaging and image analysis using a Cellomics® ArrayScan™ VTI HCS microscope. 




















Following optimisation of the parameters for automated imaging and image analysis, the 
Cellomics® ArrayScan™ VTI HCS platform was employed for an experiment using Fluc-
EGFP variants as sensors of changes in cellular protein quality control network capacity in 
NSC-34 cells expressing mutant SOD1 or CCNF. For this experiment, NSC-34 cells were 
triple-transfected as detailed in Table 5.4. As a positive control for cells under proteome stress, 
quadruplicates of control cells expressing H2B-CFP, mCherry alone and the Fluc-EGFP 




DMSO at 20 mM and subsequently diluted to 5 µM in 10% (v/v) FBS in DMEM/F-12. The 
prepared solution was added to cells at 30 h post-transfection and incubated for 18 h. For mock 
treatment, 5 µM DMSO in 10% (v/v) FBS in DMEM/F-12 was instead added to cells. 48 h 
following triple-transfections with the Fluc-EGFP variants, cells were fixed in 4% (w/v) 
paraformaldehyde (PFA, pH 7.4) for 20 min at room temperature. Cells were then washed three 
times with PBS before the addition of 100 µL of PBS to prepare for imaging on the Cellomics® 
ArrayScan™ VTI High Content Screening microscope.  
Table 5.4. Plasmid combinations used in triple transfections of NSC-34 cells in preparation for Fluc-EGFP 
experiments. 

























H2B-ECFP mCherry alone 
FlucWT-EGFP 








5.2.3 Confocal microscopy live cell imaging 
Prior to setting up the Thermo Scientific™ Cellomics® ArrayScan™ VTI HCS platform, the 
localisation patterns of each EGFP- and mCherry-tagged WT and mutant ALS-associated 
protein in transfected NSC-34 cells were characterised by imaging using a Leica TCS SP5 II 
confocal microscope with a 63× oil-immersion objective lens (Leica Microsystems, Wetzlar, 
Germany). Imaging was carried out 48 h post-transfection for single transfections and dual 
transfections with mRFPLC3 and TDP-43WT-tdT, or 24, 48 and 72 h post-transfection for dual 
transfections with mRFPubiquitin. EGFP fluorescence was excited at 488 nm by an argon laser; 
RFP fluorescence was excited at 561 nm by a DPS 561 laser. Fluorescent emissions were 
acquired by sequential scanning using the Leica Application Suite – Advanced Fluorescence 
(LAS-AF) software (version 3, Leica Microsystems, Wetzlar, Germany). Across each set of 
quadruplicate wells of cells for each transfection treatment, a minimum of 100 transfected cells 
were imaged across 10-15 fields of view per replicate. 
5.2.4 Confocal image analysis, inclusion characterisation and quantification 
To characterise the localisation patterns of each EGFP-/tGFP- and mCherry-tagged ALS-
associated protein in transfected NSC-34 cells and ensure that they corresponded with the 
patterns recorded in the literature, the images acquired by confocal microscopy were manually 
examined. To inform this characterisation, previous peer-reviewed studies revealing images of 
post-mortem spinal cord tissue from ALS patients were used to establish the morphology and 
size range of inclusions positive for mutant SOD1, TDP-43, FUS, VAPB, OPTN, UBQLN2 
and VCP. This enabled a size minimum of 2 µm to be established for categorising fluorescent 
foci as inclusions as opposed to associations of the fluorescent ALS proteins with other cellular 
structures, granules (e.g stress or transport) or other irrelevant fluorescent debris and artefacts. 
In order to quantify the percentage of VAPBWT-tGFP, VAPBP56S-tGFP, OPTNWT-EGFP, 




and VCPR191Q-tGFP inclusions that were positive for mRFPubiquitin in each dual transfection 
treatment, the numbers of transfected cells and fluorescent protein-positive foci were manually 
counted in each image acquired at 24, 48 and 72 h post-transfection. First, the numbers of 
EGFP-positive transfected NSC-34 cells in each replicate across 10-15 fields of view were 
counted. The numbers of these containing EGFP-fluorescent foci larger than 2 µm were then 
recorded as inclusions positive for each EGFP-fusion ALS protein. RFP-fluorescent foci larger 
than 2 µm were then counted as inclusions positive for mRFPubiquitin. The images collected in 
the green and red channels were then merged and the numbers of inclusions positive for EGFP 
and RFP fluorescence were counted as EGFP-fusion ALS protein inclusions positive for 
mRFPubiquitin. Finally, the numbers of inclusions positive for EGFP and RFP fluorescence were 
divided by the numbers of inclusions positive for each respective EGFP-fusion ALS protein, 
and then multiplied by 100 to calculate the proportion of ALS protein inclusions that were 
ubiquitin-positive. It should be noted that due to time limitations, the localisation patterns of 
mRFPubiquitin with mutant VAPB, OPTN and UBQLN2, of mutant VCP with TDP-43WT-tdT 
and of mutant SOD1, TDP-43 and FUS with mRFPLC3 observed here are each from n = 1 
experiment and furthermore were not confirmed through immunocytochemistry. Thus, these 
observations await confirmation by further experimentation. 
5.2.5 IncuCyte® ZOOM live cell imaging and analysis 
IncuCyte® ZOOM live cell imaging and analysis was used to carry out two different measures 
in NSC-34 cells transiently transfected with each of the EGFP- and mCherry-tagged WT and 
mutant ALS-associated proteins. Both experimental techniques are described in Chapter IV, 
section 4.2.3. Briefly, the first experimental technique was used as a measure of cell viability 
while the second technique was used to quantify numbers of transfected cells containing non-
diffusable, insoluble EGFP- or mCherry-fusion proteins. For all IncuCyte® experiments, the 




5.2.6 Developing a high content screening work flow for fluorescence-based analysis of 
cellular ALS models  
Following characterisation of the localisation patterns, the solubility and the effect on cell 
viability of each EGFP-/tGFP-/mCherry-tagged WT and mutant ALS-associated gene in 
transfected NSC-34 cells, a Cellomics® ArrayScan™ VTI HCS platform was established with 
the overarching aim that it could be used for studies with each of these cellular ALS models. 
The Thermo Scientific™ HCS Studio™ software uses image analysis algorithms, termed 
BioApplications, designed to measure a range of different cellular features and biological 
processes. These BioApplications initially detect cells or cellular objects using the fluorescence 
in one channel, Channel 1/the primary channel, and then the fluorescence in up to another five 
channels. In the primary channel, cell nuclei or other cellular regions can be fluorescently 
labelled to serve as the primary object, defined by the algorithm using a mask for the first step 
of identifying and selecting cells. The regions of the cell detected in each of the remaining 
channels depend on the mask, or region, defined by the primary object. The masks in Channels 
2-6 serve to enable measurement of different phenotypic features that report on cellular 
responses to different conditions.  
By transfecting NSC-34 cells with histone H2B-ECFP, the nuclei of cells could be detected 
based on ECFP fluorescence in Channel 1 and served as the primary object in the analysis by 
the Spot Detector BioApplications (Figure 5.1, b). As will be outlined in Section 5.2.6.3.2, for 
each fluorescence channel imaged, the appropriate masks used by the Thermo Scientific™ HCS 
Studio™ software to identify and select cells were carefully optimised to ensure that only cells 
of interest were included for analysis. An NSC-34 cell line stably transfected with H2B-ECFP 
was generated for future experiments with the HCS platform, as a cell line with constant 
expression of a nuclear-localised ECFP-fusion protein that could be used for automated cell 




workflow. As time was limited for the development of this HCS platform, image processing 
and analysis parameters in the Thermo Scientific™ HCS Studio™ software were optimised 
concurrently with the generation of this stable cell line, which was instead frozen down as 
stocks to use in future experiments.  
5.2.6.1 Generation of an NSC-34 cell line stably transfected with H2B-ECFP 
The algorithms used for automated image analysis in the Thermo Scientific™ HCS Studio™ 
software can use two different methods for automated identification of cells in each image; one 
that is used for identifying bright objects/cells on a dark background (e.g. for a fluorescently 
labeled cell nucleus in an unlabeled cell), and one that detects dark objects/cells on a bright 
background (e.g. for an unlabeled cell nucleus in a labeled cytoplasm). For the present work it 
was of interest to generate an NSC-34 cell line stably expressing a nuclear-localised fluorescent 
protein-tagged protein that would enable automated identification of cells based on each cell 
having a bright, fluorescent nucleus. Histone H2B tagged with ECFP (H2B-ECFP) was selected 
for this purpose. H2B is a component of the histone protein core of nucleosomes and is thus 
localised to the nucleus. ECFP was used due to the good separation of its excitation and 
emission maxima from those of EGFP and RFP, enabling it to be used for co-expression with 
the EGFP and RFP-tagged ALS-associated proteins used in this study. The pBOS-H2B-ECFP-
N1 construct contains the blasticidin antibiotic resistance gene. In order to generate an NSC-34 
cell line stably transfected with pBOS-H2B-ECFP-N1, the optimal concentration of blasticidin 
for selecting transfected NSC-34 cells was established by generating a kill curve. NSC-34 cells 
were seeded at 100,000 cells/mL into 24-well plates in 10% (v/v) FBS in DMEM/F-12 
containing blasticidin (CalBioChem, Cat. No. 203350) at the following concentrations: 0, 0.5, 
1, 2, 4, 6, 8 and 10 µg/mL. Quadruplicate wells of cells were treated with each different 
blasticidin concentration. Cells were imaged every 4 h for 1 week using an IncuCyte® ZOOM, 




concentration were plotted against time to establish a kill curve. From this, a blasticidin 
concentration of 6 µg/mL was established as the minimum concentration required to kill all 
non-transfected cells over 1 week. 
Following determination of the optimal blasticidin concentration to use, NSC-34 cells were 
seeded at 100,000 cells/mL into two 100 mm × 20 mm (diameter × height) Corning® tissue 
culture treated culture dishes (Cat. No. CLS430167, Corning, USA) and one 6-well plate in 
10% (v/v) FBS in DMEM/F-12. After 24 h, cells in the 100 mm × 20 mm dishes were 
transfected with 10 µg of pBOS-H2B-ECFP-N1 using 30 µL of Lipofectamine® 2000. Cells in 
the 6-well plate were used as non-transfected control cells throughout the blasticidin-selection 
process. At 48 h post-transfection, expression of H2B-ECFP in transfected cells was examined 
by imaging using a Leica DM500 fluorescent microscope. After confirming H2B-ECFP 
expression via nuclear-localised ECFP fluorescence, growth medium on cells in each dish and 
three wells of the 6-well plate was exchanged for 6 µg/mL blasticidin in 10% (v/v) FBS in 
DMEM/F-12. The remaining three wells of the 6-well plate were used as a no-antibiotic control. 
Every 2-3 days, cell growth was examined and selective medium was replaced with fresh 
selective medium. This continued until non-transfected control cells had been killed off, and 
small colonies of transfected cells began to form. Once colonies had expanded and cells had 
reached ~80% confluence, cells were passaged into two T-75 tissue culture flasks and grown to 
~80% confluence. The generation of this polyclonal stable-transfected cell line was carried out 
simultaneously to the experiments outlined in section 5.2.6.2, and time limitations prevented 
the use of this cell line in any further experiments. Thus, stocks of the cell line were frozen 
down in liquid N2 storage for use in future studies. 
5.2.6.2 Imaging using a Cellomics® ArrayScan™ VTI High Content Screening 
microscope 




transfection, or for triple-transfections with the Fluc-EGFP variants, cells were fixed 48 h post-
transfection before imaging using the 20× objective lens of a Cellomics® ArrayScan™ VTI 
High Content Screening microscope (Thermo Scientific, Waltham, USA). Fluorescence of 
ECFP-, EGFP- and tdT/mCherry-fusion proteins was imaged using excitation filters of 386 nm, 
485 nm and 549 nm, respectively. Phase contrast and fluorescent images from 20 fields of view 
per well were acquired, with image analysis parameters optimised using the Spot Detector V4 
BioApplication of the Thermo Scientific™ HCS Studio™ software, detailed in Section 5.2.6.3 
and summarised in Figure 5.1. Modifications to this BioApplication were made for optimal 
detection of transfected cells and inclusions containing the EGFP- and tdT/mCherry-fusion 
proteins. 
5.2.6.3 Optimisation of image processing and analysis parameters using the Cellomics® 
Spot Detector BioApplication 
5.2.6.3.1 Image pre-processing 
In the Thermo Scientific™ HCS Studio™ software, the first stage of automated image analysis 
is correction of background fluorescence in each image. A low pass filtration method was used 
to compute and subtract background fluorescence, in which the local background around each 
pixel is calculated, with the radius of the area sampled adjusted as determined by the user. The 
optimised parameter settings for image pre-processing are summarised in Figure 5.1, a. A radius 
value of 20 µm was found to adequately correct background fluorescence in the images of 
transfected NSC-34 cells. For all images analysed, it was selected that each BioApplication 
would reject any objects/cells lying on the image borders. The RejectBorderObjectsCh1 
parameter controls this; a value of 1 sets the algorithm to exclude analysis of any objects/cells 
located on the border of each image, while a value of 0 results in the algorithm including all 
objects/cells in the image for analysis, including those on the image border. This parameter was 








Figure 5.1. Schematic of Cellomics® ArrayScan™ VTI High Content Screening (HCS) image processing 
and analysis optimisation using Thermo Scientific™ HCS Studio™ software. To analyse the fluorescence 
intensity of EGFP-/tGFP- and tdTomato (tdT)/mCherry-fusion proteins and quantify protein inclusions containing 
EGFP-/tGFP-fusion proteins in NSC-34 cells, an image analysis algorithm designed to analyse fluorescent foci in 
cells, termed the Cellomics® Spot Detector BioApplication, was optimised using the Thermo Scientific™ HCS 
Studio™ software. Optimisation was carried out using images of NSC-34 cells triple-transfected to express H2B-
ECFP, either SOD1WT-EGFP, SOD1A4V-EGFP, TDP-43WT-tGFP TDP-43M337V-tGFP, FUSWT-tGFP, FUSR495X-
tGFP, FUSR521G-tGFP, VAPBWT-tGFP, VAPBP56S-tGFP, OPTNWT-EGFP, OPTNE478G-EGFP, UBQLN2WT-tGFP, 
UBQLN2P497H-tGFP, VCPWT-tGFP, VCPR159H-tGFP, VCPR191Q-tGFP or EGFP alone and (3) mCherry alone. Cells 
were imaged at 48 h post-transfection using the 20× objective lens of a Cellomics® ArrayScan™ VTI HCS 
microscope. (A) Raw images from Channels 1 (H2B-ECFP), 2 (EGFP-/tGFP-fusion proteins) and 3 
(tdTomato/mCherry-fusion proteins) were first pre-processed to (i) remove background fluorescence, (ii) exclude 
cells positioned on the border of each image from analysis and (iii) distinguish individual cells (‘object’ 
segmentation). (iv) Channel 1 images were additionally smoothed (blurred) to help reduce fluorescent noise that 
could lead to the false inclusion of image artefacts in subsequent analyses. (B) Biological ‘objects’, in this case 
cells, were identified using nuclear-localised H2B-ECFP fluorescence in Channel 1 images. (i) For detection of 
ECFP-fluorescent nuclei, a fluorescence intensity threshold was set using the Isodata method, which derives the 
threshold from the distribution of pixel intensities in each image. (ii) To select viable transfected cells for analysis 
and exclude image artefacts, dead cells and cell debris, cells were selected based on the size and fluorescence 
intensity of their ECFP-fluorescent nuclei. (C) The relevant measures for GFP fluorescence intensity and 
fluorescent foci were measured in Channel 2 (i) within a circular analysis mask that expanded the mask derived in 
Channel 1 by 7 µm. The green circular mask indicates cells selected for analysis, while yellow masks indicate 
fluorescent foci/‘spots’ selected for analysis. A fluorescence intensity threshold was set for Channel 2 using the 
Isodata method. An offset value of 1.11 enabled the image processing algorithm to correctly identify cells 
expressing the GFP-fusion proteins. (ii) To ensure that cells with particularly low expression of GFP-fusion genes 
were not included for analysis, GFP fluorescence intensity limits for CircAvgIntenCh2 were set to a minimum 
intensity of 100 RFU and a maximum intensity of 3241 RFU. (iii) To detect and analyse fluorescent foci 
corresponding to protein inclusions, upper and lower limits for size and fluorescence intensity were set. (D) 
Channel 3 objects were identified using the same mask as Channel 2, after establishing the fluorescence intensity 
threshold using the Isodata method with an offset value of 6. 
 
To optimise the BioApplication’s ability to resolve individual objects, an object segmentation 
method based on fluorescence intensity was used. This method separates objects/cells that are 
touching based on fluorescence intensity peaks of each pixel. Cells expressing H2B-ECFP in 
their nucleus exhibit a single, high intensity peak localised in the nucleus. Setting this 
parameter, ObjectSegmentationCh1, to a negative value sets the segmentation method to the 
Intensity method while a positive value sets it to the Geometric method based on the shape and 
size of objects, relying on indentations lying at object/cell boundaries. For the Intensity method, 
the absolute value selected governs the minimum relative height of the intensity peak to be used 
for segmentation. A value of -19 relative fluorescence units (RFU) was found to optimally 
separate touching fluorescent cells (Figure 5.1, a, iii). Object segmentation was further 
improved by additionally smoothing the Channel 1 image. Smoothing was also opted for as it 




analyses. Smoothing involves sampling the region surrounding each pixel and then replacing 
the pixel using the average value of the pixels sampled. A SmoothFactorCh1 value of 1 pixel, 
specifying the radius sampled, was determined to optimally smooth each image (Figure 5.1, a, 
iv). 
5.2.6.3.2 Identification and selection of cells for analysis 
The optimised parameter settings for identification and selection of cells for analysis are 
summarised in Figure 5.1, b. To identify H2B-ECFP-expressing NSC-34 cells using Channel 
1, a fluorescence intensity threshold was set using the Isodata method. In the Isodata method, 
the threshold is derived from the distribution of pixel intensities in each image and thus is 
dependent on each image. This method was chosen to ensure that image-to-image variations in 
H2B-ECFP intensity would not affect the analysis of cell features measured in the remaining 
channels. The Isodata thresholding method can be optimised by setting an offset value that 
alters the final threshold applied to each image. This user-defined offset alters the threshold that 
is computed automatically from the pixel intensities in the image to set a final optimised 
threshold that is then applied to each image. In the present work, an offset value of -0.164 was 
found to be optimal for altering the final threshold that was used to identify fluorescent cells as 
‘objects’ (Figure 5.1, b, i). The ‘objects’ that were identified were then filtered to select only 
viable transfected cells for potential analysis in further image processing steps and exclude 
image artefacts, dead cells and cell debris. Cells were selected based on the size and 
fluorescence intensity of their ECFP-fluorescent nuclei. A nucleus size minimum of 61 µm2 
and maximum of 628 µm2, and ECFP fluorescence intensity minimum of 227 RFU and 
maximum of 1818 RFU, were found to be appropriate for selecting nuclei of viable transfected 
cells (Figure 5.1, b, ii). 
For Channel 2, the relevant measures for GFP fluorescence intensity and spots were measured 




(CircModifierCh2 = 7) (Figure 5.1, c, i). This setting ensured that data from the entire projected 
area of the cell would be collected. To ensure that the only cells included for analyses were 
those that were successfully transfected and expressing the GFP-fusion proteins in addition to 
H2B-ECFP, a fluorescence intensity threshold was set for Channel 2 using the Isodata method. 
An offset value of 1.11 enabled the image processing algorithm to correctly identify cells 
expressing the GFP-fusion proteins while excluding cells exhibiting autofluorescence. To 
ensure that cells with particularly low expression of EGFP-fusion genes were not included for 
analysis, GFP fluorescence intensity limits for CircAvgIntenCh2 were set to a minimum 
intensity of 100 RFU and a maximum intensity of 3241 RFU (Figure 5.1, c, ii). 
5.2.6.3.3 Selection and analysis of intracellular fluorescent foci 
To measure the presence of GFP-positive inclusions in cells, the Spot Detector BioApplication 
was optimised using Channel 2. To detect and measure fluorescent foci of sizes corresponding 
to protein inclusions, as established using confocal microscopy, a spot area minimum of 2 µm2 
and maximum of 150 µm2 was set (Figure 5.1, c, iii). As inclusions are accumulations of high 
concentrations of proteins, the concentrated fluorescence of GFP-tagged proteins in inclusions 
allows them to be detected based on high fluorescence intensity. A spot average fluorescence 
intensity minimum of 150 RFU was found to detect appropriate foci corresponding to GFP-
positive inclusions. tdTomato/mCherry-tagged proteins were imaged in Channel 3. For assays 
focused on examining the localisation patterns of GFP-tagged proteins and without in-depth 
analysis of tdTomato/mCherry-tagged proteins, Channel 3 objects were simply identified using 








5.3.1 Characterisation of cellular models of SOD1-, TDP-43-, FUS-, CCNF- VAPB-, 
VCP-, OPTN-, and UBQLN2-associated ALS and optimisation of image analysis 
parameters 
Given the extraordinary molecular heterogeneity of ALS, it was of interest to create ALS 
models that collectively would represent a diversity of fALS forms. Thus, models of SOD1-, 
TDP-43-, FUS-, CCNF-, VAPB-, VCP-, OPTN- and UBQLN2-associated ALS using the 
neuronal NSC-34 cell line and EGFP-/tGFP-/mCherry-fusion plasmids were generated. The 
genetic mutations in these models were selected after careful consideration of the mutations 
that segregate with ALS; SOD1A4V (Deng et al. 1993), TARDBPM337V (Tamaoka et al. 2010), 
FUSR495X, FUSR521G (Kwiatkowski et al. 2009, Vance et al. 2009), CCNFS621G (Williams et al. 
2016), UBQLN2P497H (Deng et al. 2011), OPTNE478G (Maruyama et al. 2010), VAPBP56S 
(Nishimura et al. 2004), VCPR159H and VCPR191Q (Johnson et al. 2010, Abramzon et al. 2012, 
Koppers et al. 2012).  
Prior to using these NSC-34 models with the HCS platform, the localisation patterns of each 
EGFP-/tGFP-/mCherry-fusion WT and mutant ALS-associated protein in transfected NSC-34 
cells were characterised by imaging at 48 h post-transfection using confocal microscopy. As a 
measure of toxicity caused by the expression of each fusion gene, live cell fluorescent imaging 
was used to image and count the numbers of transfected cells (detected as EGFP-/tGFP- or 
mCherry-positive cells) over 80 h. The solubility of each protein in NSC-34 cells was examined 
using an assay to permeabilise the plasma membrane of transfected cells using saponin, 
allowing soluble intracellular proteins to diffuse out of the cell while trapping insoluble protein 
material. Cells were imaged pre- and post-permeabilisation with saponin to quantify numbers 
of transfected cells and numbers of cells containing insoluble EGFP-/tGFP- and mCherry-




aggregation propensity themselves, in each experiment NSC-34 cells were also transfected with 
empty vectors to express EGFP or mCherry alone. Confocal microscopy of cells transfected 
with EGFP or mCherry alone demonstrated that the EGFP and mCherry proteins are diffusely 
distributed throughout the cell and themselves do not aggregate (Figure 5.2, a, i and b, i). It was 
also confirmed that the expression of EGFP or mCherry alone had no effect on the viability of 
transfected cells. Numbers of cells expressing EGFP or mCherry alone steadily increased over 
the 80 h imaging period (Figure 5.2, a, ii and b, ii). 
 
Figure 5.2. Localisation patterns of EGFP and mCherry alone, and cell population growth over time of NSC-
34 cells expressing EGFP or mCherry alone. Live cell imaging of NSC-34 cells transiently transfected with (A) 
the pEGFP-N1 vector (EGFP alone) or (B) the pmCherry-C1 vector (mCherry alone). (A, i and B, i) Representative 
images of transfected cells taken using a Leica TCS SP5 II confocal microscope at 48 h post-transfection. Scale 
bars represent 10 µm. (A, ii and B, ii) To measure viability of NSC-34 cells transiently transfected to express 
EGFP or mCherry alone, cells were imaged in an IncuCyte® ZOOM and numbers of transfected cells (EGFP- or 
mCherry-positive cells) were monitored over 80 h. Graphs represent the mean ± SEM of the numbers of EGFP- 





5.3.1.1 Localisation patterns and aggregation of SOD1A4V, TDP-43M337V, FUSR495X, 
FUSR521G and CCNFS621G in NSC-34 cells 
It was important to be able to distinguish inclusions of the fusion proteins from the appearance 
of foci that could result from their normal colocalisation with other cellular structures and 
organelles; e.g. TDP-43 and FUS with SGs, OPTN with the Golgi apparatus (0.1-2 µm) (Guil 
et al. 2006, Maruyama et al. 2010). Inclusions of ALS-associated proteins are generally in the 
range 2-20 µm in diameter in human post-mortem tissue (Leigh et al. 1991, Shibata et al. 1994, 
Strong et al. 2005, Maruyama et al. 2010, Teyssou et al. 2013) and in cell culture models 
(Johnston 2000, Matsumoto et al. 2005, Matsumoto et al. 2006, Cozzolino 2008, Kuijpers et 
al. 2013, Zeineddine et al. 2015). A size minimum of 2 µm was thus established as suitable for 
categorising fluorescent foci as inclusions. The foci formed by SOD1A4V-EGFP, TDP-43M337V-
tGFP, FUSR495X-tGFP, FUSR521G-tGFP and CCNFS621G-mCherry were manually examined in 
images of cells and were consistently measured to be larger than 2 µm (Figures 5.3 and 5.4). 
The localisation patterns and solubility of SOD1A4V-EGFP, and the toxicity caused by its 
expression in NSC-34 cells, was assayed and is presented in Ch. IV (Figures 4.1 and 4.4).  
TDP-43, in addition to FUS, are predominantly nuclear-localised RBPs with additional 
cytoplasmic roles in the formation and dynamics of SGs. Imaging transfected NSC-34 cells 
using confocal microscopy, it was observed that the tGFP-tagged WT proteins remained 
localised to cell nuclei, while the TDP-43M337V, FUSR521G and FUSR495X mutants mislocalised 
to the cytoplasm and formed large aggregates and smaller foci, as is observed in ALS patient 
tissue (Figure 5.3, a, i and b, i) (Kwiatkowski et al. 2009, Vance et al. 2009, Tamaoka et al. 
2010). Although TDP-43WT-tGFP was not observed to mislocalise and accumulate into 
cytoplasmic inclusions when transfected cells were examined using confocal microscopy, after 
permeabilising the plasma membrane of transfected cells and imaging using an IncuCyte TDP-




significantly greater percentage of cells expressing TDP-43M337V-tGFP were tGFP-positive 
following saponin permeabilisation (79%) when compared to cells expressing TDP-43WT-tGFP 
(p = 0.0035). The large proportion of TDP-43WT-tGFP-expressing cells that remained tGFP-
positive after saponin treatment may be due, in part, to the concentration of saponin solution 
used, and the length of time that cells were incubated in saponin solution being insufficient to 
permeabilise the nuclear membrane inside cells. Thus, TDP-43WT-tGFP that was localised 
within nuclei may not have been released when cells were incubated with saponin solution. In 
this case, the saponin-permeabilisation assay may not be appropriate for assaying the formation 
of TDP-43 cytoplasmic inclusions, as it may not enable distinction between TDP-43 that is 
localised to nuclei and TDP-43 that has accumulated into insoluble cytoplasmic inclusions. 
Similarly, while FUSWT-tGFP was not observed to mislocalise and accumulate into cytoplasmic 
inclusions when transfected cells were examined using confocal microscopy, the saponin-
permeabilisation assay quantified that FUSWT-tGFP remained in 22.7% of transfected cells 
following incubation with saponin solution (Figure, 5.3, b, ii). Moreover, the percentage of cells 
expressing FUSR495X-tGFP that remained tGFP-positive following incubation with saponin 
solution (26.2%) was similar to that of cells expressing FUSWT-tGFP. However, there was a 
significantly greater percentage of cells expressing FUSR521G-tGFP that remained tGFP-positive 
following incubation with saponin solution (52.4%) compared to both cells expressing FUSWT-
tGFP and cells expressing FUSR495X-tGFP (FUSWT-tGFP, p = 0.0012; FUSR495X-tGFP, p = 
0.0023). As noted above, when cells expressing the FUS-tGFP constructs were examined using 
confocal microscopy, there was extensive formation of small foci (< 2 µm) and large aggregates 
by both FUS mutants (Figure 5.3, b, i). Thus, the similar percentages of cells expressing FUSWT-
tGFP and FUSR495X-tGFP that remained tGFP-positive after saponin-permeabilisation 
compared to the marked differences in their localisation patterns indicates that the saponin-




























Figure 5.3. Characterising the localisation patterns and intracellular solubility of ALS-associated TDP-
43M337V, FUSR495X and FUSR521G. NSC-34 cells were transiently transfected with (A) TDP-43WT-tGFP or TDP-
43M337V-tGFP or (B) FUSWT-tGFP, FUSR495X-tGFP or FUSR521G-tGFP. After 48 h, transfected cells were either (A, 
i and B, i) imaged using a Leica TCS SP5 II confocal microscope or (A, ii, iii and B, ii, iii) imaged on an IncuCyte® 
ZOOM, followed by incubation with 0.03% (w/v) saponin in PBS for 10 min at room temperature, before being 
imaged again on the IncuCyte. (A, i and B, i) Representative images from confocal microscopy, with white arrow 
heads indicating inclusions formed by the tGFP-fusion proteins. Scale bars represent 10 µm. (A, ii and B, ii) Cells 
were transfected in quadruplicate, and the data presented is the mean ± SEM of the percentage of transfected NSC-
34 cells containing insoluble tGFP-positive protein following permeabilisation with saponin. Differences between 
the means were determined using Student’s t test or one-Way ANOVA followed by Tukey’s Multiple Comparison 
Test. ** indicates p < 0.01. (A, iii and B, iii) Representative IncuCyte images of NSC-34 cells prior to 
permeabilisation with saponin (pre-saponin) and immediately following permeabilisation with saponin (post-
saponin), from which the graphs in A, ii and B, ii were derived. Scale bars represent 150 µm. 
 
CCNF functions as a substrate recognition subunit of Skp1-Cul1-F-box (SCF) E3 ubiquitin 
ligase complexes that mediate the ubiquitylation and proteasomal degradation of target proteins 
(D'Angiolella et al. 2013). Since the identification of the S621G CCNF mutation in ALS and 
FTD patients (Williams et al. 2016), the localisation patterns of the CCNFS621G mutant in motor 
neurons have not been investigated in detail. However, Lee et al. (2018) carried out 
immunofluorescence microscopy of CCNFS621G in Neuro-2A cells, in which CCNFS621G was 
localised to inclusion-like structures in a proportion of cells while CCNFWT generally displayed 
diffuse distribution throughout the cells.  In the present work, mCherry-tagged CCNFWT 
fluorescence was observed to have a diffuse distribution throughout the nucleus and cytoplasm 
of all imaged cells (Figure 5.4, a). In contrast, CCNFS621G-mCherry formed into particularly 
large amorphous aggregates ranging from 5 to > 10 µm. Interestingly, however, saponin-
permeabilisation of the plasma membranes of cells expressing CCNFWT-mCherry and 
CCNFS621G-mCherry revealed that both proteins formed extensively into insoluble structures, 
with > 50% of both cells transfected with CCNFWT-mCherry and cells transfected with 
CCNFS621G-mCherry containing insoluble mCherry-positive protein following permeabilisation 
(Figure 5.4, b). Nevertheless, there were significantly more CCNFS621G-mCherry-expressing 
cells containing insoluble mCherry-positive protein (67.8%) following permeabilisation than 





Figure 5.4. Characterising the localisation pattern and intracellular solubility of ALS-associated CCNFS621G. 
NSC-34 cells were transiently transfected with CCNFWT-mCherry or CCNFS621G-mCherry. After 48 h, transfected 
cells were either (A) imaged using a Leica TCS SP5 II confocal microscope or (B and C) imaged on an IncuCyte® 
ZOOM, followed by incubation with 0.03% (w/v) saponin in PBS for 10 min at room temperature, before being 
imaged again on the IncuCyte. (A) Representative images from confocal microscopy, with white arrow heads 
indicating inclusions formed by CCNFS621G-mCherry. Scale bars represent 10 µm. (B) Cells were transfected in 
quadruplicate, and the data presented is the mean ± SEM of the percentage of transfected NSC-34 cells containing 
insoluble mCherry-positive protein following permeabilisation with saponin. Differences between the means were 
determined using a Student’s t test. ** indicates p < 0.01. (C) Representative IncuCyte images of NSC-34 cells 
prior to permeabilisation with saponin (pre-saponin) and immediately following permeabilisation with saponin 
(post-saponin), from which the graph in B was derived. Scale bar represents 150 µm. 
 
5.3.1.2 The expression of SOD1A4V, TDP-43M337V, FUSR495X, FUSR521G and CCNFS621G 
cause toxicity in NSC-34 cells 
Live cell imaging of cells expressing TDP-43WT-tGFP and TDP-43M337V-tGFP to monitor cell 
population growth showed that the numbers of TDP-43M337V-tGFP expressing cells had a 




0.01) (Figure 5.5, a and b). The numbers of cells expressing TDP-43M337V-tGFP began to 
plateau after ~48 h post-transfection (24 h post-replating) while the numbers of TDP-43WT-
tGFP expressing cells continued to increase steadily until ~72 h post-transfection (48 h post-
replating). Comparison of the mean numbers of tGFP-positive transfected cells at 72 h post-
transfection showed that there was a significantly greater number of cells expressing TDP-
43WT-tGFP than there was of cells expressing TDP-43M337V-tGFP (p < 0.001) (Figure 5.5, c). 
 
Figure 5.5. ALS-associated TDP-43M337V causes toxicity in NSC-34 cells. NSC-34 cells were transiently 
transfected with TDP-43WT-tGFP or TDP-43M337V-tGFP and imaged in an IncuCyte® ZOOM over 80 h. Graphs 
represent the mean ± SEM of (A) numbers of tGFP-positive transfected cells over 80 h, (B) population growth 
rates of transfected cells and (C, i) numbers of transfected cells at 48 h post-replating, in triplicate wells of cells. 
(C, ii) Representative IncuCyte images of NSC-34 cells at 48 h post-replating, from which the graph in C, i, was 
derived. Scale bar represents 150 µm. Differences between the means were determined using Student’s t tests. ** 





The expression of FUSR495X-tGFP and of FUSR521G-tGFP was observed to cause reduced 
population growth of NSC-34 cells compared to FUSWT-tGFP (Figure 5.6). While the numbers 
of cells expressing FUSWT-tGFP continued to increase steadily over the 80 h imaging period, 
the numbers of both FUSR495X-tGFP and FUSR521G-tGFP cells began to plateau after ~40 h 
(Figure 5.6, a). There was no difference in population growth rate between the two FUS 
mutants, but both exhibited significantly reduced population growth compared to cells 
expressing FUSWT-tGFP (FUSR495X-tGFP, p = 0.0019; FUSR521G-tGFP, p = 0.0041) (Figure 5.6, 
b). At 72 h post-transfection there were significantly greater numbers of cells expressing 
FUSWT-tGFP than there were of cells expressing either of the two mutants (FUSR495X-tGFP, p 







Figure 5.6. ALS-associated FUSR495X and FUSR521G cause toxicity in NSC-34 cells. NSC-34 cells were 
transiently transfected with FUSWT-tGFP, FUSR495X-tGFP or FUSR521G-tGFP and imaged in an IncuCyte® ZOOM 
over 80 h. Graphs represent the mean ± SEM of (A) numbers of tGFP-positive transfected cells over 80 h, (B) 
population growth rates of transfected cells and (C, i) numbers of transfected cells at 48 h post-replating, in 
triplicate wells of cells. (C, ii) Representative IncuCyte images of NSC-34 cells at 48 h post-replating, from which 
the graph in C, i, was derived. Scale bar represents 150 µm. Differences between the means were determined using 
one-Way ANOVA followed by Tukey’s Multiple Comparison Test. ** indicates p < 0.01. 
 
CCNFS621G-mCherry caused striking inhibition of cell population growth, with live cell imaging 
revealing that the numbers of CCNFS621G-mCherry cells plateaued and dropped off steadily 28 
h after replating (Figure 5.7, a). Analysis of the growth rates of the cell population expressing 
the CCNF-mCherry constructs showed that the rate of growth of CCNFS621G-mCherry cells was 
markedly slower than that of CCNFWT-mCherry cells (p < 0.0001) (Figure 5.7, b). At 72 h post-
transfection the differences in growth between cells expressing CCNFWT-mCherry and 




mCherry cells than CCNFWT-mCherry cells (p < 0.0001) (Figure 5.7, c). 
Figure 5.7. ALS-associated CCNFS621G causes toxicity in NSC-34 cells. NSC-34 cells were transiently 
transfected with CCNFWT-mCherry or CCNFS621G-mCherry and imaged in an IncuCyte® ZOOM over 80 h. Graphs 
represent the mean ± SEM of (A) numbers of mCherry-positive transfected cells over 80 h, (B) population growth 
rates of transfected cells and (C, i) numbers of transfected cells at 48 h post-replating, in triplicate wells of cells. 
(C, ii) Representative IncuCyte images of NSC-34 cells at 48 h post-replating, from which the graph in C, i, was 
derived. Scale bar represents 150 µm. Differences between the means were determined using Student’s t tests. 
**** indicates p < 0.0001. 
 
5.3.1.3 The expression of UBQLN2P497H, UBQLN2P525S, OPTNE478G, VAPBP56S, 
VCPR159H and VCPR191Q cause toxicity in NSC-34 cells 
Assaying cell population growth using live cell imaging over 80 h, expression of 
UBQLN2P497H-tGFP and of UBQLN2P525S-tGFP was found to cause reductions in cell 
population growth rates compared to the expression of UBQLN2WT-tGFP (UBQLN2P497H-




the UBQLN2P497H-tGFP mutant was observed to cause greater inhibition of cell population 
growth compared to the UBQLN2P525S-tGFP mutant, with UBQLN2P497H-tGFP cells exhibiting 
slower population growth rates (p = 0.0275) and dropping down to significantly lower numbers 
by 72 h post-transfection (p = 0.0264) than UBQLN2P525S-tGFP cells (Figure 5.8, c). 
 
Figure 5.8. ALS-associated UBQLN2P497H and UBQLN2P525S cause toxicity in NSC-34 cells. NSC-34 cells were 
transiently transfected with UBQLN2WT-tGFP, UBQLN2P497H-tGFP or UBQLN2P525S-tGFP and imaged in an 
IncuCyte® ZOOM over 80 h. Graphs represent the mean ± SEM of (A) numbers of tGFP-positive transfected cells 
over 80 h, (B) population growth rates of transfected cells and (C, i) numbers of transfected cells at 48 h post-
replating, in triplicate wells of cells. (C, ii) Representative IncuCyte images of NSC-34 cells at 48 h post-replating, 
from which the graph in C, i, was derived. Scale bar represents 150 µm. Differences between the means were 
determined using one-Way ANOVA followed by Tukey’s Multiple Comparison Test. * indicates p < 0.05, *** 






In NSC-34 cells expressing the VAPB-tGFP constructs, a clear reduction was observed in the 
population growth of cells expressing VAPBP56S-tGFP compared to cells expressing VAPBWT-
tGFP (Figure 5.9). Although numbers of transfected cells were low due to low transfection 
efficiency, total cell density was high, increasing from ~70% to ~95% over the 80 h imaging 
period (data not shown). There was thus no potential effect of low total cell density on the 
proliferation or loss of the VAPB-tGFP-expressing cells. Comparison of the numbers of VAPB-
tGFP cells in the first 20 h of imaging confirmed that VAPBP56S-tGFP significantly reduced the 
population growth rate of cells (p = 0.0203) (Figure 5.9, b). The numbers of tGFP-positive cells 
expressing VAPBP56S-tGFP at 48 h post-replating were significantly lower than cells expressing 
VAPBWT-EGFP (p < 0.0001) (Figure 5.9, c), further highlighting the toxicity caused by 





Figure 5.9. ALS-associated VAPBP56S causes toxicity in NSC-34 cells. NSC-34 cells were transiently transfected 
with VAPBWT-tGFP or VAPBP56S-tGFP and imaged in an IncuCyte® ZOOM over 80 h. Graphs represent the mean 
± SEM of (A) numbers of tGFP-positive transfected cells over 80 h, (B) population growth rates of transfected 
cells and (C, i) numbers of transfected cells at 48 h post-replating, in triplicate wells of cells. . (C, ii) Representative 
IncuCyte images of NSC-34 cells at 48 h post-replating, from which the graph in C, i, was derived. Scale bar 
represents 150 µm. Differences between the means were determined using Student’s t tests. * indicates p < 0.05, 
**** indicates p < 0.0001. 
 
The expression of OPTNE478G-EGFP reduced the population growth rate of transfected cells 
compared to cells expressing OPTNWT-EGFP (Figure 5.10). In the first 20 h of imaging, the 
population growth rate of OPTNE478G-EGFP-expressing cells was significantly slower than that 
of OPTNWT-EGFP expressing cells (p = 0.0139) (Figure 5.10, b). Comparison of the numbers 
of transfected cells at 48 h post-replating showed that there were significantly more viable 
OPTNWT-EGFP-expressing cells than of OPTNE478G-EGFP-expressing cells (p < 0.001) (Figure 
5.10, c), demonstrating that overexpression of the E478G mutant caused considerable toxicity 








Figure 5.10. ALS-associated OPTNE478G causes toxicity in NSC-34 cells. NSC-34 cells were transiently 
transfected with OPTNWT-EGFP or OPTNE478G-EGFP and imaged in an IncuCyte® ZOOM over 80 h. Graphs 
represent the mean ± SEM of (A) numbers of EGFP-positive transfected cells over 80 h, (B) population growth 
rates of transfected cells and (C, i) numbers of transfected cells at 48 h post-replating, in triplicate wells of cells. 
(C, ii) Representative IncuCyte images of NSC-34 cells at 48 h post-replating, from which the graph in C, i, was 
derived. Scale bar represents 150 µm. Differences between the means were determined using Student’s t tests. * 
indicates p < 0.05, *** indicates p < 0.001. 
 
Assaying the numbers of NSC-34 cells expressing the VCP-tGFP constructs over 80 h, it was 
observed that both mutants significantly reduced the population growth rate of transfected cells 
relative to VCPWT-tGFP (Figure 5.11). The population growth rate of cells expressing 
VCPR191Q-tGFP was notably slower than that of cells expressing VCPR159H-tGFP (p = 0.004), 
and 48 h after replating cells the numbers of viable VCPR191Q-tGFP-expressing cells were much 




Figure 5.11. ALS-associated VCPR159H and VCPR191Q cause toxicity in NSC-34 cells. NSC-34 cells were 
transiently transfected with VCPWT-tGFP, VCPR159H-tGFP or VCPR191Q-tGFP and imaged in an IncuCyte® ZOOM 
over 80 h. Graphs represent the mean ± SEM of (A) numbers of tGFP-positive transfected cells over 80 h, (B) 
population growth rates of transfected cells and (C, i) numbers of transfected cells at 48 h post-replating, in 
triplicate wells of cells. (C, ii) Representative IncuCyte images of NSC-34 cells at 48 h post-replating, from which 
the graph in C, i, was derived. Scale bar represents 150 µm. Differences between the means were determined using 
one-Way ANOVA followed by Tukey’s Multiple Comparison Test. ** indicates p < 0.01, *** indicates p < 0.001 
and **** indicates p < 0.0001. 
 
5.3.1.4 Characterisation of mutant UBQLN2, OPTN, VAPB and VCP solubility, 
localisation and aggregation  
The saponin-permeabilisation assay was next used to examine the mobility and solubility of 
UBQLN2P497H-tGFP, UBQLN2P525S-tGFP, OPTNE478G-EGFP, VAPBP56S-tGFP, VCPR159H-tGFP 
and VCPR191Q-tGFP in NSC-34 cells. In cells expressing the UBQLN2-tGFP constructs it was 
found that UBQLN2WT-tGFP had a degree of immobility in cells, with 37% of transfected cells 




membranes (Figure 5.12, a). However, the two UBQLN2 mutants, UBQLN2P497H-tGFP and 
UBQLN2P525S-tGFP, remained inside significantly more cells following permeabilisation; 
65.1% (p = 0.002) and 68.1% (p = 0.0012), respectively. Interestingly, the saponin-
permeabilisation assay quantified that ~35% of both cells expressing OPTNWT-EGFP and cells 
expressing OPTNE478G-EGFP contained insoluble EGFP-positive protein following 
permeabilisation (Figure 5.12, b). As OPTNWT can associate with proteins of the Golgi 
apparatus (Sahlender et al. 2005, Maruyama et al. 2010), a proportion of OPTNWT-EGFP may 
have been bound to the Golgi and thus immobile and unable to diffuse out of cells following 
saponin treatment. Further experimentation is needed to determine the nature of this post-
permeabilisation cell-bound OPTNWT-EGFP. Through saponin permeabilisation of cells 
transfected with the VCP-tGFP constructs it was quantified that ~9.8% of cells transfected with 
VCPWT-tGFP retained the tGFP-tagged protein following membrane permeabilisation (Figure 
5.12, c). However, both VCPR191Q-tGFP and VCPR159H-tGFP remained cell-associated in 
significantly greater percentages of transfected cells (VCPR191Q-tGFP, p = 0.0222; VCPR159H-
tGFP, p = 0.0111), indicating that both mutants were relatively less mobile and had reduced 








Figure 5.12. Analysis of the release of EGFP-/tGFP-fusion mutant UBQLN2, OPTN and VCP from NSC-34 
cells following saponin-permeabilisation. NSC-34 cells were transiently transfected with (A) UBQLN2WT-tGFP, 
UBQLN2P497H-tGFP or UBQLN2P525S-tGFP, (B) OPTNWT-EGFP or OPTNE478G-EGFP or (C) VCPWT-tGFP, 
VCPR159H-tGFP or VCPR191Q-tGFP. After 48 h, cells were imaged on an IncuCyte® ZOOM, followed by incubation 
with 0.03% (w/v) saponin in PBS for 10 min at room temperature, before being imaged again on the IncuCyte. (A, 
i, B, i and C, i) Cells were transfected in quadruplicate, and the data presented in each graph is the mean ± SEM 
of the percentage of transfected NSC-34 cells containing insoluble EGFP-/tGFP-positive protein following 
permeabilisation with saponin. Differences between the means were determined using either Student’s t tests or 
one-Way ANOVA followed by Tukey’s Multiple Comparison Test. * indicates p < 0.05, ** indicates p < 0.01. 
(A, ii, B, ii and C, ii) Representative IncuCyte images of NSC-34 cells prior to permeabilisation with saponin (pre-
saponin) and immediately following permeabilisation with saponin (post-saponin), from which the graphs in A, i, 
B, i and C, i) were derived. Scale bars represent 150 µm. 
 
Unfortunately, transfections with the VAPB-tGFP constructs for the IncuCyte-based assays 
resulted in considerably low transfection efficiencies, as can be seen in the low numbers of 
tGFP-positive transfected cells in Figure 5.9. The numbers of tGFP-positive cells at 48 h post-
transfection detected pre- and post-permeabilisation with saponin for VAPBP56S-tGFP were thus 
too low for analysis. This saponin-treatment experiment also may not have been appropriate for 
VAPB, as it is an integral membrane protein and thus in its native localisation in cells is 
immobile and unable to freely diffuse out of permeabilised cells. 
The inclusion size cut-off of 2 µm established using confocal microscopy (section 5.3.1.1) was 
used to examine the association of ubiquitin with inclusions formed by VAPBP56S-tGFP, 
VCPR191Q-tGFP, VCPR159H-tGFP, OPTNE478G-EGFP and UBQLN2P497H-tGFP. Based on 
previously published work showing that ubiquitylation of misfolded proteins can determine the 
type of inclusion into which they are compartmentalised (Kaganovich et al. 2008), it was 
hypothesised that the timing of ubiquitin association with inclusions may provide insight into 
the aggregation pathways of each ALS-associated protein. At the time of the present work, the 
dynamics of ubiquitin association with SOD1A4V-EGFP, TDP-43M337V-tGFP and FUSR495X-
tGFP inclusions were being characterised by Ms. N. Farrawell (University of Wollongong, 
NSW, Australia) and have since been published (Farrawell et al. 2015). Thus, for this study, 
the localisation patterns of ubiquitin and mutant VAPB, VCP, OPTN and UBQLN2 were 




OPTNE478G-EGFP, or UBQLN2P497H-tGFP and mRFPubiquitin over 72 h. UBQLN2-positive 
inclusions in post-mortem spinal cord tissue from patients with ALS can have varying 
morphologies, including round and compact, skein-like and large, amorphous inclusions (Deng 
et al. 2011). In the present work, UBQLN2P497H-tGFP formed large cytoplasmic inclusions with 
an amorphous appearance (Figure 5.13, b). UBQLN2P497H-tGFP inclusions were consistently 
observed to colocalise with ubiquitin from 24 h through to 72 h post-transfection (Figure 5.13, 






Figure 5.13. The timing of ubiquitin colocalisation to inclusions differs between inclusions formed by mutant 
VAPB, OPTN and UBQLN2. NSC-34 cells were transiently dual-transfected with VAPBP56S-tGFP, OPTNE478G-
EGFP or UBQLN2P497H-tGFP and mRFPubiquitin, and imaged at 24 h, 48 h and 72 h post-transfection by confocal 
microscopy. (A) Percentages of inclusions containing the EGFP-/tGFP-fusion mutant proteins that were also 
positive for mRFPubiquitin in dual-transfected NSC-34 cells at 24 h, 48 h and 72 h post-transfection. At each time 
point 10-15 fields of view were imaged, with a minimum of 10 dual-transfected cells counted per field. Percentages 
of EGFP-/tGFP-fusion mutant protein inclusions containing mRFPubiquitin at each time point is the mean ± SEM 
from triplicate wells of dual-transfected cells, from n = 1 experiment. (B) Representative images of dual-
transfected NSC-34 cells at (i) 24 h, (ii) 48 h and (iii) 72 h post-transfection. White arrow heads indicate inclusions 






VAPB is a small type IV membrane protein found in the ER, in intracellular vesicle membranes 
and in the plasma membrane (Soussan et al. 1999, Foster et al. 2000, Skehel et al. 2000, 
Amarilio et al. 2005, Manford et al. 2012). The P56S mutation in VAPB causes the protein to 
oligomerise and aggregate into distinct insoluble inclusions that have been ultrastructurally 
characterised to contain ER-derived membranous tubules (Nishimura et al. 2004, Teuling et al. 
2007, Tsuda et al. 2008, Papiani et al. 2012, Kuijpers et al. 2013). In the present work, 
VAPBP56S-tGFP inclusions did not always colocalise with ubiquitin, in contrast to mutant 
UBQLN2 inclusions, as was similarly the case for TDP-43M337V and FUSR495X inclusions 
(Farrawell et al. 2015). At 24 h post-transfection ~60% of VAPBP56S-EGFP inclusions were 
colocalised with ubiquitin, increasing to ~91% after 72 h (Figure 5.13, a).  
Imaging cells co-transfected with OPTNWT-EGFP or OPTNE478G-EGFP and mRFPubiquitin using 
confocal microscopy, OPTNE478G-EGFP cells were observed to contain small EGFP-positive 
foci (< 2 µm) at 24 h post-transfection. These foci were not scored as inclusions as they could 
not be distinguished from the potential association of OPTN with the Golgi apparatus and 
related vesicular structures (Ying et al. 2010, Ying and Yue 2012). The use of 
immunofluorescence staining for proteins of the Golgi apparatus and transport vesicles would 
have enabled characterisation of the nature of these observed foci at 24 h post-transfection. At 
48 h post-transfection, OPTNE478G-EGFP foci > 2 µm were observed, and were categorised as 
inclusions (Figure 5.13, a and b, I and ii). At this time point, ~84% of inclusions colocalised 
with mRFPubiquitin, increasing to ~93% after 72 h (Figure 5.13, a and b, ii and iii).  
Interestingly, mutant VCP did not form inclusions when co-expressed with mRFPubiquitin, 
however mRFPubiquitin inclusions were observed (Figure 5.14, a). As TDP-43-positive 
inclusions are one of the hallmark features of ALS, it was next examined whether or not the 
overexpression of WT or mutant VCP caused aggregation of TDP-43WT. NSC-34 cells were co-




construct previously generated and described by Yang et al. (2010), and imaged after 48 h of 
incubation. Both VCP-tGFP variants as well as VCPWT-tGFP were observed to form inclusions 
that colocalised with TDP-43WT-tdT in all cells that were imaged (Figure 5.14, b).  
 
Figure 5.14. WT and mutant VCP do not aggregate into ubiquitylated inclusions, but are sequestered into 
inclusions when co-expressed with TDP-43WT. NSC-34 cells were transiently dual-transfected with VCPWT-
tGFP, VCPR159H-tGFP or VCPR191Q-tGFP and (A) mRFPubiquitin or (B) TDP-43WT-tdTomato and imaged by 
confocal microscopy 48 h later. Images shown are representative of 10-15 fields of view per well, and each dual 
transfection was carried out in triplicate in n = 1 experiment. White arrow heads indicate inclusions formed by the 
tGFP-, mRFP- and tdTomato-fusion proteins. Scale bars indicate 10 µm. 
 
Time limitations prevented further investigation into these findings observed for UBQLN2, 
VAPB, OPTN and VCP. Instead, the variable ubiquitin colocalisation timing found for 
SOD1A4V, TDP-43M337V and FUSR495X inclusions obtained by Ms. N. Farrawell (University of 
Wollongong, NSW, Australia) and described in Farrawell et al. (2015) was prioritised for 
further investigation. It was tested whether inclusions negative for ubiquitin might colocalise 
with mRFPLC3, a marker of autophagy. No observable relationship was observed between 
SOD1A4V-EGFP inclusions and mRFPLC3 (Figure 5.15). TDP-43M337V-tGFP and FUSR495X-tGFP 
inclusions, in contrast, were observed to be adjacent to mRFPLC3-positive foci, although they 






Figure 5.15. Mutant TDP-43M337V-tGFP and FUSR495X-tGFP inclusions are localised adjacent to mRFPLC3-
positive foci. NSC-34 cells were transiently dual-transfected with TDP-43M337V-tGFP, FUSR495X-tGFP or 
SOD1A4V-EGFP and mRFPLC3 and imaged 48 h later using confocal microscopy. Images shown are representative 
of 10-15 fields of view per well, and each dual transfection was carried out in triplicate in n = 1 experiment. White 
arrows indicate mRFPLC3 foci localised adjacent to TDP-43M337V-tGFP and FUSR495X-tGFP inclusions. Scale bars 
indicate 10 µm. 
 
 
5.3.2 Firefly luciferase mutants report on proteostasis stress in NSC-34 cells expressing 
SOD1A4V and CCNFS621G 
The optimised HCS Spot Detector assay was used for an assay comparing the effect of the 
overexpression of SOD1 and CCNF variants on the ability of the cellular protein quality control 
network to prevent the aggregation of conformationally destabilised, aggregation-prone 
mutants of firefly luciferase (Fluc). Fluc is a ~60 kDa multidomain protein that is known to be 
chaperone-dependent for folding and refolding (Nimmesgern and Hartl 1993, Schroder et al. 
1993, Frydman et al. 1994, Thulasiraman and Matts 1996, Gupta et al. 2011). It was reasoned 
that reductions in the capacity of the protein quality control network would lead to increased 




To ensure that the SpotDetector BioApplication was capable of identifying and analysing 
transfected cells and fluorescent foci reliably and accurately, images from each experimental 
condition were manually examined (Figure 5.16, a to d). While in some images transfected cells 
were occasionally not detected by the BioApplication, > 90% of ECFP- and EGFP-positive 
cells were detected (green circular masks). ‘Spot’ masks (yellow masks) were observed only 
on large foci with high fluorescence intensity, corresponding to the inclusion size and 








Figure 5.16. Optimised HCS SpotDetector BioApplication identifies and analyses transfected cells and Fluc-
EGFP foci. Representative Cellomics® ArrayScan™ VTI images showing masks (first and third rows of each 
panel) used to identify and select NSC-34 cells co-transfected with either (A) SOD1WT-tdTomato, (B) SOD1A4V-
tdTomato, (C) CCNFWT-mCherry or (D) CCNFS621G-mCherry and FlucWT-EGFP, FlucSM-EGFP or FlucDM-EGFP. 
Cells were imaged at 48 h post-transfection. Green circular masks indicate cells selected for analysis, yellow masks 
indicate ‘spots’ selected for analysis, representing aggregates. Images were acquired using a 20× objective lens. 
 
 
Proteasome inhibition of cells expressing mCherry alone confirmed that increased proteome 
stress results in increased aggregation of the Fluc-EGFP isoforms. Cells expressing mCherry 
alone that were treated with MG132 developed significantly greater numbers of FlucWT-EGFP 
(p < 0.0001), FlucSM-EGFP (p = 0.0001) and FlucDM-EGFP (p = 0.0021) aggregates compared 
to untreated cells (Figure 5.17, a, i). MG132 treatment resulted in significantly higher numbers 
of FlucWT-EGFP aggregates than FlucDM-EGFP aggregates (p = 0.0153). FlucWT-EGFP 
aggregates were significantly smaller (p = 0.002) and more brightly fluorescent (p < 0.0001) 
than FlucDM-EGFP aggregates (Figure 5.17, b, i and c, i). Aggregates of the Fluc-EGFP 
isoforms were also detected in cells expressing SOD1-tdT, with a significant increase in the 
numbers of aggregates formed in cells expressing mutant SOD1A4V-tdT compared to SOD1WT-
tdT (FlucWT-EGFP, p = 0.0331; FlucSM-EGFP, p = 0.0061; FlucDM-EGFP, p = 0.0042) (Figure 
5.17, a, ii). There were also increases in the mean size of FlucDM-EGFP aggregates (p = 0.0430) 
and fluorescence intensity of aggregates of FlucWT-EGFP (p < 0.0001), FlucSM-EGFP (p < 
0.0001) and FlucDM-EGFP (p < 0.0001) in cells expressing mutant SOD1A4V-tdT compared to 
SOD1WT-tdT (Figure 5.17, b, ii and c, ii). Interestingly, aggregation of FlucSM-EGFP and 
FlucDM-EGFP was as extensive in cells expressing CCNFWT-mCherry as those expressing 
CCNFS621G-mCherry (Figure 5.17, a, iii). Whilst aggregates of FlucWT-EGFP were also 
detected, there were significantly lower numbers of cells containing them compared to the 
numbers of cells containing aggregates of FlucSM-EGFP (p < 0.001) and FlucDM-EGFP (p < 
0.0001), both in cells expressing CCNFWT-mCherry and in cells expressing CCNFS621G-
mCherry. There was also the same trend in the size of aggregates of the Fluc-EGFP isoforms 




significantly larger aggregates of FlucDM-EGFP formed than aggregates of FlucWT-EGFP 
(CCNFWT-mCherry, p = 0.0395; CCNFS621G-mCherry, p = 0.0328) (Figure 5.17, b, iii). There 
was no significant difference in the mean fluorescence intensity of the Fluc-EGFP aggregates 
of the Fluc-EGFP isoforms between cells expressing CCNFWT-mCherry and cells expressing 








Figure 5.17. Firefly luciferase mutants report on chaperone network activity in NSC-34 cells expressing 
SOD1 and CCNF. (A) Numbers of Fluc-EGFP aggregates per 100 transfected cells, (B) mean size of Fluc-EGFP 
aggregates (µm2) and (C) mean fluorescence intensity (FI) of Fluc-EGFP aggregates imaged at 48 h post-
transfection in NSC-34 cells expressing (i) mCherry alone ± treatment with 5 µM MG132, (ii) SOD1WT-tdTomato 
or SOD1A4V-tdTomato or (iii) CCNFWT-mCherry or CCNFS621G-mCherry. Treatment with MG132 was carried out 
at 30 h post-transfection. For mock treatment, 5 µM DMSO was instead added to cells. Graphs represent the mean 
± SEM from quadruplicate wells of cells in n = 1 experiment. Differences between the means were determined 
using one-Way ANOVA followed by Tukey’s Multiple Comparison Test. * indicates p < 0.05, ** indicates p < 




The heterogeneity of ALS distinguishes it from most other neurodegenerative diseases that can 
be linked to a single or a limited number of pathogenic mechanisms and phenotypes. The 
mechanisms underlying the degeneration of motor neurons in ALS vary with the genetic 
mutations involved and the various cellular insults and damage that accumulate in the CNS 
throughout an individual’s lifetime. The ALS research field would benefit greatly from the use 
of experimental systems with HCS capacity to help navigate through this complexity. To 
address this, a project to develop a HCS methodology to use with cellular ALS models was 
undertaken. The overall objective of this work was to develop a system that could be used to 
collect descriptive phenotypic data from cellular ALS models that would enable (1) 
characterisation of the inclusion formation pathways of different ALS-associated proteins, and 
(2) the use of diverse markers of proteome stress and motor neuron dysfunction to assess 
potential therapeutic compounds and genetic modifiers of ALS gene disease mechanisms and 
toxicity. 
5.4.1 Generation and characterisation of cellular models of SOD1-, TDP-43-, FUS-, 
CCNF-, VAPB-, VCP-, OPTN- and UBQLN2-associated ALS 
Upon generating NSC-34 models of SOD1-, TARDBP-, FUS-, CCNF-, VAPB-, VCP-, OPTN- 
and UBQLN2-associated ALS, the localisation and aggregation patterns of each EGFP-/tGFP-
/mCherry fusion WT and mutant protein were examined by confocal microscopy. The solubility 




viability were assessed using IncuCyte-based live cell imaging assays. As each of these are 
overexpression models, it was imperative to first confirm that the localisation patterns of each 
WT protein were not divergent from those of the endogenous WT proteins characterised in 
previous studies; SOD1 (Mackenzie et al. 2007, Tan et al. 2007), TDP-43 (Arai et al. 2006, 
Neumann et al. 2006, Mackenzie et al. 2007, Tan et al. 2007, Ayala et al. 2008, Winton et al. 
2008, Pamphlett et al. 2009), FUS (Kwiatkowski et al. 2009, Vance et al. 2009, Mackenzie et 
al. 2011), UBQLN2 (Deng et al. 2011, Williams et al. 2012), OPTN (Maruyama et al. 2010), 
VAPB (Nishimura et al. 2004, Kanekura et al. 2006, Teuling et al. 2007, Chen et al. 2010) and 
VCP (Mizuno et al. 2003).  
Although it was not tested in the present study, in any continued work utilising these NSC-34 
cell models it would be valuable to compare the relative abundance of the exogenous ALS-
associated mutants with the levels of the corresponding endogenous proteins. The vector 
backbone of each plasmid used in this study utilised a constitutive cytomegalovirus (CMV) 
promoter, a commonly used viral promoter for mammalian expression constructs. Incorporating 
the same promoter across all ALS-associated mutant (and corresponding wild-type) plasmids 
used in this study, in theory, enabled expression levels to be similar in each NSC-34 cell model. 
This was important for enabling comparison between the effects of expression of each mutant 
protein with the corresponding wild-type protein. The CMV promoter typically facilitates 
robust expression of the encoded gene following transfection, however, it is important to note 
that other molecular factors can affect the expression and turnover of exogenous proteins. This 
means that the abundance of the exogenous protein in each cellular model cannot be predicted 
with precision and requires measurement experimentally. This could be done through Western 
blotting and immunocytochemistry. As transfections were transient, not stable, transfection 
efficiency was variable. Thus, following transfection, cells would need to be sorted to isolate 




throughout the lysate of the whole cell population (i.e. all transfected and non-transfected cells). 
Following cell sorting, cells would be lysed and Western blotted for the ALS-associated protein, 
to then compare the relative abundance of the protein between transfected and non-transfected 
cell populations. Immunocytochemistry could be used to complement the Western blots. This 
would provide the added advantage of enabling examination and comparison of the localisation 
patterns of the exogenous and endogenous ALS-associated protein between transfected and 
non-transfected cells. 
5.4.1.1 Localisation and aggregation patterns of SOD1, TDP-43 and FUS in NSC-34 
cells 
The localisation patterns of WT SOD1, TDP-43 and FUS and the ALS-associated SOD1A4V, 
TDP-43M337V, FUSR521G and FUSR495X mutants are well characterised. In human post-mortem 
tissue, mutant SOD1 is often detected in large perinuclear conglomerate inclusions (Chou et al. 
1996). TDP-43 and FUS are predominantly nuclear-localised RBPs with additional cytoplasmic 
roles in the formation and dynamics of SGs and RNA transport granules (Colombrita et al. 
2009, Liu-Yesucevitz et al. 2010, Dewey et al. 2011, McDonald et al. 2011, Bentmann et al. 
2012, Colombrita et al. 2012, Sama et al. 2013, Alami et al. 2014). Mutant TDP-43 and FUS 
accumulate in cytoplasmic inclusions in patients with TARDBP or FUS mutations, respectively 
(Arai et al. 2006, Neumann et al. 2006, Mackenzie et al. 2007, Tan et al. 2007, Ayala et al. 
2008, Winton et al. 2008, Kwiatkowski et al. 2009, Pamphlett et al. 2009, Vance et al. 2009, 
Mackenzie et al. 2011). These patterns were recapitulated in NSC-34 cells for each of the tGFP-
tagged mutant TDP-43 and FUS proteins (SOD1A4V-EGFP localisation, aggregation and 
solubility was examined and is detailed in Chapter IV). The TDP-43M337V, FUSR521G and 
FUSR495X mutants mislocalised to the cytoplasm and formed into large aggregates and smaller 
foci. FUSR521G-tGFP predominantly accumulated into large numbers of small foci. It was found 




of FUSWT-tGFP to the examined FUS-tGFP mutants, as it did not enable distinction between 
FUS-tGFP that is localised within nuclei and FUS-tGFP that has accumulated into insoluble 
cytoplasmic inclusions. However, using confocal microscopy it was observed that both FUS-
tGFP mutants mislocalised from the nucleus and accumulated into cytoplasmic inclusions. 
Thus, the saponin-permeabilisation assay was useful to compare the solubility and mobility of 
cytoplasmic inclusions formed by FUSR495X-tGFP and FUSR521G-tGFP. A significant difference 
was found between the solubilities of the two FUS mutants. The data from the saponin-
permeabilisation assay suggests that the aggregates formed by the two FUS mutants may have 
differing structural properties, with aggregates formed by the FUSR521G-tGFP mutant largely 
becoming insoluble, while under these conditions the solubility of FUSR495X-tGFP was 
indistinguishable from that of FUSWT-tGFP. Both TDP-43 and FUS contain low sequence 
complexity prion-like domains that mediate their assembly into reversible, dynamic, non-
membrane-bound hydrogel droplets that associate with RNA granule-like structures, as well as 
their assembly into irreversible fibrous prion-like aggregates  (Han et al. 2012, Kato et al. 2012, 
King et al. 2012, Li et al. 2018). Whether or not the aggregates formed by FUSR495X-tGFP 
observed in the present work develop into insoluble structures over a longer of period of time 
remains to be investigated.  
5.4.1.2 Differential timing of ubiquitin association with UBQLN2P497H, OPTNE478G and 
VAPBP56S inclusions 
Ubiquitylation is a key factor governing the fate of misfolded proteins in cells (Kawaguchi et 
al. 2003, Tan et al. 2008, Kraft et al. 2010, Zhang and Qian 2011). Ubiquitylation is associated 
with the formation of certain types of inclusions, such as the JUNQ, that serve protein quality 
control functions in cells (Kaganovich et al. 2008, Weisberg et al. 2012). To gain an 
understanding of the aggregation pathways followed by mutant UBQLN2, OPTN, VAPB and 




tagged ubiquitin. Through this work, mRFPubiquitin was observed to colocalise to inclusions 
containing UBQLN2P497H-tGFP, OPTNE478G-EGFP and VAPBP56S-tGFP, with the timing of 
colocalisation differing for each mutant protein. In contrast, inclusions containing mRFPubiquitin 
were observed at all time points in NSC-34 cells expressing VCPR191Q-tGFP or VCPR159H-tGFP, 
however there was no localisation of mutant VCP to these inclusions. 
In cells expressing UBQLN2P497H-tGFP, mRFPubiquitin colocalisation to UBQLN2P497H-tGFP 
inclusions was observed at all imaging time points. This is consistent with previous studies 
detecting UBQLN2 in the ubiquitylated inclusions in sALS and fALS patients with UBQLN2 
mutations as well as mutations in SOD1, TARDBP, FUS and hexanucleotide repeat expansions 
in C9ORF72 (Deng et al. 2011, Brettschneider et al. 2012, Williams et al. 2012). UBQLN2 is 
a member of the ubiquilin family of ubiquitin-like proteins that function in both autophagy and 
the UPS (Kleijnen et al. 2000, Ko et al. 2004, N'Diaye et al. 2009). In the UPS, UBQLN2 
delivers ubiquitylated proteins to the proteasome for degradation via its N-terminal UBL and 
C-terminal UBA domains (Kleijnen et al. 2000, Walters et al. 2002, Walters et al. 2004, Zhang 
et al. 2008). The presence of mRFPubiquitin in all observed UBQLN2P497H-tGFP inclusions from 
early on (24 h post-transfection) could be indicative of aberrant interactions between misfolded 
UBQLN2 and polyubiquitylated proteins. It may also suggest that UBQLN2P497H-tGFP was 
sequestered into protein quality control compartments, for instance, in JUNQ inclusions, as a 
protective mechanism (Figure 5.18, a). Examining UBQLN2P497H-tGFP inclusions for the 
presence of other quality control components such as 26S proteasomes and chaperones, using 
time-resolved imaging, would help in determining the formation pathway of these inclusions. 
For example, detection of quality control components in addition to the presence of ubiquitin 
in these inclusions may provide indication that UBQLN2P497H-tGFP was directed to JUNQ-like 
inclusions. Both UBQLN2 mutants were observed to cause significant growth inhibition of 




UBQLN2 in JUNQ inclusions could serve protective functions in cells. Indeed, evidence 
indicates that JUNQ inclusions function to sequester toxic misfolded protein species away from 
the cytosol, and that ubiquitylation is essential to maintain solubility of misfolded proteins for 






Figure 5.18. Summary of proposed dynamics of ubiquitin association with inclusions formed by 
UBQLN2P497H, VAPBP56S and OPTNE478G. The localisation patterns of mRFPubiquitin and (A) UBQLN2P497H-
tGFP, (B) VAPBP56S-tGFP or (C) OPTNE478G-EGFP in NSC-34 cells were tracked using live-cell imaging at 24 h, 
48 h and 72 h post-transfection. (A) mRFPubiquitin was observed to be associated with all UBQLN2P497H-tGFP 
inclusions from early on (24 h post-transfection). Ubiquitin may have been involved in sequestration of 
UBQLN2P497H-tGFP into protein quality control compartments, for instance, JUNQ inclusions, in a protective 
mechanism. (B) mRFPubiquitin was not associated with all VAPBP56S-tGFP inclusions at the earliest imaging time 
point, suggesting that a proportion of VAPBP56S-tGFP inclusions did not represent quality control compartments. 
Rather, mutant VAPB molecules may have aggregated together to form inclusions. (C) Not all inclusions formed 
by OPTNE478G-EGFP at an intermediate time point (48 h post-transfection) were associated with mRFPubiquitin, 
indicating that their formation was not ubiquitin-dependent. Ubiquitin may have been aberrantly sequestered into 




In contrast to cells expressing UBQLN2P497H-tGFP, mRFPubiquitin did not colocalise with all 
observed VAPBP56S-tGFP inclusions at an early stage (24 h post-transfection), but its association 
with the inclusions did increase over time. The association of mRFPubiquitin with VAPBP56S-
tGFP inclusions is consistent with previous work in Drosophila melanogaster, transgenic mice 
and mammalian cell culture models of VAPBP56S-ALS in which VAPBP56S inclusions are 
ubiquitylated (Kanekura et al. 2006, Ratnaparkhi et al. 2008, Papiani et al. 2012, Kuijpers et 
al. 2013, Larroquette et al. 2015). There is evidence to suggest that VAPB inclusions are a 
unique type of ERAD quality control compartment. VAPBP56S inclusions have been reported to 
contain ER tubules and proteins involved in ERAD, including VCP, Derlin-1 and BAP31 
(Teuling et al. 2007, Kuijpers et al. 2013). Kuijpers et al. (2013) found that the presence of 
VAPB inclusions was not associated with neuronal toxicity in transgenic mice. In a separate 
study on VAPBP56S transgenic mice by Qiu et al. (2013), they observed VAPBP56S inclusions in 
the spinal cord of the mutant mice, but a distinct lack of neurodegeneration. Aliaga et al. (2013) 
interestingly documented that, while they observed VAPBP56S inclusions in corticospinal and 
spinal motor neurons of transgenic mice, the effects of VAPBP56S on these two populations of 
motor neurons differed. There was upregulation of the UPR and ER stress, and of pro-apoptotic 
factors in both populations of motor neurons, but there was only degeneration of the 
corticospinal motor neurons, not of the spinal motor neurons. The ability of cells to generate 
potential ERAD quality control compartments, and thus the toxicity of VAPBP56S expression, 
appear to be variable between cell types and between different models. This could be due to 
differing expression levels of the mutant protein in different models. In the present work, the 
expression of VAPBP56S-tGFP reduced the viability of transfected NSC-34 cells. If VAPBP56S 
inclusions do represent an ERAD quality control compartment, the toxicity observed in 
transfected NSC-34 cells and in other cell culture and animal models in previous studies (Chen 




expression levels. Higher expression levels could result in overloading of the cellular ability to 
sequester VAPBP56S into potential ERAD quality control compartments, thus overwhelming this 
protective cellular strategy. Indeed, the observation in the present work that ubiquitin was not 
associated with all VAPBP56S-tGFP inclusions at the earliest imaging time point suggests that at 
least a proportion of the observed inclusions did not represent quality control compartments 
(Figure 5.18, b).  
Similarly to VAPBP56S-tGFP, not all observed OPTNE478G-EGFP inclusions were colocalised 
with mRFPubiquitin at all imaging time points. OPTNE478G-EGFP foci were not categorised as 
inclusions until 48 h post-transfection as they were consistently smaller than the inclusion size 
cut-off of 2 µm that had been established. OPTN is involved in vesicular trafficking, 
autophagosome maturation and it associates with proteins of the Golgi apparatus (Sahlender et 
al. 2005, del Toro et al. 2009), thus the small foci may have represented the localisation of 
OPTN to these structures. Indeed, OPTNWT has been documented to form granular structures 
that are closely associated with the Golgi apparatus (Maruyama et al. 2010). OPTNWT has also 
been detected on LC3-positive autophagosomes under basal autophagy conditions (Tumbarello 
et al. 2012). In the present work, the association of OPTNWT-EGFP with these structures may 
also have reduced its mobility and solubility, thus rendering the saponin permeabilisation assay 
unsuitable for examining the mobility and solubility of mutant OPTN inclusions. 
Overexpression of OPTNWT has been found to decrease the numbers of mutant huntingtin 
inclusions in Neuro2A cells through K63-linked polyubiquitin-mediated autophagy (Shen et al. 
2015). The E478G mutation in OPTN alters its ubiquitin-binding domain. Shen et al. (2015) 
observed that OPTNE478G retained an ability to bind to OPTNWT and colocalised with 
polyubiquitylated mutant huntingtin inclusions, suggesting that its association with the 
polyubiquitylated inclusions occurred indirectly through its interaction with OPTNWT. In the 




showed that their association with mRFPubiquitin increased from 48 h to 72 h post-transfection. 
The observation that not all of the inclusions formed by OPTNE478G-EGFP at an intermediate 
time point (48 h post-transfection) were associated with mRFPubiquitin suggests that their 
formation was not ubiquitin-dependent. Rather, over time ubiquitin may have been aberrantly 
sequestered into these inclusions from the cytoplasm (Figure 5.18, c). Moreover, the data 
reported by Shen et al. (2015) suggested that OPTNE478G causes toxicity through a dominant-
negative mechanism by binding to and inhibiting the activity of OPTNWT in autophagosome 
maturation, thereby inhibiting the clearance of misfolded proteins and inclusions by autophagy. 
In the present work, the expression of OPTNE478G-EGFP caused significant growth inhibition 
of NSC-34 cells, suggesting that cell viability was reduced. In these OPTNE478G-EGFP-
transfected NSC-34 cells, the potential of a dominant-negative mechanism of OPTNE478G could 
be explored using various methods. For example, interaction between OPTNE478G and OPTNWT 
and alterations in autophagy could be examined by fluorescence microscopy of NSC-34 cells 
co-transfected with RFP-tagged OPTNWT and EGFP-tagged OPTNE478G, coupled with 
immunocytochemistry for autophagy markers such as LC3I and LC3II, p62, beclin-1 and 
Lamp2a. Alterations in autophagy could also be investigated by examination of autophagic flux 
using multiple complementary techniques in parallel studies (thorough review of methods for 
studying autophagy in Klionsky et al. (2016)). Notwithstanding, accumulating evidence 
indicates that OPTNWT is broadly involved in ALS, with its detection in inclusions in spinal 
cord tissue of patients with non-OPTN-fALS and sALS in several studies (Maruyama et al. 
2010, Deng et al. 2011, Osawa et al. 2011). 
5.4.1.3 WT and mutant VCP associate with TDP-43WT in cytoplasmic inclusions 
It was interesting to observe that, when co-expressed with mRFPubiquitin, neither VCPR191Q-
tGFP nor VCPR159H-tGFP exhibited altered localisation patterns to that of VCPWT-tGFP. 




tGFP-tagged VCP mutants or VCPWT to these inclusions. The saponin permeabilisation assay 
showed that VCPWT-tGFP was retained in about a tenth of transfected cells while both VCP-
tGFP mutants were retained in significantly greater proportions of transfected cells. This 
retention of the tGFP-tagged proteins suggests that VCPWT can be present in immobile and 
insoluble forms in cells. VCP is essential for various cellular processes, including Golgi 
apparatus and ER assembly, ERAD and autophagosome maturation (Song et al. 2003, Halawani 
and Latterich 2006, Ju et al. 2009, Tresse et al. 2010, Meyer et al. 2012). The mobility of 
VCPWT would thus be reduced when it is associated with these membrane structures in cells. 
Moreover, VCPWT  has been observed to localise to aggresomes in viable, functional cells and 
to dynamically associate with other aggregated structures while mutant VCP persists in 
immobile forms in these structures (Ju et al. 2008). Additionally, VCPWT has been reported to 
colocalise with insoluble inclusions containing different disease-associated mutant proteins in 
Machado-Joseph disease (MJD), HD and PD (Kawaguchi et al. 1994, Hirabayashi et al. 2001, 
Mizuno et al. 2003, Ishigaki et al. 2004).  
As the presence of TDP-43 in inclusions is a typical feature of most non-SOD1- and non-FUS-
related ALS cases, it was explored whether there was any association of VCP with TDP-43WT 
in transfected cells. When co-expressed with TDP-43WT-tdT, VCPWT-tGFP as well as both VCP 
mutants formed inclusions that colocalised with TDP-43WT-tdT in all cells that were imaged. 
Unfortunately, time limitations prevented these observations being confirmed with repeat 
experiments. Nevertheless, the association between VCP and TDP-43 in neurodegenerative 
diseases has been investigated in several studies. As well as in ALS, mutations in VCP manifest 
as a plethora of different degenerative disorders, including hereditary spastic paraplegia (de Bot 
et al. 2012), parkinsonism (Kimonis et al. 2008), PD (Spina et al. 2013), Charcot-Marie-Tooth 
Type 2 (Gonzalez et al. 2014) and the multisystem degenerative disorder referred to as IBMPFD 




ubiquitin and TDP-43, similarly to ALS pathology (Forman et al. 2006, Neumann et al. 2007). 
Notably, as mutant VCP is not detected in these inclusions, it has been suggested that alterations 
in VCP function lead to disrupted protein degradation pathways and impaired metabolism of 
TDP-43 (Forman et al. 2006, Neumann et al. 2007). Interestingly, ALS-associated mutations 
in VCP have been linked with impaired autophagic clearance of TDP-43-, FUS-, hnRNPA1- 
and hnRNPA2B1-positive SGs and pathogenic ribonucleoprotein (RNP) granules (Buchan et 
al. 2013). Given that TDP-43 has important roles in SG dynamics, this raises the possibility 
that one of the mechanisms by which VCP mutations lead to motor neuron dysfunction and 
degeneration is through disrupted clearance of SGs. In a study using a Drosophila melanogaster 
model of IBMPFD, disease-causing VCP mutations led to a genetic interaction between TDP-
43 and VCP that enhanced degeneration (Ritson et al. 2010). TDP-43WT redistribution to the 
cytoplasm was enough to cause degeneration in this model, and toxicity was further enhanced 
through overexpression of the ALS-causing TARDBPM337V mutation with mutant VCP.  
The mechanisms by which mutations in VCP lead to neurodegeneration are likely to be 
multifaceted, but the findings from these previous studies indicate that mutant VCP disease 
mechanisms involve, to some extent, alterations in the activity of TDP-43. These alterations in 
TDP-43 activity could result from loss of VCP functions in SG clearance and protein 
degradation via the UPS and autophagy (Kwon et al. 2007, Ju et al. 2008, Buchan et al. 2013). 
Although a preliminary finding from n = 1 experiment, the mutant VCP overexpression model 
used in this study recapitulates the hallmark accumulation of ubiquitin and TDP-43WT in 
cytoplasmic inclusions observed in ALS patient tissue and diverse ALS models. Taken together, 
the reports from the literature discussed here and the preliminary finding of VCP colocalisation 
with TDP-43WT in inclusions emphasise the importance of investigating the interactions 




5.4.2 Development of an HCS assay to measure chaperone network activity in cellular 
ALS models 
The NSC-34 models of ALS generated here were examined for the localisation patterns, the 
mobility and solubility of the EGFP-/tGFP- and mCherry-fusion proteins, and for toxicity 
caused by expression of the mutant proteins. The aim of these studies was to establish disease 
phenotypes that could be used in an experimental system with HCS capacity for further studies 
into disease mechanisms, and potentially for evaluation of candidate therapeutics. This 
experimental system was generated using the Cellomics® ArrayScan™ VTI HCS platform. 
Time limitations prevented multiple image analysis algorithms, BioApplications, from being 
optimised for studies that could utilise different markers of proteome stress and motor neuron 
dysfunction. Nevertheless, optimisation of the Spot Detector BioApplication was achieved for 
investigation into reductions in cellular protein folding/re-folding capacity caused by WT and 
mutant SOD1 and CCNF. Analysis of protein folding/re-folding capacity was facilitated by co-
expression of conformationally destablised Fluc-EGFP mutants (Gupta et al. 2011) with WT 
and mutant SOD1 and CCNF. It was hypothesised that dysregulation of proteostasis 
mechanisms that may be exacerbated by ALS-associated mutations in SOD1 and CCNF would 
overload cellular proteostasis capacity, resulting in inability of the cellular pool of molecular 
chaperones to prevent aggregation of the Fluc-EGFP mutants. The optimised Spot Detector 
BioApplication enabled quantification of the numbers, the mean size and fluorescence intensity 
of aggregates formed by the Fluc-EGFP isoforms. 
The ability of the Fluc-EGFP mutants to report on proteome stress was confirmed through 
proteasome inhibition of cells expressing mCherry alone with the Fluc-EGFP isoforms. As well 
as reduced stability of the single and double Fluc-EGFP mutants, increased proteome stress also 
results in reduced stability of FlucWT-EGFP (Gupta et al. 2011). In MG132-treated cells, 




EGFP and FlucDM-EGFP, perhaps indicating that less of the WT protein misfolded and 
accumulated into the aggregates that did form. Without exogenous proteome stress induced by 
proteasome inhibition, there was negligible aggregation of the Fluc-EGFP isoforms, 
demonstrating that they were able to report on increased proteome stress. 
The overexpression of SOD1A4V-tdT resulted in increased numbers, size and fluorescence 
intensity of aggregates of the Fluc-EGFP isoforms compared to overexpression of SOD1WT-
tdT. The numbers and size of the analysed aggregates correlated with the instability of the Fluc-
EGFP isoforms, with FlucDM-EGFP forming greater numbers of larger aggregates than FlucSM-
EGFP, and more still than FlucWT-EGFP. Previous studies have reported evidence suggesting 
an association between the expression of mutant SOD1 and impaired chaperone activity 
(Bruening et al. 1999, Takeuchi et al. 2002, Tummala et al. 2005). The data from the present 
work demonstrates that the optimised HCS assay using the Fluc-EGFP isoforms is able to report 
on reduced activity of the cellular network of chaperones resulting from the expression of 
SOD1A4V. The formation of Fluc-EGFP aggregates was similar between cells expressing 
CCNFWT-mCherry and mutant CCNFS621G-mCherry. As was observed in SOD1A4V-tdT-
expressing cells, a correlation was observed between relative stability of each Fluc-EGFP 
isoform and extent of aggregation. The overexpression of CCNFWT-mCherry caused the same 
extent of Fluc-EGFP aggregation as CCNFS621G-mCherry, indicating that mutant CCNF did not 
differentially affect the folding/re-folding activity of chaperones in cells compared to CCNFWT. 
CCNF is an important protein in the UPS, as a mediator of protein ubiquitylation (D'Angiolella 
et al. 2013). Ubiquitylation of target proteins is altered in cells expressing mutant CCNF, 
causing aberrant accumulation of ubiquitylated proteins and consequent stress on the 
proteostasis network (Williams et al. 2016). The data obtained from the Fluc-EGFP HCS assay 
developed in the present work suggests that proteostasis disruption caused by mutant CCNF in 





The Fluc-EGFP isoforms were designed to act as sensors of cellular protein folding/re-folding 
capacity that would themselves have minimal biological impact in most of the commonly used 
cellular and animal models (Gupta et al. 2011). In the present work it was demonstrated that 
they are suitable for use in a HCS assay format to report on disruptions in the activity of the 
cellular chaperone network. The extent of aggregation of the Fluc-EGFP isoforms can be easily 
measured using complementary readouts from a HCS microscope, including Fluc-EGFP 
aggregate size, density (fluorescence intensity) and overall numbers in cells. The ability to 
generate these HCS readouts enables higher resolution information to be obtained from the 
Fluc-EGFP isoforms about the extent of protein folding/re-folding impairment in cells. In future 
work it would be useful to optimise a HCS assay that utilises changes in luminescence activity 
of the Fluc-EGFP isoforms (Gupta et al, 2011) as an additional measure of protein folding/re-
folding capacity in cells.  
In addition to the use of this Fluc-EGFP HCS assay to examine cellular models of SOD1A4V 
and CCNFS621G, it would be useful in future work to utilise this assay to examine protein 
folding/re-folding capacity in the cellular models of mutant TDP-43, FUS, UBQLN2, OPTN, 
VAPB and VCP generated in this work. Beyond establishing ALS-associated mutant proteins 
that impair the activity of the chaperone network in cells, this HCS assay could have potential 
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Accumulating evidence from in vitro and in vivo models, and from post-mortem spinal cord 
tissue from ALS patients, suggests that alterations in the mechanisms that maintain proteostasis 
in motor neurons may be a common molecular feature of the different genetic forms of ALS. 
The overall objective of the work presented in this thesis was to investigate the role of 
proteostasis disruption in the pathogenesis of ALS caused by mutations in different ALS-
associated genes. As the number of genes and molecular pathways implicated in ALS 
pathogenesis continues to grow, there may be value in identifying common mechanisms, and 
those distinct for each genetic mutation, that underlie the decline of motor neuron health and 
subsequent degeneration.  
The exact processes that normally maintain proteostasis but that are uniquely disturbed in motor 
neurons expressing different genetic mutations, and the processes that are commonly disturbed 
amongst these diverse genetic contexts, remain to be established. Obtaining a better 
understanding of proteostasis disruption in association with different ALS-causing mutations 
may identify novel therapeutic targets and strategies for ALS patients. In this work, two main 
experimental approaches were developed to investigate proteostasis disturbances caused by the 
expression of several ALS-causing gene variants. A yeast genetic screen was developed to 
identify differentially regulated proteins and molecular pathways associated with SOD1, TDP-
43 and FUS pathology. This approach was validated through confirmation of the relevance of 
one of the hits from the SOD1 yeast screen, UBA1, a protein that plays a critical role in 
maintaining ubiquitin homeostasis, by demonstrating that its overexpression can protect against 
SOD1A4V-mediated toxicity in neuronal NSC-34 cells. A second experimental system was 
developed that exploited a HCS platform to examine dysregulated proteostasis in neuronal cell 




research are summarised, and the significance of these findings to the study and understanding 
of ALS pathogenesis is discussed. 
 A novel approach using Saccharomyces cerevisiae to identify proteostasis 
disturbances caused by ALS-associated proteins 
The use of Saccharomyces cerevisiae to study complex neurodegenerative diseases is well 
established as many of the key molecular processes affected in these diseases are highly 
conserved and thus can be investigated in this simple eukaryote. Although many of these studies 
have provided significant insight into genes that interact with the examined disease genes, 
established high-throughput techniques have not previously been exploited to examine the 
pathological changes that occur at the protein level. Thus, to test the hypothesis that proteins 
found to have altered levels in the presence of pathological TDP-43, FUS or SOD1 are involved 
in the cellular response to these ALS genes, a fluorescent plate reader-based screening system 
using the yeast EGFP-fusion strain collection (Huh et al. 2003) was developed. By employing 
an established collection of yeast strains in which an EGFP had been integrated into the C-
terminus of the genomic locus of each yeast gene, the natural promoter of each gene was 
preserved, enabling the examination of endogenous yeast proteins in a minimally perturbed 
biological system. This approach also bypassed the need to introduce extrachromosomal 
plasmid constructs containing yeast genes fused to fluorophores, and enabled the levels of 
endogenous yeast proteins to be quantified in high-throughput format using a fluorescent plate 
reader. 
A subset of the yeast EGFP-fusion collection was selected to focus on proteins of relevance to 
pathological changes in proteostasis pathways that have previously been implicated in ALS 
(Figure 6.1, a). The collation of this subset of EGFP-fusion yeast proteins/strains is significant 
as they can now be employed in future investigations to examine proteostasis disruptions caused 




Such efforts would be valuable to provide insight into the conserved proteins and molecular 
processes that are commonly and uniquely disrupted amongst different ALS-associated gene 
variants, beyond TDP-43, FUS and SOD1. However, a major caveat of screening only against 
this pathway-focused subset is the inherent bias of this approach. Albeit, the objective of this 
approach was to identify specific proteins within this subset that may be involved in the cellular 
response to mislocalised TDP-43, FUS and mutant SOD1. Yet there may be value in further 
screening the full collection of 4156 EGFP-fusion yeast strains to remove this bias to (1) 
identify other proteins that may be involved in the cellular response to different ALS gene 
variants and (2) examine if there is enrichment in any biological process GO terms that have 
not previously been associated with ALS gene variants. 
The high-throughput plate reader-based approach used in the present study was appropriate for 
the purposes of this investigation as it enabled information on the mean response of populations 
of cells to the expression of each ALS gene mutant to be obtained. However, this approach was 
limited as information at the single-cell level on cell-to-cell variation in expression levels was 
lost. It would be interesting to follow up this screen with a microscopy approach in which 
single-cell information was obtained, to observe how variation in expression of TDP-43, FUS 
or mutant SOD1 between cells correlates with variation in the levels of the yeast EGFP-fusion 
proteins. It may also be beneficial to systematically examine the localisation patterns of the full 
collection of EGFP-fusion yeast proteins in cells expressing different ALS gene variants, using 
an automated microscopy approach similar to that described in Breker et al. (2013). 
Identification of proteins with altered localisation patterns could provide valuable information 
about the cellular response to each ALS gene variant. Such work may identify novel proteins 





6.2.1 Distinct disruptions in proteostasis caused by mutant SOD1 and mislocalised 
TDP-43 and FUS  
Employing the pathway-focused selection of 128 EGFP-fusion yeast strains and measuring the 
levels of the EGFP-fusion proteins in yeast expressing TDP-43WT, FUSWT or SOD1A4V enabled 
the identification of specific proteins that were involved in responses to the proteotoxic burden 








Figure 6.1. Summary of the proteostasis components and processes found in this PhD research to be affected 
by expression of pathological TDP-43, FUS and SOD1. (A) The molecular processes that comprise the 
proteostasis network in eukaryotes (processes that regulate RNA metabolism, gene expression and protein quality 
control), and in which disruptions have previously been implicated in the pathogenesis of ALS. Errors in RNA 
metabolism, gene expression and protein quality control processes enable the production of misfolded proteins, 
which can subsequently oligomerise and aggregate. Misfolded, oligomeric and aggregated forms of proteins have 
all been shown to disrupt the protective actions of ubiquitin, molecular chaperones, and proteasomal and 
autophagic protein degradation. However, under normal physiological conditions cells are able to buffer against 
these aberrant protein forms through ubiquitylation and the action of different molecular chaperones. Misfolded 
proteins can be re-folded into their native conformations, toxic aggregates can be directed for autophagic 
degradation or disaggregated and degraded by the proteasome, or alternatively these aberrant protein forms can be 
sequestered into protein quality control compartments (e.g. aggresomes). (B) In yeast, the heterologous expression 
of human TDP-43WT, FUSWT or SOD1A4V adds proteotoxic burden to the proteostasis network. Up-regulated 
proteins identified in yeast expressing TDP-43WT, FUSWT or SOD1A4V may be involved in augmenting the 
degradation of these aberrant ALS-linked proteins and/or other compensatory processes to restore proteostasis. 
Down-regulated proteins may be involved in aberrant interactions with pathological TDP-43, FUS or SOD1. They 
may thus have been directly disrupted through these aberrant interactions. Figure adapted from Ciryam et al. 2017. 
 
Gene expression alterations and changes in SG dynamics have been comprehensively 
investigated in relation to TDP-43 and FUS. Both proteins have functions in transcription 
regulation, pre-mRNA splicing, mRNA stabilisation and RNA transport (Buratti et al. 2001, 
Buratti et al. 2004, Mercado et al. 2005, Strong et al. 2007, Colombrita et al. 2009) and each 
have several thousand mRNA targets (Hoell et al. 2011, Polymenidou et al. 2011, Tollervey et 
al. 2011). Importantly, a key finding in this work was that alterations in processes that regulate 
gene expression were not only associated with TDP-43 and FUS, but were also altered in the 
presence of mutant SOD1. As the expression of SOD1A4V in yeast did not impact cell viability, 
contrasting to the toxicity of SOD1A4V expression in neuronal (NSC-34) cells, it is possible that 
the up-regulation of proteins involved in gene expression regulation (DCP2 and ASC1), along 
with proteins involved in the UPS and ERAD (UBA1, PRE2 and UFD1), provided cells with 
an enhanced capacity to manage the proteotoxic burden of mutant SOD1A4V. Moreover, this 
suggests that dysregulation of RNA metabolism and alterations in gene expression regulation 
may be common molecular disturbances associated with mutant TDP-43, FUS and SOD1 in 
ALS (Figure 6.1, b).  
The regulation of RNA metabolism and gene expression are necessary for maintenance of the 




Closely connected to these processes in the proteostasis network are the diverse mechanisms 
that manage protein quality control. These include mechanisms of protein folding, re-folding, 
the prevention of protein oligomerisation and aggregation, maintenance of mitochondrial 
proteostasis and ER proteostasis, protein ubiquitylation and the targeting of aberrant proteins 
for proteolytic degradation (Figure 6.1, a). The expression of TDP-43WT, FUSWT and SOD1A4V 
in yeast were each a source of proteotoxic burden to cells, and cells enacted distinct responses 
by differentially regulating key proteins involved in protein quality control mechanisms (Figure 
6.1, b). While the expression of SOD1A4V in yeast did not impair cell viability, FUSWT caused 
moderate growth inhibition and TDP-43WT markedly reduced the growth of yeast, indicating 
reduced cell viability.  
Most notable amongst the differentially-regulated proteins identified between the yeast screens 
was that up-regulation of UFD1, a key protein in maintaining ER proteostasis, correlated with 
suppression of SOD1A4V toxicity and potentially increased cellular capacity to manage 
pathological FUS. Moreover, HAC1 (IRE1 UPR signalling pathway) (Ron and Walter 2007) 
and DSK2 (ubiquitin-dependent protein degradation, including ERAD, autophagy and the UPS) 
(Medicherla et al. 2004) abundance changes formed two of three key differentials (PBP1 being 
the third) between the TDP-43WT and FUSWT screens, with both HAC1 and DSK2 found to be 
down-regulated in TDP-43WT-expressing yeast and up-regulated in FUSWT-expressing yeast. 
The increased abundance of HAC1 in FUSWT-expressing yeast, resulting from increased IRE1-
mediated splicing of HAC1 mRNA, and the increased abundance and activity of DSK2, may 
have augmented cellular capacity to restore ER proteostasis. Importantly, abnormal ER 
morphology and ER stress have been frequently observed pathological features in studies of 
post-mortem spinal cord tissue from sALS patients and murine models of mutant SOD1G93A-
linked ALS (Dal Canto and Gurney 1995, Oyanagi et al. 2008, Sasaki 2010, Lautenschlaeger 




up-regulated in post-mortem spinal cord tissue from ALS patients (Montibeller and de 
Belleroche 2018). From these observations, it stands to reason that disruption of ER proteostasis 
and UPR signalling pathways are potentially key pathological processes that occur in the motor 
neurons of individuals with ALS. Hence, the findings made in Chapter III further suggest that 
disruptions in ER proteostasis and UPR signalling pathways could be common to different 
genetic forms of ALS. As prolonged UPR signalling can lead to induction of apoptosis 
(Schroder and Kaufman 2005), further studies into the mechanisms by which ALS proteins 
cause disruptions in ER proteostasis in neuronal cells are warranted. 
DSK2 is the yeast orthologue of UBQLN2, a protein that is genetically implicated in ALS. 
UBQLN2 is a frequently detected component of inclusions in people with sALS, fALS linked 
to mutations in SOD1, TARDBP, FUS and C9ORF72 and in fALS patients with UBQLN2 
mutations (Deng et al. 2011, Mori et al. 2013, May et al. 2014). The common theme of 
UBQLN2-positive inclusions in the motor neurons of people with diverse forms of fALS and 
sALS suggests that disruption of its functions in ubiquitin-dependent protein degradation, and 
the downstream consequences of this disruption, may be prominent features that lead to decline 
of motor neuron viability in ALS. Indeed, the decreased levels of DSK2 in yeast expressing 
TDP-43WT (and decreased levels of several other proteins with key protective functions in cells), 
correlating with markedly reduced cellular viability, support the hypothesis that disruptions in 
DSK2/UBQLN2 and the conserved functions of these orthologues in conserved ubiquitin-
dependent protein degradation are detrimental in the face of the proteotoxic burden of a 
pathological protein.  
The research work of Chapter III demonstrates the utility of yeast as a simple eukaryote with 
the capacity to model the pathology caused by ALS-associated gene variants, and as a screen 
system. The key findings discussed here provide the foundation for continued investigation of 




TDP-43, FUS and SOD1. Proteins were identified that were commonly affected by the 
expression of both TDP-43WT and FUSWT (PBP1, HAC1 and DSK2), and by FUSWT and 
SOD1A4V (UFD1). However, it will be necessary to confirm that the mammalian orthologues 
(XBP1, ATXN2, UBQLN2 and UFD1L) of these common protein hits are involved in the 
cellular response to mutant TDP-43, FUS and SOD1 in neuronal cells. Moreover, although 
proteins were identified that may be involved in the cellular response to mislocalised TDP-43, 
FUS and mutant SOD1, the mechanisms of their involvement were not examined. Hence, it will 
be important to determine the specific mechanisms by which these proteins are involved in the 
response to mutant TDP-43, FUS and SOD1 in neuronal cell culture models. This work could 
be carried out using the neuronal cell culture models of SOD1A4V, TDP-43M337V and 
FUSR495X/FUSR521G generated in Chapters IV and V. As numerous mutations in the genes 
encoding these proteins have been identified in people with ALS, in future mechanistic studies 
it would be beneficial to examine the common protein hits in motor neuron models generated 
from induced pluripotent stem cells (iPSCs) derived from ALS patients with different TARDBP, 
FUS and SOD1 mutations.  
 Increased levels of UBA1 reduce SOD1A4V toxicity but do not suppress SOD1A4V 
aggregation 
A particularly intriguing observation made in Chapter III was that the expression of human 
SOD1A4V did not cause toxicity in yeast cells, which is in stark contrast to the severity of ALS 
in people carrying this mutation (Cudkowicz et al. 1997, Juneja et al. 1997). The distinct lack 
of SOD1A4V toxicity in yeast coincided with up-regulation of UBA1, PRE2 and UFD1, proteins 
with key roles in the UPS, indicating that UPS activity was augmented in yeast expressing 
SOD1A4V. UPS dysfunction is a critical occurrence that can lead to disastrous downstream 
disturbances in the cell (Yerbury et al. 2016). The UPS is responsible for the co-ordinated 




of ubiquitin in the cellular ubiquitin pools. Ubiquitin also has the essential responsibility of 
modifying target proteins to control diverse pathways such as transcription, translation, vesicle 
transport and apoptosis (Carlson et al. 1987, Palombella et al. 1994, Mimnaugh et al. 1997, 
Ciechanover 1998, Terrell et al. 1998, Hoppe et al. 2000, Lucero et al. 2000, Nakatsu et al. 
2000, Roth and Davis 2000, Katzmann et al. 2001, Muratani and Tansey 2003, de Napoles et 
al. 2004, Wang et al. 2004, Baarends et al. 2005, Ciechanover 2006, Ikeda et al. 2011). Thus, 
efficient UPS activity, and maintenance of ubiquitin homeostasis, is essential for normal 
cellular activity.  
UBA1 functions at the apex of the ubiquitin-activation and conjugation cascade and thus has 
significant responsibility in modulating the cellular distribution of ubiquitin (Ayusawa et al. 
1992, Cook and Chock 1992, Clague et al. 2015). Discovering that its levels were increased in 
yeast expressing SOD1A4V was an important finding in light of evidence from previous studies 
implicating its potentially protective role in another motor neuron disease, XL-SMA (Ramser 
et al. 2008, Wishart et al. 2014, Powis et al. 2016). Taking these findings together led to the 
hypothesis that the increased levels of UBA1 in SOD1A4V yeast formed part of a protective 
response against SOD1A4V, which was then tested (Chapter IV) using the murine NSC-34 cell 
line as a mammalian neuronal cellular model of SOD1A4V-ALS.  
Work presented in Chapter IV confirmed that the expression of SOD1A4V in NSC-34 cells 
caused disruption of normal UPS activity (Figure 4.1, e, Chapter IV), and this correlated with 
cellular toxicity. SOD1A4V aggregation into large inclusions was a prominent feature in these 
cells (Figure 4.1, c, Chapter IV). Remarkably, increasing the levels of catalytically-active 
UBA1 (but not an inactive mutant) in these cells improved cell viability (Figure 4.3, Chapter 
IV). This is significant as it demonstrates that UBA1 has the capacity to confer a protective 
effect in neuronal cells beyond the genetic context of SMA. The protective mechanism of 




been shown that aggregates formed by SOD1 variants can promote cellular toxicity by 
sequestering ubiquitin and components of the protein quality control network, diminishing 
proteostasis capacity and causing ubiquitin dyshomeostasis (Weisberg et al. 2012, Farrawell et 
al. 2018). Hence, it is likely that increasing the levels of UBA1 in SOD1A4V-EGFP-expressing 
NSC-34 cells helped to ameliorate SOD1A4V-mediated deficiency of the activated ubiquitin 
pools (Figure 6.2). By increasing the capacity of the activated ubiquitin pools, augmented 
UBA1 activity may have therefore contributed to the restoration of downstream ubiquitin-
dependent molecular processes, including the UPS, that become severely impaired in motor 
neurons as a result of the expression of ALS-causing mutations in SOD1. In this theoretical 
model, the improved viability of SOD1A4V-EGFP-NSC-34 cells overexpressing UBA1 resulted 
from re-establishment of downstream ubiquitin-dependent molecular processes and efficient 





Figure 6.2. Proposed mechanism by which increased levels of UBA1 protect against SOD1A4V-mediated 
toxicity. (A) Mutations in SOD1 lead to the production of aberrant, misfolded SOD1 in cells. Mutant SOD1 
oligomerises to form toxic oligomeric species, which are able to further aggregate. Misfolded, oligomeric and 
aggregated forms of SOD1 sequester ubiquitin, disrupting homeostasis of the cellular ubiquitin pools, including 
the activated ubiquitin pool. Dyshomeostasis of the cellular ubiquitin pools leads to impairment of downstream 
ubiquitin-dependent molecular processes, including the UPS, causing further disruption of normal cellular activity 
and eventually leading to loss of cell viability. (B) Increasing the levels of the major E1 ubiquitin-activating 
enzyme, UBA1, helps to restore SOD1A4V-mediated deficiency of the activated ubiquitin pools and to re-establish 
ubiquitin homeostasis. By helping to restore ubiquitin homeostasis, increased UBA1 activity may therefore 
contribute to restoration of downstream ubiquitin-dependent molecular processes, thereby re-establishing normal 





As ubiquitin homeostasis may be disrupted in diverse forms of ALS due to the sequestration of 
ubiquitin into inclusions, increasing the levels of UBA1 may be beneficial in the context of 
other genetic mutations associated with ALS. Importantly, the present work adds to previous 
efforts investigating the role of UBA1 in SMA, demonstrating that modulating the expression 
or activity of this key enzyme may have therapeutic potential for motor neurons beyond SMA, 
specifically in the context of SOD1A4V-associated ALS. Indeed, as post-mitotic, exceptionally 
large cells with long neurites, motor neurons have higher demands for stringent maintenance of 
proteostasis throughout the far reaches of the cytoplasm than most other cell types, including 
non-motor neurons (Urushitani et al. 2002, Onesto et al. 2011, Yerbury et al. 2016). Moreover, 
a unique subset of the motor neuron proteome encompasses metastable, aggregation-prone 
(‘supersaturated’) proteins, amounting to an exceptionally challenging environment for the 
proteostasis network (Ciryam et al. 2017).  
In future research it will be important to examine whether UBA1 expression changes occur in 
the motor neurons of ALS patients carrying mutations in SOD1 or other ALS-associated genes, 
which could be carried out using ALS patient-derived iPSC-motor neurons. It could further be 
tested if the protective effect of UBA1 observed in NSC-34 cells expressing SOD1A4V extends 
to iPSC-motor neuron models of different SOD1 mutants and other ALS-associated gene 
variants. To test this, human UBA1WT and UBA1C632S cloned into lentiviral vectors could be used 
to generate ALS patient-derived iPSC-motor neurons stably overexpressing UBA1WT and 
UBA1C632S. It will be important to identify the mechanism of UBA1-mediated protection in 
SOD1A4V-NSC-34 cells, or indeed in human iPSC-motor neurons from ALS patients. To 
evaluate the state of ubiquitin homeostasis after increasing UBA1 levels in these cellular 
models, orthogonal approaches should be employed. For example, ubiquitome analysis, first 
described in Nagarajan et al. (2017), has previously been used to show that the expression of 




(Farrawell et al. 2018). In future work this technique could be used to compare the ubiquitomes 
of SOD1A4V-NSC-34 cells overexpressing UBA1WT or UBA1C632S. This could be paired with 
experiments to compare the activated ubiquitin pools in these cells, using a technique described 
by Gavin et al. (2012). As the objective of these future studies would be to examine the potential 
of UBA1 as a target for gene therapy in ALS patients, there are important implications to 
consider. It would be crucial to examine potential side effects resulting from increased UBA1 
activity in cells. In particular, dysregulated protein ubiquitylation and UPS activity are 
implicated in some cancers, e.g. multiple myeloma and mantle cell lymphoma (Popovic et al. 
2014, Weathington and Mallampalli 2014). For instance, overactive ubiquitylation and 
degradation of the tumour suppressor, p53, may be implicated in the transformation of cells into 
a cancerous state (Scheffner et al. 1990, Michael and Oren 2003, Ciechanover and Schwartz 
2004). Thus, analysis of the ubiquitylated state of p53 and other tumour suppressors could be 
used as a way to monitor if increased UBA1 expression causes off-target effects that promote 
oncogenesis in cell culture models. Beyond these potential studies in cell culture models, any 
significant findings would need to be examined and validated using animal models. For 
example, viral-delivery of UBA1 into transgenic mouse models of mutant SOD1 could be used 
to (1) confirm the protective effect of UBA1 against mutant SOD1 in the context of a 
functioning CNS and (2) examine potential off-target effects, including ubiquitylation of p53 
and other markers of oncogenesis.  
 A high content imaging system to examine proteostasis capacity in neuronal cell 
culture models of ALS-causing gene variants 
A HCS system was developed with the aim of examining proteostasis capacity in NSC-34 cell 
culture models of ALS-causing mutations in TARDBP, FUS, CCNF, VAPB, VCP, OPTN and 
UBQLN2 in addition to the SOD1A4V NSC-34 cell model used in Chapter IV. The NSC-34 cell 




expression of these mutations caused changes in the activity of the protein quality control 
network of chaperones.  
As discussed in Chapter V, it was demonstrated that the Fluc-EGFP isoforms can be used in 
high-throughput format as a tool to measure cellular protein folding/re-folding capacity in 
cellular models of ALS-associated mutants. Applying this assay in high-throughput format 
provides the advantage of speed, combined with the capacity to gain single-cell resolution 
information about cellular phenotype using multiple readouts from the HCS platform. Although 
time did not permit the use of this novel HCS assay to examine whether there were alterations 
in the protein folding environment in the NSC-34 models of TARDBP-, FUS-, VAPB-, VCP-, 
OPTN- and UBQLN2-linked ALS, these experiments can now be readily carried out in a future 
research project. Furthermore, for ALS-associated mutant proteins that do cause reductions in 
the protein quality control capacity of neuronal cells, as is the case for SOD1A4V, this HCS assay 
has the potential to be applied in drug and genetic screening studies to identify candidate 
compounds that are able to ameliorate this deficiency. Furthermore, in future work it would be 
beneficial to develop HCS assays that could be used to explore the findings made in Chapter 
III, using the generated NSC-34 cell culture models of ALS. Extension of this work may aid in 
elucidating the specific proteostasis disturbances caused by ALS-associated mutations in 
SOD1, TARDBP, FUS, VAPB, VCP, OPTN and UBQLN2 in the context of neuronal cells. The 
HCS assays developed in this process could then be used to screen for candidate drugs that have 
the potential to target the identified proteostasis deficiencies. 
 Concluding statements 
With the accelerating progression of ALS research since the first report of SOD1 mutations in 
ALS patients (Rosen et al. 1993), there has been a steady increase in the number of genes and 
molecular processes associated with this devastating neurodegenerative disease. However, 




degeneration of motor neurons in ALS. Elucidating the proteostasis disturbances caused by 
different ALS-associated mutant proteins is therefore a necessary step towards understanding 
the pathogenic mechanisms that are unique to each gene variant and those that are common to 
all. While disturbances in the proteostasis network in ALS have been a major focus of research 
in the past two decades, there has been a lack of systematic approaches to examine multiple 
ALS-associated gene variants in parallel. This represents a significant disadvantage in the ALS 
research field since systematic, high-throughput approaches have the potential to fast-track the 
identification of therapeutic targets that are relevant to the diverse genetic contexts of people 
with ALS.  
The work presented in this PhD thesis describes the development and use of two novel high-
throughput methodologies to investigate proteostasis disturbances caused by diverse ALS-
causing mutations. By using yeast as a model system amenable to high-throughput screens, 
common alterations in the proteostasis network caused by pathological TDP-43, FUS and 
SOD1 were identified, laying the groundwork for further research. Based on this screening 
approach, the therapeutic potential of UBA1 to suppress the toxicity associated with mutant 
SOD1 expression in neuronal cells was uncovered. Moreover, this work adds to previous efforts 
investigating the relevance of ubiquitin dyshomeostasis in SOD1-linked ALS. Finally, a HCS 
assay was developed to further investigate the protein quality control sub-network of the 
proteostasis network. This HCS assay furthermore has potential for drug screening applications. 
Continued development of HCS assays that can measure the identified deficiencies in the 
proteostasis network found through the yeast screens, utilising the neuronal cell culture models 
that were generated, will be valuable in the search for therapeutic targets. Overall, this work 
provides substantial foundation for further investigation into the specific proteostasis 
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R script to fit plate reader absorbance (optical density), EGFP and DsRed fluorescence 
data: 
### 
# Plate reader curve fitting and plotting 
# Function to fit fluorescence and absorbance data 
### 
 
localMaxima <- function(x) { 
  # Use -Inf instead if x is numeric (non-integer) 
  y <- diff(c(-.Machine$integer.max, x)) > 0L 
  rle(y)$lengths 
   
  y <- cumsum(rle(y)$lengths) 
  y <- y[seq.int(1L, length(y), 2L)] 
  if (x[[1]] == x[[2]]) { 
    y <- y[-1] 
  } 
  y 
} 
 
localMinima <- function(x) { 
  # Use -Inf instead if x is numeric (non-integer) 
  y <- diff(c(.Machine$integer.max, x)) > 0L 
  rle(y)$lengths 
  y <- cumsum(rle(y)$lengths) 
  y <- y[seq.int(1L, length(y), 2L)] 
  if (x[[1]] == x[[2]]) { 
    y <- y[-1] 
  } 
  y 
} 
 
#fits a single curve i.e. a vector 
robustfit <- function(data, time, name="NA", smoothing=0.7, upto=65 ){ 
  #set up output 
  out <- list(min.fit.x = NA, min.fit.y = NA, max.fit.x = NA, max.fit.y = NA, exp.rate = NA, 
lag = NA, max.before.chosen.time = NA, rate.before.chosen.time = NA) 
   
  #time must be a numeric vector 
  time <- as.numeric(time) 
   
  #fit 
  y.spl <- smooth.spline(x = time, y= as.numeric(data), spar = smoothing) 
  xrange<-c(min(c(min(time),min(y.spl$x))), max(c(max(time),max(y.spl$x)))) 
  yrange<-c(min(c(min(data),min(y.spl$y))), max(c(max(data),max(y.spl$y)))) 
  plot(xrange,yrange,type='n', main=name) 
  lines(y.spl$x, y.spl$y,type="l", col="red") 




   
  #get the gradient through each point 
  dydt.spl <- predict(y.spl, time, deriv = 1) #using predict.smooth.spline 
  index <- which.max(dydt.spl$y) 
  t.max <- dydt.spl$x[index] 
  dydt.max <- max(dydt.spl$y) 
  y.max <- y.spl$y[index] 
  mu.spl <- dydt.max 
  b.spl <- y.max - dydt.max * t.max 
  lambda.spl <- -b.spl/mu.spl #this is the old method 
   
  #calculate lambda 
  #if it grew exponentially from the start, what time would it have reached y.max 
  #use the first 10 timepoints to establish a baseline 
  t.st <- (y.max-mean(as.numeric(data[c(1:10)])))/dydt.max 
  t.lam <- t.max - t.st 
  abline(v=t.lam, col="brown") 
  #intercept baseline and exp.slope 
  bl = mean(as.numeric(data[c(1:10)])) #we use the mean of the first 10 timepoints as a 
baseline 
  const = y.max - (dydt.max * t.max) 
  t.int = (bl-const)/dydt.max 
  abline(v=t.int, col="green") 
  if(t.int < 0){ 
    cat("Warning: improved lag negative for: ",name,"\n") 
  } 
   
  #save 
  #positive.y <- y.spl$y[y.spl$y >= 0] 
  y.above.t.int <- y.spl$y[which(y.spl$x > t.int)]  
  positive.y <- ifelse(sum(y.above.t.int > 0) == 0, y.above.t.int[y.above.t.int < 0], 
y.above.t.int[y.above.t.int > 0]) 
   
  out$min.fit.y <- positive.y[which.min(positive.y)] 
  out$min.fit.x <- y.spl$x[which(out$min.fit.y == y.spl$y)] 
   
  out$max.fit.x <- y.spl$x[which.max(y.spl$y)] 
  out$max.fit.y <- y.spl$y[which(out$max.fit.x == y.spl$x)] 
   
  out$exp.rate <- mu.spl 
  out$lag <- t.int 
   
  local_maximas = y.spl$y[localMaxima(y.spl$y)] 
  out$second.max.y = ifelse(length(local_maximas) >=2, local_maximas[2], 
local_maximas[1]) 
  out$second.max.x = y.spl$x[which(out$second.max.y == y.spl$y)] 
   
  points(out$max.fit.x, out$max.fit.y, col="grey", pch=19) 
  points(out$second.max.x, out$second.max.y, col="purple", pch=19) 




  local_minimas = y.spl$y[localMinima(y.spl$y)] 
  out$second.min.y = ifelse(length(local_minimas) >=2, local_minimas[2], local_minimas[1]) 
  out$second.min.x = y.spl$x[which(out$second.min.y == y.spl$y)] 
   
  points(out$min.fit.x, out$min.fit.y, col="blue", pch=19) 
  points(out$second.min.x, out$second.min.y, col="pink", pch=19) 
   
  #add parameter A to plot 
  abline(h=out$max.fit.y, col='orange') 
   
  #add the maximum exponential rate to plot 
  mu <- mu.spl 
  lambda <- lambda.spl 
  bla <- y.spl$x * mu 
  bla <- bla + (-mu * lambda) 
  lines(y.spl$x, bla, lw = 2, lty = 2, col="blue") 
   
  ########## get max and rate up to the given timepoint   
  out$max.before.chosen.time <- max(y.spl$y[c(1:upto)]) 
  out$rate.before.chosen.time <- max(dydt.spl$y[c(1:upto)]) 
  abline(h=out$max.before.chosen.time, col='orange',lty=2) 
   
  return(out) 
   
} 
 
#wraps robustfit to call it on every row of a matrix 
#this is just for convenience 
#returns a list of fit results, one entry per row in the same order as the input 
#name is a vector of strings 
RFall <- function(data, time, name="NA", smoothing=0.7, upto=65){ 
  #set up output 
  out <- NULL 
  for(i in 1:dim(data)[1]){ 
    n <- name[i] #otherwise all plots get all the names, even if you subset in the function call 
    cat(n, '\n') 
    out[[i]] <- robustfit(data[i,], time, n, smoothing, upto) 
  } 
   




#use sample positions to interpret layout in the plate 
#positions are the row and column 
#all wells are plotted on the same scale 
plot96 <- function(data, times, positions){ 
  #save original settings 
  mar <- par()$mar 




  par(mfrow=c(8,12)) 
  par(mar=c(0,0,0,0)) 
   
  xrange <- range(times) 
  yrange <- range(data) 
   
  column <- 1 #the current column in the plate 
  rows <- c("A", "B", "C", "D", "E", "F", "G", "H") #use to convert between out numeric 
index and the alphabetical one used on the plates 
  row <- 1 
  i <- 1 #the plot we're currently working on 
  plotnumber <- 0 
   
  while(plotnumber < 96){ 
    plot(xrange, yrange, type="n", xaxt="n", yaxt="n") 
    if(i < dim(data)[1]){ 
      if(positions[i,1] == column && positions[i,2] == rows[row]){ 
        #plot data 
        lines(times, data[i,]) 
        i <- i+1 
        column <- column + 1 
      } else { 
        #move on to the next column 
        column <- column + 1 
      } 
    } else { 
      #all the rest of the columns will be blank from this point, there are no rows left in the 
input data 
      #move on to the next column 
      column <- column + 1 
    } 
     
    plotnumber <- plotnumber + 1 
    if(column == 13){ 
      column <- 1 #we reached the end of a row, go back to the start 
      row <- row + 1 #row only ever increases 
    } 
  } 
   
  #reset plot parameters 
  par(mfrow=mfrow) 
  par(mar=mar) 
} 
 
#overview plot for any number of channels 
#data must be a list of arrays with samples in rows 
#use sample positions to interpret layout in the plate 
#positions are the row and column 
#if scale == TRUE, all wells are plotted on the same scale, otherwise the axes are rescaled for 





plot96_all <- function(data, times, positions, scale, colours = 'auto'){ 
  #save original settings 
  mar <- par()$mar 
  mfrow <- par()$mfrow 
  par(mfrow=c(8,12)) 
  par(mar=c(0,0,0,0)) 
   
  xrange <- range(times) 
  yranges <- NULL 
  if(scale == TRUE){ 
    #set the y range using ALL of the input data, so the scale is the same for all datasets 
    for(i in 1:length(data)){ 
      yranges[[i]] <- range(data) 
    } 
  } else { 
    #set the y range once per dataset 
    for(i in 1:length(data)){ 
      yranges[[i]] <- range(data[[i]]) 
    } 
  } 
   
  #colours 
  if(colours == 'auto'){ 
    colours <- rainbow(length(data)) 
  } 
   
  column <- 1 #the current column in the plate 
  rows <- c("A", "B", "C", "D", "E", "F", "G", "H") #use to convert between out numeric 
index and the alphabetical one used on the plates 
  row <- 1 
  i <- 1 #the plot we're currently working on 
  plotnumber <- 0 
   
  while(plotnumber < 96){ 
     
    if(i < dim(data[[1]])[1]){ 
      if(positions[i,1] == column && positions[i,2] == rows[row]){ 
        #plot data 
        for(j in range(1:length(data))){ 
          plot(xrange, yranges[[j]], type="n", xaxt="n", yaxt="n") 
          lines(times, data[[j]][i,], col = colours[j]) 
          if(j != length(data)){ 
            par(new=TRUE) #to put different axes on one plot. Don't want to set this the last 
time. 
          } 
        } 
        i <- i+1 
        column <- column + 1 




        #move on to the next column 
        column <- column + 1 
        plot(xrange, yranges[[1]], type="n", xaxt="n", yaxt="n") 
      } 
    } else { 
      #all the rest of the columns will be blank from this point, there are no rows left in the 
input data 
      #move on to the next column 
      column <- column + 1 
      plot(xrange, yranges[[1]], type="n", xaxt="n", yaxt="n") 
    } 
     
    plotnumber <- plotnumber + 1 
    if(column == 13){ 
      column <- 1 #we reached the end of a row, go back to the start 
      row <- row + 1 #row only ever increases 
    } 
  } 
   
  #reset plot parameters 
  par(mfrow=mfrow) 



















R script to run t tests to: 
Calculate difference, between diploid EGFP-fusion/GALTDP-43WT-DsRed, EGFP-
fusion/GALFUSWT-DsRed, EGFP-fusion/GALSOD1WT-DsRed, EGFP-fusion/GALSOD1A4V-
DsRed and the corresponding control EGFP-fusion/GALDsRedempty strains, of the yield of 
normalised EGFP fluorescence intensity from mid-exponential to stationary growth phase: 
 
setwd("insert directory location of data file") 
fitsn <- read.delim("output_A_GFP.csv", sep=",", header=T, stringsAsFactors=F) 
fitsn <- fitsn[,-1] 
rate <- as.numeric(fitsn[5, ]) 
lag <- as.numeric(fitsn[6, ]) 
max2 <- as.numeric(fitsn[9, ])  
yield <- as.numeric(fitsn[15, ])#yield_to_use (DEFAULT min.fit.y to second.max.y) 
#minfitmax2_yield <- as.numeric(fitsn [17, ])#second.max_norm.GFP_yield (min.fit.y & 
second.max.y) 
#min2max2_yield <- as.numeric(fitsn [18, ]) #second.min.2ndmax.norm.GFP_yield 
#min2maxfit_yield <- as.numeric(fitsn[19, ]) #second.min.max.fit.norm.GFP_yield 
#mid_yield <- as.numeric(fitsn [21, ]) 
 
p <- c() 
p_yield <- c() 
t_yield <- c() 
p_max2 <- c() 
t_max2 <- c() 
#estimate_yield <- c() 
#conf.int_yield <- c() 
#p_minfitmax2_yield <- c() 
#p_min2max2_yield <- c() 
#p_min2maxfit_yield <- c() 
p_rate <- c() 
p_lag <- c() 
growth_dif <- c() 
#p_mid_yield <- c() 
 
#These sequences combined run t tests of ONLY galactose-grown samples (for GLUC: (i in 
seq(1+k,20+k,2))) 
for (k in seq(1, 161, 80)) { 
   
  for (i in seq(0+k,19+k,2)) { 
    t_yield[i] = t.test(c(yield[i],yield[i+1],yield[i+20],yield[i+21]), c(yield[i+40], yield[i+41], 
yield[i+60], yield[i+61]))$statistic 
    p_yield[i] = t.test(c(yield[i],yield[i+1],yield[i+20],yield[i+21]), c(yield[i+40], yield[i+41], 
yield[i+60], yield[i+61]))$p.value 
    t_max2[i] = t.test(c(max2[i],max2[i+1],max2[i+20],max2[i+21]), c(max2[i+40], 




    p_max2[i] = t.test(c(max2[i],max2[i+1],max2[i+20],max2[i+21]), c(max2[i+40], 
max2[i+41], max2[i+60], max2[i+61]))$p.value 
    p_rate[i] = t.test(c(rate[i], rate[i+1], rate[i+20], rate[i+21]), c(rate[i+40], rate[i+41], 
rate[i+60], rate[i+61]))$p.value 
    p_lag[i] = t.test(c(lag[i], lag[i+1], lag[i+20], lag[i+21]), c(lag[i+40], lag[i+41], lag[i+60], 
lag[i+61]))$p.value 
    #p_mid_yield[i] = t.test(c(mid_yield[i],mid_yield[i+20]), c(mid_yield[i+40], 
mid_yield[i+60]))$p.value 
     
    #growth_dif[i] = log(mean(c(yield[i],yield[i+20]))/mean(c(yield[i+40], yield[i+60]))) 
  } 
} 
 
#Trying to figure out sequences for the for loop: 
#a.vector <- c(1:240) 
#a.element <- c() 
#for (k in seq(1, 161, 80)) { 
   
#  for (i in seq(0+k,19+k,2)) { 
#    a.element[i] <- a.vector[i] 




keep = !is.na(p_yield) 
p_yield = p_yield[keep] 
t_yield = t_yield[keep] 
p_max2 = p_max2[keep] 
t_max2 = t_max2[keep] 
p_rate = p_rate[keep] 
p_lag = p_lag[keep] 
 
layout.GFP <- read.delim("NAMES_REP_8_t tests.csv",sep=",",header=F,stringsAsFactors 
= F) 
 
#calculate combined score for p-values of mid.point yield and total yield 
#X <- c() 
#p_combined <- c() 
#for (i in c(1:60)) { 
#  X[i] <- -2*(log(p_mid_yield[i])+log(p_yield[i])) 
#  p_combined[i] <- pchisq(X[i],df=4,lower.tail=FALSE)  
#} 
p_values_revised = cbind(c(t(layout.GFP)), t_max2, p_max2, t_yield,p_yield,p_rate, p_lag) 
write.table(p_values_revised,"p_values_revised.txt",sep="\t",quote=F, row.names = FALSE) 
write.csv(p_values_revised,file="p_values_revised.csv") 
 
significant_yield_0.05 <- p_values_1[which(p_yield < 0.05)] 
 
#significant_minfitmax2_yield_0.05 <- p_values_1[which(p_minfitmax2_yield < 0.05)] 




#significant_min2maxfit_yield_0.05 <- p_values_1[which(p_min2maxfit_yield < 0.05)] 
#significant_rate_dif_0.05 <- layout2[which(p_rate < 0.05)] 




























Supplementary data from Deltavision OMX™ super resolution microscopy 







Figure S3.1. Characterising the localisation of yeast CDC48-EGFP and DsRed-tagged human TDP-43WT, 
FUSWT, SOD1WT and SOD1A4V in diploid strains. Representative images showing the localisation of each 
DsRed-fusion protein and CDC48-EGFP in the respective diploid strains. Diploid strains were grown for 2 nights 
in SRaf/-His/Ura broth before being diluted 20× into SGal/-His/Ura broth and grown overnight at 30 °C with 
agitation to induce expression of GALTDP-43WT-DsRed, GALFUSWT-DsRed, GALSOD1WT-DsRed, GALSOD1A4V-
DsRed or GALDsRedempty (‘empty’ vector control (DsRed alone); EV). The fluorescent proteins were examined in 
cells using the 100× oil-immersion objective lens of a DeltaVision OMX™ super resolution microscope. Outlines 





Figure S3.2. Characterising the localisation of yeast ERV25-EGFP and DsRed-tagged human TDP-43WT, 
FUSWT, SOD1WT and SOD1A4V in diploid strains. Representative images showing the localisation of each 
DsRed-fusion protein and ERV25-EGFP in the respective diploid strains. Diploid strains were grown for 2 nights 
in SRaf/-His/Ura broth before being diluted 20× into SGal/-His/Ura broth and grown overnight at 30 °C with 
agitation to induce expression of GALTDP-43WT-DsRed, GALFUSWT-DsRed, GALSOD1WT-DsRed, GALSOD1A4V-
DsRed or GALDsRedempty (‘empty’ vector control (DsRed alone); EV). The fluorescent proteins were examined in 
cells using the 100× oil-immersion objective lens of a DeltaVision OMX™ super resolution microscope. Outlines 





Figure S3.3. Characterising the localisation of yeast ENO1-EGFP and DsRed-tagged human TDP-43WT, 
FUSWT, SOD1WT and SOD1A4V in diploid strains. Representative images showing the localisation of each 
DsRed-fusion protein and ENO1-EGFP in the respective diploid strains. Diploid strains were grown for 2 nights 
in SRaf/-His/Ura broth before being diluted 20× into SGal/-His/Ura broth and grown overnight at 30 °C with 
agitation to induce expression of GALTDP-43WT-DsRed, GALFUSWT-DsRed, GALSOD1WT-DsRed, GALSOD1A4V-
DsRed or GALDsRedempty (‘empty’ vector control (DsRed alone); EV). The fluorescent proteins were examined in 
cells using the 100× oil-immersion objective lens of a DeltaVision OMX™ super resolution microscope. Outlines 






Figure S3.4. Characterising the localisation of yeast BMH1-EGFP and DsRed-tagged human TDP-43WT, 
FUSWT, SOD1WT and SOD1A4V in diploid strains. Representative images showing the localisation of each 
DsRed-fusion protein and BMH1-EGFP in the respective diploid strains. Diploid strains were grown for 2 nights 
in SRaf/-His/Ura broth before being diluted 20× into SGal/-His/Ura broth and grown overnight at 30 °C with 
agitation to induce expression of GALTDP-43WT-DsRed, GALFUSWT-DsRed, GALSOD1WT-DsRed, GALSOD1A4V-
DsRed or GALDsRedempty (‘empty’ vector control (DsRed alone); EV). The fluorescent proteins were examined in 
cells using the 100× oil-immersion objective lens of a DeltaVision OMX™ super resolution microscope. Outlines 





Figure S3.5. Characterising the localisation of yeast RPL40A-EGFP and DsRed-tagged human TDP-43WT 
and SOD1A4V in diploid strains. Representative images showing the localisation of each DsRed-fusion protein 
and RPL40A-EGFP in the respective diploid strains. Diploid strains were grown for 2 nights in SRaf/-His/Ura 
broth before being diluted 20× into SGal/-His/Ura broth and grown overnight at 30 °C with agitation to induce 
expression of GALTDP-43WT-DsRed, GALSOD1A4V-DsRed or GALDsRedempty (‘empty’ vector control (DsRed alone); 
EV). The fluorescent proteins were examined in cells using the 100× oil-immersion objective lens of a DeltaVision 












Figure S3.6. Characterising the localisation of yeast RPN10-EGFP and DsRed-tagged human TDP-43WT, 
FUSWT and SOD1A4V in diploid strains. Representative images showing the localisation of each DsRed-fusion 
protein and RPN10-EGFP in the respective diploid strains. Diploid strains were grown for 2 nights in SRaf/-
His/Ura broth before being diluted 20× into SGal/-His/Ura broth and grown overnight at 30 °C with agitation to 
induce expression of GALTDP-43WT-DsRed, GALFUSWT-DsRed, GALSOD1A4V-DsRed or GALDsRedempty (‘empty’ 
vector control (DsRed alone); EV). The fluorescent proteins were examined in cells using the 100× oil-immersion 
objective lens of a DeltaVision OMX™ super resolution microscope. Outlines of cells are indicated by white 








Figure S3.7. Characterising the localisation of yeast TRS23-EGFP and DsRed-tagged human TDP-43WT 
and SOD1A4V in diploid strains. Representative images showing the localisation of each DsRed-fusion protein 
and TRS23-EGFP in the respective diploid strains. Diploid strains were grown for 2 nights in SRaf/-His/Ura broth 
before being diluted 20× into SGal/-His/Ura broth and grown overnight at 30 °C with agitation to induce 
expression of GALTDP-43WT-DsRed, GALSOD1A4V-DsRed or GALDsRedempty (‘empty’ vector control (DsRed alone); 
EV). The fluorescent proteins were examined in cells using the 100× oil-immersion objective lens of a DeltaVision 








Figure S3.8. Characterising the localisation of yeast MDJ1-EGFP and DsRed-tagged human FUSWT and 
SOD1A4V in diploid strains. Representative images showing the localisation of each DsRed-fusion protein and 
MDJ1-EGFP in the respective diploid strains. Diploid strains were grown for 2 nights in SRaf/-His/Ura broth 
before being diluted 20× into SGal/-His/Ura broth and grown overnight at 30 °C with agitation to induce 
expression of GALFUSWT-DsRed, GALSOD1A4V-DsRed or GALDsRedempty (‘empty’ vector control (DsRed alone); 
EV). The fluorescent proteins were examined in cells using the 100× oil-immersion objective lens of a DeltaVision 








Figure S3.9. Characterising the localisation of yeast MGE1-EGFP and DsRed-tagged human FUSWT and 
SOD1A4V in diploid strains. Representative images showing the localisation of each DsRed-fusion protein and 
MGE1-EGFP in the respective diploid strains. Diploid strains were grown for 2 nights in SRaf/-His/Ura broth 
before being diluted 20× into SGal/-His/Ura broth and grown overnight at 30 °C with agitation to induce 
expression of GALFUSWT-DsRed, GALSOD1A4V-DsRed or GALDsRedempty (‘empty’ vector control (DsRed alone); 
EV). The fluorescent proteins were examined in cells using the 100× oil-immersion objective lens of a DeltaVision 








Figure S3.10. Characterising the localisation of yeast PUB1-EGFP and DsRed-tagged human TDP-43WT 
and FUSWT in diploid strains. Representative images showing the localisation of each DsRed-fusion protein and 
PUB1-EGFP in the respective diploid strains. Diploid strains were grown for 2 nights in SRaf/-His/Ura broth 
before being diluted 20× into SGal/-His/Ura broth and grown overnight at 30 °C with agitation to induce 
expression of GALTDP-43WT-DsRed, GALFUSWT-DsRed or GALDsRedempty (‘empty’ vector control (DsRed alone); 
EV). The fluorescent proteins were examined in cells using the 100× oil-immersion objective lens of a DeltaVision 








Figure S3.11. Characterising the localisation of yeast XRN1-EGFP and DsRed-tagged human TDP-43WT 
and FUSWT in diploid strains. Representative images showing the localisation of each DsRed-fusion protein and 
XRN1-EGFP in the respective diploid strains. Diploid strains were grown for 2 nights in SRaf/-His/Ura broth 
before being diluted 20× into SGal/-His/Ura broth and grown overnight at 30 °C with agitation to induce 
expression of GALTDP-43WT-DsRed, GALFUSWT-DsRed or GALDsRedempty (‘empty’ vector control (DsRed alone); 
EV). The fluorescent proteins were examined in cells using the 100× oil-immersion objective lens of a DeltaVision 

















Figure S3.12. Characterising the localisation of yeast UFD4-EGFP and DsRed-tagged human FUSWT and 
SOD1A4V in diploid strains. Representative images showing the localisation of each DsRed-fusion protein and 
UFD4-EGFP in the respective diploid strains. Diploid strains were grown for 2 nights in SRaf/-His/Ura broth 
before being diluted 20× into SGal/-His/Ura broth and grown overnight at 30 °C with agitation to induce 
expression of GALFUSWT-DsRed, GALSOD1A4V-DsRed or GALDsRedempty (‘empty’ vector control (DsRed alone); 
EV). The fluorescent proteins were examined in cells using the 100× oil-immersion objective lens of a DeltaVision 




























Figure S3.13. Distribution of raw OD600 and DsRed fluorescence intensity data from repeats of the FLUOstar® 
Optima plate reader assays of diploid yeast EGFP-fusion strains expressing DsRed-fusion human TDP-43WT, 
FUSWT, SOD1WT, SOD1A4V or DsRed alone. Diploid strains were created by mating haploid Y7039 transformed with 
pAG416GAL-TDP-43WT-DsRed (GALTDP-43WT), pAG416GAL-FUSWT-DsRed (GALFUSWT), pAG416GAL-SOD1WT-
DsRed (GALSOD1WT), pAG416GAL-SOD1A4V-DsRed (GALSOD1A4V), or pAG416GAL-ccdB-DsRed (GALDsRedempty; 
vector control) with haploid strains from the yeast EGFP fusion collection (Huh et al. 2003). After first screening 128 
different strains from the yeast EGFP fusion collection, EGFP-fusion proteins exhibiting altered levels in GALTDP-43WT, 
GALFUSWT, GALSOD1WT or GALSOD1A4V relative to GALDsRedempty strains were re-assayed to confirm the altered levels. 
Quadruplicates of each diploid strain were grown in 384-well µclear plates containing 100 µL per well of SGal/-His/Ura 
to induce expression of GALTDP-43WT, GALFUSWT, GALSOD1WT, GALSOD1A4V or GALDsRedempty in a FLUOstar® Optima 
plate reader. The absorbance (optical density [OD] at 600 nm), EGFP (excitation 485/12 nm, emission collected at 510/20 
nm) and DsRed (excitation 580/10 nm, emission collected at 612 nm) fluorescence were measured over 48 h of yeast 
incubation at 30 °C. Raw data collected for each replicate were analysed to calculate the OD600 yield (maximum OD600 – 
minimum OD600), the maximum exponential rate of change of OD600 (maximum growth rate; OD600/h), the maximum 
DsRed fluorescence intensity (Fmax) (maximum DsRed F.I. – minimum DsRed F.I.; relative fluorescence units, R.F.U.) 
and the maximum exponential rate of change of DsRed F.I. (maximum rate of DsRed F.I. increase; R.F.U./h). These data 
per replicate are presented as follows: (A) scatter plot and (B) histogram displaying the OD600 yield; (C) scatter plot and 
(D) histogram showing the maximum exponential rate of change of OD600 (maximum growth rate); (E) scatter plot and 
(F) histogram displaying the DsRed Fmax; (G) scatter plot and (H) histogram displaying the maximum exponential rate of 
change of DsRed F.I. (maximum rate of DsRed F.I. increase; R.F.U./h). 
 
 
 
 
 
 
